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Chapter 1 
General introduction
 Modern Western medicine has achieved enormous success in the last 150 years with the 
fighting disease approach as its most important concept. In summary, this entails fighting disease-
related organisms, cells and functions in the body, reducing the symptoms of disease, and the ma-
nipulation and/or substitution of non-functioning or dysfunctional parts and processes of the body 
by means of external therapeutic resources. 
Scientists, pharmaceutical industries, doctors and therapists have developed many, often suc-
cessful, strategies to fight diseases and reduce symptoms. The development of all kinds of “anti-
drugs,” for example, antibiotics, antiviral drugs, anti-inflammatory drugs, and chemotherapeutics 
have saved many lives by fighting the presence of disease-causing bacteria or viruses in the human 
organism or by fighting the abnormal cell growth of cancers with great success. The development 
of numerous types of antidepressants, anxiolytics, and antipsychotics has resulted in a major im-
provement of the quality of life of psychiatric patients by reducing their psychological symptoms. 
In addition, healthcare is increasingly more able to replace body parts (e.g. new hips and knees) 
and/ or body functions (e.g. insulin and thyroxin treatment, or the heart-lung machine during surgi-
cal procedures) by means of manipulation and/or substitution. It is expected that the development 
of this approach will continue, and that it will result in important medical innovations.
However, in recent decades, there has been a growing interest in the additional approach of 
health promotion in both healthcare and society. One of the definitions of this approach is: 
Health promotion is the process of enabling individuals, groups or societies to incre-
ase control over, and to improve their physical, mental, social and spiritual health. 
This could be reached by creating environments and societies characterized by clear 
structures and empowering environments where people are able to identify their 
internal and external resources, use and reuse them to realize aspirations, to satisfy 
needs, to perceive meaningfulness and to change or cope with the environment in a 
health promoting manner [1]. 
Within the health promotion approach, one can distinguish between preventive health promo-
tion, in which people aim to become healthier and remain healthy in order to prevent disease, and 
curative health promotion, which aims to cure disease by actively establishing or permanently 
restoring a healthy physiological and mental status.
In 1986, the first international conference on health promotion was organized in Ottawa [2], 
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and the first peer-reviewed journal of health promotion, the American Journal of Health Promo-
tion, was launched. Nowadays, health promotion programs have been established in businesses, 
communities, clinics, commercial fitness centers, and schools. In society in general, the interest 
in lifestyle factors such as physical activities, nutrition, smoking, alcohol and drugs, and sexual 
behavior patterns, which can influence health status, is still growing. In 2000, the Consortium of 
Academic Health Centers for Integrative Medicine was established to support academic medical 
practice by focusing on, among other things, achieving optimal health and healing for patients. 
Since 2000, the number of universities that are members of this consortium has increased from 11 
to 44 in North America, demonstrating the increasing interest in health promotion in the academic 
world [3]. Nowadays, health promotion is taught in academia in the areas of the social sciences 
and public health.
Although a great deal of effort has been invested worldwide, a large amount of scientific and 
practical work still has to be done in order to develop the health promotion approach to the same 
level of professionalism as the fighting disease approach.
This Chapter
 This chapter is an introduction to some specific aspects of preventive and curative health 
promotion and the contribution of this thesis to the further development of the health promotion 
approach and its integration with the fighting disease approach in healthcare. Five questions will 
guide this chapter: 
1. Is there a current need for professional health promotion?
2. What are the features of integrative medicine (IM), and can IM provide a contribution to pro-
fessional health promotion?
3. What are the features and the burden of hay fever, and what are conventional and health-
promoting anthroposophic medicine (AM) hay fever treatments? 
4. Is the holistic concept of health promotion in accordance with current thinking in the funda-
mental holism-reductionism debate?
5. What is the contribution of this thesis to the development of professional health promotion and 
its integration with the fighting disease approach in healthcare?
Answers to these questions will be provided by first describing two important reasons for the 
further development of professional preventive and curative health promotion (see Section 1.1). 
Then the fields of integrative medicine (IM), complementary and alternative medicine (CAM), 
and anthroposophic medicine (AM) are introduced (see Section 1.2). These types of medicine 
often have a long history in clinical practice, and have their core orientation towards preventive 
and curative health promotion as an additional approach to the more conventional fighting disease 
approach. Therefore, they are hypothesized to involve much tacit knowledge on health promotion. 
This tacit knowledge can be converted into explicit knowledge and must then be systematized into 
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healthcare programs, guidelines and/or protocols, and subsequently tested on quality, safety, ef-
ficacy, effectiveness and cost-effectiveness in order to become ‘evidence-based’. 
Since a large part of this thesis focuses on the conversion of the tacit knowledge and the sub-
sequent testing on the quality, safety, efficacy and effectiveness of the curative health promotion 
treatment with the anthroposophic drug Citrus/Cydonia compositum (comp.) for hay fever, a short 
introduction to hay fever and the conventional and anthroposophic treatments is presented (see 
Section 1.3). 
The presented types of health promotion often have a formal (ontological, epistemological, 
and methodological) holistic character, which is not in accordance with the current reductionist 
approaches in medicine. This is one of the reasons (besides the lack of evidence on safety, efficacy 
and effectiveness) that practitioners of conventional medicine do not easily accept CAM approa-
ches. Therefore, a short introduction to the holism versus reductionism debate in relationship to the 
fighting disease versus the health promotion approach is given. Some of the current developments 
demonstrating a shift from a reductionist towards a more holistic approach are described. They 
provide a new scientific opening for the acceptance of holistic approaches such as anthroposophic 
medicine in medicine (see Section 1.4). 
This chapter ends with the objectives and outline of the thesis (see Section 1.5).
1.1  Fertile ground for the further development of pro-
fessional preventive and curative health promotion
 Demographic developments in the Netherlands and developments in the role of patients 
in healthcare provide fertile ground for the further development of professional preventive and 
curative health promotion.
1.1.1 Prognoses regarding growth, population composition, life expectancy 
and chronic diseases in the Dutch population
 The prognosis for the coming decades is that the Dutch population will continue to grow 
and grow older, and that more than 25 percent of the population will be chronically ill. On June 
2011, the population was 16.68 million [4]. In 2008, the prognosis was that the population would 
grow to 17.5 million by 2038. Then, due to a positive migration balance and negative birth growth, 
the population would supposedly shrink back to 16.8 million by 2050 [5]. 
The percentage of people who are older than 65 is expected to increase from 15 percent or 2.5 
million people in 2009 to 25 percent or 4.2 million people in 2050, with an increasing proportion 
of individuals older than 80. The latest calculations for the Netherlands once again indicate that the 
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life expectancy of both men and women will increase in the near future. For men, their life expec-
tancy at birth is expected to rise from 78.4 in 2008 to 81.1 in 2030. The life expectancy for women 
is expected to rise during this period from 82.5 to 85.3 [6].
One of the problems that arise as a consequence of these higher life expectancies is an increase 
in the prevalence of chronic diseases. Old age is often related to chronic diseases, which increases 
the need for social and health support and medical care. During the period of 2003 to 2007, more 
than 25 percent of the Dutch population suffered from a chronic disease, and 8 percent had more 
than one chronic disease. Of those who were 65 to 74 years old, fifty percent had a chronic disease, 
as did 57.5 percent of the population aged 75 and older. Older individuals are at an increased risk 
of having a chronic disease, which is associated with a lower quality of life. For society, this will 
result in an increase in healthcare-related costs. Therefore, for both society and the individual, it 
is very important to remain as healthy as possible into old age [6-8]. Further development and im-
plementation of health promotion strategies might contribute to reducing healthcare-related costs.
1.1.2  Developments in the role and relationships of patients in healthcare
 In healthcare practice, patients are increasingly assuming the role of competent patients 
who want to take responsibility for their own therapeutic processes. They use healthcare as part 
of their strategy for resolving a health and disease-related problem [9]. Healthcare professionals 
contribute to this process. Expressions of this development include, among other things, an incre-
ase in the use of certain terms in the healthcare sector, such as empowerment, self-management, 
shared decision making, the patient’s own responsibility, and the autonomy of patients. Bopp et al. 
[10] describe the history of this development, in which patients have changed – since the 1960s to 
the year 2000 – from uninformed and incompetent (1960), informed (1970), empowered (1980), 
autonomous (1990) patients into competent patients. During the first period, the patient was hardly 
informed or not informed at all about the seriousness of his/her state of health, because he/she was 
believed to be unable to cope with this information. The doctor completely determined the ‘what’ 
and ‘how’ of the diagnosis and treatment. At the beginning of the 1970s, the concept of informed 
consent came over from the United States; it was generally accepted that patients were increasin-
gly being informed in greater detail about the nature, extent and consequences of their disease and 
the necessary medical treatment. From the 1980s onwards, self-help groups appeared and patients 
became increasingly aware of their rights. Lawyers began to work on the area of patient rights. In 
the 1990s, patients became increasingly autonomous and models such as ‘shared decision-making’ 
were developed. This demonstrated that patients were becoming increasingly involved as partners 
of the doctor or therapist. 
The development of the patient’s role from the 1960s to the end of the 1990s, primarily con-
cerns the relationship between the patient and other individuals: the doctor, representatives of the 
law, politicians, and insurers. At the end of the 20th century, the relationship between the patient 
and himself/herself is increasingly at the center. This includes such questions as: What is the role 
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I would like to play in dealing with my disease? What is my personal contribution to changing the 
status of my disease, and what does it look like? What is the doctor or therapist responsible for, and 
what am I responsible for? This is not necessarily an issue of patient rights, but rather concerns the 
sharing of responsibility. Over the past few years, the concept of patient competence has develo-
ped. This concerns the patient’s ability to comply with the tasks that the disease brings, to reflect on 
his/her own and other resources for changing his/her own health and condition, to take advantage 
of these resources, and, at the same time, to take into consideration his/her personal needs, goals 
and autonomy [10].  
The changing role of patients has made it necessary to place more emphasis in the field of heal-
thcare on developing valid, evidence-based strategies that support and enable patients to actively 
contribute to their own health and disease status. 
1.2  Integrative medicine: Integrating fighting disease 
and health promotion
1.2.1 The increasing demand for integrative medicine
 Patients around the globe are increasingly embracing complementary and alternative me-
dicine (CAM) as a contributor to health in addition to conventional medicine [11]. ‘Out-of-pocket 
expenditure’ on CAM is estimated in Australia to be as high as AU$4.13 billion (US$3.13 billion) 
per year [12], and in England, GB£450 million per year [13]. In the United States, CAM costs 
are estimated to be between US$27.0 billion and US$34.4 billion per year [14], and in 2007, they 
comprised 11.2 percent of the total out-of-pocket expenditures on healthcare in the United States 
[15].
Defining CAM is difficult because the field is very broad and is constantly changing. Accor-
ding to the National Center for Complementary and Alternative Medicine (NCCAM) in the United 
States, CAM is a group of diverse medical and healthcare systems, practices and products that are 
not generally considered to be part of conventional medicine [16]. The Cochrane Collaboration’s 
definition of complementary medicine is that it includes all such practices and ideas that are outside 
of the domain of conventional medicine in several countries, and which users define as preventing 
or treating illness or promoting health and well-being. These practices complement mainstream 
medicine by satisfying a demand, which is not met by conventional practices, and they diversify 
the conceptual framework of medicine [17]. Two of the core features of CAM are its orientation 
towards preventive and curative health promotion as an additional approach to the more conven-
tional fighting disease approach, and its holistic (compared to reductionist) and personalized ap-
proach to health and disease management.
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Complementary medicine refers to the use of CAM together with conventional medicine, for 
example, using acupuncture in addition to the normal treatments that are used to help lessen pain. 
Alternative medicine refers to the use of CAM in place of conventional medicine. Integrative 
medicine refers to a practice that combines both conventional and CAM treatments for which evi-
dence exists of their safety, efficacy and effectiveness.
A recent study by the United States National Institute of Health revealed that four out of 10 
Americans used some form of CAM in 2007 [18]. Another study in Switzerland reported that ap-
proximately 11 percent of the population had used one of five CAM streams (anthroposophic medi-
cine, homeopathy, neural therapy, phytotherapy, and traditional Chinese medicine) in 2002. In the 
Western world and industrialized countries, more than 50 percent of the population has used CAM 
at least one time in their life [19]. In the Netherlands, according to the results of the second Dutch 
national survey in general practice (DNSGP-2) [20], 6.5 percent of mainstream general practitioner 
patients had visited a CAM professional in the last year. In addition, there is an increase of doctors 
who specialize in CAM [21].
A review on the literature demonstrates that individuals who use CAM tend to be female, mid-
dle age, be more educated, and tend to have more than one medical condition [22]. The CAM doc-
tors in a Swiss study treated patients that tended to be younger, female and better educated. These 
patients also tended to have a favorable attitude towards complementary medicine and exhibited 
chronic and more severe forms of disease. The majority of alternative medicine users appear to 
have chosen CAM mainly because they wished to undergo a certain procedure; additional reasons 
include the desire for more comprehensive treatment and the expectation of fewer side effects [23]. 
Van Dulmen [11] concluded in a Dutch study comparing patients visiting conventional general 
practitioners (GPs) and three types of CAM GPs (homeopathy, acupuncture, and naturopathy), 
that, contrary to expectations, patients do not consult a CAM physician because they are disap-
pointed with mainstream GP care. CAM patients primarily appear to be seeking a physician who 
takes the time to talk with them and who will treat their complaints from a holistic viewpoint. 
Ernst and Hung [24] described the published evidence on the expectations of CAM users (in order 
of prevalence): hope to influence the natural history of the disease; disease prevention and health/
general well-being promotion; fewer side effects; being in control over one’s health; symptom re-
lief; boosting the immune system; emotional support; holistic care; improving quality of life; relief 
of side effects of conventional medicine; positive therapeutic relationship; obtaining information; 
coping better with illness; supporting the natural healing process; and the availability of treatment. 
In a referendum among the population in Switzerland in 2009, two-thirds of the voters were 
in favor of a wider coverage of CAM by public health insurance. In January 2011, based on the 
positive outcome of a national referendum, the Swiss authorities decided that five main streams of 
CAM (anthroposophic medicine, homeopathy, neural therapy, phytotherapy, and traditional Chi-
nese medicine) will be covered by the mandatory health insurance for a period of six years (2012-
2017) [25].
In the Netherlands the large number of patients attending CAM doctors and the increasing 
numbers of doctors specializing in CAM suggest that CAM will, in time, integrate with conventio-
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nal medicine [11]. However, the current debate within the Dutch medical association KNMG (Ko-
ninklijke Nederlandse Maatschappij tot bevordering van de geneeskunst) focuses on the absence 
of evidence on the safety, efficacy, effectiveness and cost-effectiveness of CAM treatments. CAM 
treatments can only be prescribed to patients if sufficient evidence is available on their safety, effi-
cacy, effectiveness and cost-effectiveness, and they are in accordance with the wishes, experiences 
and expectations of patients and other preconditions [26].
1.2.2  The efficacy, effectiveness and cost-effectiveness of CAM
 In many cases, the efficacy and effectiveness of CAM has not been proven in clinical trials 
[27]. However, a lack of proof regarding its efficacy and effectiveness is obviously not the same 
as proof of its ineffectiveness. Clearly, the status of a treatment could change CAM into conventi-
onal medicine once scientific evidence of its efficacy and effectiveness becomes available. Three 
examples of CAM treatments that have become more widely accepted by conventional medicine 
are St. John’s wort, acupuncture for specific complaints, and mindfulness. St. John’s wort has been 
used for more than 90 years in anthroposophic medicine and has become part of the conventional 
guidelines for the treatment of depression, based on scientific evidence from randomized control-
led trials [28]. Hopton and McPherson [29], on the basis of a systematic review of pooled data from 
meta-analyses, concluded that acupuncture is more than a placebo for commonly-occurring chro-
nic pain conditions. In addition, in her thesis, van den Berg [30] recently demonstrated the positive 
effects of acupuncture on obstetric health problems (breech presentation). Currently, mindfulness 
treatment, which has its origins in Eastern Buddhism, is rapidly finding its way into healthcare. It 
has been demonstrated to be effective in, for example, supporting stress reduction [31], treating 
anxiety and mood problems, buffering the reduction of CD4+ T lymphocyte counts in HIV patients 
[32], decreasing blood pressure [33], improving the acceptance of chronic pain [34], and enhancing 
the general features of coping with distress and disability in everyday life, as well as under more 
extraordinary conditions such as serious disorders or stress in clinical populations [35].
In their review, Herman et al. [36] report that some studies indicate that CAM therapies may be 
considered to be cost-effective compared with the usual care for various conditions: acupuncture 
for migraines, manual therapy for neck pain, spa therapy for Parkinson’s disease, self-administered 
stress management for cancer patients undergoing chemotherapy, pre- and post-operative oral nu-
tritional supplementation for lower gastrointestinal tract surgery, biofeedback for patients with 
‘functional’ disorders such as irritable bowel syndrome, and guided imagery, relaxation therapy 
and a potassium-rich diet for cardiac patients. A systematic review of randomized clinical trials 
(RCTs) on the use of so-called natural health products revealed evidence of the cost-effectiveness 
of these products in relation to post-operative surgery, but not regarding the other conditions that 
were assessed [37]. Studer and Busato [38] demonstrated that GPs who had completed certified 
additional training in CAM after obtaining their conventional medical degree (CAM GPs, n = 257) 
and GPs who had not (n = 174) had equal annual costs per patient, but significantly lower annual 
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costs per doctor (by 29%), although the CAM GPs took more time per patient. 
These findings highlight the fact that the health-promoting methods that are considered CAM 
today could be effective and may have significant cost-saving potential. 
1.2.3  From practice-based evidence to evidence-based practice
 Several CAM streams have a long history in clinical practice, and have developed a lot of 
expert (tacit) knowledge, but they lack sufficient scientific evidence of quality, safety, efficacy, ef-
fectiveness and cost-effectiveness. In order to provide sufficient evidence, this tacit knowledge can 
be converted into explicit knowledge and then systematized into healthcare programs, guidelines 
and/or protocols and subsequently tested on the quality, safety, efficacy, effectiveness and cost-
effectiveness in order to become ‘evidence-based’ [39]. This programmatic development ‘from 
practice-based evidence to evidence-based practice’ has only started in the last decades to varying 
degrees in the several CAM streams. Currently, several studies demonstrate the low quality of 
methodology and consequently low quality of evidence [26]. This situation is comparable to the 
situation of conventional medicine some decades ago [40]. Like what happened in conventional 
medicine in the last decades, investment in qualitatively solid research is necessary to improve the 
quality of the evidence. Based on this evidence, evidence-based CAM or IM ‘products’ for specific 
indications can be recommended to the several stakeholders, including patients, doctors, and po-
licy makers.
1.2.4  Anthroposophic medicine: Integration of fighting disease and health 
promotion
 As the anthroposophic drug Citrus/Cydonia comp. is being examined in this thesis as an 
example of curative health promotion (treatment of hay fever), this section will briefly describe the 
main features of anthroposophic medicine.
Anthroposophic medicine is an integrative diagnosis and therapy concept, an example of the 
integration of a holistic approach with a conventional approach, which has been developing since 
1921 and is currently practiced in over 60 countries. It combines mainstream scientific medicine 
with Rudolf Steiner’s anthroposophy. Anthroposophic medicine considers a human being as a 
whole entity – body, mind/soul and individuality. It aims to stimulate the self-healing forces of the 
body, restoring the balance of bodily functions and strengthening the immune system, rather than 
primarily relieving the symptoms of disease. Specific anthroposophic approaches include, among 
others, anthroposophic medicinal products, eurythmy therapy, massage therapy, art and music the-
rapy, and speech [41]. 
A recent update of a systematic review demonstrated that, in recent decades, 256 studies on the 
effects of anthroposophic medicine have been performed [42, 43], seventy of them in the last six 
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years. Based on this systematic review, the authors concluded that the research on anthroposophic 
medicine for a wide range of diseases had revealed predominantly positive results with few side 
effects, a high degree of customer satisfaction, and indications of cost-effectiveness compared with 
conventional treatment [1, 42, 43].
Within the context of the reductionism-holism debate in science and medicine (see Section 
1.4), the formal position of anthroposophic medicine is:
• There are non-material organizing principles in nature in addition to the material elements 
of reality (nature) (ontological aspect)
• There are higher, more complex levels of organization in organisms, which are responsible 
for the integrity and organizing of material elements in time, space and function (episte-
mological aspect)
• These higher levels of organization in organisms can be examined by means of qualitative-
subjective and statistical pattern exploration and pattern recognition methodologies (me-
thodological aspect)
• Health and disease can be diagnosed by integrating knowledge from the lower and higher 
levels of the organization of the system (methodological aspect)
• The anthroposophic treatment of disease must often be systems-oriented (e.g. several sub-
stances or therapies) and aimed at: 
•  Influencing different essential aspects of the relevant organizing system level in health 
and disease at the same time or in phases (poly-target-treatment)
•  Restoring balance and wholeness within the system by stimulating the higher levels of 
organization in order to regulate the lower levels (health promotion) (methodological 
aspect)
• The anthroposophic treatment of disease requires self-activity of the organism and the pa-
tient towards an optimal functioning of the higher levels of organizing among each other 
and in the regulation of the lower levels. Therefore, it is a health promotion strategy, one 
that supports and enables patients to actively contribute to their own health and disease 
status (methodological aspect).
1.3  Hay fever or seasonal allergic rhinitis: The burden of 
disease, conventional and anthroposophic treatment
 In a large part of this thesis, the chronic disease hay fever or seasonal allergic rhinitis 
(SAR) is the centre of attention. SAR is a type I immediate hypersensitivity reaction that is medi-
ated by the formation of specific Immunoglobulin (Ig)E antibodies to a seasonal allergen, leading 
to mucosal inflammation, which is characterized by sneezing, itching, rhinorrhoea, and nasal bloc-
kage. Penetrating pollen allergens induce the activation of dendritic cells in the mucosal tissue, 
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which migrate to draining lymph nodes and stimulate CD4+ helper T(h)-cells by the presentation 
of allergen-derived peptides. Due to the presence of high amounts of cytokines like Interleukin 
(IL)-4 in the lymph nodes of genetically predisposed allergic individuals, the activated T-cells 
differentiate into Th2 cells that produce large amounts of cytokines like IL-4, IL-5 and IL-13. 
Together, these cytokines induce the characteristic formation of allergen-specific IgE antibodies 
that selectively bind to high-affinity receptors expressed on mast cells in the tissue and basophilic 
granulocytes in the blood. The individual is now allergically sensitized, and upon a new encounter 
with the relevant pollen allergen, these molecules can cross-link the IgE antibodies and induce me-
diator release from the mast cells and basophils. The major mediator is histamine, which induces 
the characteristic set of SAR symptoms, including rhinoconjunctivitis, red and watery eyes, and 
respiratory complaints in the upper airways. Other characteristics in the allergically inflamed mu-
cosal tissue like hyperplasia and the activation of mast cells (IL-3 and IL-4) and eosinophils (IL-5) 
are also a consequence of the Th2-derived cytokines [44].
Under normal conditions in healthy individuals, the balance in the T-cell system between Th1 
and Th2 cells is maintained by the activity of regulatory T-cell populations, which are characte-
rized by their production of immunosuppressive cytokines like IL-10 and Transforming Growth 
Factor Beta (TGF-b). For allergies, it is now actively researched whether abnormalities in the num-
bers or functioning of such Treg populations are responsible for the aberrant and overactive Th2 
activity [45]. An overactive population of allergen-specific Th2-type cells is generally detected in 
the affected organs – the nose, eyes and upper respiratory system in SAR, but also in the peripheral 
blood mononuclear cell fraction (PBMC). Pollen from wind-pollinated grasses, trees and weeds 
and spores from fungi are the most common aeroallergens. Grass pollen is the most common cause 
of SAR. The highest levels of pollen in the atmosphere in the Netherlands are found in May, June 
and July [46].
The estimated prevalence of SAR in adults in several Western countries is 8 to 30.2 percent [47, 
48]. It is expected that both the prevalence and duration of SAR will increase, due to the current 
presence of more SAR-related tropical plants like Ambrosia in the Netherlands and longer periods 
with higher temperatures (which will result in longer and more intense blooming periods) due to 
the supposed climate changes. 
In 2008, an estimated 310,000 to 350,000 patients visiting a GP’s practice in the Netherlands 
were known to have SAR, which is less than 2 percent of the entire Dutch population. The pre-
valence of SAR patients is estimated to be much higher (4-15 times), as many SAR patients do 
not visit a GP or receive medication from their doctor. The estimated total yearly cost (of visits to 
doctors, prescriptions and visits to specialists) for all of the patients who did visit their GP in the 
Netherlands in 2008 was 7.16 million euro. The mean annual number of days that people could 
not work due to SAR symptoms is 1.88, which costs the economy an estimated 540 million euro 
per year [49].
The conventional treatment of choice is symptomatic treatment with antihistamines and/or lo-
cal corticosteroids. Immunotherapy is prescribed for a limited subpopulation of patients for whom 
treatments with antihistamines and/or local corticosteroids are insufficient and for whom immuno-
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therapy is useful [50].
Citrus/Cydonia compositum (comp.) is an anthroposophic medicine, which contains extracts of 
lemon (Citrus lemon) and quince (Cydonia oblongata) [51]. For more than eighty years, Citrus/Cy-
donia comp. has been prescribed, especially as a subcutaneous injection or a nasal spray for SAR 
patients. If the effect of this treatment in counteracting the clinical symptoms of SAR is demon-
strated in intervention studies, an immunological mechanism of action should also be provided.
1.4  The holism versus reductionism debate in relation to 
the fighting disease versus the health promotion ap-
proach
 In order to become scientifically accepted, it is necessary that, apart from providing evi-
dence of the safety, efficacy, effectiveness and cost-effectiveness of specific treatment approaches, 
the holistic concept and method of CAM is in accordance with current scientific theories. ‘One of 
the fundamental theoretical debates in science is the holism-reductionism debate that describes the 
fundamental approach to nature. 
This section summarizes the essence and current developments of the holism-reductionism 
debate, which are relevant for the acceptance of health promotion on conceptual grounds. 
1.4.1 The essence of the holism-reductionism debate
 A for this thesis relevant opposition from the philosophy of science, is that reductionism is 
usually set against holism or organicism. The statement ‘An organism is essentially nothing but a 
complex set of atoms and molecules’ lies at the heart of reductionism. At the opposite end of the 
scale, statements such as ‘You cannot just simply reduce an organism to a sack of molecules’ and 
‘The whole is greater than the sum of its composite parts’ essentially characterize holism [52]. 
The reductionist model assumes that all traits and other characteristics that are demonstrated by 
living organisms – their morphology, physiology, behavior, and ecology – can ultimately be fully 
and exclusively explained in terms of the physical and chemical molecules (DNA, proteins, etc.) 
of which the organisms are composed. Reductionism assumes that the laws, concepts and theories 
that are formulated for a higher level of organization in biology (for example, the level of the orga-
nism) can be explained by theories developed for a lower level of organization, such as the level of 
organs, tissue and cells. Ultimately, this means that all biological concepts, laws and theories can 
be reduced to physics and chemistry [52].
Three aspects must be distinguished in the reductionism versus holism debate: (1) ontological, 
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(2) epistemological, and (3) methodological aspects [52]. Ontological aspects concern the entities, 
things or substances that are assumed to make up reality (nature), what characteristics are attribu-
ted to these things or entities, and what relationships and functions can be assumed to exist between 
them. Epistemological aspects refer to one’s knowledge of reality, the way in which this knowledge 
is expressed in theories (amongst other things), and the logical connections between theories. In 
particular, these aspects deal with the links between theories, which are developed for different 
areas of reality or for different levels of organization. Methodological aspects concern the way in 
which knowledge is obtained and the basic principles, laws and strategies used in this process. This 
area is particularly related to the question of whether – in order to arrive at ‘correct’ knowledge or a 
true understanding of a certain level of organization (the level of the whole) – one should study the 
underlying lower levels of organizations (the composite parts and their interactions) or the higher 
level itself, or perhaps its relationship with other, even higher levels [52, 53].
1.4.1  The ontological level
 On the ontological level, the atomistic reductionist scientific reasoning remains practically 
unchanged. Several authors state that although science should pass beyond reductionism, there 
is no need for non-materialistic theories [54, 55]. This is one of the reasons (besides a lack of 
evidence on the safety and effectiveness/efficacy of treatment) that some of the core conceptual 
aspects of some integrative medicine streams (for example, the concepts of ‘Chi’ in Traditional 
Chinese Medicine or the ‘etheric level or organization’ in anthroposophic medicine) are not ac-
cepted. In those instances where solid evidence of the effectiveness and efficacy of IM treatments 
exists, reductionist hypotheses are presented to explain the effects. For example, acupuncture ef-
fects are hypothesized to be partly placebo effects and/or effects of the mechanical manipulation of 
the extracellular matrix [56, 57]. 
For those health-promoting IM streams that have a strong holistic ontological position, the 
current reductionist ontological position of science and conventional medicine is a major obstacle 
for acceptance. 
1.4.2  The epistemological level
 As many of the molecular biologists in the 1950s came from physics, it is not surprising 
that they extended its classical approach to the study of living organisms. Molecular biology, with 
some exceptions [58], has largely adopted a reductionist view to explain biological systems ac-
cording to the physical and chemical properties of their individual components. As Francis Crick 
(1916–2004) stated, “The ultimate aim of the modern movement in biology is to explain all biolo-
gy in terms of physics and chemistry” [59]. In due course, reductionism proved to be an extremely 
powerful analytical methodology, and it enabled scientists to analyze many basic molecular and 
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cellular processes. Complex systems exist at different levels of organization, which range from the 
subatomic realm to individual organisms to whole populations and beyond.
Nonetheless, biologists might be reaching the limits of this approach. Despite their best efforts, 
scientists are far from winning the war on cancer, owing largely to the complex nature of both the 
disease and the human organism. The human brain is a complex, nonlinear system that defies all 
reductionist and deterministic attempts to understand it [60, 61]. 
Throughout different fields of research, scientists increasingly question pure reductionist the-
ories to describe and explain the complexity of biological organizations [62-64]. Therefore, new 
theories originating from both the research fields of the biological complexity in organisms and 
the genome project demonstrate a shift from reductionist towards more holistic concepts. Three 
important holistic concepts are shortly described: systems biology, emergence, and epigenetics.
Systems biology
 Before the year 2000, only two articles contained the term ‘systems biology’ in either the 
title or the abstract in PubMed. In 2010, more than 2,500 entries had appeared with more than 
90 percent in the last five years, demonstrating the increasing interest of scientists in this topic 
[65]. “Its recent rapid resurgence at the turn of the century reflects the problems encountered in 
interpreting the sequencing of the genome and the failure of that immense achievement to provide 
rapid and direct solutions to major multi-factorial diseases” [66, p. 9]. Different than the genetic 
and microbiological approach, systems biology aims to describe, understand and explain from the 
complex biological systems that are studied: all levels of structural and functional complexity, 
explicitly including the supracellular domain [65]; their systems behavior or phenotypes; their 
networks with relationships that interact with the genome, the environment and the phenotype 
[66, 67]; their multifactorial processes involved in maintaining homeostasis and the breakdown of 
homeostasis within the system [68].
Epigenetics
 Recent insights into the mechanisms and molecular basis of gene regulation have led to the 
notion that organisms increase their complexity by altering the level of gene transcription without 
affecting their DNA base-pair sequence. This field of expertise is called epigenetics, and it refers 
to the fact that although all of the cells of an individual contain the same amount of DNA and the 
same sequences in the genome, different locations in the body instruct cells to perform different 
functions and even to react and modify their genetic potential as a way of reacting to their exposure 
to environmental factors [69]. Three main mechanisms are supposed to be responsible for epige-
netic changes: DNA methylation, histone tail modifications, and noncoding RNAs [70]. These 
induced changes are heritable and can exert their influence over several subsequent generations 
through perinatal programming, and can therefore explain why certain diseases run in families 
[71]. In addition, epigenetic mechanisms contribute to the explanation for neurophysiologic and 
psychological functioning. Therefore, they are hypothesized to provide a physiological basis for 
the perceptions of disease, health and welfare [72]. 
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Emergence
 The features of organs are not found in the cells and consciousness is not found in organs. 
In nature, higher organization levels ‘spontaneously’ arise from lower levels and, at the same time, 
influence these lower levels. For example, a cell that is transplanted from one tissue to another of-
ten changes its functions according to the new tissue [73]. “Emergent phenomena are said to arise 
out of and be sustained by more basic phenomena, while at the same time exerting a ‘top-down’ 
control, constraint or some other sort of influence upon those very sustaining processes” [74, p 
xi]. Throughout several concepts, emergent phenomena are usually characterized as irreducible, 
unpredictable or unexplainable, to require new concepts and to be holistic [75].   
The concept of emergence has received renewed attention in science in the past decades due to 
developments in a number of research programs within complexity theory, artificial life, physics, 
psychology, sociology, biology, philosophy of science and philosophy of mind [75].  
1.4.3  The methodological level
 The shift in conceptualization in biology and medicine toward a more holistic approach 
also affects the methodologies that are used to study the effects on the parts and organization levels 
of organisms. 
Systems organize themselves upwards towards larger wholes and downwards towards ever-
smaller parts. They include, for example, molecules, cells, organisms, populations (societies), and 
ecosystems. The upwards view describes holism or emergence (the complexity science view from 
different perspectives) [76], while the downwards view describes reductionism or analysis. Both 
views provide valid and valuable information, one being contextual, the other specific. Complex 
systems exist at different levels of self-organization that range from the subatomic realm to indivi-
dual organisms to whole populations and beyond. Despite their differences, they all share common 
features such as emergent properties, and randomness and order, which are both relevant to the 
behavior of overall systems. Complex systems exist on the edge of chaos, as they might exhibit 
regular and predictable behaviors [77]. However, they can also undergo sudden massive and sto-
chastic changes in response to what seem like minor modifications. The behavior of a cell, for 
example, is controlled both by the properties of its macromolecules and by the properties of the 
organ of which it is a part, as well as the surrounding extracellular matrix. The whole is not only 
more than the sum of its parts, but also less than the sum of its parts, because some properties of 
the parts can be inhibited by the organization of the whole. From an epistemological point of view, 
this means that it is not sufficient to analyze each individual part (reductionism), nor is it sufficient 
to analyze the system as a whole (holism). At the molecular level, several diseases have a common 
genetic or functional origin. Hence, a cooperative and collaborative approach to designing health 
interventions is required.
Three important shifts to a more holistic methodological approach can be distinguished. First 
of all, there is a shift from the emphasis on the methodological analysis of the parts only to me-
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thodologies that can study the spatiotemporal processes and the patterns between the parts, the 
processes (e.g. transcriptomics, metabolomics, genomics), the several levels of organization, and 
the epigenetic influences [78]. Secondly, there is increased methodological interest in a more per-
sonalized approach regarding diagnostics and treatment choices based on the unique phenotype of 
a specific organism [67]. Thirdly, there is growing interest in the integration on several levels: for 
example, the integration of data from several adjacent research fields (e.g. lifestyle research and 
genomics); the integration of methodological approaches (e.g. epidemiological studies and quali-
tative studies); and the integration of large amounts of data by means of new computational and 
mathematical tools [79]. 
In conclusion, it is evident that in the holism-reductionism debate in science, there is  a shift 
from a reductionist to more holistic approaches on the epistemological and the methodological 
levels, but not on the ontological level.
1.5  This thesis
 This thesis focuses on some of the conceptual, methodological and empirical issues in-
volved in further developing professional preventive and curative health promotion as a valid 
contribution to the continuation of innovation and cost reduction in medicine and healthcare. 
1.5.1  Objectives and outline of the thesis
Objectives
 The objectives of this thesis are:
1. To contribute to the development of a valid definition of health that can serve as an evi-
dence-based theoretical fundament for the preventive and curative approaches to health 
promotion in medicine and healthcare
2. To contribute to the development of systems biology-orientated measuring instruments that 
are able to monitor health-related changes (in, for example, immunology) on the system 
level
3. To provide scientific evidence for the curative health-promoting effects and safety of the 
anthroposophic drug Citrus/Cydonia comp. in the treatment of SAR
4. To provide scientific evidence for the cost-effectiveness of integrative medicine in the Ne-
therlands
Outline
 This thesis contains three parts. The first part is theoretical, in which both the definition of 
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health and the fundamental concepts of holism and reductionism are examined in order to provide 
a scientific basis for a holistic, preventive and curative health promotion approach in medicine and 
healthcare. The second part presents the methodology that will be used to examine the relevant 
immunological parameters of patients with SAR in a more systems-biologic (holistic) manner. The 
third part describes the acquired evidence based on the results of a series of empirical outcome stu-
dies on the clinical and immunological effects and safety of the anthroposophic (curative) health-
promoting treatment with Citrus/Cydonia comp. for SAR. 
Part 1. Epistemology of health promotion
 In Chapter 2, the literature on the definitions of health and health promotion is reviewed. 
It is hypothesized that health can be understood as the continuous activity of the inborn and/or 
acquired self-regulation skills of humans on the physical/physiological, mental and social levels, 
that is responsible for maintaining the integrity and organizing of material and cognitive elements 
in time, space and function. Health promotion supports and enables patients to actively contribute 
to their own health and disease status towards an optimal functioning of the higher levels of orga-
nizing among each other and in the regulation of the lower levels. In Chapter 3, the fundamental 
scientific discussion of holism versus reductionism is summarized. In this chapter, several scienti-
fic arguments are presented against the current reductionist point of view. This provides a scientific 
opening for a more holistic or systems biology-orientated concept of health. The Goethean phe-
nomenologic method is introduced as a qualitative methodology that enables researchers to attain 
knowledge of the structures or patterns at higher levels of organization in organisms.
Part 2. Methodology of measuring health promotion
 Chapter 4 describes a new systems biology-orientated methodological approach for de-
veloping immunological biomarkers in SAR (hay fever) research. These biomarkers are pattern 
variables that are computed by means of permuted stepwise regression analyses and based on the 
interactions between the relevant immunological parts of the subsystem of the immune system that 
is involved in SAR. It is argued that the computed pattern variables will demonstrate larger cor-
rect values (CVs) than the separate cytokines regarding the classification of cytokine samples in 
baseline and post-baseline.
Part 3. Empirical evidence of the efficacy, effectiveness, cost-effectiveness and safety 
of curative health promotion
 Chapter 5 describes the results of a survey of the experiences of Dutch doctors with the 
anthroposophic health-promoting treatment for SAR. In Chapters 6 and 7, two in vitro studies 
on the effect of the anthroposophic drug Citrus/Cydonia comp. on the relevant peripheral blood 
monocyte cells and functions of SAR patients and healthy persons are described. Chapters 8 and 
9 describe the results of two intervention studies on the health-promoting effects of the anthropo-
sophic drug Citrus/Cydonia comp. The first (pilot) study is a small cohort study in which the effect 
of Citrus/Cydonia comp. on the severity of SAR symptoms is studied. The second study describes 
Thesis Erik W. Baars   23
1
the immunological and clinical results of a RCT comparing two routes of administration of Citrus/
Cydonia comp., the nasal spray versus the subcutaneous injection route of administration. Chapter 
10 presents the results of a systematic evaluation of the reported adverse drug reactions (ADRs) 
recorded in the pharmacovigilance databases of eight German anthroposophic and homeopathic 
manufacturers covering the period of 2000 to 2009, providing relevant data for this thesis on the 
safety of Citrus/Cydonia comp. subcutaneous injections. 
General Discussion
 The final chapter of this thesis (Chapter 11, General Discussion), after presenting the main 
findings, discusses the importance of the author’s findings regarding the definition of health pro-
motion and the future of professional health promotion practices in the field of healthcare. It re-
flects on the presented systems biology-orientated methodologies, and discusses the implications 
of the empirical and evidence-based foundations of the effective treatment of hay fever with Citrus/
Cydonia comp. In addition, the results of a cost-effectiveness study (Appendix) are described, 
demonstrating the possible contribution of integrative medicine to promoting health and reducing 
healthcare costs. Finally, a reflection on the scientific status of anthroposophic medicine in light of 
current developments in the areas of holistic concepts, holistic methodologies and health promo-
tion is presented. Furthermore, future perspectives are described concerning the implementation of 
new research lines, the further development of professional preventive and curative health promo-
tion as a contribution to the further innovation of medicine and healthcare, and the investment in 
CAM/IM/AM research.
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 Abstract 
 The last decades the interest in health promotion in society and healthcare has increased 
enormously. Health promotion supplements the main (western) biomedical fighting disease appro-
ach. To further professionalize the health promotion approach, definitions of health and health pro-
motion as well as measurement instruments must be validated, and preventive and curative health 
promotion interventions should be tested for quality, efficacy, effectiveness and cost-effectiveness. 
In this article the WHO definition of health (1948) is criticized, since it is primarily oriented at end 
states and does not clarify the mechanisms responsible for reaching and maintaining these states. 
Therefore, it does not provide sufficient conceptual tools to innovate and professionalize health 
promotion activities. In order to overcome these shortcomings, the WHO and current health defi-
nitions are analyzed and revised into the definition of ‘health by self-regulation’. The definition is 
preliminarily validated by means of analyzing (1) its internal consistency, (2) its accordance with 
other scientific definitions (e.g., of epigenetics, systems biology, emergence and self-organisation) 
and (3) its accordance with empirical facts. Key features of the definition are the central position 
of dynamic and continuous self-regulation as a key organismal function and the holistic, system 
biological approach. We discuss theoretical and practical implications of the revised definition.
Keywords: definition, health, health promotion, self-regulation, holism
 
Thesis Erik W. Baars   33
22.1  Introduction
 All approximately 1027 molecules of the human body are renewed in a period of two 
weeks. In one year, approximately 97 percent of all cells of the human body have been replaced 
and, in most instances, perfectly (Bos, 2008). Every day, smaller and larger physical injuries and 
wounds in the human body are ‘spontaneously’ healed. Recent research has demonstrated an in-
verse association between childhood measles and allergic symptoms and diagnoses later in life 
(Rosenlund et al., 2009). Some cancer patients experience spontaneous tumor regression, some-
times for a few years, and sometimes for (almost) the rest of their lives (Rijke, 2001; Turner 2010). 
Others are cured or improve after severe feverish infections (Hobohm, 2005; Turner 2010). Our 
immune system has evolved to counteract - in an often-unnoticed way - assaults on the body by 
non-self infectious organisms or altered cancerous cells, either of which may compromise an in-
dividual’s health. Normally these assaults are successfully repelled and disease is prevented, and 
this resistance is due to both basic and sophisticated immune responses. Throughout history peo-
ple have encountered terrible situations like war, rape, and torture and some persons were able to 
remain healthy (Antonovsky, 1979, 1986). What makes the difference? Or more precisely: What 
is health, how does the organism keep people continuously healthy, and what is a healing process? 
How do disease and health relate to each other? If an answer to these questions is found: How can 
one use (the knowledge of) these sources to promote health in a professional way, both preventive 
and curative?
 A fighting disease approach
 Modern Western medicine, with the ‘fighting disease’ approach as its most important 
concept, has achieved enormous success in the last 150 years. In summary, the ‘fighting disease’ 
approach involves the fighting of disease-related organisms, cells and functions in the body; the 
reduction of the symptoms of disease; and the manipulation and/or substitution of non-functioning 
or dysfunctional parts and processes of the body by means of external therapeutic resources. 
Scientists, pharmaceutical industries, doctors and therapists have developed many, often suc-
cessful, strategies to fight diseases and diminish symptoms. The development of all kinds of “anti-
drugs,” e.g. antibiotics, antivirals, anti-inflammatories, and chemotherapeutics, has saved many 
lives by fighting the presence of disease-causing bacteria or viruses in the human organism or by 
fighting the abnormal cell growth of cancers with great success. The development of numerous ty-
pes of antidepressants, anxiolytics, and antipsychotics has resulted in a major improvement of the 
quality of life of psychiatric patients by reducing their psychological symptoms. In addition, heal-
thcare is increasingly able to replace body parts (e.g., hips or knees) and/ or body functions (e.g., 
insulin and thyroxin function, or the heart-lung function during surgical procedures) by means of 
manipulation and/or substitution. It is expected that the development of this approach will conti-
nue, and that it will continue to result in important medical innovations.
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 A growing interest in health promotion
 In the last decades there has also been a growing interest in the supplemental approach of 
health promotion, in both healthcare and society more broadly. Here is a definition: 
Health promotion is the process of enabling individuals, groups or societies to increase 
control over, and to improve, their physical, mental, social and spiritual health. This could 
be reached by creating environments and societies characterized of clear structures and 
empowering environments where people are able to identify their internal and external 
resources, use and reuse them to realize aspirations, to satisfy needs, to perceive meaning-
fulness and to change or cope with the environment in a health promoting manner (Eriksson 
& Lindström, 2007).
The growing interest in health promotion is reflected in the increased use of  terms such as ‘em-
powerment,’ ‘self-reliance,’ ‘responsibility,’ ‘autonomy of patients,’ and ‘shared decision-making’. 
Patients increasingly assume the role of the competent patient who wants to steer his own therapy 
process (Bopp et al., 2005). He uses healthcare as part of his solution strategy (Van der Laan, 2006). 
Although in the last decades much progress has been achieved, health promotion has a long way 
to go if it is to reach the level of development achieved by the fighting disease approach. Central 
questions that have to be answered are: What are valid definitions of health and health promotion 
that provide a solid fundament for health promotion practice?; What are valid methods and mea-
suring instruments to monitor changes in health status?; What is the quality, efficacy, effective-
ness and cost-effectiveness of preventative and curative health promotion for specific indications?; 
What is the surplus value of health promotion compared to fighting disease?; How does one opti-
mally integrate a fighting disease and health promotion approach in specific indications?
In this article we focus on the first question; we revise the 1948 WHO definition of health into a 
more valid definition of health that is more in line with current conceptualizations of health aspects 
and that is better able to support preventive and curative health promotion activities. We argue that 
the WHO definition demonstrates several shortcomings: (1) it lacks clarification of the relation-
ships between its positive subdomains (physical, mental and social health); (2) it lacks clarification 
of the relationships between its positive and negative subdomains (health and disease); and (3) it 
is not in accordance with the current empirical evidence. In addition, the WHO definition does not 
describe the (tested) mechanisms for remaining or becoming healthy, which are necessary for rati-
onal preventive and curative health promotion (Campaner, 2011). It is therefore an inadequate tool 
for supporting the innovation and professionalisation of health promotion activities.
This article contains four sections. The first section describes the 1948 WHO definition of 
health, as well its conceptual shortcomings. We also provide an overview of some of the most 
important health definitions that have been developed since then, and some of the most important 
philosophical positions towards a definition of health. The second section focuses on the clarifica-
tion of the relationships between the positive subdomains of the WHO definition (physical, mental 
and social health). The third section attempts to clarify aspects of the relationships between the po-
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2sitive and negative subdomains (health and disease). The fourth and final section presents a revised health definition for the purpose of health promotion, based on the results described in the previous 
section. Central in this definition are the systems ability or skill of self-regulation, and the adap-
tive use and maintenance of this skill across changing personal and environmental conditions of 
spatial, temporal and/or functional structures on the physical, mental and social level. We provide 
both probabalistic and mechanistic evidence in support of this definition: we demonstrate that there 
is a strong association between high levels of self-regulation and health, and a strong association 
between low levels of self-regulation and disease (probabalistic evidence), and we both describe a 
model of the different components that interact in maintaining and becoming healthy, and provide 
data on criteria of causality (e.g. temporal relation, biological plausibility, dose-response relation) 
(mechanistic evidence). Finally we examine two examples of the health promotion approach that 
are in line with the revised health definition: the prevention and treatment of seasonal allergic rhi-
nitis (hay fever) and the phase 1 treatment of chronic traumatization. In conclusion we discuss the 
value of the revised health definition, and make future research recommendation for its validation. 
2.2  The WHO health definition of 1948, current health 
definitions and their main shortcomings
2.2.1  The WHO health definition of 1948 
 The World Health Organization (WHO) defined health in 1948 as ‘a state of complete 
physical, mental and social well-being and not merely the absence of disease or infirmity’. In the 
past 63 years, it has become clear that the WHO definition is inadequate. There are four main pro-
blems with this health definition (Franke, 2008; Ten Have, 1987). First, it is unclear what the mu-
tual relationships are between the positive domains of the definition. How do physical, mental and 
social well-being relate to each other, and what are their mutual relationships and dependencies? 
Second, the relationship between the positive domains (a state of complete physical, mental and 
social well-being) and the negative domain (the absence of disease or infirmity) of the definition 
is unclear: what is the relationship between health and disease according to this definition? Third, 
the WHO definition of 1948 is not in accordance with the newer definitions of health (aspects) that 
have been developed since then and empirical facts. The fourth and last point is that the definition 
is not internally consistent, since it the definition appears to be open for multiple interpretations. 
In addition the definition is inadequate for the purposes of this paper, because it does not provide 
conceptual tools for preventive and curative health promotion.
We attempt to achieve an improvement of the WHO health concept by examining newer con-
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ceptual approaches to health, and by clarifying their possible contributions to solving the four 
categories of problems that the WHO concept presents. From this, a revised and improved health 
definition can be formulated as a basis for professional health promotion.
2.2.2  Current health and related disease definitions and their main short-
comings
 There are many different definitions and accounts of health (and disease) in the literature, 
which vary widely in style and approach. 
One type of approach is the ‘per exclusionem’ account, where health is the absence of disease 
(and vice versa). The first health definition can be logically deduced from a pragmatic definition 
of disease: disease as that which doctors and therapists treat. Health is then the absence of that 
which doctors and therapists treat (Glas, 2008). The next health definition can be deduced from 
the definition of disease as subjective suffering or a subjective complaint (Glas, 2008). The health 
definition is then the absence of subjective suffering or the absence of a subjective complaint. 
The biomedical notion of health is the absence of disease, in terms of either the expression of the 
disease entity or the conditions of the diseased state. The biomedical definition is a reductionist, 
mechanistic one. It represents a default material state of the body responsible for both physical 
and mental health. The related disease concept is disease as a lesion, a pathological or traumatic 
discontinuity of tissue or loss of function of a part. The fourth ‘per exclusionem’ definition is the 
statistical health definition, based on the conditions and functioning of the human body that is 
most common in a specific population. Boorse (1987, 1997), for example, defines health as a nor-
mal function of a part or process within members of the reference class. It is a statistically typical 
contribution by it to their individual survival and reproduction. Disease or dysfunction would then 
be the conditions and functioning of the human body that is least present in a specific population. 
The first problem with these ‘per exclusionem’ definitions is that there are several examples where, 
according to the health definition, a formal healthy state is actually a diseased state. For example, pa-
tients who are afraid of doctors or therapists and therefore do not attend healthcare institutions would 
be healthy according to the first definition. Patients with some types of cancer in the first stage or a 
bipolar disorder would not suffer from complaints and therefore would be healthy according to the 
second definition. A second conceptual problem is that the ‘per exclusionem’ concepts are purely 
descriptive, and do not provide insights into the mechanisms of maintaining health. With regard to the 
statistical approach, examples such as superior length or superior intelligence demonstrate that not all 
statistically deviant conditions are disease states and adverse. In addition, Schwartz (2007) describes 
the problem of the common disease (a disease that would be common in a population would not be 
classified as disease) and the problem of healthy populations that arise in any case where a trait’s 
lowest level of functioning in some reference class is not low enough to be dysfunctional. Kingma 
(2010) criticizes Boorse’s account of normal species function, since it fails to distinguish between 
physiological and pathological responses that are due to a specific environmental factor.
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2Two biological or environmental definitions of health are the good functioning of the body in its adaptation to the environment and health as a reserve or hygiogenetic capacity (Heusser, 1999), the 
physical ability or the self-healing capacity of the organism to, for example, recover quickly from 
a strenuous exercise or operation. Disease is then the poor functioning of the body in its adaptation 
to the environment and the lack of ability to recover quickly. The main conceptual problem with 
these biological definitions is that they are, again, purely descriptive, not presenting any insight 
into the mechanisms of health. Secondly, not all diseases have demonstrated material lesions (e.g., 
back problems). 
On the basis of their review, Westerhof and Bohlmeijer (2010) describe the triad of mental 
health: happiness (the experience of positive emotions and satisfaction with life that is experienced 
as emotional well-being), self-realization (activities that match the person’s goals and desires and 
the person’s skills and competencies that contribute to the experience of psychological well-being), 
and societal integration (that is experienced as social well-being). Regarding the well-being defini-
tion, Ryff and Singer (1998) describe four essential features of positive health: (a) leading a life of 
purpose, embodied by projects and pursuits that give potential; (b) having a quality connection to 
others, such as having warm, trusting and loving interpersonal relations and a sense of belonging-
ness; (c) possessing self-regard, characterized by such qualities as self-acceptance and self-respect; 
and (d) experience mastery, such as feelings of efficiency and control (Marcum, 2008). 
Salutogenesis (‘the origin of health’) and resilience are stress resource oriented definitions. Sa-
lutogenesis focuses on resources, and maintaining and improving the movement towards health. It 
gives the answer as to why people, despite stressful situations and hardships, remain well. It is the op-
posite of the pathogenic concept, where the focus is on the obstacles and deficits. Two core concepts 
are essential in the salutogenic theory (Antonovsky, 1979, 1987): the sense of coherence (SOC) and 
generalized resistance resources (GRRs). The ability to comprehend the whole of a stressful situation 
and the capacity to use the resources available is called sense of coherence (SOC). SOC reflects a 
person’s view of life and his/her capacity to respond to stressful situations. It is a global orientation 
to view life as structured, manageable, and meaningful or coherent. It is a personal way of thinking, 
being, and acting, with an inner trust, which leads people to identify, benefit, use, and re-use the 
resources at their disposal. Three elements, comprehensibility, manageability, and meaningfulness, 
form the SOC. The other key factors are the resources available to make possible such a movement 
towards health. The GRRs can be found within people as resources bound to their person and capa-
city, but also to their immediate and distant environment as both material and non-material qualities 
from the person to the entire society. The key factor is not what is available, but to be able to use and 
re-use the resources for the intended purpose. The GRRs provide a person with sets of meaningful 
and coherent life experiences thanks to the resources at the person’s disposal (http://www.salutogene-
sis.fi/eng/Salutogenesis.5.html). The concept of resilience is clearly related to the salutogenesis con-
cept and stems from psychology (Luthar, 2006). It is a way of explaining how people can manage life 
and live well in spite of adverse situations. As a scientific concept, it was first developed for children 
and young people and has later been expanded into adulthood. 
An often-used sociological definition (Parsons, 1981) is: health is the state of optimum capacity 
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of an individual for the effective performance of the roles and tasks for which he has been soci-
alized. Social inequalities are related to health differences. Mortality and morbidity patterns are 
related to social factors such as gender, social class, race and age (Nettleton, 2006). In his review, 
Keyes (1998) developed a framework with five dimensions of social well-being: social acceptance 
(a positive attitude towards people), social actualization (participating and believing that society 
develops itself in a positive way, believing that society realizes possibilities), social contribution 
(having the feeling that one has to offer something worthwhile to society; thinking that daily ac-
tivities are appreciated by society), social coherence (to see a social world that is understandable, 
logical and predictable; taking care of and being interested in society and the surroundings), and 
social integration (feeling a part of society; believing that you belong to, are supported by and share 
things with the society). 
2.2.3  Main philosophical approaches to defining health and disease
 Ereshefsky (2009) distinguishes three main philosophical approaches to health and disease: 
(1) naturalism, (2) normativism and (3) hybrid theories. 
Naturalists base their definitions on scientific theories. They attempt to highlight what is biologi-
cally natural and normal for humans. With regard to health they focus on physiological and psycholo-
gical states (‘is an organ or system normal or properly functioning?’) in terms of survival and repro-
duction. The term ‘disease’ is used to express a derangement of underlying physical mechanisms that 
can be scientifically investigated and clinically diagnosed. One can distinguish between the ontologi-
cal, physiological, evolutionary and genetic disease conceptions. The ontological disease conception 
is concerned with the disease causing entities (e.g., viruses). The physiological disease conception 
is concerned with the deviations from the functional norms (e.g., hypertension). The evolutionary 
disease conception is concerned with maladaptation, a lack of or inadequate defense in response to a 
challenge. The genetic disease conception involves the explanation of disease in terms of mutation in 
or the absence of genetic material (e.g., sickle cell anemia) (Marcum, 2008). 
Some of the main shortcomings of naturalism are that (1) specifications of normal states of 
organisms are not described in science (taxonomy, genetics, physiology) and the current (e.g. phy-
siological) descriptions may not be the statistically normal ones; (2) humans have several goals 
in life and some of them have nothing to do with biological fitness (survival and reproduction); 
and (3) it can be challenged that biological fitness is the goal of organisms, taking into account 
the states that biologists describe that have nothing to with this (e.g., eating for the sake of eating, 
pleasurable sex) (Ereshefsky, 2009).  
Normativists claim that our use of health and disease reflects our values towards desirable 
(health) and undesirables (disease) states. They focus on whether a psychological or physiological 
state is valued or disvalued. 
Hybrid theorists consider both components from naturalists and normativists and regard disease 
a state that is both dysfunctional and disvalued. The main problem of normativism is that it does 
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2not capture the common view that there is more to deciding whether a state is a disease than nor-mative considerations.
Finally, within the humanistic approach the term ‘illness’ is used. It includes the patient’s suf-
fering and existential concerns as part of the illness experience. This is an additional part (next to 
the diseased state) that must also be the object of therapy.  
2.2.4  Homeostasis, allostasis and heterostasis
 Next to the presented differences, there is also overlap in aspects of the health definition. 
First of all, health as a homeostatic state is somewhat explicitly a part of all health definitions 
(Franke, 2008). This is one of the oldest and lasting definitions of health and refers to the stability 
of physiological systems that maintain life, used here to apply strictly to a limited number of sys-
tems such as pH, body temperature, glucose levels, and oxygen tension; they are truly essential 
for life and are therefore maintained within a range optimal for the current life history stage (Pal, 
2008). Secondly is health as allostasis, which refers to maintaining stability through change, as a 
fundamental process through which organisms actively adjust to both predictable and unpredic-
table events (McEwan & Winfield, 2002). Thirdly, the definition of heterostasis or flexibility is a 
key element in several approaches. It refers to the situation that one is healthy when one is able to 
encounter a problem and actively overcome it. Whereas homeostasis refers to returning to the old 
situation or the old state of equilibirum, heterostasis refers to a further dynamic development of 
skills to overcome these types of health-related situations (Franke, 2008). Development of skills 
can be found on both the biological level (e.g., immunological learning and physical training pro-
cesses) and the psychosocial level (e.g., the development of self-regulating skills such as emotion 
regulation or problem solving). 
2.2.5  First step towards the integration of several health definitions
 As a first step towards the integration of the described health definitions into one valid 
health definition, the several approaches are now clustered content-wise into domains and subdo-
mains. The aim is to distinguish (like in the WHO health definition of 1948) between the physical, 
mental and social domains. 
Regarding physical health, one can distinguish five subdomains. The ability to adapt to exter-
nal challenges refers to the proper functioning of several functions of the organism in response to 
several external challenges (e.g., temperature changes, bacteria). The ability to recover from inner 
and outer influences, stress, wounds, etcetera refers to recovery in the range from executing a 
function (e.g., membrane recovery of the cell, tissue recovery after physical exercise or sleep after 
being tired) up to recovering from damaged parts of the organism (e.g., infections or wounds). Sub-
jectively feeling physically well refers to the feelings of being fit, without complaints and having 
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energy. The resources to become biological healthy refer to the physical elements that are required 
to perform proper biological adaptation and recovery (e.g., having no gene dysfunctions). Finally, 
at this moment, since the exact relationship between health and disease is not clarified, the last 
subdomain is the absence of disease.
Concerning mental health, one can distinguish four subdomains. Happiness that is experienced 
by the individual as emotional well-being is the first subdomain. Happiness is the result of positive 
emotions and a high quality of life that is associated with positive life experiences. Self-realization 
that is experienced by the individual as psychological well-being is the second subdomain. It is the 
result of having a purpose in life (meaning in life), the presence of self-acceptance and self-respect, 
the feeling of mastery in life, and a sense of coherence. The resources to become mentally healthy 
refer to the psychosocial elements that are required to become and remain happy and to realize one-
self. Finally, since the exact relationship between health and disease is not clarified at this moment, 
the fourth subdomain is the absence of disease.
Regarding social health, one can distinguish seven subdomains. Five subdomains represent a 
person with a positive view on other people and society, who feels at home in society and who par-
ticipates in it: social acceptance, social actualization, social contribution, social cohesion, social 
integration/ quality connections with others. The sixth subdomain, resources to become socially 
healthy refers to the elements that are required to effectively perform the roles and tasks for which 
an individual has been socialized. The last subdomain, since the exact relationship between health 
and disease is currently not clear, is the absence of disease.
A final important feature of the health definition is that the abilities or skills on the physical 
(adaption and recovery), mental (e.g., self-regulating problem solving skills) and social level (e.g., 
social actualization skills) can be developed by learning from experiences (heterostasis) and are 
able to deal with unexpected, new challenges (allostasis). By doing so, individuals are able to take 
care of the maintenance of the spatial, temporal and functional structures of biological, mental and 
social functioning (homeostasis).
2.3  The first problem for the WHO health definition: the 
unclarity of the relationships between the positive 
domains 
 An improvement of the health definition can be achieved if one gains more insight into 
the relationship between the positive health domains. Therefore, the question to be answered in this 
paragraph is: What is the contribution of these newer approaches to understanding the relationship 
between the positive health domains? How do (the subdomains of) physical, mental and social 
health relate to each other?
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22.3.1  The relationships between mental, emotional and physical health
 Psycho-immunological research shows that there is a two-way dialogue between the brain 
and the immune system (Zachariae, 2009). Research of the last decades demonstrates that psycholo-
gical stressors and negative emotions such as depression and anxiety result in an increased production 
of proinflammatory cytokines (Lutgendorf et al., 1999; Segerstrom & Miller, 2004). These cytokines 
play a central role in age-related or degenerative diseases such as cardiovascular disease (the leading 
cause of death), type II diabetes, arthritis, osteoporosis, Alzheimer’s disease, periodontal disease, 
some cancers, and frailty and functional decline (Kiecolt -Glaser, McGuire, Robles, & Glaser, 2002). 
Additionally, stress and depression contribute to a greater risk of infection, prolonged infectious epi-
sodes, and delayed wound healing (Kiecolt-Glaser & Glaser, 2005). These finding are in line with the 
findings that increase in conscious activities in evolution associated with an increase of the breaking 
down of the vital, anabolic processes in the organism (Bos, 2008). 
Idler and Benyamini (1997) concluded, based on a review of 27 studies, that there is a strong 
correlation between the subjective assessment of the person’s own health and predicted mortality 
in the short and long term. Pressman and Cohen (2005) concluded, based on a review of the studies 
on the relationship between positive affect and physical health, that positive affects lead to physical 
health by two pathways: directly (by means of the connected neurophysiological responses) and 
via the indirect route (persons with more positive affects exhibit better health behaviors) (Wester-
hof & Bohlmeijer, 2010). Chida and Steptoe (2008) found in a retrospective study, controlling for 
negative affects, a relationship between emotional well-being and mortality.
The review of the SOC research shows that the relationship between SOC and physical health 
is complex and not as strong as the relationship between SOC and mental health (Eriksson, 2007). 
More research in this area is necessary. Nevertheless, several findings demonstrate a clear relation-
ship between SOC and (aspects of) physical health. In a study of patients with rheumatoid arthritis 
(Callahan & Pincus, 1995), low but significant correlations between SOC and pain, and general 
health status and ADL status (r = 0.10 and r = 0.37) were found. Two studies found strong correlati-
ons between high SOC scores with low levels of HbA1c, demonstrating the stability of blood sugar 
over time (Sanden-Eriksson, 2000; Williams et al., 2004). Higher correlations (up to r = 0.50) were 
found in studies where psychosomatic characteristics were measured as sleep, appetite, headache, 
etc. (Gebert et al., 1997; Rena et al., 1996). Surtees et al. (2003) performed a cross-sectional study 
on a population of 20,579 people. A strong SOC was associated with a 30 percent reduction in 
mortality for all causes as a whole, cardiovascular disease, and cancer in men (not women), regar-
dless of social class, age, sex and the presence of chronic diseases. Krause and Shaw (2002) also 
found a positive association between personal ‘meaning’ and better health in old age. Combining 
the results of these two review studies provides indirect evidence for a relationship between SOC, 
subjectively rated health and predicted mortality in the short and long term (Eriksson, 2007; Idler 
& Benyamini, 1997).
In the study of the relationship between psyche and cancer Boesen and Johansen (2008) conclude 
that the hypothesis that psychotherapy enhances survival should be abandoned in the light of the 
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latest replication studies, which show null results for improved survival after psychotherapy. 
There is a growing amount of literature suggesting that exercise, physical activity and physical 
activity interventions have beneficial effects across several physical and mental health outcomes (Pe-
nedo & Dahn, 2005). The relationship between chronic somatic diseases and quality of life and men-
tal health is substantially researched. Comorbid conditions are associated with a poorer health-related 
quality of life. Increased age is associated with poorer physical health and better mental health. There 
is evidence that while physical function could be severely and negatively affected by both chronic 
disease and advanced age, mental health remains relatively high and stable (Hopman et al., 2009).
Based on the described results, one can conclude that there are clear indications that the pre-
sence of mental and emotional well-being can have a positive effect on aspects of physical well-
being, but not on cancer. Physical activity can have a positive effect on mental well-being, whereas 
chronic disease (together with advanced age) do not seem to affect mental health. It is clear, howe-
ver, that complex relationships exist and that more research is needed. Nevertheless we conclude 
that the three positive domains are separate elements of health that seem to influence each other.
2.4 The second problem for the WHO health definition: 
The relationship between health and disease
 The WHO definition and ‘per exclusionem’ definitions of health do not provide insights 
in the relationships between health and disease. An improvement of the health definition can be 
achieved if one gains more insight into the relationship between the health and disease domains. 
Therefore, the questions that need to be answered are: Is health the absence of disease or is it sim-
ply the opposite, and is disease the absence of health? What are the relationships between these two 
domains? This section explores the literature on this topic.
2.4.1 The relationship between mental health and disease
 Focus on self-regulation
 Throughout their life, people are in constant interaction with ‘the world’. They think 
about the things they experience, emotions come and go, and they take action in response to their 
thoughts and emotions. Often, they ignore experiences and continue with what they are doing. In 
some cases, something happens such as finding a life partner or being attacked that has a major 
impact on the rest of a person’s life. Since the disappearance of the ‘teapot cultures’ (e.g., the 
religious streams as Catholicism) that formed people’s values  and behaviors top-down, to a large 
extent, at the beginning of the 20th century (Kunneman, 1996), Western people increasingly rely 
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2on self-determination of their own values  and what significance gives them life, and self-regulation of their inner and outer life (Van Dijk, 2007). Developing self-regulatory skills to make sense of 
the things they experience (Klein Wassink, 1999) and to deal adequately with what is (from the 
outside and inside) coming at them (Boekaerts et al., 2000; Rijke, 1991) is an important task in 
life. The approach to psychosocial health as the dynamic result of the continued deployment of 
adequate self-regulatory (intellectual) skills (e.g., attention regulation, emotion regulation, social 
and problem-solving skills) implies that the absence or reduced presence of these skills in a chal-
lenging context in which the skills are needed to defend the organism or the person in response to 
a challenge might result in a form of disease. Other aetiologies (e.g., genetic hereditary disease as 
a result of insufficient genetic material) are naturally also conceivable.
 Disease due to the lack or inadequacy of self-regulatory skills
 Westerhof and Bohlmeijer (2010, p. 73, translated in English) concluded in their study 
on mental health: “The good life requires constant attention and awareness in making meaningful 
choices and whether these choices are consistent with intrinsic needs, goals and behavior regula-
tion.” People respond differently to threatening situations. Siebert (1994) examined the personality 
traits of people who remained healthy after confronting various types of very dangerous and poten-
tially traumatizing circumstances. His study resulted in a cluster of characteristics of the so-called 
‘survivor personality’, in which psycho-social self-regulation was central. In addition, Sheehy 
(1982) conducted a questionnaire survey among 60,000 Americans that examined the well-being 
of people according to the WHO definition of health. Then she extensively interviewed those who 
scored highest on the questionnaire and some of those who scored lowest, following these indivi-
duals for several years. The end result of the study was that there were no differences in the number 
of life events and shocking events between the two groups. However, what did differ between the 
two groups was that those who scored high began to handle trauma and crisis in a different way in 
the course of their lives, sometimes at a younger age and sometimes later in life. Certain qualities 
of these people who had a high well-being appeared to play an important role. Some of the qualities 
were courage, willingness to take risks, creativity, flexibility, capacity for intimacy and friendship, 
humor, energy, the belief that life has meaning, and the ability to be an example for people in crisis.
Conversely, there is the study of the personality characteristics that are risk factors for develo-
ping post-traumatic disorder, a psychiatric disorder caused by a potentially traumatic event. Youn-
ger age, higher levels of experienced threat, shyness, an inhibited personality, insecurity about 
one’s identity, avoiding leadership roles, coping with emotional suppression and wishful thinking, 
and a greater external locus of control are the main personality characteristics that increase the risk 
of acute dissociative reactions and the subsequent development of post-traumatic stress disorder 
(PTSD) (Marmar et al., 1994). There is a correlation between avoidant coping styles and the level 
of PTSD symptomatology. Problem-focused coping gives less chance of developing PTSD (Sutker 
et al, 1995). Trait anxiety and emotion-focused coping were the variables most predictive of stress-
related variables (Zeidner et al., 1993). McNally et al. (1995) found that the lower the IQ of a per-
son, the more severe the PTSD symptoms, after adjusting for combat exposure. Beere (1995) also 
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found that people who dissociate rapidly are more rigid with respect to changes in the environment, 
have less daily regularity and less emotional reaction in response to errors or conflicts at work, as 
well as in response to conflicts, errors, or negative assessments in relationships with others. At the 
end of their review, Foa et al. (1992) describe that the most important conclusion from their study is 
that in order to trigger PTSD symptoms, a stressor must not only be experienced as a potential thre-
at to life, but it must also be experienced as uncontrollable and unpredictable. In addition, a lack of 
self-regulatory skills in chronically traumatized patients is associated with a poor stabilization and 
symptom reduction-oriented treatment result (Baars et al., 2011). On the other hand, preparedness 
for torture (finding meaning), social and family support, and religious beliefs may all be protective 
against PTSD following war trauma and torture (Johnson & Thompson, 2006; Van Dijk, 1995).
The summarized literature is theoretically in accordance with the hypothesis that a form of 
psychological disease may be caused by a lack of skills to give meaning in life (MIL) and a lack of 
well-developed self-regulatory skills in the presence of specific stressors.
2.4.2  The relationship between physical health and disease
 Before discussing the relationship between physical health and disease, this paper will 
explore some aspects of physical health that will provide important ‘substance’ for the analysis of 
this relationship.
  Focus on self-regulation
 One hardly ever realizes that one’s organism is a dynamic system that, among other things, 
is characterized by constant degradation and (re)construction processes. For example, the epider-
mis is replaced every few weeks throughout one’s life, the cells of the small intestine are replaced 
every three days, and every cell is constantly in a process of renovation, demolition and construc-
tion (Rijke, 2001). Within 14 days, all 1027 molecules of the human body are replaced. Within one 
year, ninety-seven percent of all human cells are renewed (Bos, 2008). When tissues are damaged, 
there is (in most instances) a quick degradation and reconstruction of molecules, cells and tissue. 
In addition, from conception to adulthood, the organism grows from of a fusion of two cells (sperm 
and ovum) up to 1014 cells. In this period, all the organs are built and grow until probably the 25th 
year of life, while the described processes of constant renewal, demolition and construction of cells 
continue. Taken together, it is evident that a form of highly complex, continuous self-organization 
must be present for the proper functioning of the body.
In the self-regulating maintenance of the physical organism amongst others two ‘systems’ are 
important: the immune system (supported or not by the febrile reaction), and the homeostasis/
chronobiological rhythmic system.
 The immune system
 The immune system has the task of protecting the organism against harmful invaders 
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2and detecting danger coming from both inside and outside of the body (Matzinger, 2001). It is a complex system in the organism, with an innate and acquired subsystem. Here, the effect of the 
so-called T-cells as part of the acquired subsystem of the immune system is investigated. T-cells 
are the main cells controlling and regulating the immune response, but they are also responsible 
for tissue damage and autoimmune disease if they are not properly regulated. Broadly, the onto-
genetic development of T-cells is as follows. After the ‘production’ of stem cells in bone marrow, 
they travel to the thymus, where an antigen-specific selection and differentiation into CD4+ helper 
Th-cells and CD+ cytotoxic Tc-cells takes place. Both T cells that react too strongly to cells of the 
organism and those who do not respond are removed. In this way, a dynamic T-cell population 
remains that is able to properly respond to antigens. Given the dynamic properties, these T cells 
are also potentially capable of an autoimmune reaction. Various control mechanisms are present to 
prevent this (Jutel & Akdis, 2011). After contacting an internal or external antigen, a specific T-cell 
matures into a set of T cells that specifically recognizes this antigen by their specific receptor for 
that antigen. Likewise, antigen-specific B-cells will be activated to produce antigen-specific anti-
bodies. These antigen-antibody complexes are then removed from the organism. At a subsequent 
meeting between the corresponding specific T- and B-cells and the corresponding antigen, the an-
tigen will be recognized quickly because of the persistence of T-memory and B-memory cells after 
the first contact. They specifically remain for that antigen and provide a more rapid response after 
subsequent antigen contact. While antigen-specific B-cells last for months up to years, memory 
T-cells can survive for 65 years. 
This process demonstrates that there is a learning curve in the direction of self-regulatory func-
tional ‘structure’: a ‘knowing what’ in combination with a ‘knowing how’ based on a specialization 
of an initial dynamic, omnipotent power of the T-cells and B-cells to recognize foreign antigens.
 Fever
 Apart from a few exceptions, reptiles, amphibians, fish and many invertebrates often have 
fever in response to an infection. Cold-blooded animals instinctively go to warmer places in order 
to raise their body temperature. In several studies on humans, it has been demonstrated that the 
magnitude of the fever response to infection varies inversely with mortality from disease (morta-
lity) and the occurrence of disease (morbidity). For blood poisoning (sepsis or bacteriaemie) or 
peritonitis, there is a positive correlation between the severity of fever and survival of the disease. 
Conversely, other studies seem to indicate that antipyretics should be associated with increased 
mortality and morbidity. For example, there is evidence that antibiotics or antivirals disease pro-
long the duration of diseases such as smallpox and viral infections, nasal extension (Doran et 
al., 1989; Graham et al., 1990; Kluger, 2002). Some of the mechanisms of the effect of fever are 
enhanced neutrophil migration, increased production of antibacterial substances by neutrophils, 
increased production of interferon, increased antiviral and antitumor activity of interferon, and 
increased T-cell proliferation (Gelfand et al., 1998). A small rise in body temperature inhibits bac-
terial and viral replication while at the same time increasing the activity and migratory capacity of 
neutrophils. Currently, the role of fever as ‘nature’s engine’ and ‘part of a beneficial host response’ 
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is discussed again in medicine (Fowler, 2009; Dixon et al., 2010).
 In conclusion, fever is not really a failure of the organism to maintain the temperature 
within limits. Rather, it is a very highly regulated response of the organism, involving many hor-
mones and active substances that are active and almost never reach dangerously high temperatures 
(Kluger, 2002).
 Homeostasis and Chronobiological Rhythms
 In the 20th century, the research on chronobiology research increased enormously (Hilde-
brandt, Moser & Lehofer, 1998; Koukkari & Sothern, 2006). Many biochemical, physiological and 
behavioral manifestations of organisms appear to exhibit rhythmic fluctuations. Chronobiology 
is the study of these rhythms in plants, animals and humans (Koukkari & Sothern, 2006). Hilde-
brandt, Moser and Lehofer (1998) argue that all life processes are not only spatially organized, 
but are also a complex arrangement in time that tune the interaction of the various functions in 
a meaningful way. It has become clear that a rhythmic system refers to the ability of the human 
organism to show a response of adaptation in disorders, to achieve a normalized function enabling 
the return to its optimal frequency. One of the most well-known rhythms is the wake-sleep rhythm. 
Sleep is regarded as a process of recovery (Minot, 2008). Sleep deprivation leads to cognitive 
impairment, neuro-endocrine changes, mood disorders and depression. In rats, sleep deprivation 
is lethal after two to three weeks. The organism handles these rhythmic processes themselves 
(Heusser et al., 1999). The rhythm can therefore be regarded as a self-regulatory, health-creating 
activity of the organism to the polar active organ systems involved in balance. It is often used 
within a subsystem of mutually influencing pro (‘excitation’) and inhibitory (‘inhibition’) control 
(Perreau-Lenz et al, 2004; Talathi et al, 2008). Even homeostasis is conceptualized as the result 
of balance within a system. The body always tries to maintain a balance between this storage and 
utilization of energy by balancing the parasympathetic and sympathetic activities. This is known 
as sympathovagal balance. Maintenance of good health and prevention of diseases is hypothesized 
to depend on how effectively a person maintains his sympathovagal balance (Pal, 2008). Recent 
studies provide evidence that the different rhythms in the organism are interconnected, at least in 
healthy subjects, by phase coupling (Moser et al., 1995), synchronization (Challet et al., 2003; 
Cyzarz et al., 2004; Zhou et al., 2005), or mutual modulation (Hildebrandt et al., 1998; Hrushesky 
et al., 1984; Pedemonte et al., 2005). The several rhythms are orchestrated into one interconnected 
‘symphony of life’ as a precondition for maintaining health (Moser et al., 2008).
 Disease due to the lack or inadequacy of self-regulatory skills
 When physical health is the result of an ongoing self-regulatory activity of the immune 
system, the fever response and the homeostasis/ chronobiological rhythms in response to external 
and internal influences, the hypothesis can be deduced that a physical illness/disease can be caused 
by the lack or inadequacy of the self-regulatory activity or through a lack of ‘resources’ to imple-
ment self-regulatory activity. Here are some illustrative examples that substantiate this theory.
The ‘fighting disease’ approach in medicine has resulted in the situation that people in the Wes-
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2tern world in recent decades have had increasingly less contact with pathogenic microorganisms, have become more vaccinated, and have increasingly been treated with antibiotics and antipyretics. 
It is now clear that this approach, apart from its positive effects, also has its negative effects.
For example, the so-called hygiene hypothesis, that children today are experiencing few in-
fectious diseases so their immune system is not sufficiently practiced, yet stands firm (Douwes 
& Pearce, 2008). The increased preventative hygiene measures might be (partly) the cause of the 
increase in allergic diseases like eczema, hay fever and asthma in the past decades. For example, 
Rosenlund et al. (2009) found in a study of 15,000 children an inverse relationship between being 
ill from measles (and not in being vaccinated for measles) and the presence of any allergic symp-
tom or any allergic diagnosis. Foliaki et al. (2009) also found in a study of 193,412 children that 
antibiotic use in the first year of life is associated with the occurrence of asthma, eczema and rhi-
noconjuctivitis in children between the age of 6 and 7 years. In addition, several epidemiological 
studies demonstrate the protective effect of growing up on a farm, which offers contact with higher 
numbers of microorganisms (Van Mutius, 2010).
Kienle (2003) describes how in the recent period of nearly 200 years, the conceptualization of 
cancer has changed from cancer as a cellular problem to a problem of the hierarchical organization 
of the organism as a whole. Sporn (1997) describes in his review that one must regard cancer as a 
disease of the whole organism. The author claims that although molecular and cell biology have 
enormous power as analytical tools, the ultimate understanding and control of the process of carci-
nogenesis will require a synthesis at the level or tissue, organ and organism.
The ultimate in cooperation and complex dependency within living beings is the organism, 
which is composed of multiple organ systems with organs working together to perform particular 
functions but also to ensure the survival of the organisms as a whole in the ever-changing environ-
ment. In a strongly and traditional reductionist view, the human body consists of seven hierarchal 
levels of organization that can all be affected in cancer development. These levels consist of atoms 
that combine to form molecules, which combine to form cells that work together to form tis-
sues, which together form organs and subsequent organ systems that finally build up the organism. 
Therefore, the functioning of the organisms is dependent on the coordinated work of all elements 
into a cohesive unit.  
Meanwhile, by examining the relationship between the self-regulating, organizing activity of 
fever and cancer has become increasingly evident. There is an inverse correlation between diffe-
rent types of febrile illnesses in childhood and the occurrence of cancer (Hobohm et al., 2008). In 
addition, there is increasing evidence of the positive effects of febrile illnesses in the spontaneous 
healing or improvement of cancer (Coley, 1893, 1906; Hobohm, 2008).
Menke et al. (2007) describe a wound-healing model. Within this model, the inflammatory profile 
of a non-healing wound is one in which the equilibrium between synthesis and degradation has shif-
ted toward degradation. Reutelingsperger (2010) describes the role of apoptosis (programmed cell 
death) as an opposite function to ongoing cell division in organisms. Within this system, the balance 
between cell division and cell death may be disturbed, after which two types of diseases can occur as 
a result of the imbalance. When there is too little cell death over cell division, for example, mutations 
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in the gene-encoding proteins involved in the execution of cell death, diseases such as cancer and au-
toimmune diseases can occur. For example, cancer cells may have defective proteins that are not suf-
ficiently capable of activating self-killing programs, while, on the other hand, they are able to perform 
cell division. The result is an increase in cancer cells. In that case, therapies aiming at stimulation 
of the suicide program can restore the balance. The balance swings the other way by excessive cell 
death. This affects, for example, the development of metabolic syndromes such as neurodegenerative 
Alzheimer’s dementia and in the process leading to heart failure.
Finally, there is increasing empirical evidence of disturbances of chronobiological rhythms. 
The most common are disturbances of the day-night rhythm associated with impaired cognition, 
depression (Mignot, 2008), type 2 diabetes, obesity (Bass & Takahashi, 2010) and breast cancer 
(Moser et al., 2005, 2006). There are also indications that migraines are the result of excessive 
excitation or a failure of inhibition, in other words, the result of an imbalance of the relevant un-
derlying chronobiological system (Talathi, 2008).
2.5  Towards a revised and more valid definition of health
2.5.1  Focus on self-regulation
In general, there is a tendency in biology and medicine to look for reductionist explanations 
in health- and disease-related problems. For example, scientists look for the gene, molecule or 
cell that is responsible for a particular physiological or psychological effect. However, accounts 
of health such as MIL, SOC, the triad of mental health, and three physiological systems (immune 
system, the fever response and the homeostasis/ rhythmic system) focus increasingly on various 
self-regulatory organization levels. 
2.5.2  ‘Health by self-regulation’
 By integrating the health definition of the WHO from 1948 with the developed (subdo-
mains of the) definitions, relevant theories and empirical facts, a better health definition can be 
developed. Central to this is the change from thinking in end states (state of perfect health and 
absence from disease) into thinking in terms of the continuous activity of self-regulating processes 
that are responsible for reaching these states.
Health is first the proper functioning of the body (forms and functions) processes and psycho-
social processes with the absence of disease. This, however, must be considered a dynamic end 
situation in terms of ‘material elements,’ since the molecules and cells in the body are constantly 
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2replaced throughout life. Second, human health is the self-regulating ability to constantly mani-fest itself in and adapt to the environment, both physically/physiologically, mentally and socially. 
Third, health concerns the self-regulatory ability to recover from physical, mental and social endea-
vors, wounds, injuries, stress, traumatic events, etcetera. To this end, internal (e.g., certain active 
genes and proteins in the inflammatory response or specific coping strategies) and external (e.g., 
plaster for a fracture or psychological help with a shocking event) resources are necessary. Some 
self-regulatory abilities have been sufficiently built at birth, but can develop further throughout 
life (e.g., the immune system). Others should be largely developed (psychological self-regulation: 
perception, processing, reaction; sense of coherence: comprehensibility, manageability, meaning-
fulness) or trained (e.g., physical endurance) throughout life. When a person at all three levels is 
able to function optimally, the subjective experience of this is that he/she feels emotionally and 
psychological well, physically fit and energetic, without complaints and suffering, and that he/she 
has a positive view on other people and society and feels at home in society.
The relationship between the positive domains is that a high mental and social functioning 
is related through two main pathways to better physical health (directly and indirectly through 
healthy neurophysiological behavior). Conversely, physical activity can have a positive effect on 
mental well-being. One of the connections between health and disease is that physical or mental 
diseases may be the result of a lack of or inadequate physical, mental or social self-regulatory skills 
or processes. A second relationship is that psychological stressors and negative emotions adversely 
affect physical health, whereas chronic disease (together with advanced age) do not seem to affect 
mental health.
2.5.3  Connecting the revised health definition to some related theories
 Theories should be judged according to formal criteria (Oost, 1999; Oost et al., 2002), 
which state that existing theories may fail: (1) on internal conceptual grounds (logical inconsis-
tency, use of ambiguous concepts); (2) on external conceptual grounds (a theory “does not fit in” 
with other theories); and (3) on empirical grounds (a theory “does not fit in” with reality). 
The new concept is regarded as more internally consistent than the WHO concept of 1948; 
the former is broadened with conceptual information on the relationships between the positive 
domains and between health and disease, and the concept is logically consistent. Since the concept 
is based on (new) empirical evidence, it is also considered to be valid on empirical grounds. There-
fore, only the last criterion is tested here. This leads to the question of whether the concept fits in 
with some of the current important related theories of systems biology, emergence, epigenetics, 
and the self-organization of complex systems.   
 Systems biology
 Before the year 2000, only two articles contained the term ‘systems biology’ in either the 
title or the abstract in PubMed. In 2010, more than 2,500 entries had appeared with more than 90 
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percent in the last five years, demonstrating the increasing interest of scientists in this topic (Kohl 
et al., 2010). “Its recent rapid resurgence at the turn of the century reflects the problems encounte-
red in interpreting the sequencing of the genome and the failure of that immense achievement to 
provide rapid and direct solutions to major multi-factorial diseases” (Noble, 2011, p. 9). Different 
than the genetic and microbiological approach, systems biology aims to describe, understand and 
explain from the complex biological systems that are studied: all levels of structural and functional 
complexity, explicitly including the supracellular domain (Kohl et al., 2010); their systems beha-
vior or phenotypes; their networks with relationships that interact with the genome, the environ-
ment and the phenotype (Noble, 2011; Van der Greef et al., 2007); their multifactorial processes 
involved in maintaining homeostasis and the breakdown of homeostasis within the system (Van 
Ommen et al., 2009).
 Epigenetics
 Recent insights into the mechanisms and molecular basis of gene regulation have led 
to the notion that organisms increase their complexity by altering the level of gene transcription 
without affecting their DNA base-pair sequence. This field of expertise is called epigenetics, and 
it refers to the fact that although all of the cells of an individual contain the same amount of DNA 
and the same sequences in the genome, different locations in the body instruct cells to perform 
different functions and even to react and modify their genetic potential as a way of reacting to 
their exposure to environmental factors (Bernstein et al., 2007). Three main mechanisms are sup-
posed to be responsible for epigenetic changes: DNA methylation, histone tail modifications, and 
noncoding RNAs (Huang & Fan, 2011). These induced changes are heritable and can exert their 
influence over several subsequent generations through perinatal programming, and can therefore 
explain why certain diseases run in families (Barker, 2007). In addition, epigenetic mechanisms 
contribute to the explanation for neurophysiologic and psychological functioning. Therefore, they 
are hypothesized to provide a physiological basis for the perceptions of disease, health and welfare 
(Graff & Mansuy, 2008). 
 Emergence
 The features of organs are not found in the cells and consciousness is not found in organs. 
In nature, higher organization levels ‘spontaneously’ arise from lower levels and, at the same time, 
influence these lower levels. For example, a cell that is transplanted from one tissue to another 
often changes its functions according to the new tissue (Gurdon, 1986). “Emergent phenomena are 
said to arise out of and be sustained by more basic phenomena, while at the same time exerting a 
‘top-down’ control, constraint or some other sort of influence upon those very sustaining proces-
ses” (Corradini & O’Connor, 2010, p. xi). Throughout several concepts, emergent phenomena are 
usually characterized as irreducible, unpredictable or unexplainable, to require new concepts and 
to be holistic (Bedau & Humphreys, 2008).   
The concept of emergence has received renewed attention in science in the past decades due 
to developments in a number of research programs within complexity theory, artificial life, phy-
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2sics, psychology, sociology, biology, philosophy of science and philosophy of mind (Bedau & Humphreys, 2008).  
 Self-organisation
 De Wolf and Holvoet (2005, p.7) propose the following work definition for self-organisa-
tion: “Self-organisation is a dynamical and adaptive process where systems acquire and maintain 
structure themselves, without external control.” These structures can be spatial, temporal and/or 
functional. Four characteristics of self-organisation are, according to the authors, supposed to be 
essential: (1) increase of order: self-organisation needs to find sufficient order, that is a balance 
between no order and too much order, in order to reach a structure; (2) autonomy: the absence of 
external control; (3) adaptability or robustness with regard to change: adaptability in the presence 
of perturbations and change. A self-organising system is expected to cope with that change and to 
maintain its organisation autonomously; and (4) dynamical i.e. far from equilibrium: self-orga-
nization is a process. Over time, there is an increase in order, i.e. a dynamic towards more order. 
Changes influence the organised structure. In order to maintain that structure, there needs to be a 
constant dynamic that handles these changes.   
We state here that the definition “health by self-regulation” is in accordance with theories of 
systems biology, emergence, epigenetics and self-organisation of complex systems.
2.5.4  The definition of health promotion
 The fighting disease approach has its targets in eliminating disease-related organisms, 
cells and functions in the body; disease-related symptoms, and the manipulation and/ or substitu-
tion of non-functioning or dysfunctional parts of the body by means of external therapeutic resour-
ces. The health promotion approach is the process of enabling individuals, groups or societies to 
increase control over and improve their physical, mental, social and spiritual health (Eriksson & 
Lindstrom, 1997). Based on the results of this study, one can conclude that health promotion aims 
at improving the development and quality of the self-organizing skills on the physical, mental and 
social level, and at improving the integration of these higher organization levels with the lower 
levels and parts of the system. 
 An example of the integration of the fighting disease and curative health promotion  
 approaches in hay fever treatment
 Allergic rhinitis is a condition characterized by sneezing, watery nasal discharge, and 
nasal obstruction and itching. It is an increasingly prevalent condition, particularly in the Western 
world where it affects around 20% of the adult population. Allergic rhinitis is divided into seasonal 
allergic rhinitis (SAR) (hay fever), which is triggered by pollens and moulds, and perennial al-
lergic rhinitis (PAR) in which house dust mites and pet dander are the predominant triggers. The 
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spectrum of severity is wide.
The increasing prevalence of allergic rhinitis in Western countries is associated with modern 
lifestyle. The (hygiene) hypothesis is that high living standards and hygienic conditions are cor-
related with an increased risk for the development of an allergic disease. Due to reduced exposure 
to microbial components, the proposed allergy-preventing potential of these factors is no more 
present in sufficient qualities and/or quantities, which leads to an imbalance of the immune system 
with a predisposition to the development of allergic disorders (Garn and Renz, 2007; Mas and 
Horner, 2008).
The treatment of choice of SAR is the treatment with local or oral antihistamines and/or local 
corticosteroids. Both types of treatment are typical fighting disease treatments, whereas these tre-
atments (1) are manipulating disease-related dysfunctioning or pathophysiological processes in the 
body: respectively the overproduction of histamine (antihistamines) and the chronic inflammatory 
reaction as a result of a too active allergic Th2 pathway in the immune system (local corticoste-
roids); and (2) reduce the disease-related symptoms. However, these interventions do not change 
the diseases status or set the precondition for a healing process that changes the organism into a 
healthier status. Therefore, allergic rhinitis patients that are treated in this way (symptomatically), 
will have to be treated for the rest of their lives.
A second type of allergic rhinitis treatment is immunotherapy. It is indicated in a limited sub-
population of patients and includes a significant number of sufferers with severe symptoms that 
are resistant to treatment with usual pharmacotherapy (antihistamines and topical nasal cortico-
steroids) (Sachs et al., 2006). Optimal treatment effects are established in three years. During 
treatment patients receive, often on a weekly basis allergy shots. Each allergy shot contains a tiny 
amount of the specific substance or substances that trigger the allergic reactions. Allergy shots 
contain just enough allergens to stimulate the immune system — but not enough to cause a full-
blown allergic reaction. Over time, the dose of allergens in each of the allergy shots increases. This 
helps to get the organism used to the allergens (become desensitized). The immune system builds 
up a tolerance to the allergens, and the allergy symptoms diminish over time. Immunotherapy is a 
typical curative health promotion therapy, since the effect of the therapy is a permanent change into 
a better health status that is based on an improvement of the organism’s ability or in other words its 
organic skill to cope with specific allergens. The working mechanism of this type of health promo-
tion is, analogue to psychotherapeutic phobia treatment, the increase of the exposure to a stimulus 
in order to desensitize the reaction to the stimulus.  
A third type of allergic rhinitis treatment is treatment with Citrus/Cydonia comp. subcutane-
ous injections and/ or nasal spray. The experiences of prescribing GP’s is that SAR patients are 
claiming to permanently suffer less from hay fever symptoms or even that they are free from 
complaints after the treatment with Citrus/Cydonia comp.. The effect is occurring within a period 
of two weeks, up to three months, after treatment onset. The effect is optimal after a treatment of 
several years (4). Positive effects, without side effects, were also observed in two cohort studies: 
a group of 13 patients suffering from grass pollen SAR treated with subcutaneous injections (5) 
and in a group of 140 patients, who were treated with nasal spray (6). In a randomized trial compa-
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2ring two routes of administration (nasal spray versus subcutaneous injections), immunological and clinical effects of both routes were demonstrated. In the immunological studies the effects of this 
treatment were the induction of regulatory (IL-10 producing) T-cell subsets and the suppression 
of the Th2 pathway cytokines IL-4 and IL-5. The working mechanism of this type of health pro-
motion is, analogue to psychotherapeutic skills training (e.g. emotion regulation, problem solving) 
the improvement of skills that are able to inhibit unwanted reactions and restore the balance of the 
functional of the subsystem as a whole.
Combining the best of both worlds of fighting disease and (preventative and curative) health 
promotion in order to improve the health status of healthy or diseased persons is an important goal 
to strive towards. The integration of both approaches could result in:
Preventative health promotion recommendations for parents about handling hygiene during 
childhood of their children and the safe use of for example probiotics as a replacement for bacteria 
exposure in normal life situations.
Integration of fighting disease and curative health promotion in treating SAR. A quick reducti-
on of SAR symptoms can be achieved by means of antihistamines and topical nasal corticosteroids 
treatment, and can be combined with either/or immunomodulation (especially in severe, pharma-
cotherapy resistant SAR) or treatment with Citrus/Cydonia comp..
 An example of the integration of the fighting disease and curative health promotion  
 approaches in phase 1 treatment of chronic traumatization 
 Prospective longitudinal and retrospective studies have demonstrated that chronic child-
hood abuse and neglect may have pervasive effects on adult function (Anda et al., 2006; MacMil-
lan et al., 2001; Putnam, 2003; Springer, Sheridan, Kuo & Carnes, 2007; Teicher, Andersen, Polca-
ri, Anderson & Navalta, 2002). Childhood abuse and neglect has also been found to be associated 
with borderline personality disorder (Herman, Perry & Van der Kolk, 1989; Ogata et al., 1990), 
somatization disorder (Saxe et al., 1994), eating disorders (Herzog, Staley, Carmody, Robbins & 
Van der Kolk, 1993), sexual disorders (Putnam, 2003), DSM-IV Axis I diagnoses of dissociative 
disorders (Boon & Draijer, 1993; Ross et al., 1991; Ross, Norton & Wozney, 1989), post-traumatic 
stress disorder (PTSD) (Bremner, 1993; Widom, 1999), substance abuse disorders (Putnam, 2003) 
and a range of persistent symptoms more complicated than those of PTSD, often called “complex 
PTSD” (Herman, 1992) or “disorders of extreme stress not otherwise specified” (DESNOS; Pel-
covitz et al., 1997; Roth, Newman, Pelcovitz, Van der Kolk & Mandel, 1997).  This paper refers to 
the DESNOS symptom clusters as the diagnosis of complex PTSD; however, it is important to note 
that ‘complex PTSD’ is subsumed under “Associated descriptive features and mental disorders” of 
PTSD in the DSM-IV classification (APA, 1994, p. 425).
The current clinical standard of care for complex trauma-related disorders is phase-oriented 
treatment (Brown, Scheflin & Hammond, 1998; Chu, 1998; Courtois, 1999; Herman, 1992; Van 
der Hart, Nijenhuis & Steele, 2006). In most of these models, there are typically three phases of 
treatment involving 1) stabilization and symptom reduction, 2) integration of traumatic memories, 
and 3) reintegration of the personality and rehabilitation. This treatment model does not imply that 
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the phases will occur strictly sequentially. Rather, phase 2 treatment will periodically alternate with 
phase 1 treatment, and later in the course of therapy, phase 2 and phase 1 work will alternate with 
phase 3 treatment (Courtois, 1999; Van der Hart, Brown & Van der Kolk, 1989). Not all patients 
are able to reach phase 2 (Boon, 1997). 
Two central first phase treatment goals are: the reduction of symptoms (depression, anxiety, 
etcetera) and breaking maladaptive patterns (e.g., drug abuse, self-mutilation as a means to cope 
with stress) and subsequently developing adequate coping skills. Symptom reduction can generally 
be accomplished with psychiatric fighting disease drugs such as antidepressants and anxiolytica. 
Psycho-education and skills training (e.g., learning skills, management and modulation of distress, 
emotion regulation skills, critical thinking and judgment skills, problem-solving and social skills) 
are important health promotion treatments. Psycho-education and skills training help patients to 
develop self-regulation skills, which can be defined as the adaptive use of skills across changing 
personal and environmental conditions (Boekaerts et al., 2000). 
The reduction of symptoms only is, in most instances, not sufficient to reach phase 2. On the 
other hand, the development of self-regulation skills can only be reached when patients are treated 
before and/or in addition to symptom reduction pharmaceutics (Baars et al., 2011). Consequently, 
the phase 1 treatment of chronic traumatization must be regarded as an integrated fighting disease 
and health promotion approach.
2.6  Discussion
 Based on a conceptual analysis of historic and current health-related concepts and an 
analysis of the conceptual shortcomings of the WHO health concept of 1948, a revised health de-
finition ‘health by self-regulation’ was constructed. The validity of the concept was preliminarily 
and successfully tested, since the internal consistency of the concept was improved compared to 
the WHO concept of 1948; the concept was based on empirical evidence, and it fit in with some 
of the current important relevant theories of systems biology, epigenetics, emergentism, and self-
organization. Valid definitions of health (and disease) are very important, since they provide an 
entrance for preventive and therapeutic action (Canguilhem, 1991).
Compared to the WHO health definition we regard the presented definition ‘health by self-
regulation’ an improvement since, contrary to the WHO definition, (1) it provides information on 
the relationships between the positive domains, (2) it provides information on the relationships 
between health and disease, (3) is based on both probabilistic and mechanistic evidence, and (4) 
it provides conceptual information for the further development and innovation of preventive and 
curative health promotion strategies in clinical practice.
The major limitation of the study is that only a limited amount of literature on the health pro-
motion and fighting disease concepts and empirical evidence was analyzed. Therefore, further 
conceptual analysis, improvement and validation of the presented concept are required.   
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view of the literature (Huber et al., 2011). The result of this conference was that health should be 
conceptualized as the ability to adapt and to self manage.  
The new definition provides a theoretical fundament that can be further explored and refined, 
based on the analysis of other theories and empirical evidence. It can also help the further con-
ceptualization of the role of, for example, fever and inflammation in young age but also in the 
treatment of, for example, cancer, and the conceptualization of the development of (biological and 
psychosocial) health promotion skills. Furthermore, it provides a framework to study the role of 
chronobiological imbalances of subsystems in various diseases. 
The definition can provide an evidence-based fundament for the development and validation 
of health promotion strategies in clinical practice. Three steps can be taken: (1) the designing of 
preventive and curative health promotion strategies based on the validated health definition; (2) the 
testing of quality, efficacy, effectiveness and cost-effectiveness of preventative and curative health 
promotion strategies for specific indications; and (3) the integration of fighting disease and health 
promotion strategies for specific indications. 
Important future research topics are: (1) the exact relationship between meaning in life and 
psychosocial functioning and physical health; (2) the exploration of the surplus value of health pro-
motion compared to fighting disease; (3) the development and testing of optimal integration of the 
fighting disease and health promotion approaches for specific indications; (4) further exploration of 
the exact health promotion mechanism and its interactions with the genome, environment, epige-
netic mechanism, etcetera; and (5) the development and validation of the methods and measuring 
instruments for monitoring changes in health status in addition to disease status changes.
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Abstract
 The concept of naturalness can be used to characterize organic agriculture and to distin-
guish it from conventional agriculture, provided naturalness not only refers to the non-use of syn-
thesized chemicals, but also to the ecological and systemic principles, and to a respect for the inte-
grity of living organisms. Examples of the implicit use of the integrity concept in agriculture will 
be described to show its practical aspects and implications. The (non-atomistic) holistic concept of 
integrity of organisms has been the subject of severe scientific criticism – specially from in essence 
ontological reductionists. In their view, an organism is essentially no more than a complex set of 
atoms and molecules and its integrity a nonconcept. In order to reach scientific acceptance of the 
integrity concept and to support its use in organic agricultural practice, it needs further underpin-
ning. In this article, based on a critical analysis of (a) ontological and methodological aspects of 
reductionism, and (b) expert knowledge and the process of pattern recognition and application, the 
validity of the holistic concept of integrity will be explored. 
 Additional keywords: holism-reductionism debate, wholeness of organisms
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3.1 Introduction
 During the last decades it has become evident that the concept of naturalness can be used 
to characterize organic agriculture and to distinguish it from conventional agriculture, provided 
naturalness refers to (1) abstaining from the use of artificially synthesized chemicals, (2) adopting 
the ecological principles, and (3) respecting the integrity of living organisms as a holistic concept 
of thinking (e.g. Lammerts Van Bueren et al., 2003; Verhoog et al., 2003; Lammerts Van Bueren & 
Struik, 2005). 
In this paper we focus on the holistic concept of the integrity of organisms.
Starting at the beginning of the 1990s, the concept of integrity received increasing attention 
in bioethical literature. For example, in the biotechnology discussion the concept of ‘genetic inte-
grity’ (Vorstenbosch, 1993) was used in connection with the genome of an individual animal. Lam-
merts Van Bueren et al. (2003) distinguished four levels of integrity in relation to plant breeding 
in organic farming: (1) integrity of life, (2) planttypic integrity, (3) genotypic integrity, and (4) 
phenotypic integrity. Similar kinds of levels were first developed in relation to the genetic enginee-
ring of animals. Expanding on the concept of ecosystem integrity, Thompson (1997) introduced 
the notion of functional integrity in the discussion on sustainability in livestock farming. We shall 
argue that, besides this explicit use of the concept of integrity, in agricultural practice there is also 
an implicit use of this concept. 
In spite of this explicit and implicit use of the integrity concept, the concept of integrity has 
hardly been accepted in agricultural sciences. This is mainly due to the philosophical background 
of many scientists who are reductionists and therefore consider an organism in essence no more 
than a complex set of atoms and molecules. In their view, an organism is best studied in an expe-
rimental setting where man’s purported subjectivity has been completely eliminated and where 
features of objects and (causal) relationships between the objects can be examined (Looijen, 1998). 
In this scientific approach there is no room for a holistic concept of integrity, a concept that refers 
to the existence of a real holistic being. The denial of the latter implies that organisms can be con-
structed in accordance with human desires and that there is no need for research methodologies at 
higher levels than the level of pure matter: mainly atoms and molecules.
In order to defend a holistic approach of integrity that not only is acceptable to agricultural 
practice but also to agricultural sciences, it is necessary to strengthen the philosophical basis of this 
new concept. This is done in this article by means of:
• a critical analysis of some ontological and methodological aspects of reductionism, and 
• a reflection on the methodological role of expert knowledge expressed by practitioners.
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3.2 The implicit use of the integrity concept in agricul-
tural practice
 In agricultural practice and in the way people treat domesticated and wild animals, the con-
cept of integrity has already been used for many years, although often in an implicit rather than an 
explicit way. For example, animal breeder and geneticist Frederik Bakels integrated knowledge of 
the domestication process, the habits and living conditions of wild cows into his breeding goals and 
concepts. His central foci were the cow’s needs as a ruminant and its perfect body shape based on 
wild cows rather than the cow as an efficient producer of proteins and fat (Bakels & Postler, 1986). 
Bakels’ implicit awareness of animal integrity was transformed in his breeding concept based on 
‘longevity’ and ‘lifetime production’.
Animal ethologist Temple Grandin developed slaughter houses and improved walking ways 
for cattle, based on her empathic knowledge of and involvement with animal needs. In relation to 
her autistic personality, Grandin developed the ability to see the animal-specific fears during their 
walking into a new and strange environment and she was able to adapt this environment taking into 
account the animal’s needs (Grandin & Johnson, 2005).
In the 1960s, animal ethologist Jane Goodall was criticized by the main-stream scientific com-
munity, because she gave names to the chimpanzees instead of ‘objective’ numbers. In those days 
animals were seen as unconscious machines. In her view, however, animals are sentient beings 
(Goodall & Bekoff, 2002). Her present work on chimpanzee protection and chimpanzee liberation 
is based on her empathic involvement with the animals in their natural environment. Her scientific 
methodologies have been adopted by animal ethologists observing other mammals (elephants, 
wolves, gorillas) (Turner & D’Silva, 2006). For other examples see Verhoog (2007) in this issue. 
The concept of integrity is also important for answering ethical questions within organic agricul-
ture, such as whether specific treatments of organisms are ‘acceptable’. In (organic) agriculture, the 
acceptance of the concept of integrity has three major consequences. First, there are consequences 
for our basic attitude towards living organisms. Instead of treating an animal as if it were ‘a piece 
of meat’ or ‘an efficient milk factory’, we encounter a real and true ‘being’ with a specific nature. 
This refers to the natural living approach to animal welfare in organic agriculture (Wagenaar & 
Langhout, 2007). On the basis of the notion of animal sentience, we have to treat the animal in a 
respectful way (Turner & D’Silva, 2006). 
Secondly, we should develop a personal relationship with this ‘being’, like we do in the en-
counter with fellow human beings, in order to develop an insight into its wholeness. Instead of 
creating the ultimate professional gap between subject and object in the search for measurable, 
objective knowledge of the parts and their relationships, we have to ‘catch’ its identity in the way 
it expresses itself in the organization of the parts in time (e.g. physiological processes) and place 
(e.g. morphological processes) (e.g. Schad, 1971; Bortoft, 1996). This is exactly what experienced 
practitioners implicitly do and what the research topic is in experiential science (Baars & Baars, 
2007). Goethean phenomenological science as defined below is an exact and explicit methodology 
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to acquire embedded insight into the observed. The method is currently used in several areas of 
agriculture, such as landscape development (Pedroli et al., 2007), plant breeding and research into 
medicinal herbs. A third consequence directs our way of handling organisms to focus on the cre-
ation of preconditions in such a manner that the being is able to express itself in an optimal way.
3.3 An introduction to the holism-reductionism debate
 In the foregoing we have explained that the holistic concept of integrity is an important 
concept in organic agriculture, either explicitly based on ethical reflection, or implicitlyby expe-
rienced practitioners. But a better philosophical foundation is needed. For this we have to join the 
holism–reductionism debate. A negative way of defending holism is showing the shortcomings of 
reductionism. A positive way is to refer to the importance of pattern recognition in science, which 
is based on a holistic perception.
3.3.1 Definitions and historical development
Definitions
 In the philosophy of science, reductionism is usually set against holism or organicism. The 
statement: ‘An organism is essentially nothing but a complex set of atoms and molecules’ lies at the 
heart of reductionism. At the opposite side of the scale, statements such as ‘You cannot just simply 
reduce an organism to a sack of molecules’ and ‘The whole is greater than the sum of its compo-
sing parts’ essentially characterize holism (Looijen, 1998). The reductionist model argues that all 
traits and other characteristics demonstrated by living organisms – their morphology, physiology, 
behaviour and ecology – can ultimately be fully and exclusively explained in terms of the physical 
and chemical molecules (DNA, proteins, etc.) of which they are composed. Reductionism assumes 
that the laws, concepts and theories formulated for a higher level of organization in biology (for 
example the level of the organism) can be explained by theories developed for a lower level of 
organization, such as the level of organs, tissue and cells. This means that ultimately all biological 
concepts, laws and theories can be reduced to the physical and chemical (Looyen, 1998). 
Three aspects must be distinguished in the reductionism-versus-holism debate: (1) ontological, 
(2) pistemological, and (3) methodological aspects (Looyen, 1998). Ontological aspects concern 
the question what entities, things or substances are assumed to make up reality (nature); what 
characteristics are attributed to these things or entities, and what relationships and functions can 
be assumed to exist between them. Epistemological logical aspects are about our knowledge of re-
ality; the way in which this knowledge is expressed in theories (amongst other things), and logical 
connections between theories. In particular, these aspects deal with links between theories deve-
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loped for different areas of reality or for different levels of organization. Methodological aspects 
concern the way in which knowledge is obtained and the basic principles, laws and strategies used 
in the process. This is particularly related to the question whether – in order to arrive at ‘correct’ 
knowledge or understanding of a certain level of organization (the level of the whole) – we should 
study the underlying lower levels of organizations (the composing parts and their interactions) or 
the higher level itself, or perhaps its relationship with still higher levels.
The division of holism and reductionism into these three aspects has important implications for 
our understanding of the positions of the distinctive scientific approaches. At all three levels either 
holistic or reductionist choices can be made. At the ontological level one can theoretically distin-
guish between ontological reductionism (so-called atomism) and ontological holism (so-called 
vitalism, emergentism and organicism). Atomism implies that the entities of the ‘lowest’ level of 
organization (atoms, subatomic particles, quantum particles, etc.) are somehow ‘fundamental’: 
they are the ‘building blocks’ of nature. Ontological reductionism states that, for instance in the 
discussion on genetic engineering, there is nothing but only DNA or that in causal explanations of 
biological results there is nothing but laws of physics and chemistry. In contrast, vitalism claims 
that animate nature is different from inanimate nature in that there are non-material forces opera-
tive in living beings. Another interpretation of holistic ontology is found in emergentism. In this 
holistic view, at each higher level of organization new and irreducible properties appear that are not 
present at lower levels. These so-called ‘emergent’ properties are defined as properties of wholes 
that are not possessed by their composing parts. At the epistemological level one can distinguish 
between provincialism – the reductionist view that biology, like chemistry, is a special branch or 
province of physics – and autonomism, which defends biology’s autonomy with respect to physics 
and chemistry.
At the methodological level, the reductionist strategy to obtain knowledge of higher levels 
of organization is to study lower level entities and interactions between them. The best way to 
understand phenomena at the level of the whole is to study causal mechanisms at the level of its 
constituent parts. Holists, on the other hand, claim that in order to obtain knowledge of a certain 
organization level in biology, one must not study (or at least not only) the lower levels of organi-
zation, but (also) the higher level itself as well as its relationships with still higher levels. Because 
of the emphasis put on the study of wholes at their own level of organization, holism is often as-
sociated with a descriptive or phenomenological method (Looijen, 1998).
Historical development
 Reductionist and organicist or holistic descriptions and theories have alternated in science 
since the Middle Ages. Verhoog (1993) summarizes this trend as follows: “In the medieval notion 
of reading the Book of Nature, nature is seen as an organism, as the body of Mother Earth, a har-
monious and self-regulating entity that is treated with respect. In the 16th century this concept of 
nature was replaced by the concept of ‘fallen nature’. Nature is now seen as disorderly and chaotic; 
the ‘blind’ forces of nature must be controlled by human reason. So man is no longer seen as an 
intrinsic element in a nature created by God. The measurable parts of Nature are objectified and 
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materialistically reduced during the mainstream of scientific development of the 16th and 17th cen-
turies. In a nature no longer guided by a divine providence, humans are free to manipulate and use 
nature as an instrument and for their own purpose. Experimental science provided the means to do 
this.”
In addition to the development of reductionist scientific thinking, Gloy (1996) de-scribes the 
historical development of holistic thought as a development in stages: current ecological thinking 
was preceded by natural magic in the Renaissance (end 14th – end 16th century), by Leibniz’ 
Monadology, by the natural philosophy of German Idealism and the Romantic Movement, and by 
vitalistic and holistic concepts at the start of the 20th century. Reductionism often dominates cur-
rent social and scientific thinking. 
3.3.2 A critical analysis of reductionism
 There are three central statements related to the theory of reductionism that can be used as 
objects of criticism:
1. All traits and other characteristics demonstrated by living organisms – their morphology, 
physiology, behaviour and ecology – can ultimately be fully and exclusively explained in 
terms of the molecules (DNA, proteins, etc.) of which they are composed. There are no hi-
gher levels or non-atomistic organizing principles present (reductionist ontology).
2. The specific concepts, laws and theories used in the sciences of higher levels of organiza-
tions of organisms can eventually all be reduced, step by step, to the fundamental theories 
of physics. There is no need for non-reducible holistic theories about reality (reductionist 
epistemology).
3. The strategy to obtain knowledge at higher levels of organization is to study lower-level 
entities and interactions between them. The best way to understand phenomena at the level 
of the whole is to study causal mechanisms at the level of their constituent parts. There is 
no need for holistic methodologies that specifically obtain knowledge from the level of the 
whole (reductionist methodology). 
In this article, we shall restrict ourselves mainly to the two central statements: 1 and 3. 
So the leading research questions for this article are:
• What is the tenablity of reductionist ontology?
• What is the tenability of reductionist methodology?
• What is the philosophical basis for a non-atomistic holistic concept of integrity of organisms?
Although this article discusses thoughts on integrity in agriculture, several topics from other sci-
entific fields will be used in the criticism of the reductionism theory. This is justified, since the 
reductionism theory is the general basis for reductionist scientists to criticize the holistic concept 
of integrity of organisms in all scientific fields, including agriculture.
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Criticism of reductionist ontology in molecular biology
 As stated above, ontological reductionism or atomism implies that the entities of the ‘lo-
west’ level of organization (atoms, sub-atomic particles, quantum particles, etc.) are somehow 
‘fundamental’. They are the indivisible ‘building blocks’ of nature, the ‘cement of the universe’. 
However, Gloy (1995) states that since the atomism theory was introduced three fundamental pro-
blems with this theory have not been solved (sufficiently). First of all, in no version of the atomism 
theory, the fundamental opposition has been solved between the postulate of smallest indivisible 
parts and simultaneously the postulate of their spatial extension. Secondly, although necessary 
content-wise, within the atomism theory mechanistic and teleological thought remain unconnec-
ted. Thirdly, it still remains to be seen whether or not the elements of a mechanistic world view will 
ever be able to construct living nature. So far, this view does not seem to be able to do this. All ‘new 
organisms produced by men’ (e.g. cloned animals) have originated from already living organisms, 
and they have not been built from the fundamental ‘building blocks of nature’. 
The limitations of reductionist thinking are also demonstrated in genetic research. Original re-
ductionist paradigms are (1) DNA – and in some viruses RNA – forms the genetic material, (2) the 
genetic stream of information goes from DNA to RNA to protein, and (3) the basic DNA sequence 
transforms, via the RNA, exactly into the amino acid sequence of the polypeptides. Furthermore, 
the assumption that a single gene encodes for a single protein is currently refuted in various man-
ners. All options are possible: (1) a gene encodes for a protein, (2) a gene encodes for several pro-
teins, (3) many genes encode for the same protein, and (4) many genes encode for many proteins 
(Ho, 1999). In the inheritance of genetic information between generations, there is more than only 
the inheritance of the DNA; frequently, so-called ‘epigenetic inheritance’ occurs (Russo et al., 
1996; Jablonka & Lamb, 2005). In several studies the determining importance of context in gene 
expression has been described (e.g. Gurdon, 1999; Ho, 1999). For example, the transplantation of 
DNA nucleids of highly specialized cells into other surroundings shows that both the function and 
the devel-opmental stage are adopted (Kienle & Kiene, 2003). Molecular biologists argue, howe-
ver, that in many cases, reductionist thinking itself was able to explain and to incorporate all new 
data, by extending its theoretical fundament accordingly. In addition, they state that current and 
future unexplained phenomena would eventually be explained by experimentally tested reductio-
nistic hypotheses.
Furthermore, genetically equal cells differentiate systematically into distinguishable cell ty-
pes and distinguishable protein compositions and therefore distinguishable gene expressions. This 
leads to the question how the different genes are switched on and off when the genetic ‘equipment’, 
the ‘genetic programme’ is the same everywhere. This is the so-called logical dilemma of develop-
mental biology (Hamburgh, 1971). The cause must therefore be sought outside of the DNA: ‘epi-
genetically’. In people and animals extra cellular forms and patterns such as arms and legs occur in 
equal cell types (bone, skin cells, etc.); the extra cellular form, the spatial partitioning of the equal 
cells, is therefore independent of gene expression (Müller & Hassel, 2002). 
Comparative evidence indicates substantial incongruities between genetic and morphological 
evolution, and demonstrates that the same genotypes do not necessarily correspond with identical 
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phenotypes (Lowe & Wray, 1997). On the one hand, genetic and developmental pathways can 
change over evolutionary time even when morphology remains constant (Felix et al., 2000); on 
the other, similar gene expression patterns can be associated with different morphologies (Muller 
& Newman, 2003). Nijhout (1990) concludes that genes do not cause or control morphogenesis; 
they enable it to take place. 
Summarizing we can conclude that ontogenesis and morphogenesis of organisms show that – 
in addition to DNA – other sources of information, organization and other heredity flows must be 
present (Kienle & Kiene, 2003; Jablonka & Lamb, 2005). 
Criticism concerning an ontological reductionist approach of the organization of 
organisms
 Ontological reductionism also states that there are no higher-level, non-atomistic organizing 
principles. However, research on topics linked by one common underlying theme, the organization 
of the elements of organisms in time and place (e.g. self-regulation, immunology, chronobiology, 
morphology, complexity), questions the tenability of the reductionist view. For example, Müller & 
Hassel (2003) describe with regard to the research on (the origin and the diversification of) orga-
nismal form that the nature of the determinants and rules for the organization of design elements 
constitutes one of the major unsolved problems in the scientific account of organismal form. The 
Neo-Darwinian paradigm that still represents the central explanatory framework of evolution can 
account for the phenomena it concentrates on, namely variation of traits in populations. However, 
it leaves aside a number of other aspects of evolution, such as the roles of developmental plasticity 
and epigenesis or of non-standard mechanisms such as assimilation. Most importantly, according 
to the authors, it completely avoids the origin of phenotypic traits and of organismal form. As to 
the organization of matter several authors conclude: “It is clear that what the parts (molecules and 
ions) are doing and the patterns they form are what they are because of their incorporation into the 
system-as-a-whole. In fact, these are patterns within the system in question.” (Peacocke, 2003). 
“The parts would not be behaving as observed if they were not parts of that particular system (the 
‘whole’). The state of a system-as-a-whole is affecting (i.e., acting like a cause on) what the parts, 
the constituents, actually do. Many other examples of this kind could be taken from the literature 
on, for example, self-organizing and dissipative systems.” (Peacocke, 2003); “The properties or the 
behaviour of the parts can be explained only in terms of their function in the whole: they contribute 
to the adequate functioning, the survival and reproduction of the whole. According to organicists 
(holists), such functional explanations are indispensable in biology. And because they do not occur 
in physics and chemistry, they form an important argument in favour of biology’s autonomy with 
respect to these other sciences” (Looijen, 1998). On the basis of research in complexity of orga-
nisms, Service (1999) concludes that when we get to a certain network complexity, we completely 
fail to understand how it works.
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Criticism concerning an ontological reductionist approach of the psycho-social 
aspects of man
 In a strictly reductionist approach, the various aspects of the psycho-social aspects of 
man can ultimately be explained by reductionist physico-chemical theories. This so-called issue 
of physicalism is central to the philosophy of mind and a currently extensively debated topic. 
In a review Stoljar (2001) states that there are three main arguments against physicalism: (1) 
the notion of qualia or felt qualities of experience, (2) the problem of intentionality of mental 
states, and (3) methodological issues. According to many authors (e.g. Chalmers, 1997) the 
qualia or experience problem is the unsolved mystery and the argument against physicalism in 
the philosophy of mind. Being able to discuss this topic only briefly, we shall focus on this main 
argument: “The notion of qualiaraises puzzles of its own, puzzles having to do with its connec-
tion to other notions such as consciousness, introspection, epistemic access, acquaintance, the 
first-person perspective and so on.” When we think and perceive, there is a whir of information 
processing, but there is also a subjective aspect. “Why is it that when our cognitive systems en-
gage in visual and auditory information processing, we have visual or auditory experiences: the 
quality of deep blue, the sensation of middle C? How can we explain why there is something it is 
like to entertain a mental image, or to experience an emotion?” (Chalmers, 2004, p. 619). “But, 
for example, would purely objective research into colour vision ever have discovered that certain 
colour combinations are very pleasant, or that some colours appear warm, others cold, or that 
some people hear coloured sounds?” (Gordon 2004, p. 227). “It is widely agreed that experience 
arises from a physical basis, but there is no good explanation of why and how it so arises. Why 
should physical processing give rise to a rich inner life at all? It seems objectively unreasonable 
that it should, and yet it does” (Chalmers, 2004, p. 619). 
Although the physicalism debate has not reached its finale, for the time being we can con-
clude that there are strong arguments against a strictly reductionist approach towards the various 
psycho-social aspects of man.
Criticism on reductionist methodology
 The golden standard of methodology in reductionist science is the experiment. The ex-
periment is a phase in the so-called empirical cycle in which a hypothesis is tested. The entire 
empirical cycle includes the phases of: (1) observation, (2) induction, (3) deduction, (4) testing 
(of the hypothesis by means of the experiment), and (5) evaluation (whether the tested hypothe-
sis based on the experimental results can be rejected or not).
Several authors have criticized (aspects of) the phases of the empirical cycle (e.g. Hume, 
1896; Chalmers, 1999; Gloy, 2003; Gordon, 2004) as well as the experiment specifically in its 
role as the golden standard (e.g. McComas, 1996; Chalmers, 1999; Kiene, 2001). In this article 
we focus on the problem that the empirical cycle does not fully cover the reality of the scienti-
fic process. This is especially true for the generation of new hypotheses. Neither induction nor 
deduction is able to produce new hypotheses (Broeders, 2003). Therefore, already Peirce (1878) 
introduced the term of abduction, next to induction and deduction. Abduction is to look for a 
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pattern in a phenomenon, and suggests a hypothesis.
More generally, the studies of for example the great discoveries in science (e.g. Van Der 
Bie, 2003), creative thinking (e.g. Robertson, 2001), and intuition (e.g. Davis-Floyd & Sven 
Arvidson, 1997) show that there is always a creative moment in ‘producing new insight’. Even 
the toughest empirical scientist who tries to follow the empirical cycle rigorously must depend 
on intuitive moments that bring new insight, even if – as an empirical scientist – he is striving 
towards excluding metaphysical elements. Davidson (2003) describes on the basis of his review 
that so far no satisfactory explanation has been found for the phenomenon of new insights as ‘the 
sudden realizations of a solution’. In the context of his study on the great discoveries in science, 
Van Der Bie (2003) describes this phenomenon of new insight as the creative moment in which a 
new pattern enters man’s consciousness that subsequently causes a new ranking order of known 
facts and observations within the context of this pattern. 
In other words, we can conclude that even in reductionist methodology there is a holistic mo-
ment in which holistic patterns arise in the researcher’s mind that organize the already existing 
knowledge parts into a new whole.
3.4 A non-atomistic holistic approach
 The critical analysis of several aspects of both the reductionist view on matter, its organi-
zation, its relationship to psycho-social aspects of man, and some aspects of reductionist metho-
dology with regard to the generation of new hypotheses demonstrates some of the shortcomings 
of reductionism and opens the gate towards a non-atomistic holistic approach of nature. With 
this we mean an approach that is also holistic in an ontological sense, thus accepting the status 
of living organisms as whole beings. Every time we mention holism we mean with this term 
the non-atomistic interpretation of holism. The acceptance of the existence of whole entities at 
a specific ontological level implies that we should use a holistic methodology as well. This we 
can find in pattern detection and pattern recognition, which play an important role in hypothesis 
generation, creative thinking, and pattern application. This topic of cognitive handling of pat-
terns is also central in another way of gaining and using knowledge – often neglected in the 
discussion on scientific methods: namely the methodological role of expertise. However, as the 
methodological use of expert knowledge serves as a holistic methodology that is able to obtain 
knowledge from the level of the whole, we shall explore the topic of expertise and the holistic 
methodological role of pattern recognition and pattern application in handling the level of the 
whole of organisms.
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3.4.1 Reflection on expert knowledge, pattern recognition and pattern  
application
 Adequately diagnosing and solving unique complex and context-specific problems can 
be performed by experts on the basis of so-called tacit knowledge, craftsmanship, the ‘clinical 
look’ or ‘breeder’s eye’ (e.g. Snoek, 1993; Glas, 1997; Robertson, 2001). Experienced workers 
seem to have learned, consciously or unconsciously, to handle prevailing laws and situations, and 
in doing so have developed self-regulation skills based on valid and practical, useful knowledge 
(‘appropriate conclusions and correct predictions’). Self-regulation can be defined as the  adaptive 
use of skill across changing personal and environmental conditions (Boekaerts et al., 2000). Ex-
pert knowledge is represented at an intermediate level of abstraction and is called the ‘moderately 
abstract conceptual representation’: a compromise between different abstractions like comparisons 
in the disciplines of physics and chemistry and concrete specific problems (Zeitz, 1997). The key 
element of expert information processing is the intuitive recognition and application of a pattern 
(‘Gestalt’) (e.g. Van Der Laan, 2006). 
Although there are differences in approach, the various scientific explanation models agree that 
pattern recognition is a process of matching between (e.g. visual) stimuli and information from 
memory. There are three kinds of theories that try to understand the phenomenon of pattern recog-
nition: (1) template matching theories, (2) feature detection theories, and (3) prototype theories 
(Lund, 2001). None of these theories, however, is able to explain all phenomena. This is true in par-
ticular for the influence that context, expectations and experience have, although many examples 
indicate that pattern recognition is influenced by these (Robertson, 2001). Lund (2001) describes 
that the influence of context, expectation and experience seems to be explained best by ‘top-down’ 
theories of perception, in which recognition is supposed to take place from the whole (‘top’) to the 
parts (‘down’).
3.4.2 What exactly matches what?
 An important next question presenting itself is: What exactly matches what? Two examples 
will be presented to illustrate this. When somebody sings a melody and subsequently sings it five 
tones higher, a song is produced in which none of the notes of the first melody returns a second 
time. It is clear that in both melodies not a single element is the same. Nevertheless, we immedia-
tely recognize that exactly the same melody is sung in both cases. Another example concerns the 
fact that people are able to recognize patterns they learned in a specific domain in another domain, 
which is the case, for example, in many scientific discoveries (Van Der Bie, 2003). The explanation 
is that – in the recognition of the melody or a pattern in a new domain – what exists between the 
parts or in the specific relationship (e.g. in space and time) between the parts (e.g. the tones in the 
melody) is recognized. This theory is confirmed by research results concerning the development of 
self-regulatory skills by experts, in which, as was said earlier, pattern recognition is central.
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There are various models describing the stages in the development of self-regulation skills in 
expertise (Schumacher & Czerwinski, 1992; Glaser, 1996; Boekaerts et al., 2000). Taking together 
these three models, we can conclude that this development is closely related to the development 
of expertise, based on the internalization of a model. That model in turn is based on knowledge of 
systematic connections or relationships of the system. A match occurs between this internal know-
ledge (in the memory) on the one hand, and on the other hand any specific form in which these 
relationships appear. At the stage of ‘self-regulation’, after all, we are dealing with an ‘adaptive 
use of skill across changing personal and environmental conditions’. In other words, we are dea-
ling with the possibility to recognize a universal pattern in whatever specific manifestation (during 
the knowledge acquisition process) and the application of a universal pattern in whatever specific 
manifestation (during the knowledge acquisition process). 
In conclusion, we may state that both pattern recognition and pattern application require a 
match between the universal connection in itself on the one hand, and the specifically perceived 
connection between specifically perceived ‘data points’ on the other. In philosophical terms, a 
‘match’ occurs between the universal and the specific, in which the universal appears and ensures 
the connection.
3.4.3 The holistic methodological role of pattern recognition and pattern 
application in handling the level of the whole of organisms
 Goethean phenomenology (Seamon & Zajonc, 1998) is a methodology that studies both 
the underlying lower levels of organizations (the composing parts and their interactions) and the 
higher level itself with the aim to arrive at ‘correct’ knowledge or understanding of the level of the 
whole of organization. It is a methodology that fulfills the criteria of a scientific method (Baars, 
2005). It is based on specifically trained judgement skills of the researcher. By using the phenome-
nological approach, the factual knowledge obtained through reductionism is placed in a larger per-
spective. Then, the researcher arrives at the level of wholeness that is responsible for the cohesive 
organization of the organism in time and place.
Several researchers successfully performed studies that demonstrated levels of wholeness in for 
example plants (Bockemühl, 1985; Bockemühl & Järvinen, 2005), mammals (Schad, 1971), phy-
siology (Van Tellingen, 2003) and immunology (Van Der Bie, 2006). In all studies it was demon-
strated that the level of wholeness determines the relationships between the parts at the underlying 
lower levels of organizations. By means of pattern recognition the researcher is able to recognize 
the universal level of wholeness as the organizing principle in whatever specific manifestation at 
the underlying lower levels of organizations. By means of pattern application the researcher can 
organize the conditions of lower levels of organizations in such a way that the level of wholeness 
can serve as the organizing principle of the composing parts in time and place.
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3.5 Concluding remarks
 A central focus within the thoughts on integrity within (organic) agriculture is formed 
by the (non-atomistic) holistic concept of the non-reducible wholeness of organisms and by the 
methodical role of expert knowledge and craftsmanship. The breeder’s eye that enables the ex-
perienced breeder to catch this level of integrity in understanding and using it in his (breeding) 
activities, may serve as an example. The non-atomistic concept of integrity states that organisms 
are self-organizing entities in which an ontological level of wholeness is responsible for the inter-
connectedness and the balanced harmony of its parts, for its characteristic species-specific nature, 
for its functional and morphological wholeness, and finally for the balance struck with its species-
specific environment. This ontological level of wholeness can be distinguished from the level of 
the ‘parts’ of the organism. 
In this article our aim was to develop and present a philosophical underpinning of a non-
atomistic, holistic concept of integrity of organisms. To that end we drew up critical analyses of se-
veral aspects of reductionist ontology and methodology, demonstrating some of the shortcomings 
of reductionism. For this we were inspired by the ideas of Oost (1999), who states that existing 
theories may fail:
• on internal conceptual grounds: logical inconsistency, use of ambiguous concepts;
• on external conceptual grounds: a theory “does not fit in” with other theories;
• on empirical grounds: a theory does not fit in with reality.
Reductionism ‘does not fit in’ with the different theories on the organization of matter but also 
does not match with several empirical facts concerning the organization of matter. Furthermore, 
the analyses at both the ontological and the methodological level demonstrated the need for the 
acceptance of the existence of a level of wholeness that can be distinguished from the level of the 
parts. Besides this negative evidence for the importance of holistic approaches, positive evidence 
can be found in what is known about pattern detection, recognition and application. This philosop-
hical underpinning may serve as a first step towards a wider acceptance of this concept of integrity: 
not only in (organic) agricultural practice, but also in science.
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Abstract
 Background: The immune system, a complex set of integrated responses, often cannot be 
explained, predicted, or monitored by examining its separate components as biomarkers. Combi-
ning different components may therefore be a suitable approach to develop relevant biomarkers 
reflecting immune system functioning in an appropriate way. 
 Methods: Here we compute and test pattern variables that should reflect immune system 
functioning on the systems level. Computation was based on a dataset (from a randomized control-
led trial comparing two routes of administration) of allergen-specifically induced expression levels 
of cytokines (IL-1β, IL-5, IL-10, IL-12, IL-13, IL-17, IFN-γ and TNF-α) and symptom severity 
scores from 22 seasonal allergic rhinitis (SAR) patients measured before and after six weeks of 
treatment with medicinal products containing Citrus and Cydonia. By means of stepwise regres-
sion analyses we explored and tested pattern variables of the immunological data using permuted 
stepwise regression (PStR) to distinguish optimally between (immunological) baseline and post-
baseline data for the whole treatment group (22 patients) and the two separate treatment groups 
(11 patients in each group). The validity of the stepwise selection method for the computed pattern 
variables was tested by means of random permutation tests and evaluated with the cross-validated 
correct rate of classification (CV correct).
 Results: For the total group a pattern variable was computed with three variables: IL-10 
(day 7), TNF-α (day 1) and IL-10 (day 1) (CV correct: 0.91; p < 0.001; R2 = 0.66), demonstrating 
a small improvement from the model with IL-10 (day 7) only (CV correct: 0.84; p < 0.001; R2 = 
0.47). For the subcutaneous injection group a pattern variable was computed with four variables: 
IL-10 (day 7), IL-10 (day 1), IL-17 (day 7) and IFN-γ (day 7) (CV correct: 0.90; p < 0.01; R2  = 
0.78), demonstrating a very small improvement from the model with IL-10 (day 7) only (CV cor-
rect: 0.86; p < 0.01; R2 = 0.58). For the nasal spray group a pattern variable was computed with 
three variables: IL-10 (day 7), TNF-α (day 1) and IL-10 (day 1) (CV correct: 0.95; p < 0.01; R2 = 
0.79), demonstrating a moderate improvement from the model with IL-10 (day 7) only (CV cor-
rect: 0.79; p < 0.05; R2 = 0.37).
 Conclusion/discussion: In this study three robust systems biology-orientated biomarkers 
for the monitoring of SAR were computed that demonstrated small to moderate improvement 
compared to monitoring of a single cytokine (IL-10 (day 7)) (CV correct improvement: 0.07 (total 
group), 0.04 (subcutaneous injection group), 0.16 (nasal spray group)). Further computation and 
biomarker validation with larger datasets, including data from healthy persons and SAR patients, 
is indicated.
 Keywords: biomarkers, cytokines, systems biology, permuted stepwise regression, seaso-
nal allergic rhinitis, Citrus, Cydonia
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4.1  Introduction
  The immune system is increasingly found to participate in the development of several chro-
nic illnesses including allergy, thus motivating the targeting of the immune system to sustain health 
at all ages and to modulate the risk of certain chronic illnesses. Biomarker examination is a means 
of monitoring and validating such immunomodulatory approaches. These biomarkers are generally 
associated with communicatory molecules including cytokines, chemokines, acute-phase proteins, 
heat-shock proteins and antibodies. However, consensus on the appropriate markers to monitor the 
maintenance of a healthy immune system or the improvement of an imbalanced immune system 
remains elusive, primarily because biological heterogeneity precludes readily identifiable thres-
holds for the prevention of chronic disease (Albers et al., 2005; Kant, 2010). However, the use of 
a constellation of markers and proteomics, of which cytokines and cytokine receptors would be a 
major part, represent potential novel avenues of exploration (Jacobs et al., 2005). 
Since we expect no single marker to fully reflect immune status, since the analyses of multiple 
separate biomarkers can be difficult to interpret, and since most physiological systems are charac-
terized by homeostatic control with large interconnectedness between the elements of the system, 
combining analyses of various physiologically related biomarkers may prove suitable and efficient. 
To achieve this goal, analysis methods are used that are generally based on prevailing immuno-
logical hypotheses about the role of environmental factors (including allergens) in maintaining 
health and preventing disease. Alternatively, one can focus on generated applications that provide 
selected clusters of biomarkers indicative of immune activity and permit objective and quantita-
tive estimates of the effect of immune interventions and can predict associations with particular 
health outcomes. These (systems biology-orientated) methods usually combine feature selection 
with repeated sampling to investigate the main relations in the data, like for instance with permuted 
stepwise regression (PStR) (Andersson et al., 2009, 2011). 
In this study we focus on biomarkers for seasonal allergic rhinitis (SAR) or “hay fever”, a type 
I immediate hypersensitivity reaction mediated by specific IgE antibodies to a seasonal allergen, 
leading to chronic mucosal inflammation characterized by sneezing, itching, rhinorrhoea, and nasal 
blockage. An overactive population of allergen-specific Th2-type cells is generally detected in the 
affected organs - the nose, eyes, and upper respiratory system in SAR, but also in the peripheral 
blood mononuclear cell fraction (PBMC). The diverse CD4+ helper T cell populations consist of 
Th0, Th1, Th2, Th3, Th17, and Th22 cells, as well as various subsets of regulatory T cells (Akdis 
et al., 2004; Akdis and Akdis, 2009; Bonilla and Oettgen, 2010). These T cell subsets are identi-
fied based on the production of signature cytokines after exposure to the specific allergen, such 
as interferon-gamma (IFN-γ) from Th1 cells, interleukin (IL)-5 and IL-13 from Th2 cells, and 
IL-10 from regulatory T cells (Treg). The differentiation of Th1 cells is induced after activation of 
monocytes as antigen-presenting cells, subsequently producing IL-12p70 as the active cytokine. 
The generation of Th2 cells is dependent upon other environmental factors and various cytokines, 
including IL-10 itself (Fujimura and Okamoto, 2010; Chaplin, 2010).
Cytokine genes are only expressed after activation and full differentiation of the T cells, and 
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this production is highly variable among humans, partly due to an extensive degree of polymor-
phism in the cytokine genes. Therefore, in order to establish the effects of interventions, it is our 
hypothesis that it is critical to compare sets or patterns of cytokines rather than absolute levels of 
cytokine production in stimulated, cultured PBMCs with full differentiation of T cell subsets. 
Here we demonstrate the development and testing of a set of pattern variables for monitoring 
intervention effects in SAR patients. At first we explored and tested pattern variables of the immu-
nological data using permuted stepwise regression (PStR) to distinguish optimally between (im-
munological) baseline and post-baseline data. PStR is a technique for building statistical models 
automatically, by selecting variables from a pre-defined set of candidate variables and testing the 
significance of the complete selection procedure with random permutation (Andersson et al., 2009, 
2011). Computation was based on a dataset (from a randomized controlled trial comparing two 
routes of administration) of allergen-stimulated PBMC culture supernatant levels of cytokines (IL-
1β, IL-5, IL-10, IL-12, IL-13, IL-17, IFN-γ, and TNF-α) from 22 seasonal allergic rhinitis (SAR) 
patients measured before and after six weeks of treatment with either Citrus/Cydonia comp.® 
(compositum) 1% solution for injection or Gencydo® nasal spray (Baars et al., 2011).
The use of systems biology-orientated pattern variables should improve the separate biomarker 
approach in monitoring health related changes as a result of the effect of immune interventions. 
Therefore the following hypotheses were tested in this study: 
1. Even in a homogeneous group of SAR patients the individual production of cytokines is 
highly variable among humans, partly due to an extensive degree of polymorphism in the 
cytokine genes. This high variability will result in a broad range of cytokine production mea-
surements and a non-normally distributed dataset.
2. The computed (data-driven) pattern variables demonstrate larger cross-validated correct rate 
of classification (CV correct) values (Hellgren et al., 2008) than the separate cytokines with 
regard to the classification of cytokine samples in baseline and post-baseline.
3. The computed pattern variables demonstrate statistically significant baseline to post-baseline 
changes.
4.2  Materials and methods
4.2.1  Dataset
  Our dataset derived from a randomized, controlled trial with 22 SAR patients (Baars et al., 
2011) that studied the efficacy and safety of Citrus/Cydonia comp.® 1% solution of injection or 
Gencydo® nasal spray for the treatment of SAR. The two medicinal products are identical in their 
composition; the objective of the trial was identification of the more favorable route of adminis-
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Table 4.1. Baseline characteristics for the two treatment groups
Variable Citrus/Cydonia 
comp.
(n = 11)
Gencydo
(n = 11)
p-value
Sex: 
Number (percentage)
Male
Female
6 (55%)
5 (45%)
2 (18%)
9 (82%)
ns
Age (years) (sd) 37.0 (13.1) 37.6 (10.5) ns
Height (cm) (sd) 176.3 (9.6) 170.6 (7.4) ns
Weight (kg) (sd) 69.5 (10.6) 66.4 (8.9) ns
Smokers: 
number (percentage)
2 (18%) 1 (9%) ns
Alcohol consumption:
number (percentage)
None
Occasionally
Regularly
  0 (0%)
10 (91%)
  1 (9%)
3 (27.3%)
7 (63.6%)
1 (9%)
ns
Ethnic origin: 
number (percentage)
Caucasian
Asian
11 (100%)
  0 (0%)
9 (82%)
2 (18%)
ns
Blood pressure at 
screening (mmHg) (sd)
119 (24)/ 73 (14) 104 (16)/ 72 (9) ns/ns
Heart rate at screening 
(beats per minute)
72 (10) 70 (6) ns
RAST grass pollen 3.8 (1.3) 3.9 (1.1) ns
RAST birch pollen 1.9 (1.8) 2.3 (2.1) ns
Usual SAR symptom 
severity during the pollen 
season (total score anam-
nestically) (sd)
Sneezing
Itching nose
Watery nasal 
discharge
Total score
1.9 (0.5) 
1.8 (0.8)
1.9 (0.9)
5.6 (1.9)
2.3 (0.5) 
2.1 (0.5) 
2.1 (0.5)
6.5 (1.2)
ns
SAR symptom severity 
scores in the morning 
during the wash-out pe-
riod (total score) (sd)
6.6 (4.5) 8.0 (4.6) ns
SAR symptom severity 
scores in the evening 
during the wash-out pe-
riod (total score) (sd)
6.1 (3.7) 9.7 (5.2) ns
ns = not significant
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tration (subcutaneous injections versus nasal spray). The trial was a national (The Netherlands), 
stratified (age: 18-40 years or 41-60 years; and radioallergosorbent testing (RAST) scores (Quillen 
and Feller, 2006) for birch pollen: > 2 or < 3; with a balanced randomization for age and RAST 
scores), comparative, single-blind laboratory clinical trial with two parallel groups with 11 patients 
in each group. All eligible patients were recruited from a single center, the Louis Bolk Institute in 
Driebergen, NL. The first patient was enrolled on May 19, 2009 and the last patient completed the 
study on August 11, 2009.
4.2.2  Pollen counts
  Pollen counts were acquired on a daily basis for grass pollen and birch pollen from the 
Leiden University Medical Centre (http://www.lumc.nl/con/1070/85683/105795/105824/) during 
both the wash-out period and the treatment period.
4.2.3  Patients
 Eligible participants were all adults, aged 18 to 60 years, suffering from SAR for at least 
two years, with a RAST for grass pollen ≥ 2, and suffering from sneezing, itching nose, and wa-
tery nasal discharge, with a severity score of at least two of the three symptoms ≥ 2 (ranging from 
0 = not present to 3 = severe) and requiring the use of antihistamines and/or corticosteroids for 
treatment of SAR symptoms for at least the preceding two years. Exclusion criteria were chronic 
inflammatory autoimmune diseases, allergy (hypersensitive) to one of the constituents of Citrus/
Cydonia comp.® or Gencydo® nasal spray, pharmacological treatment of allergic rhinitis or use of 
other preparations containing Citrus and/or Cydonia extracts within the two weeks prior to study 
enrollment, use of cromoglycates in the last month before study onset, pregnancy or lactation, and 
severe internal or systemic disease. We also excluded patients with concomitant pharmacological 
treatment for SAR such as antihistamines, corticosteroids, or other preparations and patients who 
participated in another clinical trial simultaneously or within the four weeks prior to enrollment in 
this study. 
Baseline homogeneity of the treatment groups was accomplished with regard to the following 
SAR related aspects: RAST scores (grass pollen and birch pollen), worst SAR symptom severity 
during the previous pollen season (anamnestically), SAR symptom severity scores in the morning 
and the evening during the wash-out period and onset of interventions (data not shown). Homo-
geneity of the treatment groups was accomplished with regard to the following SAR non-related 
aspects: sex, age, height, weight, smoking status, ethnic origin, remaining medical history, prior 
medication, vital signs and physical examination (Table 4.1).
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4.2.4  Treatment 
  After a one-week (for patients that had not been treated for SAR in the week before enroll-
ment) or a two-week (for patients that had been treated for SAR in the week before enrollment) 
wash-out period, patients were assigned to four strata and then randomized to a six-week treatment 
period. A randomization list was generated with the Random Allocation Software Program version 
1.0 (Saghaei, Isfahan University of Medical Sciences, Iran) using a random block size of two in 
order to guarantee a balanced allocation. 
Patients received the treatment in accordance with the Summary of Product Characteristics; ei-
ther Citrus/Cydonia comp. 1% subcutaneous injections (1 mL ampoules, available under the trade 
name Gencydo® 1%, manufacturer Weleda AG, Schwäbisch Gmünd, Germany) twice per week, 
or the Gencydo nasal spray (available under the name “Gencydo neusspray” in the Netherlands, 
manufactured by Weleda AG, Schwäbisch Gmünd, Germany) four times per day (1-2 sprays in 
each nostril). This strategy resulted in the nasal spray group receiving four times the active dose 
compared with the injection group. Citrus/Cydonia comp. 1% solution for injection and Gencydo 
nasal spray are medicinal products that contain identical amounts of lemon juice (Citrus limon) and 
aqueous extract from the fruit of a quince (Cydonia oblonga). One milliliter of these preparations 
contains 8-12 mg C. limon juice corresponding to 0.65 mg fruit acid, calculated as citric acid, and 
30 mg C. oblonga aqueous extract (drug-extraction-rate 1:2.1). 
For more than eighty years, Citrus/Cydonia comp. has been prescribed for SAR patients. Cli-
nical experiences (De Bruin and Baars, 2001), three in vitro studies (Baars and Savelkoul, 2008; 
Gründemann et al., 2010), two cohort studies (Baars and De Bruin, 2005; Rother and Oexle, 2008), 
and a randomized controlled trial (Baars et al., 2011) support the efficacy and safety of Citrus/
Cydonia comp. and Gencydo, respectively, in SAR treatment.
4.2.5  Efficacy variables
  Primary efficacy variables: Cytokine analyses
 Primary endpoints were SAR-related changes in immunological parameters between the 
start of the treatment (baseline) and after six weeks of treatment (post-baseline). From each patient 
8 mL of peripheral blood were collected; PBMCs were isolated. PBMCs were cultured in Yssel’s 
medium at 37ºC in a humidified atmosphere with 5% CO2 at a density of 1x106 viable cells/mL. 
Cells were plated out in 48 well plates at a concentration of 1x106 cells/mL and cultured at 37ºC. 
After five hours, in which the cells adapted to the culture conditions, various stimuli or a matching 
volume of medium were added. Cultures were stimulated polyclonally with 150 ng/mL anti-CD3 
plus 100 ng/mL anti-CD28 monoclonal antibodies (BD Pharmingen, San Diego, CA, USA) or cul-
tured in medium only (Jeurink et al., 2008). In addition, we performed allergen-specific stimulation 
of 106 cells/mL in 1 mL cultures with applied pollen extract (Phl p 1 from Timothy grass [Phleum 
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pratense]; Biomay Vienna, Austria; 10 μg/mL in medium). The proliferation capacity, cell survi-
val, toxicity, and total production capacity of several cytokines in the culture supernatants of the 
PBMCs were analyzed at day 1 (IL-1β, IL-10, IL-12, IL-17, IFN-γ, and TNF-α: demonstrating the 
reaction of the innate immune system) and at day 7 (IL-5, IL-10, IL-12, IL-13, IL-17, and IFN-γ: 
demonstrating the reactions of specialized T cell subsets) (Akdis et al., 2004; Chaplin, 2010) es-
sentially according to well-established procedures (Jeurink et al., 2008). Examples of the reasons 
to choose these specific cytokines to monitor immunological SAR treatment effect (Ozdemir et al., 
2009; Deraz, 2010) (for more detailed information, see: Baars et al., 2011) are: 
1. (Grass pollen stimulated minus medium stimulated) IL-10 and TNF-α at day 1: representing 
the inflammatory state of the SAR-related immune system
2. (Grass pollen stimulated minus medium stimulated) IL-10 at day 7: representing (regulatory) 
T cells (Tregs)
3. (Grass pollen stimulated minus medium stimulated) IFN-γ at days 7: representing Th1 activity
4. (Grass pollen stimulated minus medium stimulated) IL-1β at day 1; IL-5 and IL-13 at day 7: 
representing Th2 activity
Cytokine production was detected with the Cytometric Bead Array (CBA, BD Biosciences, San 
Diego, CA, USA). All buffers used in this protocol were obtained from the BD CBA Soluble Pro-
tein Master Buffer Kit (BD Pharmingen, San Diego, CA, USA) and the procedure was performed 
according to the manufacturer’s protocol. The detection limits were 1.1 pg/mL for IL-1β, 2.2 pg/
mL for IL-12p70, 0.3 pg/mL for IFN-γ, 0.7 pg/mL for TNF-α, 1.1 pg/mL for IL-5, 0.13 pg/mL for 
IL-10, 0.6 pg/mL for IL-13, and 0.3 pg/mL for IL-17. Levels below the detection level could not be 
measured reliably, but still might have exerted a biological effect. Nevertheless for the statistical 
analyses of the data a real value needed to be entered. For that reason a value of  “0” was selected 
for all production levels below the detection level. The samples were measured on the FACSCanto 
II, using Flow Cytometry Analysis (FCAP) software (BD Biosciences, San Diego, CA, USA). 
   Secondary efficacy variables: Symptom severity
 Secondary efficacy variables were the change in nasal and non-nasal allergic rhinitis 
symptom severity before treatment start and after each week of treatment. The severity of nasal 
symptoms (nasal obstruction, itching nose, sneezing, and watery nasal discharge) and non-nasal 
symptoms (itchy/burning eyes, watery eyes, redness of eyes, and itching ears/throat) were recor-
ded twice per day (in the mornings and evenings) by the patient. The disease-specific severity 
questionnaire was provided to the patient as an online questionnaire in Dutch: 0 = no symptom, 1 
= mild, 2 = moderate, and 3 = severe. Completion of the online questionnaires by the participants 
was checked daily. Total symptom scores (TSS) were analyzed during wash-out, and in treatment 
weeks 1-5. Due to a very low pollen count during week 6, the data from week 6 were excluded 
from the analyses (for more detailed information see: Baars et al., 2011). Missing values were re-
placed in two ways, mean week scores and Last Observation Carried Forward (Waladkhani, 2008), 
and subsequently compared. 
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4.2.6  Statistical analysis
   Software
 Statistical analyses were performed with SPSS 17.0 (SPSS Inc., Chicago, USA) and with 
Matlab version 7.11.0 (R2010b, The Mathworks, Natick, MA, USA).
   Statistical analyses of the primary efficacy variables: Cytokine analyses
 To test the effectiveness of Citrus/Cydonia comp. 1% solution for injection as compared to 
Gencydo nasal spray with respect to the primary target variables, descriptive statistics, Student’s 
t-tests, and non-parametric Wilcoxon Signed Ranks tests were performed to compare means and 
mean base-10 log transformed scores of the immunological parameters in both groups. 
In order to demonstrate the high variability of the cytokine production levels in homogenous 
groups means, ranges and skewness ratios of all cytokines were analyzed. A skewness ratio (statis-
tic/ Standard Error) < 2 or >2 was regarded as a non-normal distribution. 
   Statistical analyses of the secondary efficacy variables: Symptom severity
 Mean scores and standard deviations were calculated for each week. Then, Student’s t-
tests, non-parametric Wilcoxon Signed Ranks tests, and multivariate analysis techniques were used 
to compare the symptom severity mean week scores in the subcutaneous and the nasal spray group 
for each of the five weeks.
  Computation of pattern variables by means of permuted stepwise regression (PStR) 
 To identify potential pattern variable biomarkers of interest, immunological samples from 
all 22 SAR patients were analyzed at baseline and after 6 weeks of treatment. In addition, baseline 
to post-baseline changes were separately analyzed for the two treatment groups (Gencydo nasal 
spray and Citrus/Cydonia comp. 1% solution for injection) .
The permuted stepwise regression procedure as described in Andersson et al. (2011) was ap-
plied on immunological data. Stepwise regressions with five different methods (forward stepwise 
selection (StepwiseForwardP) and stepwise selection (StepwiseP) using fine tuning with lower 
p-values to select variables for inclusion in the model (Draper and Smith, 1998), least absolute 
shrinkage and selection operator (Lasso) (Efron et al., 2004; Tibshirani, 1996), a rescaled version 
of Lasso (ConeLasso) and orthogonal matching pursuit (OMP) (Mallat and Zhang, 1993)) were 
computed to find subsets of cytokines that permitted the classification of cytokine samples in base-
line and post-baseline. Sets of potential regression models were generated using a minimum of one 
and a maximum of nine cytokines. Final selection of reliable subsets of explanatory cytokines was 
based on random permutation tests with permuted subjects and repeated measures permuted within 
subjects. Random permutation tests were performed on the complete stepwise regression procedu-
re including the selection of subsets of cytokines based on the highest R2. For each maximum num-
ber of cytokines, we tested for 9999 permutations whether the permuted R2 was equal to or above 
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90% of the calculated true R2. In other words, we assessed if there was a significant gap (10%) 
between the calculated true R2 and the distribution of all permuted R2s. Random permutation tests 
resulting in a p-value below 0.05 were considered significant. The cross-validated correct rate of 
classification, CV correct, was computed with 5-fold cross-validation averaged over 20 replication
4.3 Theory
4.3.1  Computation of systems biology-orientated biomarkers 
  Systems biology aims at a more holistic understanding of biology (Chong and Ray, 2002), 
a systems-level understanding. This objective requires an examination of the structure and dyna-
mics of function in cells and organisms, rather than the characterization of isolated parts of a cell 
or organism (Kitano, 2002).
 In order to develop systems biology-orientated biomarkers capable of monitoring health and 
disease-specific changes at the systems level, one can compute pattern variables that are either 
(more) data-driven or (more) hypothesis-driven. Computation of data-driven patterns variables in-
vestigates the relationships among all measured immunological components of the studied disease. 
Computation of hypothesis-driven patterns variables is based on investigating the relationships 
among a subset of previously, theoretically identified and relevant immunological components of 
the studied disease.
4.4 Results
4.4.1 Raw immunological data set of a homogeneous group of SAR patients 
demonstrating a broad range of cytokine production and a non-nor-
mal distribution
 The hypothesis tested here was that even in a homogeneous group of SAR patients (see 
2.3) the individual production of cytokines is highly variable among humans, partly due to an 
extensive degree of polymorphism in the cytokine genes as a potential, but likely, explanation. 
This high variability will result in a broad range of cytokine production measurements and a non-
normally distributed dataset. Tables 4.2 and 4.3 show the baseline and post-baseline cytokine pro-
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Table 4.2. Baseline and post-baseline measurements of cytokine production levels of separate cytokines 
demonstrating broad ranges and non-normal distributions of data Gencydo group)
Baseline Post-baseline
Variable Mean (SD) Range Skewness
(statistic/ SE)
Mean (SD) Range Skewness
(statistic/ SE)
Day 1:  
innate  
immunity
IL-1b# 42 (106.5) 1-362 0.65 70.7 (181.0) 2-615 4.48*
IL-10 79.4 (51.4) 11-187 1.17 62.8 (41.5) 12-136 1.98
IL-12 0.2 (0.5) 0-2 n.a. 0 0 n.a.
IL-17 0.4 (1.0) 0-3 5.02* 0.2 (0.8) 0-3 n.a.
IFN-γ 1.5 (2.4) 0-7 4.58* 2.8 (4.9) 0-15 4.97*
TNF-α 43.4 (46.9) 8.1-170.6 2.02* 48.1 (49.8) 3.8-156.3 3.96*
Day 7: 
specific T 
cell subsets
IL-10 314.8 
(250.7)
61.0-890.2 3.87* 172.3 
(133.3)
54.4-500.9 3.29*
IL-12 0.6 (0.9) 0-2.5 0.12 1.3 (1.7) 0-5.3 1.40
IFN-γ 2,010.4 
(2,361.8)
112.3-
6,578.3
1.73 1,089.1 
(1,231.8)
52.8-3,345.6 3.69*
IL-5 301.7 
(257.3)
12.7-881.2 2.65* 205.4 
(126.8)
43.0-450.3 1.79
IL-13 271.6 
(281.9)
32.3-912.2 4.78* 176.3 
(180.8)
30.7-656.7 3.40*
IL-17 168.4 
(150.0)
4.4-483.7 2.08* 200.7 
(265.6)
3.5-785.5 1.41
# all cytokine measurements are in pg/mL 
* Skewness ratio (statistic/SE) < -2 or > 2
SD = standard deviation
SE = Standard error of skewness
n.a. = Not applicable
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Table 4.3. Baseline and post-baseline measurements of cytokine production levels of separate cytokines 
demonstrating broad ranges and non-normal distributions of data (Citrus/Cydonia comp. group)
Baseline Post-baseline
Variable Mean (SD) Range Skewness 
(statistic/ SE)
Mean (SD) Range Skewness 
(statistic/ SE)
Day 1: 
innate im-
munity
IL-1β# 6.5 (3.0) 2-12 4.96* 146.9 (319.9) 2-1079 4.96*
IL-10 113.1 (80.9) 16-252 1.50 122.2 (90.3) 34-330 0.70
IL-12 0 0 n.a. 0.2 (0.4) 0-1 0
IL-17 0.3 (1.0) 0-3 3.93* 0 0 n.a.
IFN-γ 1.0 (2.7) 0-9 2.25* 6.4 (19.8) 0-66 3.06*
TNF-α 51.9 (38.9) 15.7-136.2 3.48* 28.0 (33.4) 4.2-122.2 2.23*
Day 7: 
specific T 
cell subsets
IL-10 252.3 
(291.1)
34.5-1,066.8 1.85 297.1 
(275.6)
82.6-1,024.5 2.44*
IL-12 1.2 (1.2) 0-2.7 1.89 1.1 (1.2) 0-3.7 1.81
IFN-γ 2,428.4 
(2,458.4)
124.2-
7,371.9
1,93 1,722.3 
(1,206.9)
635.7-
5,076.9
1.72
IL-5 455.4 
(518.4)
39.4-1,747.4 1.80 329.3 
(219.0)
75.0-797.9 0.87
IL-13 706.9 
(1,598.8)
16.2-5,458.9 2.26* 412.6 
(573.6)
34.7-1,934.0 3.17*
IL-17 61.6 (65.7) 2.7-206.5 1.21 152.6 
(144.7)
12.4-433.3 2.15*
# all cytokine measurements are in pg/mL 
* Skewness ratio (statistic/SE) < -2 or > 2 
SD = standard deviation
SE = Standard error of skewness
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Table 4.4. The computation of an optimal pattern variable model by means of a permuted stepwise regression 
(PStR) on all cytokines for the total group
N R2 P-value Method CV  
correct
N of 
var.
Variables in the model Regression weights 
of variables
Inter-
cept
44 0.47 0.0002 CL 0.84 1 IL10d7 -0.85 2.21
44 0.58 0.0002 StFP 0.88 2 IL10d7 IL10d1 -1.07 0.53 1.67
44 0.56 0.0003 L 0.87 2 IL10d7 TNFd1 -0.89 -0.37 2.83
44 0.66 0.0002 OMP 0.91 3 IL10d7 TNFd1 IL10d1 -1.10 -0.37 0.52 2.29
CL = ConeLasso
L = Lasso
StFP = Stepwise Forward Procedure
OMP = Orthogonal Matching Pursuit
Table 4.5. The computation of an optimal pattern variable model by means of a permuted stepwise regres-
sion (PStR) on all cytokines for the Citrus/Cydonia group
N R2 P-
value
Method CV 
cor-
rect
N 
of 
var.
Variables in the model Regression weights 
of variables
Inter-
cept
22 0.58 0.0064 L 0.86 1 IL10d7 -0.86 2.23
22 0.66 0.0083 L 0.85 2 IL10d7 IL10d1 -1.05 0.50 1.76
22 0.74 0.0063 L 0.87 2 IL10d7 IL10d1 IL17d7 -1.22 0.60 0.23 1.49
22 0.78 0.0085 L 0.9 3 IL10d7 IL10d1 IL17d7 IFN-G d7 -1.22 0.76 0.26 -0.21 1.75
L = Lasso
Table 4.6. The computation of an optimal pattern variable model by means of a permuted stepwise regres-
sion (PStR) on all cytokines for the Gencydo group
N R2 P-
value
Method CV 
correct
N of 
var.
Variables in the model Regression weights 
of variables
Inter-
cept
22 0.37 0.0133 StFP 0.79 1 IL10d7 -0.85 2.19
22 0.59 0.0012 StFP 0.86 2 IL10d7 TNFd1 -0.85 -0.60 3.06
22 0.79 0.0018 StFP 0.95 2 IL10d7 TNFd1 IL10d1 -1.21 -0.64 0.80 2.26
CL = ConeLasso
L = Lasso
StFP = Stepwise Forward Procedure
OMP = Orthogonal Matching Pursuit
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Figure 4.1. The additional effect of TNF-α for the Gencydo group but not for the Citrus/Cydonia comp. 
group with regard to the classification of cytokine samples in baseline and post-baseline as compared to the 
effect of IL-10 for both groups; CCc = Citrus/Cydonia comp.; Gen = Gencydo; 0 = baseline; 1 = post-baseline
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duction levels of the patients included in the SAR study. The tested hypothesis was confirmed, 
since more than 55.8% (24/43) of the cytokine data were not normally distributed, and the broad 
range of all cytokine measurements in both treatment groups demonstrated the large variations 
from subject to subject. The non-normal distribution of the dataset implied the necessity of base-10 
log transformation of all data.
4.4.2 The computation of pattern variables using PStR that would demon-
strate larger CV correct values than the separate cytokines and statis-
tically significant baseline to post-baseline changes
 It was hypothesized that we were able to compute (data-driven) pattern variables that 
would demonstrate larger CV correct values than the separate cytokines with regard to the classifi-
cation of cytokine samples in baseline and post-baseline. In addition it was hypothesized that these 
pattern variables would demonstrate statistically significant baseline to post-baseline changes. Af-
ter base log 10 transformation of all cytokine data, we performed a permuted stepwise regression 
(PStR) on all cytokines for the total group, the Gencydo group and the Citrus/Cydonia group with 
all five different regression approaches. Only the statistically significant results are presented here.
For the total group a pattern variable was computed with three variables: IL-10 (day 7), TNF-α 
(day 1) and IL-10 (day 1) (CV correct: 0.91; p < 0.001; R2 = 0.66) (Table 4.4, 4th row: N of varia-
bles = 3), demonstrating a small improvement compared to the model with IL-10 (day 7) only (CV 
correct: 0.84; p < 0.001; R2 = 0.47) (Table 4.4, 1st row: N of variables = 1). 
For the subcutaneous injection group a pattern variable was computed with four variables: IL-
10 (day 7), IL-10 (day 1), IL-17 (day 7) and IFN-γ (day 7) (CV correct: 0.90; p < 0.01; R2 = 0.78) 
(Table 4.5, 4th row: N of variables = 4), demonstrating a very small improvement compared to 
the model with IL-10 (day 7) only (CV correct: 0.86; p < 0.01; R2 = 0.58) (Table 4.5, 1st row: N 
of variables = 1). For the nasal spray group a pattern variable was computed with three variables: 
IL-10 (day 7), TNF-α (day 1) and IL-10 (day 1) (CV correct: 0.95; p < 0.01; R2 = 0.79) ) (Table 
4.6, 3rd   row: N of variables = 3), demonstrating a moderate improvement compared to the model 
with IL-10 (day 7) only (CV correct: 0.79; p < 0.05; R2 = 0.37) (Table 4.6, 1st row: N of variables 
= 1). The random permutation tests for the three pattern variables resulted in p-values of 0.0002 
(total group), 0.0085 (Citrus/ Cydonia comp.) and 0.0018 (Gencydo), demonstrating valid, robust 
prediction models with significant differences between baseline and post-baseline.
Figure 4.1 demonstrates the importance of TNF-α (day 1) in addition to IL-10 (day 7) for the 
classification of cytokine samples in baseline and post-baseline, for the Gencydo group but not for 
the Citrus/Cydonia comp. group. For both groups there is a significant difference between baseline 
(0) and post-baseline (1) for IL-10 (day 7) (horizontal level of Figure 4.1). For TNF-alpha (vertical 
level of Figure 4.1) this was only the case for the Gencydo group. 
The tested second and third hypotheses were confirmed, since we were able to compute three 
robust statistically significant pattern variables that demonstrated larger CV correct values than 
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the separate cytokines with regard to the classification of cytokine samples in baseline and post-
baseline. The computed pattern variables demonstrated also statistically significant baseline to 
post-baseline changes.
4.4.3  Summary of the results of the secondary efficacy variables symptom 
severity and safety
 Both routes of administration demonstrate a statistically significant reduction in SAR 
symptom severity, with larger effects of the subcutaneous route of administration. In the Citrus/
Cydonia group a statistically significant SAR symptom reduction was measured already after one 
week and two weeks of treatment, in the morning and the evening, respectively. In the Gencydo 
group a statistically significant SAR symptom reduction was measured already after two weeks of 
treatment in the evening. TSS reduction of the subcutaneous route of administration was larger in 
the morning, but not in the evening. Cohen’s delta effect sizes were larger for the subcutaneous 
route of administration (= large) than the nasal spray route of administration (= medium), both in 
the morning and the evening. During the treatment period, a total of 9 adverse events (AEs) were 
observed with none of the AEs classified as serious. Also the in vitro analyses demonstrated ac-
ceptable cell survival, with no signs of toxicity. The overall conclusion of the safety analysis in this 
study is that both routes of administration of Gencydo and Citrus/Cydonia comp. are safe for use 
by SAR patients (for more detailed information about the secondary efficacy variables, see: Baars 
et al., 2011).
4.5 Discussion
 In this study at first we confirmed the problem of high inter-individual variability of cyto-
kine production among humans for the use of separate cytokines as biomarkers. Even in this study 
with a controlled, homogeneous group of SAR patients, the individual production of cytokines was 
highly variable. This wide individual biological variability in cytokine production levels may arise 
from factors such as circadian rhythm, sex, age, and smoking status (De Roos & MacArdle, 2008; 
Duramad et al., 2004). Alternatively, the observed inter-individual variability might be partly due 
to an extensive degree of polymorphism in the cytokine (receptor) genes as a potential, but likely, 
explanation (Kubistova et al., 2006). Therefore three robust, systems biology-oriented, pattern 
variable biomarkers for the monitoring of SAR were computed, that demonstrated small to mode-
rate improvement in the classification of cytokine samples in baseline and post-baseline compared 
to the monitoring of the separate cytokine (IL-10 (day 7)) (CV correct improvement: 0.07 (total 
group), 0.04 (Citrus/Cydonia group), 0.16 (Gencydo group)). This study therefore provides a new 
and solid strategy in the field of immunology for the development of objectively quantifiable, high-
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quality biomarkers that are relevant to the analysis of potential activity of new therapeutics for the 
treatment of allergic diseases. The procedure that is successfully used in other new scientific areas 
like for example proteomics (Kim et al., 2010), is expected to be widely applicable in immune-
mediated diseases.
Currently, in immunological research practice, multiple cytokines in particular are often mea-
sured in relation to immune responses under diseased conditions or in response to treatments. Ho-
wever, the interpretation of these observed data is most often subjective and based on the relative 
importance of some, but not all, different cytokines. This obscures the validity of the observed im-
mune responses and compromises the comparison of different studies in literature. The presented 
approach in this study provides an improvement for this situation by offering an objectively hand-
ling of the complete cytokine response and making the data available for objective and standardi-
zed analysis in patients.
The presented approach is also an improvement for statistical procedures that analyze several 
predictive variables at the same time and by doing that, provide more information than by analyzing 
separate variables. Like in proteomics, genomics, metabolomics, etcetera, extracting useful multi-
variate relations from measured data is not so straightforward and an ongoing learning process. We 
think that this relative new methodology, combining stepwise regressions with permutation tests, 
can offer valuable insights in immunological multivariate relations. With respect to the stepwise 
regressions relationships among multiple variables predicting a response can be modeled addi-
tive in a linear or multiplicative way. The resulting regression weights define the optimal balance 
between the predictive variables for obtaining the most accurate prediction. Imagine an example 
with two predictors where the difference between the variables or the product of the variables (the 
interaction) is related to the response. The specific additive or multiplicative relation can be found 
by applying respectively linear or loglinear regression with the two predictors. One can intuitively 
understand that the relations found in regression models can compensate for the high variability in 
the predictors by realizing that the predicted values are proportional to the weighted mean of the 
predictors with weights fixed to the regression weights. As long as there is no overfitting the weigh-
ted mean will have less variability than the separate predictors. In the methods presented here the 
permutation tests monitor the robustness of the stepwise regressions and prevent overfitting.
The results provide also relevant information for the comparison of the immunological effects 
of the nasal (Gencydo) and the subcutaneous (Citrus/Cydonia comp.) route of administration of 
these effective treatments for hay fever. For both groups the most important effects come from IL-
10 (day 7), which reflect modulation of differentiated Treg activity. However, for the nasal spray 
route of administration in addition TNF-α (day 1) and IL-10 (day 1) contribute to the treatment ef-
fect (CV correct improvement of 0.16). The production level of monocyte-derived TNF-α and IL-
10 reflects the local chronic SAR-related inflammatory activity between baseline and post-baseline 
In addition, the observed kinetics at day 7 after allergen-specific stimulation, reflects the activation 
state of the immune system due to the activity of monocytes, which are the largest producers of 
IL-10 in the PBMC, and induced already by day 1 after allergen exposure. Subsequently, also the 
gradual and delayed induction of regulatory T cell subset (Treg) by day 7 will be inhibited as these 
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cells use the IL-10 as a selective autocrine growth factor (Akdis et al., 2004; Akdis and Akdis, 
2009; Kant, 2010). The observed kinetics can be interpreted as a decrease in the activation state of 
the immune system due to a decrease in the activity of monocytes and a reduction of the chronic 
inflammation (TNF-α (day 1)). This additional effect can be attributed to the acute local effect of 
the nasal spray route (for more detailed information, see: Baars et al., 2011).
There are two major theoretical arguments for an increasing focus on a pattern-oriented or a 
systems biology approach for the development of valid immune system biomarkers. First, focusing 
on the pattern of relationships overcomes the large inter-individual variations in cytokine produc-
tion. Since these relationships, other than the calculated mean scores of separate immunological 
components, are independent of the absolute magnitude of the component’s production, individual 
changes can be compared more precisely. Second, studying the systems-level changes in the re-
lationships among separate immunological components accounts for the observation that changes 
in the production of one immunological component can lead to compensatory changes in others 
(Atkinson et al., 2001). 
The systems biology-oriented approach for developing biomarkers may also innovate outcome 
studies in SAR treatment (Kitano, 2002). Until now, in designing SAR outcome studies, clinical 
symptoms have been regarded as primary efficacy parameters, and immunological parameters are 
relegated to a secondary status (EMEA, 2002); indeed, measurements of separate immunological 
parameters are often unreliable. The systems biology-oriented pattern variables proposed in this 
study offer a first step toward reliable biomarkers of immune activity that could be used in SAR 
outcome research. Similar approaches could result in the development of reliable immune system 
biomarkers for use in different studies and different diseases. Additionally, our results support a 
holistic, systems-biology view of the immune system in terms of practical application. 
The major limitations of this study are the small group sizes (11 patients in each group) and the 
absence of data from healthy persons and from categories of SAR patients with varying symptom 
severities. The small group sizes may have resulted in imprecise computation of the pattern vari-
ables, since larger samples provide more precise calculations. The absence of data from healthy 
persons and categories of SAR patients prevented to study in a more controlled setting the diffe-
rences between health and (levels of) disease. We expect that computation with a larger and better 
dataset will provide larger differences between results based on computing pattern variables and 
results based on analyzing only separate variables. The presented study must therefore be regarded 
as a first study exploring the possible contribution of permuted stepwise regression approaches to 
the development of pattern variables that reflect immunological activity on the system level, with 
promising results.
Future (replication) studies on the applicability of this PStR procedure to SAR are indicated 
with larger populations, with categories of SAR patients with varying symptom severities, and 
with a control group of healthy persons. These study design changes will allow the computation 
of pattern variables that are able to distinguish among disease severities and between disease and 
health more precisely. This PStR procedure may also be applicable to other immune-mediated 
diseases; datasets describing rich cytokine sets will determine the critical parameters that can be 
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combined in the various pattern variables. 
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PART 3
Empirical studies on the efficacy and safety  
of the curative health promotion treatment  
of seasonal allergic rhinitis  
with Citrus/Cydonia comp.
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Chapter 5
Citrus/Cydonia Comp. 
for Seasonal Allergic Rhinitis 
 
Use in General Practice
Practice-based evidence from a survey among anthroposophic doctors* 
E.W. Baars & A. de Bruin
* This is a summary and arrangement from the publication by A. de Bruin & E. Baars (2001), 
“Citrus/Cydonia comp. use in general practice. A survey among anthroposophic physicians. Driebergen: 
Louis Bolk Instituut” for use in this thesis.
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Abstract
 Background: In order to become currently accepted in conventional medicine, CAM 
streams have to develop practice-based evidence and subsequently evidence-based practices. 
 Objective: To obtain an overview of the experiences of Dutch Citrus/Cydonia comp. pres-
cribing anthroposophic doctors with the treatment of seasonal allergic rhinitis (SAR). This provi-
des the first practice-based evidence on anthroposophic SAR treatment. 
 Methods: A survey was sent to 80 doctors of the Dutch Association of Anthroposophic 
Physicians (NVAA). After two weeks a reminder was sent to the non-responders. 
 Results: The subcutaneous route of administration of Citrus/Cydonia comp. is the most 
favoured, with the nasal spray route of administration coming a close second. There is much vari-
ation between doctors in the way they prescribe Citrus/Cydonia comp. regarding the period of the 
year, the concentration, and frequency of the prescribed drug. Doctors combined the use of Citrus/
Cydonia comp. with other medicinal or non-medicinal therapies for a large group of their patients. 
More than 50 percent of the doctors expect an effect within two weeks, and 94 percent of the 
doctors expect to see an effect within three months after treatment onset. One-third of the doctors 
indicated that they had sometimes observed side effects on administration of Citrus/Cydonia comp. 
(most often pain (due to the injection or injection fluid) or local skin reactions).  
 Conclusion/ Discussion: There is first practice-based evidence based on the expert know-
ledge of prescribing doctors that the anthroposophic SAR treatment with Citrus/Cydonia comp. 
(with or without additional therapies) is safe and effective. Further intervention studies are indica-
ted. 
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5.1 Introduction
 Citrus/Cydonia compositum (comp.) is an anthroposophic medicine, which contains ex-
tracts of lemon (Citrus limon (L.) Burm. f.) and quince (Cydonia oblonga Mill.) (De Bruin and 
Baars, 2001). It has been prescribed in clinical practice in Europe for more than 80 years to patients 
with hay fever or seasonal allergic rhinitis (SAR). In this period, anthroposophic doctors have em-
pirically developed expert knowledge regarding the (side) effects, routes of administrations, and 
the necessity of co-medication/ co-therapies of Citrus/Cydonia comp. in SAR treatment. 
However, in this evidence-based medicine period, expert knowledge is insufficient funda-
ment for medical professionalism. In order to become scientifically accepted in medicine, expert 
knowledge must be explicated, embedded in valid theories, systematized in protocols, guidelines 
or healthcare programmes, and subsequently tested in increasingly more controlled ways (e.g. 
starting with routine outcome monitoring on effects, safety and patient satisfaction up to placebo-
controlled randomized clinical trials). 
This study took the first step in the development of practice-based evidence by explicating the ex-
pertise of anthroposophic doctors experienced in prescribing Citrus/Cydonia comp. in SAR treatment.
5.2 Methods
 A new questionnaire was designed by the researchers of the Louis Bolk Instituut in Drie-
bergen, the Netherlands. The questionnaire consisted of both open and closed questions, covering 
three domains: (1) general information on practice and expertise of the doctors; (2) experiences 
with diagnosis, prescription behaviour and side effects of Citrus/Cydonia comp. in SAR treatment, 
and (3) experiences with the effectiveness of Citrus/Cydonia comp. in SAR treatment.
After a thorough evaluation on face-validity by a small group of anthroposophic doctors, the 
questionnaire was approved and distributed by mail amongst anthroposophic general practitioners 
as well as to consultative working doctors who are all connected to the Nederlandse Vereniging van 
Antroposofische Artsen (NVAA) (Dutch Association of Anthroposophic Physicians). In total, 80 
questionnaires were sent out. After two weeks a reminder was sent to the non-responders. 
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5.3 Results
5.3.1 Response rate
 A total of 39 of 80 sent questionnaires were completed and returned to the research insti-
tute, providing a response rate of 49 percent.
5.3.2 Practice and patient characteristics
 The responding doctors were both general practitioners and consultative working doctors. 
The average number of patients in their practices was 1,960 (range: 100 - 3,500). Seventy percent 
of the doctors treated, on average, between 10 and 50 SAR patients annually per season per prac-
tice. Based on this doctor population (n=39), this means that the experiences with SAR treatment 
is based on, in total, between 570 and 1,650 SAR patients treated per season. Both GPs and (of 
course) consultants treat patients on a consultative basis. However, 78 percent of the GPs state that 
the proportion of patients treated on a consultative basis is less than 10 percent of the total number 
of patients treated for SAR.
5.3.3 Forms of administration
 Citrus/Cydonia comp. was available in several forms on the Dutch market: as ampoules, 
nasal spray, salve, and eye drops. In general practice, the main forms prescribed were ampoules, 
eye drops and nasal spray. The salve was rarely prescribed. Of the three commonly prescribed 
forms, the doctors demonstrated a preference for ampoules administrated as subcutaneous injec-
tions (30 doctors). The nasal spray was their second choice (17 doctors). The main reason for this 
preference was the anticipated effect of the subcutaneous route of administration. The main reason 
for prescription of the nasal spray was the local effect, since the SAR symptoms are restricted to 
nasal symptoms in most patients. Another reason for prescribing the nasal sprays was that this 
method of administration is free of the (sometimes) painful side effects of the injections. 
5.3.4 Use of Citrus/Cydonia comp. in SAR treatment 
 Eighty percent of the doctors used Citrus/Cydonia comp. as a basic remedy in SAR treat-
ment. There was a great deal of variation in the time of the year doctors prescribe Citrus/Cydonia 
comp. More than 25 percent of the doctors only treated patients prophylactically with Citrus/Cydo-
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nia comp., while more than 60 percent treated patients both before and during the pollen season. In 
addition, approximately 50 percent of the doctors treated patients with Citrus/Cydonia comp. only 
during the pollen season. The reason was that many patients only visit the doctor when they have 
symptoms, and this is, of course, during the pollen season. 
Not only the timing of the treatment by doctors, but also the concentrations of Citrus/Cydonia 
comp. ampoules used to treat SAR patients varied between doctors. All the concentrations (0.1% 
- 7%) were administered in practice, but the 0.1%, 1% and 5% concentrations were particularly 
commonly prescribed (by 19, 30 and 21 doctors, respectively). The two lowest concentrations 
(0.1% and 1%) together accounted for 65 percent of the prescribed ampoules.  
Regarding the frequency of the administered injections, the doctor’s preference depended part-
ly on the time of treatment: prior to or during the pollen season. Prior to the pollen season, eighty 
percent of the doctors administered the injections twice per week, and only 13 percent once per 
week. During the pollen season, the frequency of injections varied between two and three times per 
week, given to 37 percent and 47 percent of SAR patients, respectively. However, the frequency 
did not depend only on the period in which the injections were administered; it could also be influ-
enced by the patient’s reaction to the injections. No or little reduction of symptoms could lead to 
an increase of the frequency of administration.
5.3.5 Simultaneous use of other therapies
 Ninety-eight percent of the doctors sometimes or always prescribed another medication for 
simultaneous use with Citrus/Cydonia comp. The percentage of doctors who sometimes or always 
prescribed Citrus/Cydonia comp. simultaneously with another non-medicinal therapy was slightly 
lower, but still high (74%). The simultaneous use of other forms of therapy was mainly due to the 
fact that the doctors wished to increase the efficacy of the SAR treatment. 
Concerning simultaneous use of other medicinal therapy, the doctors mainly indicate that they 
prescribe other medicines to reduce the symptoms if Citrus/Cydonia comp. does not produce the 
desired results. They also introduce other anthroposophic medicines that can affect the systems le-
vel of the organization. These ‘other’ medicines can be conventional drugs (80%), anthroposophic 
remedies (80%), or other remedies (homeopathic remedies (15%), etc.). The use of these conven-
tional drugs is justified on the grounds of the strong symptom-reducing nature of these remedies. 
5.3.6 The effectiveness of Citrus/Cydonia comp. in SAR  patients 
 On average, an improvement is anticipated in 50 percent of patients after one year of mo-
notherapy with Citrus/Cydonia comp. The majority of the doctors believe that this percentage of 
patients would rise if: (1) the treatment was continued for several years in succession, and (2) other 
therapies were used simultaneously.
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In the absence of any effect during treatment with Citrus/Cydonia comp., the doctor can (1) 
vary the frequency and/or concentration of Citrus/Cydonia comp., or (2) switch to a different the-
rapy such as eurythmy therapy, diet, or art therapy. Sixty-six percent of the doctors indicated that 
increased frequency was always or sometimes worthwhile if the results were only moderate. Twen-
ty-five percent of the doctors indicated that in the case of inadequate results, they always increased 
the concentration, and 56 percent of the doctors stated they sometimes did so.
Of the doctors who switch to another therapy when therapy with Citrus/Cydonia comp. is in-
effective, fifty-one percent resort to prescribing conventional remedies, thirty-six percent opt for 
other anthroposophic ‘SAR medication,’ and forty-nine percent will prescribe other anthroposop-
hic non-SAR medication as an alternative therapy. 
Concerning the effect of treatment with Citrus/Cydonia comp. during the season, ninety-four 
percent of doctors indicated that the effect would appear within three months, and of these, fifty 
percent believed that the effect would occur within two weeks.
5.3.7 Side effects
 One-third of the doctors indicated that they had sometimes observed side effects on ad-
ministration of Citrus/Cydonia comp. Side effects were most often pain due to the injection or in-
jection fluid (especially the higher concentrations that contain more Citrus) or local skin reactions 
(irritation, itching, redness).  
5.4 Discussion
 The aim of the survey was to obtain an overview of the experiences of Dutch, Citrus/Cydo-
nia comp. prescribing doctors with SAR treatment. The results demonstrate that the subcutaneous 
route of administration of Citrus/Cydonia comp. is the most favoured, with the nasal spray route 
of administration coming a close second. There is much variation between doctors in the way they 
prescribe Citrus/Cydonia comp. regarding the period of the year, the concentration, and frequency 
of the prescribed drug. Doctors combined the use of Citrus/Cydonia comp. with other medicinal 
or non-medicinal therapies for a large group of their patients. More than 50 percent of the doctors 
expected an effect within two weeks, and 94 percent of the doctors expected to see an effect within 
three months after treatment onset. One-third of the doctors indicated that they had sometimes 
observed side effects on administration of Citrus/Cydonia comp. (most often pain and local skin 
reactions). 
Several CAM streams have a long history in clinical practice, and have developed a lot of 
expert (tacit) knowledge, but they lack sufficient scientific evidence of quality, safety, efficacy, 
effectiveness, and cost-effectiveness. In order to provide sufficient evidence, this tacit knowledge 
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can be converted into explicit knowledge and then systematized into healthcare programs, guide-
lines and/or protocols, and subsequently tested on the quality, safety, efficacy, effectiveness, and 
cost-effectiveness in order to become ‘evidence-based’ (Baars and Van der Bie, 2008). The results 
of the survey provide important practice-based evidence that can be used to take the next steps 
in the development of evidence-based practice of anthroposophic SAR treatment integrated with 
conventional SAR treatment. 
The major limitation of this study is that it provides results based on expert knowledge only. 
Expert knowledge in the hierarchy of quality of evidence in outcome studies is regarded as very 
low-quality evidence. Nevertheless, this study provides positive practice-based evidence that pro-
vides a justification for designing and executing controlled trials to obtain high-quality evidence 
of the safety, efficacy, effectiveness, and cost-effectiveness of the anthroposophic SAR treatment.
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*Erratum: After publication we changed the following error in the text in paragraph 3.1 in accor-
dance with our experimental findings:
“Citrus/Cydonia comp. had no effect on cell survival and did appear to be toxic for PBMC cell 
subpopulations.” is changed into “Citrus/Cydonia comp. had no effect on cell survival and did 
not appear to be toxic for PBMC cell subpopulations.”
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Abstract
 In two in vitro studies, we examined the immunological (pathways of the) effects of Citrus/
Cydonia comp. from, respectively, a healthy and an allergic donor; peripheral blood mononuclear 
cells (PBMCs) were isolated out of peripheral blood and analyzed in vitro after polyclonal stimu-
lation of T-cells. The differentiation capacity and the influence with regard to Th1 (IFN-γ) and Th2 
(IL-5) cells were examined. Citrus/Cydonia comp. has a selective effect on the differentiation of 
T-cells by producing relatively more IL-10 than IL-12. By that, it also seems to have an effect on 
the induction of regulatory (IL-10 producing) T-cell subsets. It is in vitro capable of neutralizing (to 
some extent) the changes, characteristic to allergic rhinitis, with regard to the maturation, differen-
tiation, and activity of the immune system. Thus, Citrus/Cydonia comp. can potentially restore the 
disturbed immune state of rhinitis patients, which essentially could be sufficient to make allergic 
symptoms disappear permanently.
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6.1  Introduction
 Allergic rhinitis is a condition characterized by sneezing, watery nasal discharge, and nasal 
obstruction and itching. It is an increasingly prevalent condition, particularly in the Western world 
where it affects around 20% of the adult population. Allergic rhinitis is divided into seasonal al-
lergic rhinitis (hay fever) which is triggered by pollens and moulds, and perennial allergic rhinitis 
in which house dust mites and pet dander are the predominant triggers. The spectrum of severity 
is wide and includes a significant number of sufferers with severe symptoms that are resistant to 
treatment with usual pharmacotherapy (antihistamines and topical nasal corticosteroids) [1]. The 
mean prevalence of allergic rhinitis in several Western countries is 12% [2].
Seasonal allergic rhinitis or hay fever is a type I immediate hypersensitivity reaction mediated 
by specific IgE antibody to a seasonal allergen, leading to mucosal inflammation characterized 
by sneezing, itching, rhinorrhoea, and nasal blockage. Pollens (6–40 m in diameter) from wind-
pollinated grasses, trees, weeds, and spores from fungi are the most common aeroallergens. Grass 
pollen is the most common cause of seasonal allergic rhinitis. The highest levels of pollen in the 
atmosphereare found in May to July and pollen concentrations of 50 grains/mm3 are associated 
with symptoms in all susceptible people. The treatment of choice of seasonal allergic rhinitis is the 
symptomatic treatment with local or oral antihistamines and/or local corticosteroids. Immunothe-
rapy, including sublingual immunomodulation therapy, is indicated in a limited subpopulation of 
patients [3].
Citrus/Cydonia comp. is an anthroposophic medicine, which contains extracts of lemon (Ci-
trus lemon) and quince (Cydonia oblongata) [4]. For over eighty years now, the medicine “Citrus/
Cydonia comp.” is being prescribed as a subcutaneous injection or as a nasal spray for patients 
who suffer from seasonal allergic rhinitis. A survey on clinical experiences, carried out among 
a group of 39 active Dutch general practitioners [4], indicates that the subcutaneous treatment 
with Citrus/Cydonia comp. ampoules is profoundly effective. Firstly, a permanent effect from the 
treatment with Citrus/Cydonia comp. tends to be experienced, which indicates that the patients in 
question are claiming to lastingly suffer less from hay fever or even that they are free from com-
plaints. Secondly, the effect is occurring within a period of two weeks, up to three months, after 
the actual treatment. Thirdly, the effect is optimal after a treatment of several years. Moreover, 
the survey pointed out that preventive administration before the start of the pollen season with 
Citrus/Cydonia comp. may be even more efficacious to the patients in question. Recently, positive 
effects by Citrus/Cydonia comp. were obtained among a group of 13 patients with the following 
characteristics: (a) allergic to grass pollen, (b) suffering from hay fever, on average, for nine years, 
and (c) the necessity for the use of antihistamines with regard to the nature of the complaints [5]. 
In addition, a prospective, observational study on the effect of Citrus/Cydonia comp. nasal spray 
on hay fever symptoms reported positive results without side effects in 140 patients [6]. We now 
performed in vitro studies to study the possible immunological (pathways of the) effects of Citrus/
Cydonia comp.
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6.2 Materials and Methods
6.2.1  Blood Donors
 From a healthy and an allergic individual, 8 mL of blood was collected in sodium heparina-
te-coated vacutainers (BD Biosciences, San Diego, Calif, USA). The allergic individual was sensi-
tized for birch pollen (RAST 6+) and grass pollen (RAST 4+), and he was also food allergic with 
a positive skin prick test on apple and cherry. The blood was subsequently diluted 1:1 with IMDM 
containing GlutaMAX (IMDM; Gibco-BRL, Paisley, Scotland) before the density gradient centri-
fugation on Ficoll-Paque PLUS (Amersham Biosciences, Uppsala, Sweden). The PBMC layer was 
washed twice with IMDM and the cell viability and cell concentration were determined by Trypan 
blue exclusion. An informed consent was obtained before the sample collection and the performed 
experiments were approved by the local ethical committee.
6.2.2 Culture Conditions
 PBMCs were cultured in Yssel’s medium at in a humidified atmosphere with 5% at a density 
of viable cells/mL. Yssel’s medium consisted of IMDM supplemented with 1% Penicillin-Streptomy-
cin (Gibco BRL), extra additions according to Yssel et al. [1984], and 1% human AB serum (Gibco 
BRL). Cells were plated out in 48 well plates at a concentration of cells/mL and cultured at . After five 
hours of adaptation to the culture conditions, the various stimuli or a matching volume of medium 
were added. Cultures were stimulated with 150 ng/mL anti-CD3 plus 100 ng/mL anti-CD28monoclo-
nal antibodies (BD Pharmingen, San Diego, Calif, USA) or cultured in medium only [7].
6.2.3  Citrus/Cydonia Comp. Stimulation
 Both conditions (negative and positive controls) took place in the presence of Citrus/Cydo-
nia comp. 100 L/1 mL culture in two dilutions (undiluted and 1:3 dilution in culture medium). The 
extract (Gencydo) was obtained from (Weleda, Zoetermeer, The Netherlands).
6.2.4 Cell Viability
 Half a million PBMCs were washed and subsequently incubated with 2 L Annexin V-APC 
(BD Biosciences) in 200 L Annexin V buffer according to the manufacturer’s protocol. After an 
incubation period of 15 minutes on ice, the cells were spun down (400 g for 10 minutes) and re-
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suspended in 200 L Annexin V buffer and 2 L PI (1 mg/mL; Sigma, St. Louis, Mo, USA). The cells 
were then analyzed on a flow cytometer (FACS array, BD Biosciences).
6.2.5  Immunological Phenotype
 The immunological phenotype of PBMC subsets was determined by staining the surface 
antigens with the following two monoclonal antibody () mixtures: (1) -hCD3 (PE-Cy7), -hCD4 
(PE), -hCD8 (APC), and -hCD25 (APC-Cy7); (2) -hCD3 (PE-Cy7), -hCD14 (APC), -hCD16 (PE), 
-hCD19 (APC-Cy7), and -hCD56 (PE). All antibodies were purchased at BD Biosciences.
Per well, cells were spun down in a 96 wells U-bottom plate. The cells were incubated with 
staining buffer (1% FCS and 0.1 M in PBS) containing the surface markers or the matching isotype 
controls for 30 minutes on ice in the dark. The cells were washed once with PBS and resuspended 
in PBS for flow cytometry. The four-color flow cytometric acquisition was performed on an FACS 
array, using the BD FACS-array software. An electronic gate was set to exclude debris and at least 
10 000 events/samples were acquired. The percentages of positive cells were corrected for the 
isotype control.
6.2.6  Proliferation Capacity
 The proliferation capacity of the PBMC was studied by intracellular expression of the nu-
clear Ki-67 antigen (Ki-67; BD Pharmingen). The Ki-67 antigen is absent in the nuclei of resting 
cells, but present in all other phases of the cell division cycle as well as in the mitosis phase [8]. 
In each well, PBMCs were incubated with 100 L Cytofix/Cytoperm (BD Pharmingen) for 15–20 
minutes on ice to fix and permeabilize the cells. Cells were washed twice with perm/wash buffer 
(BD Pharmingen) and incubated with anti-Ki-67 PE antibody, or the matched isotype control, di-
luted in perm/wash buffer for 30 minutes on ice in the dark. Hereafter, the cells were washed with 
perm/wash buffer, resuspended in PBS, and measured on the flow cytometer. Values are expressed 
as cells positive for the Ki-67 mAb corrected for the isotype control.
6.2.7  Cytokines
 PBMC culture supernatants were analyzed for their IL-1b, IL-12, IFN-γ, TNF-α, IL-4, IL-5, 
IL-10, and IL-13 contents. The cytokine production was measured with Cytometric Bead Assay Flex 
Sets (BD Pharmingen). All buffers used in this protocol were obtained from the BD CBA Soluble Pro-
tein Master Buffer Kit (BD Pharmingen). Supernatants were collected, stored at −20, and tested within 
2 weeks. The procedure was performed according to the manufacturer’s protocol. The samples were 
measured on the FACS array, using the FCAP software. The sensitivity limits for quantitative determi-
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nations, according to the manufacturer, were 1.1 pg/mL for IL-1, 0.3 pg/mL for IL-4 and IFN-γ, 0.5 pg/
mL for IL-5, 2.3 pg/mL for IL-10, 2.2 pg/mL for IL-12, 0.6 pg/mL for IL-13, and 0.7 pg/mL for TNF-α.
6.3  Results
6.3.1  Effect of Citrus/Cydonia Comp. on Healthy Donor Pbmc
 PBMCS were isolated and analyzed for their subset composition. The percentages of the 
subsets PBMC were 63% CD3+ T-cells (with 50.4% CD4+ Th-cells and 12.6% CD8+ Tc-cells), 8% 
CD19+ B cells, 5% CD14+ monocytes, and 12% CD16/CD56+ NK cells. After one day (Table 6.1) 
and four days (Table 6.2) of culture, the results showed that Citrus/Cydonia comp. not only induced 
T-cell proliferation directly, but also activated monocytes resulting in a selective cytokine production 
(TNF-α, IL-1β, IL-10, and IL-12). However, Citrus/Cydonia comp. induced more IL-10 than IL-12 
production most likely derived from monocytes, thereby stimulating the outgrowth of immunore-
gulatory (IL-10) monocytes more than the immunoreactive (IL-12) subsets of monocytes. These 
monocyte-related effects of Citrus/Cydonia comp. were detectable within one day and were found 
in cultures with a normal therapeutic dose. Subsequently, T-cell activation and proliferation were su-
prastimulated by Citrus/Cydonia comp. over the polyclonal stimulation alone. Citrus/Cydonia comp. 
had no effect on cell survival and did not1 appear to be toxic for PBMC cell subpopulations.
Table 6.1. Mean scores after one day (healthy donor).
Medium Medium  
+ Citrus/Cydonia comp. 1
Medium  
+ Citrus/Cydonia comp. 1:3
Proliferation (%) 3 (1)* 13 (3) 1 (1)
Cell death (%) 88 (12) 82 (11) 87 (5)
Cytokines (pg/mL)
TNF-α 13 (4) 3315 (129) 13 (1)
IL-1b 25 (6) 3535 (147) 15 (2)
IL-10 22 (9) 918 (52) 12 (1)
IL-12 12 (3) 46 (12) 12 (2)
IFN-γ 15 (2) 55 (8) 25 (3)
IL-4 10 (2) 12 (1) 10 (1)
IL-5 12 (2) 28 (3) 10 (1)
1 After publication we added the word “not” in the text in accordance with our experimental 
findings.
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Percentages of proliferating cells and cells in apoptosis of PBMC cultures of a healthy donor stimu-
lated for one day with medium or Citrus/Cydonia undiluted and 1:3 diluted. In the supernatants of 
these cultures, cytokines were measured by flow cytometric analysis in the Bead Assay Flex Sets 
system. Cytokine levels in pg/mL. *All results are described with standard deviations (SDs).
Table 6.2. Mean scores after four days (healthy donor).
Medium Anti-CD3/28 Medium 
+ Citrus/
Cydonia 
comp. 1
Medium + 
Citrus/ 
Cydonia 
comp. 1:3
Stimulation + 
Citrus/Cydonia 
comp. 1
Stimulation + 
Citrus/ 
Cydonia comp. 
1:3
Prolifera-
tion (%)
3 (1)* 42 (8) 3 (1) 1 (1) 48 (11) 40 (2)
Cell 
death (%)
88 (12) 61 (11) 87 (8) 92 (11) 65 (12) 60 (6)
Cytokines (pg/mL)
TNF-α 13 (2) 8483 (987) 15 (2) 13 (2) 9647 (733) 8117 (566)
IL-1b 15 (3) 4134 35 (11) 15 (1) 4858 (247) 4037 (138)
IL-10 12 (2) 9553 18 (8) 12 (2) 12276 (566) 5662 (931)
IL-12 12 (1) 84 26 (9) 12 (2) 238 (87) 185 (77)
IFN-γ 15 (2) 34355 15 (1) 15 (2) 48800 (12778) 37750 (12501)
IL-4 12 (2) 134 12 (1) 12 (2) 55 (12) 106 (28)
IL-5 12 (2) 375 12 (2) 12 (1) 118 (45) 266 (56)
Percentages of proliferating cells and cells in apoptosis of PBMC cultures of a healthy donor stimulated for four days 
with medium alone, polyclonal stimulation with anti-CD3 plus anti-CD28 antibodies, or polyclonal stimulation in the 
presence of Citrus/Cydonia preparation undiluted and 1:3 diluted. In the supernatants of these cultures, cytokines were 
measured by flow cytometric analysis in the Bead Assay Flex Sets system. Cytokine levels in pg/mL. *All results are des-
cribed with standard deviations (SDs).
6.3.2  Effect of Citrus/Cydonia Comp. on an Allergic Donor Pbmc
 After four days (Table 6.3), the results demonstrated that Citrus/Cydonia comp. was able 
to restore the reduced IL-10 production in PBMC cultures of the allergic individuals. The stronger 
immunoregulatory balance (IL-10) and a curbed augmented Th2 response (a decrease of IL-4 and 
IL-5 production) was accompanied by an increased production of IL-12 and a reduced production 
of IFN-γ. Even after 4 days, monocyte stimulation by Citrus/Cydonia comp. was detected by the 
production of TNF-α and IL-10.
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Table 6.3. Mean scores after four days (allergic donor).
Medium Stimulation  
with anti-CD3/28
Stimulation +  
Citrus/Cydonia comp.
Proliferation (%) 1 (1)* 48 (12) 57 (12)
Cell death (%) 78 (8) 59 (16) 55 (8)
Cytokines
TNF-α 10 (1) 5782 (154) 6893 (738)
IL-1b 10 (1) 2275 (339) 3772 (665)
IL-10 10 (1) 2331 (452) 7634 (1299)
IL-12 10 (1) 134 (26) 335 (89)
IFN-γ 10 (1) 9778 (452) 11668 (1638)
IL-4 10 (1) 456 (87) 138 (18)
IL-5 10 (1) 667 (154) 227 (85)
Percentages of proliferating cells and cells in apoptosis of PBMC cultures of an allergic donor stimulated for four days 
with medium alone, polyclonal stimulation with anti-CD3 plus anti-CD28 antibodies, or in the presence of Citrus/Cydonia 
undiluted preparation. In the supernatants of these cultures, cytokines were measured by flow cytometric analysis in the 
Bead Assay Flex Sets system. Cytokine levels in pg/mL.*All results are described with standard deviations (SDs).
6.4  Discussion
 Here, we show that Citrus/Cydonia comp. has a selective effect on the differentiation of 
T-cells with regard to the production of cytokines; the production of IL-10 is relatively larger than 
that of IL-12. By that, Citrus/Cydonia comp. also seems to have an effect on the induction of regu-
latory (IL-10 producing) T-cell subsets. Hence, as a consequence, Citrus/Cydonia comp. might be 
producing an allergy reducing effect, at which it does not concern Th1 induction and the reduction 
of the allergen-specific Th2 response, bearing the risk of induction of a chronic inflammation and 
very likely even an increased risk for autoimmunity.
Recent developments mainly concern the field of allergen-specific immunotherapeutic proto-
cols. This immunotherapy is widely believed to occur through restoration of the disturbed Th1-Th2 
balance [9–12], either linked to the induction of allergen-specific (blocking) IgG4 antibodies, or to 
the induction of regulatory T-cell subsets. The exact role which the regulatory T-cell subsets play 
with regard to these mechanisms is not yet indistinct. With regard to the development of these im-
munotherapeutic protocols, special allergen preparations, obtained from purified natural or recom-
binant produced allergens, are necessary and need to be developed.
Citrus/Cydonia comp. is likely to induce more regulatory T-cells, whether CD4+CD25+Fosp3+ 
natural or antigen-induced IL-10 and/or TGF-b producing Tr-cells, that are, therefore, very im-
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munosuppressive, and which are capable of reducing allergen specifically activated Th2 cells. Our 
results imply that Citrus/Cydonia comp. does not induce a complete state of immunosuppression, 
resulting in a diminished resistance against infections and a reduced protection against tumors. 
This is consistent with the long-term clinical experiences and the results of the empirical studies 
on the use of Citrus/Cydonia comp.
Based on these in vitro investigations, we hypothesized that Citrus/Cydonia comp. is capable 
of neutralizing (to some extent) the changes, characteristic to allergic rhinitis, with regard to the 
construction, the maturation, the differentiation, and the activity of the immune system. By that, it 
is possible to explain the therapeutic positive effects on allergic rhinitis patients treated with Citrus/
Cydonia comp. found in previous studies and clinical practice.
The conclusions based on this study are of great importance, since the standard treatment of 
allergic rhinitis is based on the long-term use of antihistamines, potentially in combination with 
a local application of corticosteroids, in case of persisting and/or serious symptoms. Those treat-
ments tend to reduce the symptoms, but they do not possess any immunotherapeutic potency them-
selves. This implies that it is compulsory for individual patients to keep on using such medicines 
for many years. Based on our pilot data, indicating that in vitro Citrus/Cydonia comp. is capable of 
modulating the Th1-Th2 balance, we actually expect Citrus/Cydonia comp. to have an immunothe-
rapeutic potency. This adds to the clinical therapeutic effect from Citrus/Cydonia comp., both as an 
injection and as a topical application. This implies that a long-term treatment with Citrus/Cydonia 
comp. injections during several years, before the start of the pollen season, can potentially restore 
the disturbed immune state of rhinitis patients, which essentially could be sufficient to make the 
allergic complaints disappear.
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Abstract
 This study examined the effects of the combined product, Citrus e fructibus/Cydonia e 
fructibus (Citrus/Cydonia) (Citrus and Cydonia: each 0.01g/mL), and separate products of Citrus 
(0.01 g/mL) and Cydonia (0.01 g/mL) on the immunological pathways involved in seasonal aller-
gic rhinitis (SAR). Peripheral blood mononuclear cells (PBMCs) from five healthy and five grass 
pollen-allergic donors were isolated and analyzed in vitro after polyclonal and allergen-specific sti-
mulation of T-cells in the presence of the three extracts. The analyses demonstrated acceptable cell 
survival with no signs of toxicity. Citrus mainly had a selective effect on reducing allergen-specific 
chronic inflammatory (TNF-α; Citrus compared to Cydonia and Citrus/Cydonia: -87.4 (p < 0.001) 
and -68.0 (p < 0.05), respectively) and Th2 pathway activity (IL-5; Citrus compared to Cydonia: 
-217.8 (p < 0.01); while, both Cydonia and Citrus/Cydonia mainly affected the induction of the 
allergen-specific Th1 pathway ((IFN-γ; Cydonia and Citrus/Cydonia compared to Citrus: 3.8 (p < 
0.01) and 3.0 (p < 0.01), respectively). Citrus and Cydonia demonstrated different working mecha-
nisms in the treatment of SAR and the combination product did not demonstrate larger effects than 
the separate preparations. Further effectiveness and efficacy studies comparing the effects of the 
products on SAR in vivo, are indicated. 
  Keywords: seasonal allergic rhinitis, Citrus/Cydonia, in vitro study, immunological pathways
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7.1  Introduction
 Citrus/Cydonia is an anthroposophic medicine, which contains extracts of lemon (Citrus li-
mon (L.) Burm. f.) and quince (Cydonia oblonga Mill.) [1]. For over eighty years, the combination 
of preparations from Citrus and Cydonia has been prescribed as a subcutaneous injection or nasal 
spray for patients who suffer from seasonal allergic rhinitis (SAR). Both in vitro [2,3] and clinical 
studies [4-6] have demonstrated that Citrus/Cydonia might be effective in treating SAR. Previous 
immunological analyses demonstrated it has an effect on the induction of regulatory (IL-10 pro-
ducing) T-cell subsets and on the suppression of the Th2 pathway cytokines, IL-4 and IL-5 [2], in 
vitro. Another in vitro study demonstrated that Citrus/Cydonia significantly reduced the histamine 
production and the inflammatory mediator release from mast cells in a dose-dependent manner 
[3]. Although positive immunomodulating activity has been reported for the combination product, 
Citrus/Cydonia, the extent that each of the two active substances, Citrus and Cydonia, contribute 
to the observed effects is not known.
In this in vitro study, we compared the effects of the combination product, Citrus/Cydonia, 
and the separate products, Citrus and Cydonia, on SAR-related immunological components. The 
primary hypothesis of the present study, based on traditional use in clinical practice, was that the 
combination preparation Citrus/Cydonia would demonstrate larger SAR-related treatment effects 
in vitro than the single preparations of Citrus and Cydonia. The secondary hypothesis was that 
treatment with Citrus, Cydonia and Citrus/Cydonia would demonstrate larger treatment effects (as 
expected in SAR patients) in vitro, in the healthy group compared to the SAR group. This hypo-
thesis was based on the assumption that the three products support the SAR-related self-healing 
capacity of the organism and that this capacity is already stronger in healthy persons than in SAR 
patients before treatment. 
7.2  Materials and Methods
 This study was conducted according to the study protocol previously accepted by the me-
dical ethical committee. No violations or deviations to the study protocol were noticed.
7.2.1  Investigational Products
 The three preparations were obtained from WALA Heilmittel GmbH (Bad Boll/Eckwäl-
den, Germany). Citrus/Cydonia (Citrus e fructibus / Cydonia e fructibus, batch no 008 704C) is a 
solution for subcutaneous injection. One ampoule of 1 mL contains: 0.1 g Citrus medica ssp. limo-
num e fructibus ferm 33c Dil. D1 HAB, methode 33c and 0.1 g Cydonia oblonga e fructibus ferm 
33b Dil. D1 HAB, methode 33b. Excipients were sodium chloride, sodium hydrogen carbonate and 
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water for injection. Citrus (Citrus e fructibus, batch no 008 702C) is a solution for subcutaneous 
injection. One ampoule of 1 mL contains: 1 g of Citrus medica ssp. limonum e fructibus ferm 33c 
Dil. D2 HAB, methode 33c in a sodium chloride, sodium hydrogen carbonate solution for injecti-
on. Cydonia (Cydonia e fructibus, batch no 008 703C) is a solution for subcutaneous injection. One 
ampoule of 1 mL contains: 1 g of Cydonia oblonga e fructibus ferm 33b Dil. D2 HAB, methode 
33b in a sodium chloride, sodium hydrogen carbonate solution for injection.
7.2.2  Blood donors and preparation of blood samples
 Blood was collected from two groups of participants: SAR patients and healthy persons. 
The experiments performed were approved by the local medical ethical committee and informed 
consent was obtained before sample collection. 
Eligible participants from the SAR group were all adults of both sexes; aged 18 to 40; who gave 
written informed consent; suffered from SAR for at least two years; had a RAST score ≥ 2 for both 
grass pollen and birch pollen; suffered from the following nasal symptoms: sneezing, itchy nose, 
nasal obstruction, and watery nasal discharge; with a severity score ≥ 2 for at least three of the four 
symptoms (ranging from 0 = not present to 3= severe) and the necessity to use antihistamines and/
or corticosteroids for the treatment of symptoms for at least the last two years. Exclusion criteria 
were: chronic inflammatory autoimmune diseases such as Type I - diabetes mellitus, rheumatoid 
arthritis, multiple sclerosis, psoriasis or Crohn’s disease; allergic (hypersensitive) to one of the 
constituents of Citrus e fructibus / Cydonia e fructibus; asthma; use of other preparations contai-
ning Citrus and/or Cydonia extracts within the last two weeks prior to enrolment into the study; 
use of cromoglycates in the last month before study onset; concomitant pharmacological treatment 
indicated for seasonal allergic rhinitis such as antihistamines, corticosteroids or other preparations 
in the last two weeks before study onset; anti-allergy immunotherapy in the previous two years; 
participation in a further clinical trial at the same time or within the previous 4 weeks prior to en-
rolment into this study; pregnancy or lactation; severe internal or systemic disease (e.g. cardiac, he-
patic, renal diseases); a known history of drug, alcohol and/or medication dependence or addiction. 
Eligible participants from the healthy group were men and women; aged 18 to 40 who  gave 
written informed consent; had a RAST score for SAR related pollen = 0; did not have the following 
nasal symptoms during the pollen season: sneezing, itching nose, nasal obstruction, and watery 
nasal discharge; and no history of SAR symptoms for at least two years. Exclusion criteria: chronic 
inflammatory autoimmune disease such as Type I - diabetes mellitus, rheumatoid arthritis, multiple 
sclerosis, psoriasis or Crohn’s disease; allergic (hypersensitive) to one of the constituents of Citrus 
e fructibus / Cydonia e fructibus; asthma; participation in a further clinical trial at the same time 
or within the previous 4 weeks prior to enrolment into this study; pregnancy or lactation; severe 
internal or systemic disease (e.g. cardiac, hepatic, renal diseases); drug, alcohol and/or medication 
dependence or addiction.
All eligible participants were recruited from a single center, the Louis Bolk Institute (Drieber-
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gen, NL). The first participant was included on June 24, 2010 and the last participant completed 
the study on August 3, 2010. Blood samples were taken on July 22, 2010 (2 participants), July 30, 
2010 (5 participants), and August 3, 2010 (3 participants). From each person in the SAR group and 
healthy group, 3 x 8 mL of blood was collected in sodium heparinate-coated vacutainers (BD Bi-
osciences, San Diego, Calif, USA). The blood was subsequently diluted 1:1 with Iscove’s Modified 
Dulbecco’s Media (IMDM) containing GlutaMAX (IMDM; Gibco-BRL, Paisley, Scotland) before 
density gradient centrifugation using Ficoll-Paque PLUS (Amersham Biosciences, Uppsala, Swe-
den). The PBMC layer was washed twice with IMDM and the cell viability and cell concentration 
were determined by Trypan blue exclusion.
7.2.3  Culture conditions and stimulations
 PBMCs were cultured in Yssel’s medium at 37°C in a humidified atmosphere with 5% 
CO2 at a density of 1x106 viable cells/mL. Immunological phenotyping of freshly isolated PBMC 
was performed on a FACS Canto II (BD Pharmingen, San Diego, USA), using monoclonal antibo-
dies and the procedure from BD Pharmingen (San Diego, USA). Cells were plated out in 48 well 
plates at a concentration of 1x106 cells/mL and cultured at 37°C. After five hours, in which the cells 
adapted to the culture conditions, various stimuli or a matching volume of medium were added. 
Cultures were stimulated polyclonally with 150 ng/mL anti-CD3 plus 100 ng/mL anti-CD28 mo-
noclonal antibodies (BD Pharmingen, San Diego, Calif, USA) or cultured in medium only [7]. In 
addition, we performed allergen-specific stimulation of 106 cells/mL in 1 mL cultures with applied 
pollen extract (Phl p 1 from Timothy grass, Phleum pretense; Biomay Vienna, Austria; 10 μg/mL 
in medium). Supernatants of the stimulated cultures were harvested after 1, 4 and 7 days of culture 
and stored at -80°C for later cytokine analysis.
7.2.4  Stimulation with Citrus /Cydonia, the single products of Citrus and 
Cydonia, relative to medium control
 Three experimental conditions and one control condition were evaluated. Experimental 
conditions: (a) Citrus, 0.01 g/mL; (b) Cydonia, 0.01 g/mL; and (c) Citrus/Cydonia, 0.02 g/mL 
(Citrus and Cydonia: each 0.01g/mL).  The (negative) control condition and dilution medium was 
Yssel’s medium. Samples of culture supernatants were taken after 24 hrs to elucidate monocyte re-
activity; after four days to evaluate the effects of medium and polyclonal stimulation; and after se-
ven days to evaluate the effects of the three extracts, Citrus, Cydonia, and Citrus/Cydonia, relative 
to a medium control for grass pollen-specific stimulation. Cytokine concentrations were measured 
in culture supernatants using labeled antibody preparations and flow cytometry measurements.
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7.2.5  Cell viability 
 Early apoptosis and late apoptosis/necrosis was assessed on freshly prepared and 7 day 
cultured cells using double staining with APC-Annexin V and propidium iodide (PI) [8]. On day 
0 half a million cells from the isolated PBMCs of the individuals were washed and subsequently 
incubated with 2 μL Annexin V-APC (BD Biosciences, San Diego, Calif, USA) in 200 μL Annexin 
V buffer according to the manufacturer’s protocol. After a 15 min incubation period, the cells were 
spun down (400 g for 10 min) and resuspended in 200 μL Annexin V buffer and 2 μL PI (1 mg/mL; 
Sigma, St. Louis, Mo, USA). The cells were then analyzed on a flow cytometer (FACS array, BD 
Biosciences, San Diego, Calif, USA) as detailed in sections 2.6 and 2.7.
7.2.6 Immunological phenotype
 On day 0 the immunological phenotype of PBMC subsets was determined by staining 
the surface antigens with the following two monoclonal antibody (α) mixtures: (1) α-hCD3 (PE-
Cy7), α-hCD4 (PE), α-hCD8 (APC), and α-hCD25 (APC-Cy7); (2) α-hCD3 (PE-Cy7), α-hCD14 
(APC), α-hCD16 (PE), α-hCD19 (APC-Cy7), and α-hCD56 (PE). All antibodies were purchased 
at BD Biosciences (San Diego, Calif, USA). For each well, 5x105 cells were spun down in a 96 
well U-bottom plate. The cells were incubated with staining buffer (1% FCS and 0.1M NaN
3
 in 
PBS) containing the surface markers or the matching isotype controls for 30 min on ice in the dark. 
The cells were washed once with PBS and resuspended in PBS for flow cytometry. The four-color 
flow cytometric acquisition was performed on a FACS array, using the BD FACS-array software. 
An electronic gate was set to exclude debris and at least 10,000 events/samples were acquired. The 
percentage of positive cells was corrected for the isotype control.
7.2.7  Proliferation capacity
  On days 4 and 7 the proliferation capacity of the PBMCs was studied by intracellular 
expression of the nuclear Ki-67 antigen (Ki-67; BD Pharmingen, San Diego, Calif, USA). The Ki-
67 antigen is absent in the nuclei of resting cells, but present in all other phases of the cell division 
cycle as well as in the mitosis phase [8,9]. In each well, 5x105 PBMCs were incubated with 100 μL 
Cytofix/Cytoperm (BD Pharmingen, San Diego, Calif, USA) for 15–20 min on ice to fix and per-
meabilize the cells. Cells were washed twice with perm/wash buffer (BD Pharmingen, San Diego, 
Calif, USA) and incubated with anti-Ki-67 PE antibody or the matched isotype control, diluted in 
perm/wash buffer, for 30 min on ice in the dark. Hereafter, the cells were washed with perm/wash 
buffer, resuspended in PBS, and measured on the flow cytometer. Values are expressed as cells 
positive for the Ki-67 mAb, corrected for the isotype control.
Thesis Erik W. Baars   133
7
7.2.8  Cytokines
 On days 1, 4 and 7 PBMC culture supernatants were analyzed for their IL-1b, IL-12, 
IFN-γ, TNF-α, IL-5, IL-10, and IL-13 contents. The cytokine production was measured with Cy-
tometric Bead Assay Flex Sets (BD Pharmingen, San Diego, Calif, USA). All buffers used in this 
protocol were obtained from the BD CBA Soluble Protein Master Buffer Kit (BD Pharmingen, San 
Diego, Calif, USA). Supernatants were collected, stored at −20°C, and tested within 2 weeks. The 
procedure was performed according to the manufacturer’s protocol. The samples were measured 
on the FACS array, using the FCAP software. The sensitivity limits for quantitative determinations, 
according to the manufacturer, were 1.1 pg/mL for IL-1b, 0.3 pg/mL for IFN-γ, 0.5 pg/mL for IL-5, 
2.3 pg/mL for IL-10, 2.2 pg/mL for IL-12, 0.6 pg/mL for IL-13, and 0.7 pg/mL for TNF-α.
7.2.9  Definition of positive effects
 A non-allergic, healthy state is hypothesized to represent a balanced state within the immu-
ne system with a relatively high level of IL-10 (demonstrating sufficient immunoregulation) and 
a balance between the Th1 pathway (e.g. IFN-γ) and the Th2 pathway (e.g. IL-5 and IL-13). SAR 
is associated with relatively low levels of IL-10, a chronic inflammatory activity (e.g. TNF-α), an 
overproduction of Th2 pathway cytokines and an imbalance between the Th1 and Th2 pathways 
[9, 10]. The following changes in cytokine production levels were therefore regarded as positive 
immunological SAR treatment effects [9-14] (Figure 7.1):
1. The induction of (regulatory) T-cells (Treg): increase of (grass pollen stimulated minus me-
dium stimulated) IL-10 on day 7, often accompanied by monocyte-derived IL-10 on day 1.
2. The induction of Th1 activity: increase of (grass pollen stimulated minus medium stimulated) 
IFN-γ on day 7, often accompanied by monocyte-derived IFN-γ on day 1.
3. The reduction of Th2 activity: reduction of (grass pollen stimulated minus medium stimula-
ted) IL-5 and IL-13 on day 7, often accompanied by monocyte-derived IL-1b on day 1, which 
is essential for the outgrowth of Th2 cells. 
4. The reduction of chronic inflammatory activity: reduction of (grass pollen stimulated minus 
medium stimulated) monocyte-derived TNF-α on day 1. 
5. The restoration of the Th1/Th2 balance: an increase in (grass pollen stimulated minus me-
dium stimulated) IFN-γ/IL-5 and IFN-γ/IL-13 ratios on day 7.
6. The restoration of the Treg/Th2 balance: an increase in the (grass pollen stimulated minus 
medium stimulated) IL-10/TNF-α ratio on day 1; the increase of (grass pollen stimulated 
minus medium stimulated) IL-10/IL-5 and IL-10/IL-13 ratios on day 7.  
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7.2.10  Statistics
 Pearson Chi-square tests were performed on all relevant donor characteristics. For the PBMC 
subsets, we calculated all immunological outcome parameters (day 1: IL-1b, IL-10, IL-12, TNF-α, 
and IFN-γ; day 7: IL-5, IL-13, IL-10, and IFN-γ), the relevant ratios (day 1: IL10/TNF-α and IFN-γ/
TNF-α; day 7: IL10/IL-5, IL-10/IL-13, IFN-γ/IL-5, and IFN-γ/IL-13), the mean scores, and 95% 
confidence intervals of cytokine production levels after grass pollen stimulation by subtracting the 
medium stimulation values. Subsequently, ANOVA (with Tamhane correction in case of unequal 
distribution) and unpaired t-tests were used to determine statistically significant differences between 
(1) the means of the three SAR groups that were stimulated in the presence of the three experimental 
extracts, (2) the means of the three healthy groups that were stimulated in the presence of the three 
experimental extracts, and (3) the means of the SAR groups and the healthy groups that were stimula-
ted in the presence of the three experimental extracts. GLM Repeated Measures tests were performed 
to determine statistically significant differences between the means of the three total groups (total 
group = SAR group and healthy group) that were stimulated in the presence of the three experimental 
extracts. All statistical analyses were performed with SPSS 18.0 (SPSS Inc., Chicago, USA).
Figure 7.1. Seasonal allergic rhinitis related immunological subsystems, pathways and cytokines
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7.2.11  Blinding
 All researchers were blinded to the identity of the products, which were numbered A, B, 
and C by the manufacturer. Unblinding took place after all statistics had been performed.
7.3 Results
7.3.1  Blood donors
 The SAR group and the healthy group demonstrated no statistically significant differen-
ces with regard to: sex (both groups: 3 women and 2 men); ethnicity (both groups: all Cauca-
sian); age (means and standard deviations): 35.2 (10.5) and 43.4 (10.9) years, respectively; height 
(means and standard deviations): 1.79 (0.1) and 1.77 (0.1) meters, respectively; weight (means and 
standard deviations): 75 (12.6) and 74 (9.2) kg, respectively; systolic blood pressure (means and 
standard deviations): 113 (13.2) and 117 (12.0) Hg, respectively; diastolic blood pressure (means 
and standard deviations): 71 (7.5) and 78 (5.7) Hg, respectively; and heart rate (means and standard 
deviations): 65 (3.8) and 65 (8.7), respectively. RAST scores (means, standard deviations and ran-
ges) for grass pollen and birch pollen respectively were 3.6 (1.5, range: 2-6) and 3.6 (0.9, range: 
3-5) for the SAR group, and 0 and 0 for the healthy group (Table 7.1).
The mean percentages of the PBMC subsets for the SAR group were: 58.8% CD3+ T cells 
(with 40.4% CD4+ Th cells and 18.4% CD8+ Tc cells), 6.2% CD19+ B cells, 16% CD14+ mo-
nocytes, and 9.6% CD16/CD56+ NK cells. The mean percentages of the PBMC subsets for the 
healthy group were: 60.0% CD3+ T cells (with 39.4% CD4+ Th cells and 20.6% CD8+ Tc cells), 
7.0% CD19+ B cells, 15.8% CD14+ monocytes, and 8.8% CD16/CD56+ NK cells.  There were no 
statistically significant differences in the mean scores of the subsets between the SAR group and 
the healthy group. 
7.3.2 Effects on viability
 Citrus (Fig. 7.2A), Cydonia (Fig. 7.2B), and Citrus/Cydonia (Fig. 7.2C) had no effect on in 
vitro cultured blood mononuclear cell survival and did not appear to be toxic to the PBMC subpo-
pulations by Annexin V-PI staining.
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Table 7.1. Baseline characteristics seasonal allergic rhinitis (SAR) group and Healthy group
Variable SAR group 
(n = 5)
Healthy group 
(n = 5)
p-value
Sex:  
Number (percentage)
Male 
Female
3 (60%) 
2 (40%)
3 (60%) 
2 (40%)
n.s.
Ethnicity:  
number (percentage)
Caucasian 
Asian
5 (100%) 
0 (0%)
5 (100%) 
0 (0%)
n.s.
Age (year) (sd) 35.2 (10.5) 43.4 (10.9) n.s.
Height (cm) (sd) 179 (10) 177 (10) n.s.
Weight (kg) (sd) 75 (12.6) 74 (9.2) n.s.
Blood pressure at 
screening (systolic/ dias-
tolic) (mmHg) (sd)
113 (13.2)/ 71 (7.5) 117 (12)/ 78 (5.7) n.s.
Heart rate at screening 
(beats per minute)
65 (3.8) 65 (8.7) n.s.
RAST grass pollen 3.6 (1.5) 0
RAST birch pollen 3.6 (0.9) 0
n.s. = not significant
Figure 7.2. Representative example of a flow cytometric analysis profile of live, necrotic and apoptotic 
cells after in vitro culture of human PBMC stimulated in the presence of either Citrus (A) or Cydonia (B) or 
their combination (C). Citrus (100 µL/mL), Cydonia (100 µL/mL) or the combination Citrus/Cydonia (100 
µL/mL) were added to 0.5 x 106 PBMC in 1 ml cultures which were stimulated with grass pollen extract 
(10 mg/mL) for 7 days. Staining was performed with Annexin V-APC and PI and measured on a BD flow 
cytometer.
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7.3.3  Effects on PBMCs from allergic donors
 The mean cytokine scores after one day culture and seven days culture are presented in Ta-
ble 7.2 and Table 7.3, respectively, and Figure 7.3 and Figure 7.4, respectively. Citrus demonstra-
ted a larger reduction of chronic inflammatory activity than Cydonia and Citrus/Cydonia (TNF-α 
(day 1): -87.4 (95% CI: -120.3 to -54.5), p < 0.001) and -68.0 (95% CI: -100.9 to -35.1), p < 0.05, 
respectively) and had a larger effect on the restoration of the allergen-specific Treg/Th2 balance 
(IL-10/TNF-α (day 1): 0.34 (95% CI: 0.20 to 0.49), p < 0.001 and 0.32 (0.17 to 0.47), p < 0.01, res-
pectively). Citrus was also more powerful than Cydonia in the reduction of Th2 pathway activity in 
both the innate reaction (IL-1b (day 1): -12.4 (95% CI: -22.3 to -2.5), p <0.05) and the outgrowth 
of the allergen-specific specialized T cell subsets (IL-5 (day 7): -217.8 (95% CI: -361.9 to -73.7), 
p < 0.01). Citrus also demonstrated larger effects than Citrus/Cydonia on the reduction of the Th2 
Table 7.2. Differences in mean cytokine scores after one day PBMC cultures in the SAR group, healthy 
group, and total group (grass pollen stimulation minus medium stimulation)
Citrus Cydonia Citrus/Cy-
donia
Citrus  
vs.  
Cydonia 
p-value
Citrus vs. 
Citrus/
Cydonia
 p- value
Cydonia 
 vs. 
Citrus/
Cydonia 
p- value
IL-1b* SAR 8.2 (7.0) 20.6 (5.0) 14.6 (8.9) p < 0.05 ns ns
Healthy 2.4 (2.3) 17.6 (6.7) 18.8 (8.0) p < 0.01 p < 0.01 ns
Total group 5.3 (5.8) 19.1 (5.8) 16.7 (8.3) p < 0.001 p < 0.01
IL-10 SAR 64.0 (14.4) 59.2 (10.1) 54.0 (8.2) ns ns ns
Healthy 53.0 (15.2) 65.2 (14.4) 69.6 (3.9) ns ns ns
Total group 58.5 (15.1) 62.2 (12.1) 61.8 (10.2) ns ns ns
TNF-α SAR 94.8 (9.0) 182.2 (15.2) 162.8 (37.4) p < 0.001 p < 0.05 ns
Healthy 105.6 (25.2) 160.2 (13.2) 143.2 (23.9) p < 0.01 p < 0.05 ns
Total group 100.2 (18.7) 171.2 (17.7) 153.0 (31.3) p < 0.001 p < 0.001
IFN-γ SAR 3.0 (1.9) 6.8 (1.1) 6.0 (1.2) p < 0.01 p < 0.01 ns
Healthy 3.0 (1.6) 6.0 (1.4) 5.4 (1.1) p < 0.01 p < 0.05 ns
Total group 3.0 (1.6) 6.4 (1.3) 5.7 (1.2) p < 0.001 p < 0.001
IL-10/ 
TNF-α
SAR 0.7 (0.1) 0.3 (0.1) 0.4 (0.1) p < 0.001 p < 0.01 ns
Healthy 0.5 (0.2) 0.4 (0.1) 0.5 (0.1) ns ns ns
Total group 0.6 (0.2) 0.4 (0.1) 0.4 (0.1) p < 0.01 p < 0.01
* The mean score (SD) in pg/mL is presented for all cytokine measurements; ns, not significant.
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Figure 3. Summary of differences in mean scores after one 
  day PBMC cultures in the SAR group, healthy group and total group 
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Figure 4. Summary of differences in mean scores after seven days PBMC 
cultures in the SAR group, healthy group and total group 
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pathway activity of the allergen-specific specialized T cell subsets (IL-13 (day 7): -447.2 (95% 
CI: -855.9 to 38.5), p < 0.05). Both Cydonia and Citrus/Cydonia demonstrated larger effects than 
Citrus on the innate induction of Th1 pathway activity (IFN-γ (day 1): 3.8 (95% CI: 1.8 to 5.8), p 
< 0.01 and 3.0 (95% CI: 1.0 to 5.0), p < 0.01, respectively. 
7.3.4  Effects on the PBMCs from healthy donors
 Similar to the results in the allergic donor group (Table 7.2), Citrus demonstrated a larger 
effect in the healthy donor group than Cydonia and Citrus/Cydonia on the reduction of chronic 
inflammatory activity (TNF-α (day 1): -54.6 (95% CI: -84.2 to -25.0), p < 0.01 and -37.6 (95% CI: 
-67.2 to -8.0), p < 0.05, respectively) but not on the restoration of the Treg/Th2 balance (IL-10/
TNF-α - day 1). As in the allergic donor group, Citrus was also more powerful than Cydonia in 
the healthy donor group in reducing Th2 pathway activity in both the innate reaction (IL-1b (day 
1): -15.2 (95% CI: -23.7 to -6.7), p < 0.01) and the outgrowth of the allergen-specific specialized 
T cell subsets (IL-5 (day 7): -217.8 (95% CI: -371.4 to -64.2), p < 0.01). Unlike the results in the 
allergic donor group, Citrus also demonstrated larger effects than Citrus/Cydonia on the reduction 
of Th2 pathway activity in both the innate reaction (IL-1b (day 1): -16.4 (95% CI: -24.9 to -7.9), 
p <0.01) and the outgrowth of the specialized T cell subsets (IL-5 (day 7): -353.4 (95% CI: -507.0 
to -199.8), p < 0.001). Finally, Citrus was more powerful than Citrus/Cydonia in restoring the Th1/
Th2 balance (IFN-γ/ IL-5 (day 7): 0.75 (95% CI: 0.38 to 1.12), p < 0.01).
Both Cydonia and Citrus/Cydonia also demonstrated larger effects than Citrus on the innate 
induction of the Th1 pathway (IFN-γ (day 1): 3.0 (95% CI: 1.1 to 4.9), p <0.01 and 2.4 (95% CI: 
0.5 to 4.3), p < 0.05, respectively). In addition, Cydonia was more powerful than Citrus/Cydonia 
on the allergen-specific T cell subset related induction of the Th1 pathway (IFN-γ (day 7): 120.6 
(95% CI: 10.8 to 230.4), p < 0.05) and the restoration of the Th1/Th2 balance (IFN-γ/IL-5 (day 7): 
0.38 (95% CI: -0.02 to 0.78), p < 0.05) (Table 7.3). 
 
7.3.5  Effects on the total group
 As in the allergic donor group and the healthy donor group, Citrus demonstrated a larger re-
duction of chronic inflammatory activity than Cydonia and Citrus/Cydonia (TNF-α (day 1): -71.0 
(95% CI: -92.5 to -49.5), p < 0.001 and -52.8 (95% CI: -74.3 to -31.3), p < 0.001, respectively). 
As in the SAR group, Citrus demonstrated larger effects than Cydonia and Citrus/Cydonia in the 
restoration of the Treg/Th2 balance (IL-10/TNF-α (day 1): 0.23 (95% CI: 0.11 to 0.35), p < 0.01 
and 0.17 (95% CI: 0.05 to 0.29), p < 0.01, respectively). As in the allergic donor and healthy donor 
groups, Citrus was also more powerful than Cydonia in the reduction of Th2 pathway activity in 
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both the innate reaction (IL-1b (day 1): -13.8 (95% CI: -20.0 to -7.6), p < 0.001) and the outgrowth 
of the allergen-specific T cell subsets (IL-5 (day 7): -217.8 (95% CI: -331.8 to -103.8), p < 0.01). 
As in the healthy donor group, Citrus was also more powerful than Citrus/Cydonia in the reduction 
of Th2 pathway activity in both the innate reaction (IL-1b (day 1): -11.4 (95% CI: -17.6 to -5.2), 
p < 0.01) and the outgrowth of the allergen-specific T cell subsets (IL-5 (day 7): -231.3 (95% CI: 
-345.3 to -117.3), p < 0.001).
Both Cydonia and Citrus/Cydonia demonstrated larger effects than Citrus on the innate inducti-
on of the Th1 pathway activity (IFN-γ (day 1): 3.4 (95% CI: 2.1 to 4.7), p <0.001 and 2.7 (95% CI: 
1.4 to 4.0), p < 0.001, respectively), which was also found in the allergic donor and healthy donor 
groups. In addition, Cydonia was more powerful than both Citrus (unlike the results of the other 
groups) and Citrus/Cydonia (like the results in the healthy donor group) on the allergen-specific T 
cell subset related induction of Th1 pathway activity (IFN-γ (day 7): 95.6 (95% CI: 3.2 to 188.0), p 
< 0.05) and 111.6 (95% CI: 19.2 to 204.0), p < 0.05, respectively). In addition, as in the healthy do-
nor group, both Citrus and Cydonia were more powerful than Citrus/Cydonia in the restoration of 
Th1/Th2 balance (IFN-γ/IL-5 (day 7): 0.37 (95% CI: 0.06 to 0.68), p < 0.01 and 0.56 (95% CI: 0.26 
to 0.87), p < 0.001, respectively. Finally, unlike the results in the allergic donor group and the heal-
thy donor group, Citrus/Cydonia demonstrated a larger effect on the allergen-specific T cell subset 
related induction of Treg activity (IL-10 (day 7): 26.4 (95% CI: 1.1 to 51.7), p < 0.05) (Table 7.4).
7.3.6  Comparison of the effects on PBMCs from allergic and healthy donors
 Statistically significant differences between the allergic donor group and the healthy donor 
group were demonstrated on day 1 with regard to: TNF-α in the Cydonia group (182.2 vs. 160.2, 
respectively, p < 0.05) and IL-10 (day 1) in the Citrus/Cydonia group (54.0 vs. 69.6, respectively, 
p < 0.05); and on day 7 with regard to IL-5 in the Citrus group (509.9 vs. 358.0, respectively, p < 
0.05).
7.3.7 Comparison of the results in the different groups
 In all three groups (allergic donor, healthy donor, and total group) Citrus consistently de-
monstrated a selective effect on the reduction of chronic inflammatory activity compared to the 
other two extracts and on the reduction of allergen-specific Th2 pathway activity (Table 7.4: IL-1β, 
TNF-α, and IL-5). Cydonia and Citrus/Cydonia consistently demonstrated a selective effect on the 
induction of the innate Th1 pathway activity compared to Citrus (Table 7.4: IFN-γ - day 1) in all 
three groups.
In the allergic donor group and the total group, Citrus demonstrated a larger restoration of 
Treg/Th2 balance compared to the other two extracts (Table 7.4: IL-10/ TNF-α). In the healthy 
donor group and the total group, Citrus induced a reduction in the activity of an allergen-specific, 
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specialized T cell subset related Th2 pathway compared to Citrus/Cydonia (Table 7.4: IL-5). Citrus 
also demonstrated a restoration of the Th1/Th2 balance compared to Citrus/Cydonia (Table 7.4: 
IFN-γ/ IL-5) and Cydonia demonstrated a larger effect on the induction of the allergen-specific, 
specialized T cell subset related Th1 pathway compared to Citrus/Cydonia (Table 7.4: IFN-γ-day 
7). All analyses with regard to cell viability demonstrated acceptable cell survival, with no signs of 
toxicity, providing evidence for the safety of the three extracts (data not shown).
7.4  Discussion
 In this in vitro study we examined the immunological effects of the combined product, 
Citrus e fructibus/Cydonia e fructibus (Citrus/Cydonia), and separate products Citrus and Cydonia 
on PBMCs from a group of five healthy and five grass pollen allergic donors to study possible dif-
ferences in the working mechanisms and magnitude of the effects. Previous in vitro studies and 
clinical studies already repeatedly demonstrated positive treatment effects of Citrus/Cydonia on 
immunological and clinical SAR related elements [2-6]. The primary hypothesis of the present 
study was that the combination product Citrus/Cydonia would demonstrate larger SAR-related im-
munological treatment effects in vitro than each of the single products. The secondary hypothesis 
was that the healthy group would demonstrate larger SAR-related immunological treatment effects 
in vitro than the SAR group.
In grass pollen allergies, a state of chronic inflammation in the upper airways is reminiscent 
of allergen-induced activity of the innate immune system, which can be analyzed by the presence 
of TNF-α and IL-1b on day 1 in allergen-induced in vitro PBMC cultures. The allergen-induced 
outgrowth of various T-cell subsets in vitro is widely considered to be reminiscent of the presence 
of selected cytokines after seven days of culture, including IFN-γ (a signature Th1 cytokine), IL-5 
(a signature Th2 cytokine), and IL-10 (a signature Treg cytokine) [9, 10, 13, 14].  Based on our 
results, we conclude that Citrus and Cydonia appear to have different working mechanisms. Citrus 
has mainly a selective effect on the reduction of chronic inflammatory activity and the reduction of 
allergen-specific Th2 pathway activity; while, Cydonia has mainly a selective effect on the induc-
tion of the innate related, allergen-specific Th1 pathway activity. In theory the combination product 
Citrus/Cydonia would, therefore, provide an effective therapy that targets SAR from different and 
possibly additive or synergistic working mechanisms. However, the empirical results demonstrated 
that Citrus/Cydonia does not provide larger effects than the separate components, both with regard 
to the reduction of the allergen-specific Th2 pathway activity and the induction of the innate rela-
ted, allergen-specific Th1 pathway activity in vitro. Thus, the first hypothesis needs to be rejected. 
Based on these results, further effectiveness and (placebo)controlled efficacy studies are indicated 
to compare the effects of the three products on SAR in vivo. 
The differences between the SAR group and the healthy group (TNF-α in the Cydonia group, 
IL-10 (day 1) in the Citrus/Cydonia group, and IL-5 in the Citrus group) and the comparison of the 
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results of both groups (Table 7.3) demonstrates overall larger and more effects in the healthy group. 
These results implicate effects on both the innate arm of the immune response (monocyte-derived 
TNF and IL-10 production) and the potential Th2 arm of the adaptive immune response (reflected 
by the IL-5 effect). The second hypothesis of this study could therefore be confirmed, providing 
empirical underpinning of the assumption that the products support the SAR-related self-healing 
capacity of the organism and that this capacity is already stronger in healthy persons than in SAR 
patients before treatment. 
The positive effects of Citrus and Cydonia are in line with fundamental studies on the immu-
nomodulating compounds of these fruits. The extracts of Citrus [15] and Cydonia [16, 17] contain 
several immunologically active compounds, including organic acids, polyphenols, flavonoids, and 
pectins. For example, flavonoids are mainly present in Citrus fruits as their glycosyl derivatives 
[18]. Flavonoids appear to be able to regulate acute and chronic inflammatory responses and to 
suppress production of tumor necrosis factor-α (TNF-α), by macrophages, microglial cells, and 
mast cells stimulated with lipopolysaccharide (LPS) and others via toll-like receptors (TLRs), and 
TNF-α-mediated acute and chronic inflammatory responses [19-21]. And for example, the pectins 
in Cydonia extract generally contain a galacturonic acid. This immunomodulatory compound may 
strengthen innate-immune responses that may be beneficial in specific conditions, such as attenu-
ation of allergic disease [22,23]. 
The major limitation of this study is that it is an in vitro study that provides, within the classic 
evidence hierarchy framework, only limited evidence on the effectiveness of the examined extracts 
in vivo. However, the results are in line with previous in vitro studies [2,3] and an in vitro study 
within an in vivo randomized controlled trial [5], demonstrating the positive SAR related immuno-
logical effects of Citrus/Cydonia.
7.5  Conclusion
 It appears that Citrus and Cydonia have different working mechanisms in the treatment of 
SAR in vitro. Citrus mainly inhibits the chronic inflammatory activity and the SAR related Th2 
pathway activity, whereas Cydonia mainly promotes the SAR related Th1 pathway activity. The-
oretically, the combination of both extracts would provide an optimal treatment that would target 
SAR from different directions. However, in this in vitro study, the combination product Citrus/
Cydonia did not demonstrate larger effects than Citrus and Cydonia separately.
The primary hypothesis of the present study, that the combination preparation Citrus/Cydonia 
as a whole would demonstrate larger SAR-related treatment effects in vitro than each of the single 
preparations, was rejected. The secondary hypothesis, that the healthy group would demonstrate 
larger SAR-related treatment effects in vitro than the SAR group, was confirmed. 
Future studies could focus on the comparison of the effects of the separate extracts and the 
combination product in vivo.
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Abstract
 Objectives: The aim of this study was to study the effect of Gencydo® (Weleda AG, Arles-
heim, Switzerland) injections on hayfever symptoms.
 Design: This is a therapeutic causality report based on the practices of 13 Dutch general 
practitioners.
 Subjects: Thirteen (13) patients with a mean history of hayfever with grass pollen allergy 
of 9 years duration, who in previous years used conventional hayfever medication because of the 
severity of symptoms during the pollen season.
 Interventions: Gencydo injections were given in 12 patients before the onset of and during 
the grass pollen season, and in one patient during the grass pollen season only.
Outcome measures: Nasal and non-nasal hayfever symptom severity, use of rescue medication 
(antihistamines or corticosteroids), and subjective experiences of patients were used as outcome 
measures.
 Results: Nine (9) of 13 patients showed no increase of symptom severity during the so-
called pollen season. Both the mean maximal total nasal symptom score per patient and the mean 
total nasal symptom score for the entire study group during the days with a grass pollen count >100 
were mild. Percentages of individual “strong” or “severe” nasal symptom scores were low. There 
was no statistically significant difference in mean total nasal symptom score between the period 
when the pollen count was <100 and the period when it was >100. Conventional rescue medication 
for hayfever was used only eight times, all by one person. Nine (9) patients (69%) reported an 
improvement of symptoms (eight patients cited strong improvement and one patient noted slight 
improvement).
 Conclusions: There are clear indications that Gencydo treatment was effective in a large 
subgroup of the research population.
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8.1 Introduction
 Gencydo® is an anthroposophical medicine that has been specifically prescribed for the 
treatment of hayfever for more than 80 years. A survey of experienced doctors who often prescribe 
Gencydo, concerning their experience in practice, showed that Gencydo is expected to produce an 
effect within a few days to a maximum of 3 weeks. The doctors estimated the maximal efficacy of 
Gencydo as a monotherapy for hayfever at no greater than 50%.1 Because the effect of Gencydo on 
hayfever has not adequately been studied, an outcome study was performed. The central research 
question was whether Gencydo injections are effective in patients with hayfever and known grass 
pollen allergy during the grass pollen season.
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8.2 Materials and methods
Fig. 8.1. Overview of study patients from first to last weeks of study, in relation to pollen count (birch, 
grass, and oak), type of seasonal allergy, and subjective assessment of the effect of the treatment.
Black lines indicate birch pollen; grey lines, oak pollen; white lines, grass pollen.
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8.2.1 Design
 To determine the effect of Gencydo injections on hayfever symptoms an outcome study 
was designed based on therapeutic causality report (TCR) methodology.2,3* Central in this study 
design was the methodologic element that the relationship between the time spans of an illness (or 
symptom) before and after intervention can be an important guide to detect the causal relationship 
between intervention
and subsequent effect. The methodologic principle here is that if a symptom has existed for a 
long time and disappears shortly after the application of a therapy, this indicates the efficacy of the 
treatment. In this situation there is a pictorial correspondence between (the onset of) treatment and 
(the onset of) improvement. Besides that, more certainty can be achieved when each of the times of 
symptom start, treatment start, and symptom disappearance is not synchronous among the random 
selected cases in the study.3
8.2.2 Study population and eligibility criteria
 Patients were randomly recruited for the study through various participating doctors. Thirt-
een (13) patients were recruited, 12 before the start of the grass pollen season and the remaining 
patient during the grass pollen season (Fig. 8.1).
Inclusion was based on the following criteria: age > 18 years; history of grass pollen hayfever 
> 2 years; severity of symptoms: the presence of the need to use conventional medication (antihis-
tamines and/ or corticosteroids) for the treatment of hayfever symptoms during the pollen season 
in previous years; and willingness to comply with the study (i.e., to have injections as prescribed 
and to complete questionnaires). The study population consisted of two men and 11 women with 
a mean age of 38 years range: 13–69 years). The mean history of grass pollen allergy was 9 years 
(range: 2–30 years).
8.2.3 Intervention
 During the study period (March to July 2001), patients were treated with Gencydo injec-
tions with a dose and frequency as prescribed by their doctor over an average period of 8 weeks. 
Adaptation of the prescribed dose and frequency was permitted. The use of other prophylactic 
medication was not allowed. Rescue medication was twofold: first patients were asked to use Gen-
cydo injection fluid as a nasal spray; if this was not sufficient treatment of the symptoms (according 
to the subjective view of the patient), conventional symptomatic medication (such as antihistami-
nes and/or corticosteroids) was allowed. Use of all medication was recorded. 
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8.2.4 Instruments
 During the study the patients were requested to complete several questionnaires at conven-
tional intervals over an average period of 12 weeks. All questionnaires and symptom scores were 
recorded in a patient diary containing all applicable forms. The questionnaires were completed as 
described below.
Daily symptom score sheet.4 This questionnaire was completed each morning and evening, 
noting the following items: nasal (blocked nose, itchy nose, sneezing or a runny nose) and non-
nasal symptoms (itchy/ burning eyes, watery eyes, redness around the eyes, itchy ears/ palate) on 
a 4-point scale (0 = none, 1 = mild, 2 = strong, and 3 = severe). Both total nasal score (TNS) and 
total nonnasal score (TNNS) could vary between 0 and 12. The overall symptom score was defined 
as the sum of TNS and TNNS. Using symptom scores remains a reliable method for measuring the 
level of symptoms.5
Final assessment in accordance with Evans.6 This questionnaire was completed at the end of 
the intervention period and is a yardstick for the patient’s subjective view on the efficacy of the 
study treatment.
Pollen count. Grass, birch, and oak pollen counts were recorded daily, based on data from the 
Leiden University Hospital (Fig. 8.1).7
8.2.5 Data analyses
 Data were entered using SPSS Data Entry, version 2.0 (SPSS Inc., Chicago, IL) and both 
statistically analyzed with SPSS, version 10.0, and Microsoft Excel (Microsoft Corp., Redmond, 
WA) and visually analyzed. The analyses performed are described below.
Symptom curve score analyses. In the cases of patients who started treatment before the grass 
pollen season, effective treatment would result in a symptom curve in which the symptoms remained 
relatively mild during the “hayfever days” or days with a grass pollen count > 100 (“horizontal 
symptom curve”) in comparison to the previous period of low birch, oak, and grass pollen counts. 
In the cases of patients who started during the pollen season, effective treatment would also be ex-
pressed in a falling symptom curve (“falling symptom curve”). The choice for this form of analysis 
is based on TCR methodology3 combined with the literature that shows that in general it may be 
concluded that pollen count level is strongly related to the onset and severity of symptoms experi-
enced by patients during the hayfever season.8–11 Medication use has been reported to increase until 
the grass pollination peaks.12 A grass pollen count >100 is related to severe hayfever symptoms.7
Mean maximal total nasal score during high pollen count. Effective treatment would result in a 
low percentage of patients who individually only have mild symptoms on average.
Mean total nasal score for the entire study population during high pollen count. Effective treatment 
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would result in only mean mild symptom scores during high pollen count for the entire study population.
Difference in TNS means between high and low pollen count periods. Effective treatment would 
result in the absence of a difference in TNS means between the period with high pollen count 
(>100) and the period with low pollen count (<100).
Percentage of strong or severe nasal symptoms in relation to the overall number of nasal symp-
toms scores. Effective treatment would result in a low percentage of strong or severe symptom 
scores, both throughout the study period and during the period with a grass pollen count >100.
Rescue medication. Effective treatment would result in a low number of use of antihistamines 
and corticosteroids. 
Subjective judgment of treatment effect. Effective treatment would result in a high percentage of 
patients indicating that symptoms are improved by Gencydo treatment.
8.3 Results
8.3.1 Symptom score curve
 Horizontal symptom curve. Nine (9) patients (69%) showed a horizontal symptom curve. 
In two patients (15.5%) the symptom score in the high grass pollen count was higher than the score 
in the low pollen count period. In two patients (15.5%) the symptom curve could not be analyzed 
because of missing data (Fig. 8.2).
Falling symptom curve. Only one patient started the treatment with Gencydo injections during 
the high grass pollen count period. The symptom curve of this patient was falling (Fig. 8.3).
8.3.2 Mean maximal total nasal score during high pollen count
 During 14 days of the study period the grass pollen count was >100. Two (2) patients did 
not complete their questionnaires during this period, so they were taken out of this part of the 
analysis. In the other 11 patients the maximal total nasal symptom scores in the mornings and the 
evenings on each of the days were described as mild (Fig. 8.4).
8.3.3 Mean total nasal score for the entire study group during high pollen count
 Both in the morning and in the evening the mean total nasal symptom score per week 
remained <4. Thus on average the entire study group experienced only mild symptoms at most 
experienced (Fig. 8.5).
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POLLEN COUNT BIRCH, OAK AND GRASS
- 20 April until 9 July 2001 -
0
50
100
150
200
250
300
1 7
13 19 25 31 37 43 49 55 61 67 73 79
birch pollen
oak pollen
grass pollen
Figure 2. Horizontal symptom curve
69
0
20
40
60
80
yes no unclear
n = 13
p
er
ce
n
ta
g
e
Figure 3. Falling symptom curve
100
0
20
40
60
80
100
120
yes no
n=1
pe
rc
en
ta
ge
0
50
100
n=13
Figure 6. Incidence of the use of regular 
rescue medication 
0
2
4
6
grass pollen count < 100 grass pollen count > 100
n=13
Figure 7. Patients' subjective assessment of the 
degree of improvement in their symptoms
0
20
40
60
80
strong
improvement
slight
improvement
no
improvement
I don't know
n=13
pe
rc
en
ta
ge
Figure 8. Patients' subjective assessment of the 
effect of Gencydo injections on their symptoms
0
10
20
30
40
50
60
70
stron
improvement
slight
improvement
no
improvement
I don't know
n=13
pe
rc
en
ta
ge
15,5 15,5
0
Figure 4. total nasal score during pollen days 
with a grass pollen count >than 100
100
0
20
40
60
80
100
120
morning evening
n=11
pe
rc
en
ta
ge
100 maximum mild
maximum strong
mild strong severe
Figure 5. Group mean nasal symptom score during grass 
pollen c unt > 100
3
5
61,5
7,5 7,5
23
61,5
7,5 7,5
23
Figure 6. Incidence of the use of Gencido-like
rescue medication 
0
50
100
150
grass pollen count < 100 grass pollen count > 100
n=13
202
56
200
250
pe
rc
en
ta
ge
Fig. 8.7. Incidence of the use of conventional rescue medication.
156   Evidence-based curative health promotion
8.3.4 Differences in TNS means between high and low pollen count periods
 The total nasal symptom scores (morning) in weeks 13–15, the weeks before the period 
when the grass pollen count was >100, were compared to the total nasal symptom scores (morning) 
for the 14 days that the grass pollen count was >100. One patient was excluded from the analysis 
because of several missing values. The few remaining missing values were replaced with the series 
means. The Wilcoxon test (nonparametric method) for paired observations in small numbers sho-
wed no significant difference between these two periods.
8.3.5 Rescue medication
 In periods with a pollen count <100, Gencydo-like rescue  medication was used 202 times. 
Gencydo-like medication was used 56 times during the periods with a pollen count >100 (Fig. 8.6). 
A total of eight times applied to one patient only (Fig. 8.7).
8.3.6 Percentage of strong or severe nasal symptoms in relation to overall 
number of nasal symptoms scores
 The percentages of individual nasal symptom scores reported as strong or severe over the 
entire study period were low (Tables 8.1 and 8.2).
8.3.7 Subjective judgment of treatment effect
 Nine (9) of the 13 patients (69%) judged that symptoms had been reduced. Eight (8) pa-
tients (61.5%) indicated that there had been a strong improvement, and one patient (7.5%) indi-
cated a slight improvement. One patient (7.5%) reported that symptoms had remained the same. 
Three (3) patients
(23%) said that they did not know whether their symptoms had been reduced (Fig. 8.8). Nine 
(9) of the 13 patients (69%) also said that it had been the treatment with Gencydo injections that 
was responsible for the reduction of symptoms. Eight (8) patients (61.5%) found that Gencydo had 
greatly improved their symptoms, and 1 patient (7.5%) indicated that Gencydo had slightly redu-
ced symptoms. One (1) patient (7.5%) reported that Gencydo had had no effect, and three patients 
(23%) stated that they did not know whether the product had had any effect (Fig. 8.9).
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Fig. 8.9. Patients’ subjective assessments of effects of Gencydo injections on their symptoms.
Table 8.1. Percentages of individual nasal symptom scores reported as strong
Symptom 
Morning (%), 
entire period
Morning (%),  
period grass 
pollen count >100
Evening (%), 
entire period
Evening (%), 
period of grass  
pollen count >100
Blocked nose 10.9 12.7 11.9 13.0
Itchy nose 8.9 13.2 9.5 13.6
Sneezing 10.9 11.7 9.6 18.2
Runny nose 11.5 21 9.9 19.1
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Table 8.2. Percentages of individual nasal symptom scores reported as severe
Symptom 
Morning (%), 
entire period 
Morning (%), 
period of grass  
pollen count >100 
Evening (%),
entire period
Evening (%),
period of grass  
pollen count >100
Blocked nose 0.8 0 0.9 0.9
Itchy nose 0.5 0.3 0.7 0.0
Sneezing 3.1 1.5 2.6 4.0
Runny nose 3.5 6.1 2.5 3.8
8.4 Discussion
 In this study the effect of Gencydo injections on patients with hayfever and a grass pollen 
allergy were examined. The research population had a mean hayfever history of 9 years, and in for-
mer years the necessity to use conventional hayfever medicines to control symptom severity. The 
expectation was therefore that without conventional hayfever medications the effect of Gencydo 
injections would be expressed in low total nasal and non-nasal symptom scores during the pollen 
season and especially during the period with a grass pollen count >100.
The analyses of symptom curves, the use of rescue medication, and patients’ own subjective 
assessments show that there was an improvement in the symptoms in many of the patients both 
individually and in the group as a whole. Of particular importance here are the various analyses of 
the severity of the overall nasal symptoms during the period with a grass pollen count >100. These 
analyses show that (1) on average during this period, the sample group as a whole experienced 
only mild symptoms; and (2) the highest total nasal score in this period was reported to be mild in 
100% of patients. Thus despite the high pollen count none of the individual patients had strong or 
even severe symptoms. This also points to only a small increase in symptoms despite the increase 
in pollen count.
Although this study design did not control for the influence of a placebo effect, this appeared 
not to have influenced the observed effect to a great extent. The main reason for this assumption is 
that results of Danish empirical research recently cast serious doubt on the existence of a placebo 
effect.13
Because the patients were aware of the purpose of the research it is possible that the patients 
under-reported their symptoms or reported the severity of these symptoms as being less severe 
than they actually were. This possibility certainly cannot be excluded, but it does not seem likely 
that this contributed significantly to the ultimate effect. The study used the same symptom score 
questionnaire,4 which has often been used in clinical studies with good results. 
On the basis of this study it can be concluded that there are clear indications that Gencydo 
injections was effective in the treatment of hayfever, at least in some of the population. Future re-
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plicated studies, possibly with larger numbers of patients, greater checks for possible information 
bias, and control groups will clarify whether the effect is replicable and whether there are specific 
prognostic subpopulations of hayfever patients in whom Gencydo injections have a greater or les-
ser effect. It would also be worthwhile, given the anthroposophical nature of the medication and 
the experience of the prescribing doctors, to carry out multiyear research to determine the optimal 
outcome of Gencydo injections. The reason for this is that Gencydo injections are expected to 
achieve their optimum outcomes of treatment of hayfever only after several years. A multiyear 
study could determine the outcomes of this treatment.
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Abstract
 Background: Clinical experiences, in vitro and clinical studies have demonstrated the cu-
rative potency and safety of Citrus/Cydonia compositum in seasonal allergic rhinitis treatment.   
 Objectives: To compare the efficacy and safety of two routes of administration (nasal 
spray versus subcutaneous injections). 
 Methodology: Design: a national, randomised, comparative clinical trial with two parallel 
groups. Participants: 23 patients fulfilled the study requirements. Intervention: after a one- or two-
week wash-out period, 23 patients were randomized to a 6 weeks treatment period. 
 Outcomes: Immunological and symptom severity changes, and safety. Immunologic out-
come assessments were blinded to group assignment. 23 patients were randomized and from 22/23 
patients (11 in each group) blood samples were analyzed before and after treatment. 
 Conclusion: Both routes of administration demonstrate immunological and clinical ef-
fects, with larger inflammatory and innate immunological effects of the nasal spray route and larger 
allergen-specific clinical effects of the subcutaneous route, and are safe. 
 Keywords: seasonal allergic rhinitis, Citrus/Cydonia comp., Gencydo, subcutaneous injec-
tion, nasal spray, randomized clinical trial, curative health promotion
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9.1 Introduction
 Seasonal allergic rhinitis (SAR) or hay fever is a type I immediate hypersensitivity reaction 
mediated by specific IgE antibody formation to a seasonal allergen, leading to mucosal inflamma-
tion characterized by sneezing, itching, rhinorrhoea, and nasal blockage. Pollen from wind pollina-
ted grasses, trees, weeds, and spores from fungi are the most common aeroallergens. The estimated 
prevalence of SAR in adults in several Western countries is 8 - 15% [1,2]. The treatment of choice 
is the symptomatic treatment with antihistamines and/or local corticosteroids. Immunotherapy is 
indicated in a limited subpopulation of patients that are insufficiently treated with antihistamines 
and/or local corticosteroids [3]. Since SAR is a chronic disease and the treatment of choice for 
most patients is purely symptomatic, most SAR patients must be treated for decades. 
Citrus/Cydonia compositum (comp.) 1% solution for injection and Gencydo nasal spray are 
medicinal products, which contain exactly the same ratio of constituting substances, lemon juice 
(Citrus limon, succus) and an aqueous extract from quince (Cydonia oblonga, fructus rec.): 1ml 
contains 8-12 mg Citrus limon, succus, corresponding to 0.65 mg fruit acid, calculated as citric 
acid and 30 mg aqueous extract from Cydonia oblonga, fructus rec. (1:2.1). For more than eighty 
years, Citrus/Cydonia comp. has been prescribed for SAR patients. 
The experiences of prescribing general practitioners (GP’s) is that SAR patients are claiming 
to permanently suffer less from hay fever symptoms or even that they are free from complaints 
after the treatment with Citrus/Cydonia comp. [4]. Positive effects, without side effects, were also 
observed in two cohort studies: a group of 13 patients suffering from grass pollen SAR treated with 
subcutaneous injections [5] and in a group of 140 patients, who were treated with nasal spray [6]. 
Recently, the immunological pathways underlying the positive effects of Citrus/Cydonia comp. in 
SAR patients were studied in vitro [7, 8]. These studied demonstrated a restoration of the disturbed 
immune state of allergic rhinitis patients by direct modulation of the Th1/Th2 balance. Such a 
perturbed Th1/Th2 balance is widely considered the hallmark of allergic disease [9]. In addition, 
it was demonstrated that Citrus/Cydonia comp. significantly reduced the histamine production and 
the inflammatory mediator release from mast cells in a dose-dependent manner [8]. 
The objectives of this study were to assess and compare the immunological and clinical effects 
and to assess the safety of two routes of administration (subcutaneous injection versus nasal spray) 
of Citrus/Cydonia comp. 1% in order to determine which route of administration demonstrated 
superior efficacy and safety. 
9.2 Methods
 This is a national, stratified (age: 18-40 or 41-60; and RAST (radioallergosorbent testing) 
scores for birch pollen: > 2 or < 3; with a balanced randomization), comparative, single-blind 
(laboratory) clinical trial with two parallel groups conducted in The Netherlands. 
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9.2.1 Participants
 Eligible participants were all adults aged 18 to 60, suffering from SAR for at least two 
years, with a RAST for grass pollen ≥ 2, suffering from the following nasal symptoms: sneezing, 
itching nose and watery nasal discharge, with a severity score of at least two of the three symptoms 
≥ 2 (ranging from 0 = not present to 3= severe) and the necessity to use antihistamines and/or cor-
ticosteroids for treatment of symptoms for previous (at least two) years. Exclusion criteria were: 
chronic inflammatory autoimmune diseases; allergic (hypersensitive) to one of the constituents of 
Citrus/Cydonia comp. or Gencydo nasal spray; pharmacological treatment of allergic rhinitis or 
use of other preparations containing Citrus and/or Cydonia extracts within the last two weeks prior 
to enrolment into the study; use of cromoglycates in the last month before study onset; concomitant 
pharmacological treatment indicated for seasonal allergic rhinitis such as antihistamines, cortico-
steroids or other preparations; participation in a further clinical trial at the same time or within the 
previous 4 weeks prior to enrolment into this study; pregnancy or lactation; and severe internal or 
systemic disease. 
9.2.2 Ethics
 The medical ethical committee (STEG-METC, Almere, The Netherlands) approved the 
study. Individual patients gave written informed consent.
9.2.3 Interventions
 Patients received the treatment in accordance with the Summary of Product Characteris-
tics; either Citrus/Cydonia comp. 1% subcutaneous injections (1 mL, ampoules available under 
the trade name Gencydo® 1%, manufacturer Weleda AG, Schwäbisch Gmünd, Germany) twice 
per week, or the Gencydo nasal spray (1-2 sprays in each nostril) four times per day (available 
under the name “Gencydo neusspray” in the Netherlands, manufacturer Weleda AG, Schwäbisch 
Gmünd, Germany). This application strategy resulted in the nasal spray group receiving four times 
the active dose compared with the injection group. The composition of Citrus/Cydonia comp. 1% 
solution for injection and Gencydo nasal spray spray is identical. Both medicinal products contain 
lemon juice (Citrus limon) and an aqueous extract from the fruit of a quince (Cydonia oblonga): 
one milliliter of these preparations contains 8-12 mg C. limon juice corresponding to 0.65 mg fruit 
acid, calculated as citric acid, and 30 mg C. oblonga aqueous extract (drug-extraction-rate: 1:2.1).
Thesis Erik W. Baars   165
9
9.2.4 Objectives
 The objectives of the present study were to test (1) the immunological (primary objective) 
and clinical (secondary objective) superior efficacy of the subcutaneous route of administration 
compared to the nasal spray route of administration; and (2) the safety of both routes of adminis-
tration (tertiary objective) in a group of adult, grass pollen SAR patients. 
The primary hypothesis was that the subcutaneous route of administration demonstrated su-
perior immunological efficacy; the secondary hypothesis was that the subcutaneous route of ad-
ministration demonstrated superior clinical efficacy; and the third hypothesis was that both routes 
of administration were safe. Based on the results of the study, one route of administration will be 
studied in a future placebo-controlled, randomized trial.
9.2.5 Outcomes
 Primary endpoints were SAR-related changes in immunological parameters between the 
start of the treatment (baseline) and after six weeks of treatment (post-baseline). From each patient 
8 ml of peripheral blood was collected from which peripheral blood mononuclear cells (PBMCs) 
were isolated. PBMCs were cultured in Yssel’s medium at 37°C in a humidified atmosphere with 
5% CO2 at a density of 1x106 viable cells/mL. Cells were plated out in 48 well plates at a concen-
tration of 1x106 cells/mL and cultured at 37°C. After five hours, in which the cells adapted to the 
culture conditions, various stimuli or a matching volume of medium were added. Cultures were 
stimulated polyclonally with 150 ng/mL anti-CD3 plus 100 ng/mL anti-CD28 monoclonal antibo-
dies (BD Pharmingen, San Diego, Calif, USA) or cultured in medium only [10]. In addition, we 
performed allergen-specific stimulation of 106 cells/ml in 1 ml cultures with applied pollen extract 
(Phl p 1 from Timothy grass, Phleum pretense; Biomay Vienna, Austria; 10 μg/ml in medium).
 The proliferation capacity, cell survival, toxicity and total production capacity of several cyto-
kines (e.g., IL-10, TNF-α, IFN-γ, IL-4, IL-5 and IL-13) in the culture supernatants of the PBMCs 
were analyzed at day 1 (demonstrating the reaction of the innate immune system) and day 7 (de-
monstrating the reactions of specialized T cells subsets) in the laboratory [10,11]. The following 
changes in cytokine production levels were regarded as a positive immunological SAR treatment 
effect [12-14]: 
1. The reduction of activation state of the SAR related immune subsystem: reduction of (grass 
pollen stimulated minus medium stimulated) IL-10 and TNF-α at day 1;
2. The induction of (regulatory) T-cells (Tregs): increase of (grass pollen stimulated minus 
medium stimulated) IL-10 at days 1 and 7;
3. The induction of Th1 activity: increase of (grass pollen stimulated minus medium stimula-
ted) IFN-γ at days 1 and 7;
4. The reduction of Th2 activity: reduction of (grass pollen stimulated minus medium stimu-
lated) IL-1β at day 1; IL-5 and IL-13 at day 7; 
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5. The reduction of chronic inflammatory activity: reduction of (grass pollen stimulated mi-
nus medium stimulated) TNF-α at day 1; 
6. The restoration of the Th1/ Th2 balance: the increase of (grass pollen stimulated minus 
medium stimulated) IFN-γ/ IL-5 and IFN-γ/ IL-13 ratios at day 7; and/or 
7. The restoration of the Treg/Th2 balance: the increase of (grass pollen stimulated minus 
medium stimulated) IL-10/ TNF-α ratio at day 1; the increase of (grass pollen stimulated 
minus medium stimulated) IL-10/ IL-5 and IL-10/ IL-13 ratios at day 7.  
Secondary efficacy variables were the change in nasal and non-nasal allergic rhinitis symptom 
severity before treatment start and after each week of treatment. The severity of nasal symptoms 
(nasal obstruction, itching nose, sneezing, and watery nasal discharge) and non-nasal symptoms 
(itchy/burning eyes, watery eyes, redness of eyes, and itching ears/throat) symptoms were recorded 
twice per day (in the mornings and evenings) by the patient. The disease-specific symptom severity 
questionnaire was provided to the patient as an online questionnaire in Dutch: 0 = no symptom, 1 
= mild, 2 = moderate, and 3 = severe. Completion of the online questionnaires by the participants 
was checked daily. 
Blood samples for immunological analyses were taken before and after six weeks of treatment. 
SAR related symptom severity scores were measured twice a day (morning and evening) during 
both the one-week or two-week washout and the six-week treatment periods.
Pollen counts were acquired on a daily basis for grass pollen and birch pollen from the Lei-
den University Medical Centre (http://www.lumc.nl/con/1070/85683/105795/105824/, Figure 9.2) 
during both the washout period and the treatment period. Safety was measured by means of adverse 
events surveillance and laboratory parameters (abnormal findings in the immunological analyses).
9.2.6 Sample size
 Based on an expected mean difference of IL-10 of 1.834 pg/ml, which is in line with the 
former in vitro studies [7], with a two-sided 5% significance level and a power of 95%, a sample 
size of 14 patients per group, thus in total 28 patients, was necessary.
9.2.7 Randomization-Sequence generation
  Pre-stratification on age (18-40 or 41-60) and RAST scores for grass pollen (> 2 or < 3) 
was used to divide participants into four subgroups. For allocation of the participants, a computer-
generated list of random numbers was used. The randomization list was generated with the Ran-
dom Allocation Software Program version 1.0 (Saghaei, Isfahan University of Medical Sciences, 
Iran) using a random block size of two in order to guarantee a balanced allocation. 
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9.2.8 Randomization-Allocation concealment
 After a one-week (for patients that had not been treated for SAR in the week before enroll-
ment) or a two-week (for patients that had been treated for SAR in the week before enrollment) wash-
out period, patients were assigned to four strata and then randomized to a six-week treatment period. 
9.2.9 Randomization-Implementation
The two investigational medicinal products were assigned to treatment A and treatment B by the 
sponsor for all patients who were assigned randomly to either one of the two treatment groups. The 
label assignment was kept at the sponsor’s site until all study data had been entered in the study 
database.
9.2.10 Blinding
 The procedure of label assignment and random allocation to treatment A and treatment B 
was carried out to guarantee a blinded analysis of the primary efficacy variable, the immunological 
laboratory parameters. Laboratory personnel had no information about any treatment of patients 
during the period of all laboratory procedures and analyses. Unblinding took place after all statis-
tics had been performed.
9.2.11 Statistical analyses
 Only evaluable patients, with immunological parameters measured before randomization 
and post-baseline (after six weeks of treatment), were included in the primary analysis for each 
primary efficacy variable (Per Protocol Set, PPS). In order to eliminate the impact of drop outs on 
efficacy results, in addition a subset of observed cases (OC) was evaluated. This subset included 
data only from randomized patients who did not discontinue prematurely and were available for 
evaluation at the designated assessment times. Missing values of the immunological parameters 
(e.g. values below cytokine detection limits) were not replaced. Missing values of the symptom se-
verity scores, in absence of a major protocol violation, were replaced in two ways: by week means 
and last observation carried forward (LOCF) [15], and subsequently compared.
Regular descriptive statistics were performed with regard to demographical and categorical 
data. To test the primary hypothesis, superiority of Citrus/Cydonia comp. 1% solution for injection 
as compared to Gencydo nasal spray with respect to the primary target variable changes in immu-
nological parameters, descriptive statistics, Student’s t-tests and non-parametric Wilcoxon Signed 
Ranks tests were performed to compare means and mean base-10 log transformed scores of the 
168   Evidence-based curative health promotion
immunological parameters in both groups and to calculate 95% confidence intervals. 
To test the secondary hypothesis, superiority of Citrus/Cydonia comp. 1% solution for injection 
as compared to Gencydo nasal spray with respect to the secondary target variable lower seasonal 
allergic rhinitis symptom severity scores, mean scores and standard deviations per week were cal-
culated. Then, multivariate analysis techniques were used to compare the symptom severity mean 
week scores in the subcutaneous and the nasal spray group for each of the 6 weeks and to calculate 
95% confidence intervals. In addition, Cohen’s delta was calculated for both routes of administra-
tion to estimate the effect sizes. 
The safety analysis was based on the Full Analysis Set (FAS) of all patients who took at least 
one dose of the randomised study medication. During the course of the study, all adverse events, 
irrespective of the relationship to the study medication or study procedure, were recorded on the 
adverse event forms contained in the Case Report Form (CRF). During each monitoring visit, the 
person responsible for monitoring of the clinical trial and the investigator reviewed all adverse 
events. With respect to all adverse events, the investigator was responsible for ensuring that correct 
and complete information was documented on the adverse event forms in the CRF. The assess-
ment of the severity of an adverse event (AE) (mild, moderate, severe) was also performed by the 
investigator. The causal relationship with the administration of the investigational drug or a study 
procedure was assessed according to the categories as described by the Uppsala Monitoring Centre 
and recommended by the WHO (certain, probable, possible, unlikely, conditional and unassessi-
ble), both by the investigator and the sponsor.
9.3 Results
9.3.1 Participants flow
 From 34 included patients, 11 patients dropped out before randomization either due to too 
low RAST score for grass pollen (n = 8), withdrawal of informed consent (n = 1), use of medica-
tion during wash-out period (n = 1) or too mild symptoms (n = 1). After randomization at baseline, 
the Full Analysis Set (FAS) contained 23 patients (12 patients in the Citrus/Cydonia group and 11 
patients in the Gencydo group). There was one dropout in the Citrus/Cydonia group after three 
weeks of treatment due to an adverse event. From another patient in the Citrus/Cydonia group the 
second blood sample got lost and therefore immunological analyses could not be performed. For 
the immunological analyses there were 22 patients (11 patients in each group) in the Per Protocol 
Set (PPS) and 21 patients (10 patients in the Citrus/Cydonia group and 11 patients in the Gencydo 
group) in the Observed Cases (OC) subgroup (Figure 9.1).
Patients were visited during the screening, before the start of the treatment and at the end of the 
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treatment. A telephone visit was performed after three weeks of treatment. 
A total of 20 out of 23 patients (87%) started treatment in weeks 23 and 24: 10 of the 12 patients 
in the Citrus/Cydonia comp. group (83%) and 10 of the 11 patients in the Gencydo group (91%). 
Three other patients started in week 26: two patients in the Citrus/Cydonia comp. group and one 
patient in the Gencydo group (data not shown).
9.3.2 Recruitment
 All eligible patients were recruited from a single centre, the Louis Bolk Institute (Drieber-
gen, NL). The first patient was included on May 19, 2009 and the last patient completed the study 
on August 11, 2009. 
9.3.3 Baseline characteristics and baseline homogeneity
 Baseline homogeneity of the treatment groups was accomplished with regard to the fol-
lowing SAR related aspects: RAST scores (grass pollen and birch pollen), worst SAR symptom 
severity during the previous pollen season (anamnestically), SAR symptom severity scores in the 
morning and the evening during the wash-out period (Table 9.1) and onset of interventions (data 
not shown). Homogeneity of the treatment groups was accomplished with regard to the following 
SAR non-related aspects: age, height, weight, smoking status, ethnic origin, remaining medical 
history, prior medication, vital signs and physical examination. Homogeneity of the treatment 
groups was not accomplished with regard to gender as a SAR non-related aspect.
9.3.4 Pollen counts
 The grass pollen counts during the wash-out period and the treatment period demonstrated 
that the grass pollen season in this period, apart from week 22, was not severe and the influence 
of the birch pollen was almost null (number of grains of pollen in a cubic meter of air/ 24 hours) 
(Figure 9.2). Grass pollen counts higher than 100 were measured in only four days in week 22, 
thus before the treatment period. After week 27, the week means were lower than 15. Since pollen 
counts higher than 80 – 100 are correlated with severe symptoms, and pollen counts higher than 
10 - 15 are correlated with mild symptoms, the period after week 27 is not clinically relevant for 
this study [16].
Since patients had their wash-out period for one week or two weeks and in different weeks the 
mean pollen count during the entire wash-out period was calculated. We calculated the exact mean 
pollen count in the wash-out period by adding all real pollen counts from day 1 to day 7 of the first 
wash-out week per patient and subsequently calculating the means of the pollen count. This resul-
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Enrollment Assessed for eligibility (n= 34 )
Excluded  (n= 11)
    Not meeting inclusion criteria (n=10)
   Declined to participate (n=1)
   Other reasons (n=0)
Randomized (n=23) (Full Analysis Set)
Allocated to Citrus/ Cydonia comp. 
intervention (n=12)
 Received allocated intervention (n=12)
 Did not receive allocated intervention (n=0)
Allocated to Gencydo intervention (n=11)
 Received allocated intervention (n=11)
 Did not receive allocated intervention (n=0)
Lost to follow-up (n=0)
Discontinued intervention (due to ADR) (n=1)
Follow-Up
Allocation
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Analysed  (n=11) (Per Protocol Set)
 
 Excluded from analysis (due to lost 
blood sample) (n=1) > (Observed Cases: n=10)
Analysis
Analysed  (n=11) (Per Protocol Set) 
 Excluded from analysis (n=0)
Figure 9.1. Participant flow: primary efficacy analysis data sets
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ted in a mean pollen count in the wash-out period of 44.6 (sd = 11.6) for the whole population, 46.8 
(sd = 17.5) for the Citrus/Cydonia comp. group and 39.1 (sd = 10.7) for the Gencydo group. These 
differences between both treatment groups were small, not statistically significant and clinically 
irrelevant, since the categories of symptom severity that are correlated to pollen count are: mild 
(10/15 – 45/50), moderate (45/50 – 80/100) and severe (80/100 and higher), which implicated that 
both mean scores (39.1 and 46.8) were mild/ (borderline) moderate.
9.2.5 Numbers analyzed
 23 patients were randomized (Full Analysis Set). From 22 patients (11 in each group) blood 
samples were analyzed before and after treatment (Per Protocol Set) and from 21 patients (10 pa-
tients in the Citrus/Cydonia group and 11 patients in the Gencydo group) in the Observed Cases 
(OC) subgroup (Figure 9.1).
From 20 of the 23 randomized patients (10 in each group) symptom severity scores were ana-
lyzed.
9.2.6 Primary outcome variables: immunological analyses
Analyses at day 1 of allergen-specific stimulation
 The analyses demonstrated acceptable cell survival, with no signs of toxicity (<5 % apop-
totic cells, data not shown). Base-10 log transformations of the data, deemed mandatory due to an 
unequal distribution. 
The cytokine analyses of the PPS comparing medium stimulation versus allergen stimulation, 
demonstrated statistically significant increases both at baseline vs post-baseline of IL-10 (Gencydo 
group: 1.29 (95% CI: 1.15 – 1.44), p < 0.001 vs. 0.97 (95% CI: 0.56 – 1.37), p < 0.001), (Citrus/
Cydonia group: 1.03 (95% CI: 0.70 – 1.37), p < 0.001 vs. 1.19 (95% CI: 0.64 – 1.74), p < 0.01) and 
TNF-α (Gencydo group: 1.44 (95% CI: 1.18 – 1.71), p < 0.001 vs. 1.02 (95% CI: 0.51 – 1.53), p < 
0.01) (Citrus/Cydonia group: 1.34 (95% CI: 0.76 – 1.91), p < 0.001 vs. 0.96 (95% CI: 0.62 – 1.30, 
p < 0.001) in both treatment groups, but not of IFN-γ cytokine production (data not shown). 
Comparison of the results of allergen stimulation minus medium stimulation at baseline and 
post-baseline, demonstrated a reduction in TNF-α production level in the Gencydo group (-0.50 
(95% CI: -0.08 to -0.93), p < 0.05), (Table 9.2). Comparing results of allergen stimulation at base-
line and post-baseline demonstrated also a reduction of TNF-α in the Gencydo group (PPS: -0.36 
(95% CI: -0.02 to -0.71), p < 0.05 vs. OC: -0.33, p < 0.05). IL-10 and IFN-γ levels demonstrated 
no statistically significant changes. The analyses of the OC subgroup demonstrated no significant 
differences compared to the analyses of the PPS.
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Analyses at day 7 of allergen-specific stimulation
 The analyses of the PPS and OC demonstrated only a baseline to post-baseline decrease 
of IL-10 cytokine production (Citrus/Cydonia comp. group (PPS vs. OC): -0.68 (95% CI: -0.37 to 
-1.0), p < 0.01 vs. 0.67, p < 0.05; Gencydo group: -0.44 (95% CI:-0.19 to -0.68), p < 0.01) and no 
statistically significant changes in all other cytokines (IL-12, IL-5, IL-13 and IFN-γ and relevant 
ratios of cytokines) in both groups (Table 9.3).
9.2.7 Secondary efficacy results: symptom severity
 Total symptom scores (TSS) were analyzed during washout, and week 1 until week 5 of 
treatment. Due to a very low pollen count during week 6, data of week 6 of treatment were ex-
cluded from the analyses. Missing values were replaced in two ways: mean week scores and Last 
Observation Carried Forward. When compared to the dataset without the missing values, the mean 
week scores demonstrate only small, non-significant differences (data not shown). 
A one-way-analysis of covariance (ANCOVA) with parallel regression lines of the TSS morn-
ing data demonstrated a statistically significant overall reduction of TSS scores in the period from 
wash-out to respectively 2, 3, 4 and 5 weeks (Figure 9.3). After three weeks of treatment until five 
weeks of treatment there was also a statistically significant difference between (the level of the par-
allel regression lines of) the two treatment groups, demonstrating larger effects of the subcutaneous 
route of administration. Non-parametric tests demonstrated statistically significant differences be-
tween wash-out and all weeks of treatment (week 1 - 5) for the whole group; between wash-out and 
weeks 2 – 5 of treatment for the Citrus/Cydonia group; and no statistically significant differences 
between wash-out and all separate weeks of treatment for the Gencydo group. The TSS reduction 
in the Citrus/Cydonia group between washout and week 5 of treatment was 4.8 (95% C.I.: 1.7 to 
7.9) (Table 9.4). The analyses of the PPS demonstrated small but not significant differences (data 
not shown).
A one-way-analysis of covariance (ANCOVA) with parallel regression lines of the TSS eve-
ning data demonstrates a statistically significant overall reduction of TSS scores in the period 
from wash-out to 2, 3, 4 and 5 weeks (Figure 9.4). There was a statistically significant difference 
between (the level of the parallel regression lines of) the two treatment groups at all times of 
treatment. Non-parametric tests demonstrated statistically significant differences between wash-
out and all weeks of treatment (week 1 - 5) for the whole group, the Citrus/Cydonia group and the 
Gencydo group. The TSS reduction between washout and week 5 of treatment was 4.5 (95% C.I.: 
1.7 to 7.2) in the Citrus/Cydonia group, was 4.1 (95% C.I.: -0.4 to 7.8) in the Gencydo group, and 
was 4.3 (95% C.I.: 2.2 to 6.4) in the total group (Table 9.4). The analyses of the PPS demonstrated 
small but not significant differences (data not shown). 
Cohen’s delta effect sizes (wash-out versus five weeks of treatment) were calculated for both 
the pooled data of all patients, and the Citrus/Cydonia group and the Gencydo group separately. 
Cohen’s delta effect size for the pooled data of all patients in the morning was medium and large 
Thesis Erik W. Baars   173
9
in the evening (respectively: 0.65 and 0.99). Cohen’s delta effect sizes were large for the subcuta-
neous route of administration, both in the morning and the evening (respectively: 1.19 and 1.37), 
and for the nasal spray route of administration medium, both in the morning and the evening 
(respectively: 0.49 and 0.79) (but the nasal spray morning scores difference was not statistically 
significant). In order to control for possible bias due to the natural course of the disease (whereas 
the pollen count was very low after week 27), we post hoc reanalyzed the Cohen’s delta effect sizes 
of all data without the data of the three patients that started treatment in week 26. Cohen’s delta 
effect sizes for the pooled data of all patients now were large both in the morning and the evening 
(respectively: 0.98 and 0.81). Cohen’s delta effect sizes again were large for the subcutaneous 
route of administration, both in the morning and the evening (respectively: 1.32 and 1.20), and for 
the nasal spray route of administration were now large in the morning and medium in the evening 
(respectively: 0.87 and 0.45) (but the nasal spray morning scores difference was still not statisti-
cally significant).
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Figure 9.2: Mean grass pollen counts per week. Weeks 21–35 (2009).
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9.2.8 Adverse events
 The safety analysis set consisted of the 23 randomised patients of the Citrus/Cydonia and 
the Gencydo group. During the treatment period, a total of 9 adverse events (AEs) were observed 
in 6/23 patients (26.1%). The number of patients suffering from AEs in the Citrus/Cydonia group 
(five AEs in 2/12 patients; 16.7%), was lower compared to the Gencydo group (four AEs in 4/11 
patients; 36.4%). The incidence of adverse events was comparable between the two treatment 
groups. None of the AEs were classified as serious. A causal relationship could not be excluded 
in all of these adverse events. In the Citrus/Cydonia group, three AEs were assessed as ‘probably 
related’ and two as ‘possibly related’. In the Gencydo group, 3 AEs were assessed as ‘certain rela-
ted’ and 1 AE as ‘probably related’. One patient in the Citrus/Cydonia group terminated the study 
prematurely due to an AE (itching skin), which was assessed as ‘possibly related’ to the study me-
dication. Three of the nine AEs were of mild intensity, they all occurred in the Gencydo group. Two 
AEs in one patient in the Citrus/Cydonia group and one AE in the Gencydo group were classified 
as moderate. Three AEs in the Citrus/Cydonia group, all in one patient, were classified as severe. 
There were no serious AEs.
9.3 Discussion
 In this study we compared two routes of administration (nasal spray (Gencydo) versus 
subcutaneous injections (Citrus/Cydonia comp.) on immunological and clinical effects of SAR tre-
atment and safety in a randomized controlled trial. The primary hypothesis was that the subcutane-
ous route of administration demonstrated superior immunological efficacy; the secondary hypothe-
sis was that the subcutaneous route of administration demonstrated superior clinical efficacy; and 
the third hypothesis was that both routes of administration were safe. Based on the results of this 
study, one route of administration would be selected to be further tested in a placebo-controlled, 
randomized trial.
9.3.1 Interpretation
 The immunological data comparing medium stimulation versus allergen stimulation, 
reflect a rapid stimulation of the monocyte compartment in the stimulated PBMC fraction and 
thus indicates the activation of a local innate immune response by the treatment in both treatment 
groups. In addition, the reduction of the production level of TNF-α in the Gencydo group reflects 
a decrease in the chronic SAR-related inflammatory activity between baseline and post-baseline. 
Overall, the observed kinetics at day 1, are consistent with a reduction of an allergic inflammatory 
condition with larger effects in the Gencydo group. This inhibition of inflammation is substantiated 
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Table 9.1. Baseline Characteristics (Full Analysis Set)
Variable Citrus/Cydonia 
comp. (n = 12)
Gencydo
(n = 11)
p-value
Sex:  
Number (percentage)
Male
Female
7 (58%)
5 (42%)
2 (18%)
9 (82%)
0.049*
Age (year) (sd) 36.8 (12.4) 36.9 (10.7) 0.97
Height (cm) (sd) 177 (9.5) 170.6 (7.4) 0.09
Weight (kg) (sd) 70.8 (11.2) 66.4 (8.9) 0.3
Smokers: 
number (percentage)
3 (25%) 1 (9%) 0.31
Alcohol consumption:
number (percentage)
None
Occasionally
Regularly
  0 (0%)
11 (91.7%)
  1 (8.3%)
3 (27.3%)
7 (63.6%)
1 (9%)
0.15
Ethnic origin: 
number (percentage)
Caucasian
Asian
12 (100%)
  0 (0%)
9 (82%)
2 (18%)
0.12
Childbearing potential:
number (percentage)
Capable
Sterile
Postmenopausal
3 (60%)
1 (20%)
1 (20%)
8 (88.9%)
1 (11.1%)
0 (0%)
0.31
Blood pressure at screening 
(mmHg) (sd)
120 (23)/ 73 (14) 104 (16)/ 72 (9) 0.09/ 
0.77
Heart Rate at screening 
(beats per minute)
72 (9) 70 (6) 0.56
RAST grass pollen 3.7 (1.2) 3.9 (1.2) 0.76
RAST birch pollen 2.2 (1.8) 2.3 (2.1) 0.82
Usual SAR symptom 
severity during the pollen 
season (total score anam-
nestically) (sd)
Sneezing
Itching nose
Watery nasal 
discharge
Total score
2.1 (0.3) 
1.9 (0.7)
1.9 (0.7)
5.9 (1.4)
2.3 (0.5) 
2.1 (0.5) 
2.1 (0.5)
6.5 (1.2) 0.5
SAR symptom severity sco-
res in the morning during 
the wash-out period (total 
score) (sd)
6.6 (4.5) 8.0 (4.6) 0.55
SAR symptom severity 
scores in the evening during 
the wash-out period (total 
score) (sd)
6.1 (3.7) 9.7 (5.2) 0.19
* p < 0.05, ** p < 0.01, *** p < 0.001
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Table 9.2. Log10 transformed allergen stimulation minus medium stimulation at day 1: baseline versus 
post-baseline cytokine production levels
Log10 (allergen stimula-
tion minus medium 
stimulation) at baseline 
(range)
Log10 (allergen  stimu-
lation minus medium 
stimulation) at post-
baseline (range)
Mean difference 
(95% CI)
Gencydo IL-10# 1.91 (1.16 – 2.39) 1.85 (1.23 – 2.51) ns
IFN-γ 0.07 (0.01 – 0.34) 0.03 (0.1 – 0.28) ns
TNF-α 1.60 (1.16 – 2.12) 1.09 (0.25 – 2.08) -0.50* (-0.08 to -0.93)
Citrus/ 
Cydonia
IL-10 1.64 (0.66 – 2.25) 1.60 (0.95 – 2.12) ns
IFN-γ 0.09 (0.1 – 0.50) 0.15 (0.1 – 0.84) ns
TNF-α 1.20 (-1.10 – 2.23) 1.34 (0.29 – 2.18) ns
Total 
group
IL-10 1.77 (0.66 – 2.39) 1.73 (0.95 – 2.51) ns
IFN-γ 0.08 (0.1 – 0.50) 0.09 (0.1 – 0.84) ns
TNF-α 1.40 (-1.10 – 2.23) 1.21(0.25 – 2.18) ns
* = p value < 0.05
Table 9.3. Changes in cytokine production at day 7 allergen specific stimulation: baseline versus post-
baseline
Citrus/Cydonia comp. Gencydo 
Variable Baseline
(PPS/OC)
Post-base-
line
(PPS/OC)
Change
(PPS/OC)
(95% CI)
Baseline Post-baseline Change
(95% CI)
IL-10# 2.36/2.37 1.68/1.70 -0.68*
(-0.37 to -1.00)/-0.67*
2.22 1.79       -0.44* 
 (-0.19 to -0.68)
IL-12 0.15/0.16 0.26/0.29 0.11/0.13 0.27 0.25 -0.02
IFN-γ 3.01/3.1 2.7/2.8 -0.31/-0.3 3.14 3.17 0.03
IL-5 2.21/2.27 2.06/2.05 -0.15/-0.22 2.29 2.3 0.01
IL-13 2.28/2.4 2.22/2.22 -0.06/-0.18 2.40 2.43 0.03
# all cytokine scores (IL-10,  IL-12, IFN-γ, IL-5 and IL-13) are log10 transformed scores
PPS = Per Protocol Set
OC = Observed Cases
* p < 0.05, ** p < 0.01, ***  p < 0.001 
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Figure 9.3. Mean total symptom scores from wash-out until five weeks of treatment in the morning 
Figure 9.4. Mean total symptom scores from wash-out until five weeks of treatment in the evening
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by the concomitant increase in monocyte-derived IL-10 production that profoundly suppresses 
the TNF-α production. The production level of monocyte-derived TNF-α and IL-10 reflects the 
local chronic SAR-related inflammatory activity between baseline and post-baseline. In addition, 
the observed kinetics at day 7 after allergen-specific stimulation, reflects the activation state of the 
immune system due to the activity of monocytes, which are the largest producers of IL-10 in the 
PBMC, and induced already by day 1 after allergen exposure. Subsequently, also the gradual and 
delayed induction of regulatory T-cell subset (Treg) by day 7 will be inhibited as these cells use the 
IL-10 as a selective autocrine growth factor [17, 18]. The observed kinetics can be interpreted as 
a decrease in the activation state of the immune system due to a decrease in the activity of mono-
cytes, which are the largest producers of IL-10 in the PBMC, and induced already by day 1 after 
allergen exposure, and a reduction of the chronic inflammation (TNF-α (day 1)). This additional 
effect can be attributed to the acute local effect of the nasal spray route. This decreased outgrowth 
of Tregs must then be the result of the effective treatment installed in these patients. The unaltered 
production levels of IL-5 and IL-13 (cytokines representing Th2-pathway) are consistent with 
a slower reacting T-cell compartment in these patients [19]. The frequency of allergen-specific 
T-cells will still be significant, probably in the order of 1: 300, in these patients as they are in the 
pollen season and this arm of the immune system will still be triggered in vivo which compromises 
the Th2 analysis ex vivo [17, 20-22]. The monocyte compartment, being an essential part of the 
innate immune system, by definition will react faster on induced changes in the patient than the 
adaptive immune system, which is dependent on the frequency of allergen-specific T-cells and 
allergen-specific IgE antibody-forming B-cells.
The overall conclusion on the immunological data is that both routes of administration demon-
strate positive immunological effects on SAR-related cytokine production levels both in the innate 
reaction and in the reaction of the allergen-specific T cell subsets, with a larger innate reaction of 
Table 9.4. Mean total symptom scores wash-out versus five weeks of treatment: morning and evening 
scores (n = 20)
Wash-out week 
mean (range)
Treatment week 5 
mean (range)
Change (95% CI)
Morning scores
     Citrus/Cydonia comp. 6.6 (2.1 – 15.2) 1.7 (0 – 6.4) 4.8 (1.7 – 7.9) 
     Gencydo 8.0 (0.6 – 14.3) 5.3 (0.3 – 11.4) ns
     Total 7.3 (0.6 – 15.2) 3.5 (0 – 11.4) 3.8 (1.3 – 6.3)
Evening scores
     Citrus/Cydonia comp. 6.1 (1.7 – 11.8) 1.6 (0 – 5.0) 4.5 (1.7 – 7.2)
     Gencydo 9.7 (0.3 – 16.5) 5.6 (0 – 15.0) 4.1 (0.4 – 7.8)
     Total 8.0 (0.3 – 16.5) 3.6 (0 – 15.0) 4.3 (2.2 – 6.4)
Total symptom scores can vary from 0 – 24:  0 – 8: mild; 9 – 16: moderate; 17 – 24: severe.
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the nasal spray route of administration. Both routes of administration appear to stimulate the mono-
cyte compartment into a more immunoregulatory phenotype (day 1: medium stimulation compared 
to allergen stimulation increase of IL-10 and TNF-α). The day 1 results, reflecting the innate im-
mune reaction, demonstrate more effect of the local Gencydo nasal spray route of administration 
with a reduction of the chronic inflammatory activity of the allergic Th2 pathway in vivo (baseline 
to post-baseline reduction of (allergen stimulation) TNF-α). The day 7 results demonstrate com-
parable effects in reduction of Treg production levels (baseline to post-baseline reduction of IL-10 
(allergen stimulation)) of both routes of administration, which can be interpreted as a decrease 
in activation state of the immune system due to a decrease in the activity of both monocytes and 
regulatory T-cells. 
The overall conclusion of the clinical data is that both routes of administration demonstrate a 
statistically significant reduction in SAR symptom severity, with larger effects of the subcutaneous 
route of administration. In the Citrus/Cydonia group a statistically significant SAR symptom re-
duction was measured already after one week and two weeks of treatment, in the morning and the 
evening respectively. In the Gencydo group a statistically significant SAR symptom reduction was 
measured already after two weeks of treatment in the evening. TSS reduction of the subcutaneous 
route of administration was larger in the morning, but not in the evening. Cohen’s delta effect sizes 
were larger for the subcutaneous route of administration than the nasal spray route of administra-
tion, both in the morning and the evening. During the treatment period, a total of 9 adverse events 
(AEs) were observed with none of the AEs classified as serious. Also the in vitro analyses de-
monstrated acceptable cell survival, with no signs of toxicity. The overall conclusion of the safety 
analysis in this study is that both routes of administration of Gencydo and Citrus/Cydonia comp. 
are safe for use by SAR patients.
This study demonstrates that both routes of administration have profound immunological and 
clinical effects on seasonal allergic rhinitis, with larger clinical effects of the subcutaneous route of 
administration and larger immunological (innate) effects of the nasal spray route of administration. 
Therefore the primary hypothesis was rejected and the secondary hypothesis was confirmed. Both 
AEs analyses and in vitro immunological analyses demonstrate that both Citrus/Cydonia comp. 
and Gencydo are safe treatments, so that also the third hypothesis was confirmed. 
The small groups, the relatively low pollen counts during the study period and the absence of 
placebo groups for both the subcutaneous injection and the nasal spray routes of administration are 
the most important limitations of this study. The small groups might have led to an underestima-
tion of both clinical and immunological differences between the treatment groups. Larger groups 
might have provided more precise estimations of means and smaller standard deviations, so that 
possible other immunological treatment effects might have been detected. The relatively low pol-
len counts have hampered to evaluate the efficacy of both routes of administration on severe SAR 
symptoms. However, the differential pollen counts during the short-term intervention during the 
allergen season did not influence the presence of peripheral blood T-cells and their allergen-specific 
induced reaction profile. This is consistent with recent evidence showing that immunotherapy of 
birch pollen hay fever patients left allergen-specific Th2 cells unchanged after one year, but incre-
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ased regulatory T-cells that were considered responsible for the observed relief of symptoms. The 
expected rise in allergen-specific Th1 cells occurs even later after treatment [23]. The absence of 
placebo groups prevented the estimation of the exact specific effect of both routes of administration 
by means of controlling for placebo effects. 
9.3.2 Generalizability
 As the intervention was implemented for both sexes, adults from 18 - 60, both grass pol-
len and birch pollen SAR the results indicate that a large subgroup of the SAR patient population 
might benefit from both routes of administration of this treatment.
9.3.3 Overall evidence
 The positive results of this study are in line with clinical experiences [4], in vitro studies 
[7,8] and cohort studies [5,6].
Based on the results of this study and previous studies, we can conclude that placebo-controlled 
clinical trials on short-term and long-term treatment are indicated and adequate to determine the 
specific effects of both routes of administration. Since the clinical effects (being the primary ef-
ficacy variable in SAR trials [24]) were larger in the subcutaneous route of administration and the 
day 7 immunological results were comparable, we choose to test the subcutaneous route of admin-
istration in future placebo-controlled clinical trials.
Since both the antihistamines and/or local corticosteroids treatment are purely symptomatic, 
and immunotherapy is a treatment with (increasing doses of) pollen allergens, Citrus/Cydonia 
comp. must be regarded as a new, curative type of treatment that can potentially restore the dis-
turbed immune state of SAR patients permanently. Since there is no stimulation of the immune 
system with gradually increasing doses of the substances to which a person is allergic, but more a 
controlled regulation of the activity of the immune system, another working mechanism regarding 
curative health promotion must be hypothesized.
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Abstract 
 Background: Medicinal solutions for injection are frequently applied in anthroposophic 
medicine and homeopathy. Despite their extensive use, there is little data published on the safety 
of these medicinal products.
 Objective: The aim of this study was to update the safety status of anthroposophic and 
homeopathic solutions for injection through a systematic evaluation of the reported Adverse Drug 
Reactions (ADRs). 
 Methods: ADRs were extracted from the pharmacovigilance databases of eight German 
anthroposophic and homeopathic manufacturers covering the period of 2000-2009. These eight 
manufacturers represented in total more than 94% of the sales of anthroposophic and homeopathic 
solutions for injection in Germany. Analysed ADRs included reports in humans only, reports from 
post-marketing surveillance, literature cases and clinical/safety trials and spontaneous reports from 
healthcare professionals and patients. ADRs derived from medicinal products not prepared accord-
ing to the HAB (German Homeopathic Pharmacopoeia) were excluded.
 Results: Within the time frame of 10 years, in total 303 million solutions for injection 
(ampoules) were sold. During this same period 486 case reports were identified, corresponding to 
a total number of 1180 ADRs. Of  all case reports, more than 70% (349/486) included ADRs that 
were listed (e.g. stated in the package leaflet) and 9% (46/486) of the reports were classified as 
serious. The most frequently reported ADRs were pruritus, followed by angioedema, diarrhoea, 
erythema and nausea. A total of 27% (322/1180) were localized reactions for example; application 
or injection site erythema, pain, swelling and inflammation. The overall incidence of ADRs associ-
ated with injections was less than 4 per 1 million sold ampoules and classified as very rare.
 Conclusions: Our systematic evaluation of ADRs in the German pharmacovigilance da-
tabases demonstrated that the rate of ADRs as associated with anthroposophic and homeopathic 
solutions for injection is very low. Furthermore, most reported ADRs were listed and one quarter 
consisted of local reactions. These findings suggest an excellent safety profile of solutions for in-
jection as therapeutically applied in anthroposophic medicine and homeopathy, where the overall 
incidence of ADRs was very rare.
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10.1 Introduction 
 Medicinal solutions for injection, manufactured in accordance with the German Homoeo-
pathic Pharmacopoeia (HAB, 2009), are therapeutically applied in anthroposophic medicine and 
homeopathy for a wide range of conditions. The therapeutic use of these parenteral administration 
forms in homeopathy was first described in the 19th century (Kafka, 1867). In 1923/24, Steiner 
recommended injections as one of the main routes of administration for anthroposophic medication 
(1925). Nowadays, more than 90 million medicinal ampoules are sold per year worldwide. German 
anthroposophic and homeopathic manufacturers produce over 90% of these ampoules (ECHAMP, 
2003). 
Previous studies have shown that anthroposophic and homeopathic practitioners often favour 
the parenteral dosage form as their first choice of administration in the treatment of acute and 
chronic diseases (de Bruin, 2001; Baars, 2005). The reason for this preference over other dosage 
forms is the anticipated better and quicker clinical effect of injections, the possibility to control 
compliance (injection is general given by physician/therapist or nurse) and the fact that the exact 
location of administration can be chosen. Other advantages of injections described are that active 
ingredients do not have to pass the gastrointestinal tract or skin barrier and that the point of injec-
tion can be chosen in line with acupuncture trigger points to achieve an optimal systemic or local 
effect (Stock, 2002). 
Despite the extensive use of injections in anthroposophic medicine and homeopathy, there is 
little data published on the safety of these parenteral dosage forms. Safety data from clinical tri-
als are sparse. A few observational and/or post-marketing surveillance studies with homeopathic 
medications for injections have reported few side effects (Gottwald, 2000; Zenner, 1990). In the 
absence of safety data from controlled clinical trials, anthroposophic and homeopathic practitio-
ners throughout Europe were surveyed about their experiences with safety issues of subcutaneous 
injection of medications. It was demonstrated that more than 98% of the practitioners never, very 
rarely or rarely observed any adverse reaction caused specifically by the injections. Adverse effects 
mentioned were local redness, haematoma, local pain, allergic reaction and others (Baars, 2005).
Physicians and other healthcare providers should report possible drug-related adverse events, 
including adverse drug reaction (ADRs) as associated with anthroposophic and homeopathic medi-
cations. It is the obligation of the marketing authorisation holder to analyse drug risks and report 
those to the regulatory authorities. A first evaluation of ADRs by Stock (2002) in the pharmacovigi-
lance databases of one homeopathic and two anthroposophic German manufacturers reported a 
very low number of adverse reactions for solutions for injection in the period between 1990 and 
1999; approximately one per nine million sold doses. Since 2006, pharmacovigilance procedures 
and systems have been significantly improved, electronic reporting systems became mandatory for 
serious case reports and guidelines for pharmacovigilance were published (Eudralex, 2008). The 
aim of the present study was to update the safety status of parenteral dosage forms of anthropo-
sophic and homeopathic medications. 
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10.2 Methods
 A systematic evaluation was carried out on the ADRs related to solutions for injection and 
reported between 2000 and 2009 as identified in the pharmacoviligance databases of eight partici-
pating German anthroposophic and homeopathic manufacturers.
10.2.1 Data extraction
 Retrospective evaluation of adverse drug reactions documented in the pharmacovigilance 
databases of eight German manufacturers from January 1, 2000 to December 31, 2009 was carried 
out for the purpose of this study. Of the eight participating manufacturers, six were homeopathic 
manufacturers and two were anthroposophic manufacturers, all together covering an estimated > 
94% (estimated on the basis of sales data) of the total sales of anthroposophic and homeopathic 
solutions for injection on the German market.
Inclusion criteria for data extraction were: Adverse events for which a causal relationship 
between the event and a suspected drug could not be excluded and therefore were classified as 
Adverse Drug Reaction (ADRs) (terminology see ICH-E2A guidelines, 1995); ADRs that were 
associated with the parenteral dosage forms and with Germany as country of occurrence; ADRs 
reported between January 1, 2000 and December 31, 2009; ADRs reported by health care profes-
sionals and patients (both medically confirmed and medically non confirmed) and ADRs reported 
from post-marketing surveillance, clinical/safety studies, as well as case reports identified from lit-
erature. Excluded from data extraction were ADRs reported for injectables with active ingredients 
not prepared according to the HAB (2009) and ADRs from solutions for injection for which it was 
clearly noted that they were applied orally.  
The ADRs extracted from the pharmacovigilance database included details on product cat-
egory (single = one active ingredient,  or complex product = more than one active ingredient), 
calculated dilution of active substance (< 1:10.000 or ≥ 1:10.000), route of parenteral adminis-
tration (subcutaneous, intramuscular, intravenous, intracutaneous, intraarticular and periarticular), 
amount administered (1, 2 or 10 ml), date of onset, source of report (spontaneous, literature, clini-
cal studies/safety studies not published, other; such as registries, poison information centre, etc.), 
qualifications of reporter (health professional, patient; report medically not confirmed, patient; 
report medically confirmed or other; lawyer etc.), description of ADR including seriousness and 
listedness, gender and age of the patient. All ADRs were coded in MedDRA including allocations 
to the respective System Organ Class (SOC). 
Patient exposure was estimated from each participating manufacturer by providing yearly total 
sales data (2000-2009) of the number of units (ampoules), as well as the yearly sales data of the 
specific product for which the ADR was reported.
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10.2.2 Data analysis 
 Data were extracted from the pharmacovigilance databases in the period from May to Sep-
tember 2010, using a data extraction Excel form and transferred to the SPSS database (IBM, SPSS 
(PASW) Statistics version 18,0, Somers, NY, USA). Tabulation of the different categories of ADRs 
was performed by descriptive analysis. Pearsonís Chi-square tests were used to analyse differences 
between the ADR subgroups and a p-value of <0.05 was regarded as indicating a statistically 
significant difference. The overall incidence of ADRs of injections was calculated as the sum of 
ADRs reported in 10 years, per amount of ampoules (estimated patient exposure) sold in the same 
period. Subsequently ADRs were classified depending on its incidence into very common (≥10%), 
common (1% < x < 10%), uncommon (0.1% < x <1%), rare ( 0.01% < x < 0.1%) and very rare < 
0.01%. 
10.3 Results
 Data on ADRs of parenteral dosage forms as reported to eight German anthroposophic and 
homeopathic manufacturers, collected between January 1, 2000 and December 31, 2009 were ex-
tracted from their pharmacovigilance databases. The majority of manufacturers (five out of eight) 
had systemically evaluated ADRs during this 10-year period. One manufacturer had data available 
for an 8-year period (2002-2009), one manufacturer for a period of 6 years (2004-2009) and one 
manufacturer for a period of 3 years (2007-2009). As shown in Figure 10.1, the total number of 
ampoules sold by the eight participating manufacturers in Germany slightly decreased as from 
2005, averaging about 28.8 million ampoules on a yearly basis during the last 5 years. The annual 
total number of ADRs as reported within the time frame of 2000-2009 is depicted in Figure 10.2. 
Here it is shown that there are significantly more cases reported in the last three years, 2007-2009 
compared to the previous period (p < 0.001). Out of 486 case reports, a total number of 1180 ADRs 
were reported since some patients experienced more than one ADR per case report (Table 10.1). 
The overall incidence of ADRs with injections in the period 2000-2009 was calculated as < 4 per 1 
million sold ampoules and classified as very rare. Although the incidence rate of ADRs calculated 
for the last 3 years (2007-2009) was doubled in comparison to the ten-years period, e.g. <8 per 1 
million sold ampoules, it was still categorized as very rare.
All 486 case reports represented a total of 161 different individual products for injection (some 
products appeared more than once in the pharmacovigilance database). About 9% (46/486) of all 
product-related case reports were serious. Furthermore, the majority (72%) (349/486) of all case 
reports included ADRs that were listed, e.g. the reported ADR is listed in the Summary of Product 
Characteristics or package leaflet (Table 10.1). A further analysis was carried out to investigate 
which route of administration was associated most with the reporting of unlisted (unknown) ADRs. 
188   Evidence-based curative health promotion
The subcutaneous injections had significantly higher reports of unlisted ADRs compared to the 
intramuscular injections (n = 97 versus n = 10, respectively; p<0.01) and intravenous injections 
(n= 97 versus n = 20; p<0.001). Most case reports were reported spontaneously and by healthcare 
professionals (Table 10.1). The majority of ADRs (58%; 280/486 ) occurred in adults in the age of 
19 up to 64 years. A total of 27% (132/486) was reported in patients over 65 years. A very low per-
centage of ADRs were reported in children between 12-18 years of age (1%; 7/486) and 11 years 
and younger (1%; 5/486). In 13% (62/486) of the cases, the age was unknown.
 
The most frequently reported ADRs were pruritus, angioedema (swelling of dermis or subcu-
taneous tissue), diarrhoea, erythema and nausea (Table 10.2). Furthermore, most ADRs reported 
were classified as skin and subcutaneous tissue disorders and general disorders and administration 
site conditions. A total of 27% (322/1180) of all reported ADRs was a local reaction, i.e. coded 
as application or injection site erythema, pain, swelling, inflammation, itching, etc. (results not 
shown). As shown in Table 10.3, serious case reports on ADRs occurred significantly more fre-
quently as compared to non-serious case reports in (1) male subjects, (2) subjects of 65 years and 
older, (3) upon injection with complex products, (4) with products of a dilution <1:10.000, and (5) 
of all parenteral dosage forms, the majority related to intramuscular injection. Pain in extremity 
(n=15), brain stem infarction (n=4), aphthous stomatitis (n=4), cerebral ischemia (n=4) and tongue 
disorder (n=4) were labelled most frequently as serious ADRs. The brain stem infarction was re-
ported in one patient only, however, this was presented within the pharmacovigilance database as 
four separate case reports since the patient was injected simultaneously with a total of 4 different 
products for injection. With aphthous stomatitis and cerebral ischemia the serious ADR also oc-
curred in one patient only, in which it was not possible to causally relate the ADR to one of the 
four individual injected remedies. All serious case reports were classified as being serious since the 
patient in question was either hospitalised or significantly disabled. Although a causal relation to 
injection of the medications could not be ruled out completely, it was assessed in all cases as more 
likely that the hospitalisation or disability had occurred in the course of the already ongoing disease 
(such as multiple sclerosis, diabetes, etc.). 
10.4 Discussion 
 To our knowledge, this is the first study to provide a thorough systematic evaluation of 
collected and spontaneous reported ADRs for parenteral dosage forms of anthroposophic and ho-
meopathic medications. In the period between 2000-2009, a total of 486 cases were identified in 
Germany with a total of 1180 reported ADRs. In relation to the overall sales data of ampoules 
within that same period (303 million ampoules), the incidence rate of ADRs as associated with 
solutions for injection was found to be very rare, i.e. less than 4 ADRs per 1 million sold ampoules. 
Compared to other countries worldwide, anthroposophic and homeopathic solutions for injection 
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Figure 10.1. Total sales of anthroposophic and homeopathic solutions for injection (ampoules) in Germany
Figure 10.2. Total number of case reports with anthroposophic and homeopathic solutions for injection in Germany
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are most frequently prescribed in Germany (ECHAMP, 2003). With the 8 anthroposophic and ho-
meopathic manufactures participating in the study, almost full coverage of the German market was 
reached. Thus the present findings are expected to be highly representative for the safety status of 
anthroposophic and homeopathic medications in general. 
Most ADRs were reported in adults aged 19 to 64 years, whereas very few ADRs were reported 
in children. The low number of ADR reports in children can be explained by the current German 
regulation for authorization of anthroposophic and homeopathic parenteral dosage forms. Those 
parenteral dosage forms with a therapeutic indication are often not indicated for children under the 
age of 12 years because the specific indication does not apply to children. Furthermore, physicians 
usually do not prefer solutions for injection in children. 
About 9% of all case reports were classified as serious and seemed to occur significantly more 
frequently in males, with complex medications, dilutions < 1:10.000 and in adults of 65 years and 
older. With respect to the latter, a clear correlation between increasing age and higher ADR report-
ing rates is known (Routlegde, 2003). The finding that 9% of all case reports were classified as be-
ing serious seems relatively high, but has to be interpreted with caution. First, all ADRs were cat-
egorised as being serious because of hospitalisation or disability of patients. This was most likely 
due to the ongoing severe disease and/or co-morbidity of the patient rather than to administration 
Table 10.1. Overview of number and category of ADRs reported from 2000-2009
Number Category
1180 Total number of reported ADRs
486
          161         
Number of case reports*
       number of individual products
          440
          46
       non-serious 
       serious
          349
          135
          2
        listed  
        unlisted 
        not known
          
          457
          1
          28
Source
       spontaneous  
       literature
       clinical studies
          357
          53
          76
Reporter
       healthcare professional 
       consumers 
       not known 
* Per case, more than one ADR can be reported
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of the anthroposophic or homeopathic solutions for injection itself. Other observational studies on 
anthroposophic and homeopathic medications did not report of any serious adverse events  (Gott-
wald, 2000; Hamre, 2006; Zenner, 1990). One explanation might be the under-reporting of non-
serious and listed ADRs by health care professionals or patients in the present study. Most package 
leaflets of anthroposophic and homeopathic medications in Germany clearly state that adverse re-
actions that are not listed in the leaflet should be reported to a physician or a pharmacist. This may 
lead to under-reporting of listed non-serious adverse reactions. Nevertheless, the incidence rate of 
serious ADRs with homeopathic injections was extremely rare (less than 4 serious ADRs per 10 
million sold ampoules). In comparison, a recent study on the management of knee osteoarthritis 
with corticosteroid injections reported an incidence of severe infectious complications as high as 1 
in 3000 injections (McGarry, 2011). 
The ADRs that were identified were mostly related to skin and subcutaneous tissue disorders 
and or general disorders and administration site conditions. About one quarter of ADRs was re-
lated to the injection procedure itself. With respect to the relative safety of the frequently applied 
parenteral dosage forms, most serious ADRs (in relation to non-serious ADRs) were reported with 
intramuscular injections. In addition, most unlisted ADRs were reported with the subcutaneous 
route of administration. No conclusions could be drawn about the overall safety of the different 
parenteral dosage forms. This was due to the fact that it was not possible to calculate sales data per 
administration dosage form as most solutions for injections as applied in anthroposophic medicine 
and homeopathy are registered for more than one administration form. 
Our present study suffered from some unavoidable limitations. The first one is that of under-
Table 10.2. ADRs* and System Organ Class most frequently reported
ADR Frequency
Pruritus 62
Angioedema 41
Diarrhoea 38
Erythema 35
Nausea 35
System organ class Frequency
Skin and subcutaneous tissue disorders 298
General disorders and administration site conditions 211
Gastrointestinal disorders 149
Nervous system disorders 83
Vascular disorders 75
*Preferred term according to MedDRA
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reporting of ADRs to the manufacturers. Practitioners and other healthcare providers may not al-
ways report on suspected or unsuspected ADRs. However, our findings are in line with data from 
a prospective observational study by Hamre et al. (2006) in which adverse effects were monitored 
intensively. In this study an incidence rate of one ADR per 382 patient-months of anthroposophic 
medications use (all dosage forms) was observed. With a daily dose of 0.7, a calculated ADR in-
cidence rate in the Hamre study would be classified as very rare (<0.01%) as well. Furthermore, 
comparable results were reported in a European survey among anthroposophic and homeopathic 
practitioners (Baars, 2005). The majority of practitioners (87%) had never or very rarely (1 or 
<1:10.000 treated patients) observed an ADR with anthroposophic or homeopathic solutions for 
injection, whereas 2.6% had rarely observed any ADR and 1.7% occasionally (8.9% gave no re-
Table 10.3. Serious versus non-serious case reports
Category Serious Non-serious p-value
Male
Female
Not known
33
12
1
87
353
-
0.001*
0-64 years
≥ 65 years and older
Not known
4
26
16
288
106
46
0.001*
Single product
Complex product
Not known
0
45
1
57
383
-
0.05*
Listed
Unlisted
Not known
36
9
1
313
126
1
0.25
<1:10.000
≥1:10.000
Not known
42
3
1
320
117
3
0.01*
1 ml 
2 ml
Other/ not known
26
19
1
306
129
5
0.31
sc injection**
im injection
2
10
142
39
0.001*
sc injection**
iv injection
2
20
142
200
0.01*
im injection**
iv injection
10
20
39
200
0.05*
*Indicating a significant difference (p < 0.05) between serious and non-serious case reports, using the Pearsonís Chi-
square test. ** Data on the most frequently used parenteral dosage forms are depicted.
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sponse). Another limitation is that patient exposure or use was estimated on the basis of the number 
of ampoules sold. All ampoules sold are not necessarily prescribed and used. Furthermore, case 
reports for which it was clear that the solutions for injection were administered orally, were ex-
cluded from data analysis. However, due to off-label use, some sales data may represent patients 
that have taken ampoules orally rather than parenteral. Based on practitionerís prescription behav-
iour (Baars, 2005; Hamre, 2006), the oral use of ampoules is not expected to be high; nevertheless 
it cannot be excluded. A major limitation of systematic evaluations of pharmacovigilance data in 
general is that they highly depend on the quality of the reporting and monitoring system. During 
the last three years in Germany, as well as in other European countries, pharmacovigilance operat-
ing procedures have been considerably improved. The introduction of the Volume 9a guidelines 
for pharmacovigilance which came into force in 2008 has attributed to this improvement. In the 
present study it became apparent that the collection and spontaneous reporting of ADRs has sig-
nificantly increased during the last 3 years when compared to the previous years. This increase in 
reports can partly be explained by the fact that one participating manufacturer submitted data for 
evaluation only for these last three years. Furthermore, improved pharmacovigilance procedures 
may also contribute to this increase. Thus repetition of this systematic evaluation of pharmacovigi-
lance data within a time frame of 5 years is warranted.
10.5 Conclusions
 This is the first study to provide a systematic evaluation of the safety of anthroposophic and 
homeopathic solution for injection from pharmacovigilance databases. Our results indicated that 
solutions for injection as applied in anthroposophic medicine and homeopathy have an excellent 
safety profile. This included complex products and those that are not highly diluted. These results 
provide reliable data for risk-benefit ratio calculations of anthroposophic and homeopathic paren-
teral dosage forms. 
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Chapter 11
General discussion
 This thesis studies curative health promotion as an additional approach to the fighting 
disease approach in medicine in general, and specifically, in seasonal allergic rhinitis. The context 
for the study is the enormous improvement of the health status and life expectancy of individual 
persons in Western society over the last 150 years, which is, apart from general hygiene measures 
in society, primarily the result of the success of the fighting disease approach in medicine and so-
ciety. However, with increasingly more people reaching high ages in the 21st century, rising costs 
due to the high life expectancy accompanying an increase in chronic diseases and subsequently an 
increase in medical costs, the issue of the further development of professional health promotion 
becomes even more relevant. How does one keep the health status of persons high enough in order 
to ensure a high quality of life for the individual and low costs for society? A second reason for an 
increased interest in health promotion comes from the changed role of patients in the last decades. 
More patients are assuming the role of competent patients who regard themselves as responsible 
for actively managing their own disease and health status and actively using available (health-
promoting) resources to influence this health status. 
The main strength of medicine has been its fighting disease approach. This involves the fighting 
of disease-related organisms (e.g. bacteria, viruses), cells and functions in the body (e.g. cancer); 
the reduction of disease-related symptoms (e.g. hay fever symptoms, pain or headache); and the 
manipulation and/ or substitution of non-functioning or dysfunctional parts of the body (e.g. hor-
mone therapy or hip replacement surgery) by means of external therapeutic resources. In the last 
decades, however, the interest in an additional, both preventive and curative, health promotion 
approach has increased in society and healthcare.
Integrating the best of both worlds by combining these two approaches in a logical and pro-
fessional way is an objective towards which medicine could strive in order to meet the problems 
of the low health status of the elderly and the increase of medical costs, both of which are due to 
an ongoing increase in the prevalence of chronic diseases. However, whereas the fighting disease 
approach already has a long scientific history, science on health promotion as a serious approach 
in medicine is still relatively young. Preconditions for becoming a professional approach are that 
there have to be valid concepts of health and health promotion, valid methodologies to monitor 
(changes in) health states, and empirical studies on the efficacy, effectiveness and cost-effective-
ness of concrete preventive and curative health promotion interventions for specific diseases.
This thesis contributes to the further professional development of health promotion by studying 
the concept of health, the methodology to monitor (changes in) health states, the effects and safety 
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of Citrus/Cydonia comp. on seasonal allergic rhinitis as an example of curative health promotion, 
and the cost-effectiveness of integrative medicine in the Netherlands.
11.1  Main findings
 The first objective of this thesis is to contribute to the development of a valid definition of 
health that could serve as a solid, evidence-based fundament for professional preventive and cura-
tive health promotion as a supplement to the main (western) biomedical fighting disease approach. 
Therefore, the authors performed literature studies on health concepts and the holism-reductionism 
debate (Chapters 2 and 3). 
We criticized the WHO definition of health (1948), since it is primarily oriented at end states 
and does not clarify the mechanisms responsible for reaching and maintaining these states. There-
fore, it does not provide sufficient conceptual tools to innovate and professionalize health promo-
tion activities. In order to overcome these shortcomings, the WHO and current health definitions 
were analyzed and revised into the definition of  ‘health by self-regulation’ (Chapter 2). This defi-
nition can best be regarded as a non-atomistic holistic concept of integrity, stating that organisms 
are self-organizing entities in which ontological (higher organization) levels of wholeness are re-
sponsible for maintaining the integrity and organizing of its parts, for the interconnectedness and 
the balanced harmony of its parts, for its functional and morphological wholeness, and finally, for 
the balance struck with its environment. This ontological level of wholeness can be distinguished 
from the levels of the ‘parts’ of the organism. The definition is preliminarily validated according to 
the criteria of Oost [1, 2] by means of analyzing (1) its internal consistency (logical inconsistency, 
use of ambiguous concepts), (2) its accordance with other scientific definitions (a theory “does not 
fit in” with other theories) (e.g., of epigenetics, systems biology, emergence and self-organisation) 
and (3) its accordance with empirical facts (a theory “does not fit in” with reality). Key features of 
the definition are the central position of dynamic and continuous self-regulation as a key organis-
mal function and the holistic, system biological approach. Health promotion supports and enables 
patients to actively contribute to their own health and disease status towards an optimal functioning 
of the higher levels of organizing among each other and in the regulation of the lower levels.
The second objective is to develop and test biomarkers for the monitoring of curative health 
promotion interventions on the systems level. Therefore, pattern variables that should reflect the 
functioning of the immune system on the system level were computed and tested (Chapter 4). 
Computation was based on a dataset of cytokines and symptom severity scores from a random-
ized controlled trial. By means of permuted stepwise regression of the cytokine data, three robust 
systems biology-orientated biomarkers for the monitoring of SAR were computed, which dem-
onstrated small to moderate improvement compared to monitoring of a single cytokine. Baseline 
versus post-baseline comparison of mean scores of the pattern variables demonstrated statistically 
significant baseline versus post-baseline changes. 
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 The third objective of the thesis is to study the effects and safety of Citrus/Cydonia comp. 
in SAR treatment as an example of a curative health promotion intervention for a specific indica-
tion (Chapters 5 to 10). Based on a survey among experienced prescribing general practitioners, 
two in-vitro studies, and two intervention studies (a cohort study and one randomized controlled 
trial comparing two routes of administration), it can be concluded that evidence exists for both the 
clinical and immunological effects of Citrus/Cydonia comp. in SAR treatment. 
On the immunological level, evidence is provided that Citrus/Cydonia comp. is able to in-
hibit the chronic inflammatory reaction and overproduction of the Th2 pathway cytokines and 
promote self-regulation within this SAR-related subsystem of the immune system (Chapter 6). It 
appears that Citrus and Cydonia have different working mechanisms in SAR treatment in vitro: 
Citrus mainly inhibits the chronic inflammatory activity and the SAR-related Th2 pathway activity, 
whereas Cydonia mainly promotes the SAR-related Th1 pathway activity (Chapter 7). 
Regarding safety of Citrus/Cydonia comp., one can conclude that it is a very safe treatment. 
In both  in-vitro studies, the product had no effect on blood mononuclear cell survival and did 
not appear to be toxic for the PBMC cell subpopulations (Chapters 6 and 7). In the clinical stud-
ies, no serious adverse events occurred (Chapters 8 and 9). The systematic evaluation of German 
pharmacovigilance databases within the time frame of six years (2005-2010), covering a total of 
approximately 1.1 million sold solutions for injection on the German, Dutch and Belgian market, 
demonstrated no reported adverse drug reactions for this product (Chapter 10).
11.2 Reflection on the main findings
11.2.1  Reflection on health concepts and their relevance to professional        
 health promotion
 As described in Chapter 1, the interest in becoming and remaining healthy if possible, even 
until an advanced age, is high. However, compared to the fighting disease approach, the scientific 
fundament of understanding and explaining health, of conceptualizing health and health promo-
tion, and of testing health promotion programs is relatively in its infancy and urgently needs a solid 
evidence base research.  As described, the proposed concept is based on an analysis of empirical 
studies on several health (promotion) conceptual approaches and is therefore in line with current 
empirical evidence and literature about health. 
The newly developed concept of health (Chapter 2) is at least theoretically important in two 
ways. First of all, the current knowledge of parts of the health concept is logically integrated, and 
some of the central questions concerning the theoretical relationships between the positive domains 
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of health and between health and disease are (partly) answered. Some aspects, for example, the 
relationship between a sense of coherence and physical health, remain unclear and more research is 
required to clarify this relationship. Secondly, the concept provides an evidence-based fundament 
for developing new preventive and curative health promotion interventions and strategies. 
The implications for clinical practice are first that sufficient evidence exists to further promote 
preventive and curative health promotion. However, a lot of scientific and practical work has to be 
conducted in order to reach a professional integration of both the fighting disease and the health 
promotion approaches.
Future research should focus on further specifying the relationships between the positive do-
mains, the positive (‘health’) and the negative (‘absence of disease’) domain, empirically testing 
new preventive and curative health promotion interventions and strategies, and the development 
and empirical testing of the professional, effective, cost-effective and safe integration of both ap-
proaches in specific indications.
11.2.2  Reflection on system biology-orientated methodologies
 This thesis explores the use of both qualitative and statistical methodologies for pattern 
exploration and recognition on the system levels of organisms. It describes the Goethean pheno-
menological method as a qualitative methodology that studies both the underlying lower levels of 
organizations (the composing parts and their interactions) and the higher level itself, with the aim 
to arrive at ‘correct’ knowledge or an understanding of the emergent, higher organization levels of 
the organism (Chapter 3). In addition, permuted stepwise regression analysis was used to compute 
pattern variables that measure the relationships between two or more variables, which were able 
to better distinguish between baseline and post-baseline measurement in a randomized trial than 
separate variables (Chapter 4).
 The search for these types of pattern recognition methodologies fits well with the increa-
sing interest in the systems approach in biology and medicine over the last ten years. Increasingly 
the ‘one gene, one drug, one disease’ approach, which has dominated drug development in the last 
decades, is challenged by decreasing clinical attrition rates and functional genomics studies. This 
demonstrates the robustness of the phenotype in the single-gene knockout approach paradigm [3]. 
The two single most important reasons for attrition in clinical development are a lack of efficacy 
and clinical safety or toxicology, which each account for 30 percent of the failures. Scientists are 
focusing more on the systems level. For example, Van der Greef et al. [4] characterize systems 
biology in medicine as the art and practice of mapping patterns of relationships. Ma’ayan et al. 
[5] describe the search for regulatory patterns during signal propagation in a mammalian cellular 
network. Van Ommen et al. [6] describe a network biology model of micronutrient-related health. 
Hopkins [3] presents the network pharmacology as the next paradigm in drug discovery using po-
lypharmacology. Barabasi et al. [7] use the term ‘network medicine’ as a network-based approach 
to human disease. Within this system biology approach, new statistical methods are developed 
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aiming at pattern exploration and pattern recognition [4, 8]. 
 In addition, the value and use of subjective pattern recognition in professional practice 
(Chapter 3) has received increasing scientific attention. For example, Dalston and Galison [9] 
describe in their study on the historical development of scientific objectivity that trained judgment, 
which is able to detect patterns (e.g. in an X-ray), is the latest type of scientific objectivity in history 
after development of the mechanical and structural objectivity approach. Adequately diagnosing 
and solving unique complex and context-specific problems can be performed by experts on the 
basis of so-called tacit knowledge, craftsmanship, the ‘clinical look’ or ‘breeder’s eye’ [10 – 12].
Experienced workers seem to have learned, most of the time unconsciously, to handle prevai-
ling laws and situations. In doing so, they have developed self-regulation skills based on valid and 
practical, useful knowledge (‘appropriate conclusions and correct predictions’). Self-regulation 
can be defined as the adaptive use of skill across changing personal and environmental condi-
tions [13]. Expert knowledge is represented at an intermediate level of abstraction and is called 
the ‘moderately abstract conceptual representation’: a compromise between different abstractions 
like comparisons in the disciplines of physics and chemistry and concrete, specific problems [14]. 
The key element of expert information processing is the intuitive recognition and application of a 
pattern (‘Gestalt’) [9, 15]. The professional use of pattern recognition in medicine has been emp-
hasized by, for example, Goudsmit [16], who describes the use of pattern recognition as a phro-
netic (‘practical wisdom’) skill in clinical reasoning, and Stolper et al. [17], who describe the gut 
feelings as a third valid track in general practitioners’ diagnostic reasoning (in addition to medical 
decision-making and medical problem-solving). Smulders [18] emphasized the value of subjecti-
vity and intuition as virtues in treating individual patients in clinical practice next to applying the 
results of epidemiological studies.  
Interestingly, the initial indication of the use of Citrus and Cydonia was performed by Rudolf 
Steiner and the doctor Ita Wegman in 1925 [19], based on qualitative pattern recognition of the 
organizing level of these plants. This was performed long before the use of microbiological, epide-
miological and immunological studies and the use of statistical pattern recognition methods, also 
demonstrating the potency of methodologically, subjective qualitative pattern recognition.    
Some of the theoretical and practical implications of the development and application of qua-
litative and statistical methodologies for pattern exploration and recognition on the system levels 
of organisms are that the development (and further validation) of measuring instruments will be 
increasingly based on holistic concepts of relationships between parts of the systems relevant for 
health and disease. In addition, qualitative and statistical pattern recognition methodologies will 
increasingly be used in the diagnostics and monitoring of effects in clinical practice. These metho-
dologies, as demonstrated in the role of expertise, also have the potential to improve the diagnostic 
and therapeutic methodologies regarding individualization, as is the aim in current personalized 
medicine approaches. 
The shortcomings of these studies are that the Goethean phenomenological method (Chapter 
3) is only used in scientific and clinical practice, but has not been validated as a research methodo-
logy according to the current scientific standards. Therefore, further validation of this method for 
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use in scientific and clinical practice is recommended. The main shortcomings of the development 
of pattern variables by means of permuted stepwise regression (Chapter 4) are that they are based 
on small group sizes and that data are absent from healthy persons and from categories of SAR 
patients with varying symptom severities. In addition, even more sophisticated pattern recognition 
statistical tools can be developed and applied, which are able to detect patterns of relationships 
between ‘parts of the system’ even more precisely. 
Future studies on the applicability of permuted stepwise regression to SAR are indicated with 
larger populations, with categories of SAR patients with varying symptom severities, and with a 
control group of healthy persons. These study design changes will allow the computation of pattern 
variables that are able to more precisely distinguish among disease severities and between disease 
and health more. This procedure and other statistical pattern recognition procedures may also be 
applicable to other immune-mediated diseases; datasets describing rich cytokine sets will deter-
mine the critical parameters that can be combined in the various pattern variables. 
11.2.3 Reflection on the effectiveness and safety of Citrus/Cydonia comp.
 This thesis presented an overview of the evidence of clinical and immunological effects 
of Citrus/Cydonia comp. in the treatment of SAR (Chapters 5 to 10). The overall positive clinical 
results are in line with other in vitro studies, which demonstrated that Citrus/Cydonia comp. sig-
nificantly reduced the histamine production and the inflammatory mediator release from mast cells 
in a dose-dependent manner [20], and which demonstrated the positive effects of several immuno-
logically active compounds of Citrus and Cydonia like flavonoids and pectins on SAR [21 - 27]. 
Citrus and Cydonia, at least in-vitro, appear to have different working mechanisms that support 
each other.
Based on the GRADE classification [28, 29], which is developing as an internationally ac-
cepted standard for classifying the quality of evidence and the classification of recommendations 
to patients, doctors and policy makers, one can conclude that the quality of the current evidence 
of the effect of Citrus/Cydonia comp. on SAR is moderate. The evidence to support this claim 
comes from two cohort studies (Chapter 8) [30] and a randomized trial (Chapter 9), as well as from 
in-vitro studies [20] that demonstrated a reduction in histamine production and the inflammatory 
mediator release from mast cells in a dose-dependent manner. 
Evidence on the safety of this treatment has been provided by three in-vitro studies, two cohort 
studies, a randomized controlled trial, and a systematic evaluation of German pharmacovigilance 
databases (Chapters 6 to 10) [20, 30], thus demonstrating that this treatment is very safe.
These results may add to the further conceptualization of SAR treatment, since the working 
principle of Citrus/Cydonia comp. appears to differ from the various treatments: antihistamines 
(symptomatic prevention of histamine release), corticosteroids (symptomatic reduction of inflam-
matory activity) and immunotherapy (curative exposure to increasing doses of allergens) [31]. 
Based on current clinical knowledge and scientific evidence, it is hypothesized that Citrus/Cydonia 
Thesis Erik W. Baars   201
11
comp. is working on the organizational level of the allergy-related subsystem of the immune sys-
tem, is promoting the regulation of the Th1/Th2 balance, and might therefore actually be a cura-
tive health-promoting remedy (Chapters 6 and 7). Since a difference appears to exist between the 
subcutaneous and nasal spray routes of administration, the role of the extracellular matrix, which 
is changed by the subcutaneous route of administration in promoting the self-organization of the 
immune system, must also be a part of further research and conceptualization (Chapter 9). 
The use of Citrus/Cydonia comp. for SAR treatment fits well with the current orientation in 
medicine and pharmacology, which aims at multi-target treatment (network pharmacology [3, 7] 
and polypharmacology instead of the ‘one-size fits all’ approach. As described in Chapter 7, Citrus 
and Cydonia appear to have different working mechanisms in SAR treatment in vitro (Chapter 7): 
Citrus mainly inhibits the chronic inflammatory activity and the SAR-related Th2 pathway activity, 
whereas Cydonia mainly promotes the SAR-related Th1 pathway activity. A combination of both 
working mechanisms is hypothesized to have a cumulative effect on SAR.  
Like the combination of immunotherapy (only indicated for a small group of SAR patients), 
Citrus/Cydonia treatment might be integrated with corticosteroid and antihistaminic treatment in 
order to develop a SAR treatment strategy that integrates the best of both worlds in fighting disease 
and health promotion.
The major shortcoming of the studies is the lack of placebo-controlled trials. Therefore, recom-
mendations for future research are the funding, designing and execution of both placebo-controlled 
RCTs to study the specific effect of Citrus/Cydonia comp. in vivo, and pragmatic trials in which 
the optimal treatment for individual patients can be studied. Then within the context of a research 
program, the optimal integration of fighting disease and health promotion approaches in SAR treat-
ment must be studied. Finally, cost-effectiveness studies are indicated to compare the cost-effects 
of treatment of Citrus/Cydonia comp. with current treatments. Based on this additional evidence, 
a solid recommendation (and subsequent integration into the guidelines) on the use for SAR treat-
ment can be made for patients, clinicians and policy makers [32].
11.3  Cost-effectiveness of health promotion
 Since it was hypothesized that health promotion strategies could contribute to cost re-
duction in healthcare, a summary is presented of a cost-effectiveness study in which the possible 
contribution of integrative medicine to the reduction of healthcare costs was studied (Appendix).
Since there is a lack of cost-effectiveness data of CAM in the Netherlands, this study compared 
the performance of general practitioners who have completed certified additional training in CAM 
after obtaining their conventional medical degree (GP-CAMs) with general practitioners who have 
not (GPs). More specifically, GP-CAMs with additional training in anthroposophic medicine, ho-
meopathy, or acupuncture (approximately 1 percent of GPs for each of these CAM types) were 
considered.
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A dataset from a Dutch health insurer was used, containing quarterly information on healthcare 
costs (care by general practitioner (GP), hospital care, pharmaceutical care, and paramedic care), 
dates of birth and death, gender, and the six-digit postcode of all approximately 150,000 insurees, 
for the years 2006 to 2009. Data from 1913 conventional GPs were compared with data from 79 
GPs with additional CAM training in acupuncture (25), homeopathy (28), and anthroposophic 
medicine (26). 
Patients whose GP has completed additional CAM training have 0–30 percent lower healthcare 
costs and mortality rates, depending on age groups and the type of CAM. The lower costs result 
from fewer hospital stays and fewer prescription drugs. Since the differences are obtained while 
controlling for confounders, including neighborhood-specific fixed effects at a highly detailed le-
vel, the lower costs and longer lives are unlikely to be related to differences in socioeconomic 
status. 
Possible explanations include selection (e.g. people with low interest in medical interventions 
might be more likely to choose CAM) and better practices (e.g. less overtreatment, more focus on 
preventive and curative health promotion) by GPs with knowledge of complementary medicine. 
More controlled studies (replication studies, research based on more comprehensive data, cost-
effectiveness studies on CAM for specific diagnostic categories) are required.
These findings underscore the fact that the health-promoting methods that are considered CAM 
today could be effective and might have significant cost-saving potential.
11.4  Reflection on the scientific fundament of anthropo-
sophic medicine
 Since Citrus/Cydonia comp. is an example of anthroposophic medicine (AM), and provi-
ding evidence of the safety, efficacy, effectiveness and cost-effectiveness is necessary but not suf-
ficient for scientific acceptance, a final reflection on the scientific fundament of AM is also given. 
Many regard AM as an alternative medicine stream, which has not proven to be effective, is unsafe, 
and is conceptually not in accordance with science and medical practice [33]. This could be related 
to the low esteem of AM in the medical profession. Many, if not all, of these characteristics are 
untrue. 
11.4.1 Anthroposophic medicine as a form of complementary and integrative 
medicine
 First of all, AM must be regarded as a complementary, integrative stream of medicine 
based on and funded in conventional medicine [34]. Doctors, most therapists, and nurses are first 
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trained in conventional medicine, and then receive AM training. In addition to the conventional 
use, medical knowledge and observations are also used in qualitative pattern recognition to gain 
knowledge of higher levels of the human organism and nature in order to diagnose and treat on 
these higher levels of the organization [34]. 
11.4.2 Health technology assessment of anthroposophic medicine 
 Regarding the efficacy, effectiveness and cost-effectiveness of AM, Kienle et al. [35, 36] 
performed an update of a health technology assessment on AM. This study demonstrated that a total 
of 265 clinical studies investigated the efficacy and effectiveness of AM: 38 randomized controlled 
trials, 36 prospective and 49 retrospective non-randomized controlled studies, and 90 prospective 
and 52 retrospective studies without control groups. These studies investigated a wide spectrum 
of AM treatments in a multitude of diseases, 38x whole system of AM, 10x non-pharmacological 
therapies, 133x AM mistletoe products in cancer, and 84x other AM medication treatments. Most 
studies revealed a positive result for AM. However, the methodological quality differed substan-
tially; some studies showed major limitations, whereas others were reasonably well conducted. 
Higher-quality trials still showed a positive result, and external validity was usually high. Side 
effects or other risks are rare and usually mild to moderate. Safety studies generally show high 
tolerability.
How can these results be judged when compared to conventional medicine? Smulders et al. 
[37] summarize the epidemiological evidence of common therapeutic actions in conventional 
medicine: almost half are hardly or never studied, and efficacy has only been demonstrated un-
equivocally for 13 percent of them. For the rest of common therapeutic actions in conventional 
medicine, the support from epidemiological studies ranges from ‘probably useful’ (23%) to ‘pro-
bably useless or even harmful’ (4%). Until now, a lack of qualitative solid evidence has not been a 
reason to ban common therapeutic actions from conventional medicine. This should then also not 
be the case for AM, since this would imply a double standard, especially since the current body 
of empirical evidence demonstrates positive results on the effects, high safety levels and possible 
cost-effectiveness. In addition, the AM concept is increasingly in accordance with the systems bio-
logy-orientated ‘network medicine’ (see Section 11.4.1). Instead of banning AM from healthcare, 
current knowledge provides reason for more funding of research and practice in order to further 
develop and test AM concepts and to acquire high-quality evidence on cost-effectiveness. These 
considerations are even more applicable when considering complementary medicine in general.
11.4.3 The accordance of the concept of anthroposophic medicine with other 
theories
 Regarding the statement that the concept of AM is theoretically not in accordance with 
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science and medical practice, the characteristics of AM, as already described in the Introduction 
(Chapter 1), are summarized:
1. There are non-material organizing principles in nature in addition to the material elements 
of reality (nature) (ontological aspect)
2. There are higher, more complex levels of organization in organisms, which are responsible 
for the integrity and organizing of material elements in time, space and function (epistemo-
logical aspect)
3. These higher levels of organization in organisms can be examined by means of qualitative-
subjective and statistical pattern exploration and pattern recognition methodologies (me-
thodological aspect)
4. Health and disease can be diagnosed by integrating knowledge from the lower and higher 
levels of the organization of the system (methodological aspect)
5. The anthroposophic treatment of disease must often be systems-oriented (e.g. several sub-
stances or therapies) and aimed at: 
a. Influencing different essential aspects of the relevant organizing system level in health 
and disease at the same time or in phases (poly-target-treatment)
b. Restoring balance and wholeness within the system by stimulating the higher levels of 
organization in order to regulate the lower levels (health promotion) (methodological 
aspect)
6. The anthroposophic treatment of disease requires self-activity of the organism and the pa-
tient towards an optimal functioning of the higher levels of organizing among each other 
and in the regulation of the lower levels. Therefore, it is a health promotion strategy, one 
that supports and enables patients to actively contribute to their own health and disease 
status (methodological aspect).
Points 2-6 are conceptually fully in line with the concepts of system biology, epigenetics and 
emergentism (Chapter 1) and the current scientific and healthcare practice orientation towards 
‘network medicine’, ‘polypharmacology’ and ‘poly-target treatment’ [3, 4, 7, 38]. The only aspect 
in which the anthroposophic formal aspects differ from current scientific thinking is the ontologi-
cal aspect. Since this is a very delicate discussion (for most scientists, the ontological reductionist 
materialistic position is the basis of science), this topic is separately reflected, thus demonstrating 
that some of the major scientific questions that remain unanswered are related to the ontological 
question: ‘of what is reality (nature) made of?’
11.4.4 Final reflection on ontology within the holism and reductionism debate
 Ontological aspects concern the question of what entities, things or substances are assumed 
to make up reality (nature), what characteristics are attributed to these things or entities, and what 
relationships and functions can be assumed to exist between them [38]. On the ontological level, 
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one can distinguish theoretically between ontological reductionism (atomism) and ontological ho-
lism (vitalism, emergentism and organicism). Atomism holds that the entities of the ‘lowest’ level 
of organization (atoms, sub-atomic particles, quantum particles, etc.) are somehow ‘fundamental’, 
that they have an ontological ‘surplus value’ over entities of higher levels. They are the ‘building 
blocks’ of nature, the ‘cement of the universe.’ Vitalism claims that the animate nature differs from 
inanimate nature in that an additional non-material force is operative in living beings. Emergent-
ism is the view that at each higher level of organization, new and irreducible properties appear 
(emerge) that are not present at lower levels. These are called ‘emergent’ properties and defined as 
properties of wholes, which are not possessed by their component parts, neither when taken sepa-
rately nor when put together in other partial combinations. Organicism is the view that living or-
ganisms are complex, hierarchically structured wholes, whose parts are all functionally integrated 
in and co-ordinated by the whole. Consequently, the parts behave differently than they would when 
in isolation: they are co-ordinated by the whole. This means that not only do its parts determine the 
whole, but also that the parts are determined by the whole. 
 One of the conceptual elements of AM is that there are non-material organizing principles 
in nature in addition to the material elements of reality (nature). In current science, this position is 
most often regarded as fully unscientific. Although there is increasingly more scientific consensus 
that a reductionist explanation of (the development of) complex organisms is too simple, two con-
cepts are regarded as sufficient material explanations for the complexity of organisms: epigenetics 
and emergentism. Epigenetics is ‘‘the study of changes in gene function that are mitotically and/or 
meiotically heritable and that do not entail a change in DNA sequence.’ [40] “Emergent phenom-
ena are said to arise out and be sustained by more basic phenomena while at the same time exerting 
a ‘top-down’ control, constraint or some other sort of influence upon those” [41]. 
 Although both concepts are currently at the center of scientific debate, this thesis challeng-
es the validity of the central notion that higher organizational, epigenetic levels of organism arise 
spontaneously as a result of the assemblage of the material parts only by describing and discussing 
some of the unanswered scientific questions that are related to the ontological topic. 
Until now, man has not been able to create life experimentally from matter only, and the ques-
tion remains whether he will ever be able to do so [42]. Man has merely manipulated existing life 
into new forms or phenotypes. Therefore, one also has to consider the non-atomistic holistic hypo-
thesis that life is more than the emergent organization that spontaneously arises from assembling 
the material parts. 
The latest insights into the epigenetic mechanisms state that DNA methylation, histone tail 
modifications, and noncoding RNAs are responsible for changes in gene expression and the sub-
sequent development of specific cells for specific tissues without changing the underlying DNA 
sequence [43]. However, this leaves the question unanswered as to how these mechanisms regu-
lated themselves in the spatiotemporal development from the zygote stage to all later stages of 
the organism. How do the zygote and the further stages know which mechanism to use and which 
choices to make during mitosis? Where does the orientation towards differentiation in different 
tissues originate (especially in the zygote stage, which is characterized by a lack of localization 
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within an organism)?
Is emergentism really able to explain each phase of the development in time and space of the 
human fertilized egg (one cell) over 25 years, from one zygote into a fully physical developed 
human being with approximately 1027 molecules of human cells, that throughout the development 
is able to renew each molecule within two weeks, that is able to replace 97 percent of all cells of 
their body within one year, and that is constantly able to heal smaller and larger physical injuries 
and wounds of the human body? 
The next issue is the field of the relationship between physical matter and the hypothesized 
production of ‘substance’ and content of non-material qualities. How is physical matter able to 
produce ontological non-material qualities like thoughts and feelings, and intuitions? How do neu-
robiological processes ‘produce’ perceptions of the world? How can one understand the qualia or 
states of phenomenal consciousness, which are purely intrinsic and not dependent on the causal 
relationships between the brain and the outside world [44]? Where does the intuitive sense of 
knowing (‘it’s on the tip of my tongue’) [45] that arises before thought and speech originate? 
Where do the new ‘intuitions’ in human history that have the characteristic of representing ‘a way 
of direct knowing that seeps into conscious awareness without the conscious mediation of logic 
and the rational process’ originate [45]? How can one explain human pattern recognition, the key 
element of expert information processing, whereas three major theories (template matching the-
ories, feature detection theories, and prototype theories) [46] are not able to explain all aspects 
of pattern recognition? Where does one find in the organism the intermediate level of abstraction 
that is called the ‘moderately abstract conceptual representation’ (MACR): a compromise between 
different abstractions like comparisons in the disciplines of physics and chemistry and concrete, 
specific problems [14], and that is able to ‘produce’ all expressions from one pattern and recognize 
one pattern in all expressions? How can one explain the exceptional skills of some of the ‘savants’, 
individuals with IQ levels that are potentially in the normal range but who have developmental 
disorders (particularly autism), and who demonstrate remarkable abilities or skills. Some savants, 
for example, are able to successfully perform calculation exercises with lightning speed without 
any aids or previous education; this makes the characteristic performance so remarkable. There 
is currently no widely accepted cognitive theory to explain the combination of talent and deficit 
found in savants [47]. 
What is the ontological quality of non-verbal meaning? Everybody can experience that there 
is a difference between the meaning of something, and the thoughts and words one has. One’s 
perception of the meaning first refers to the whole that is experienced, and afterwards shapes the 
individual components that collectively express the meaning. The occurrence of specific typing 
errors, for example, shows that “the former” can disturb “the latter.” People may have already 
typed a letter that should appear later in the sentence. Presumably, most people have had a similar 
experience, where they know exactly what they want to say before they say it. This is even clearer 
in those moments when a person cannot find the right words, and/or the spoken words do not match 
precisely what he/she really wants to say. Apparently, one can compare inner words with some-
thing that already exists, which is subjectively experienced and has wordless meaning.
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All described examples demonstrate scientific questions that are directly related to the ontolo-
gical question currently approached by the same type of scientific (materialistic and reductionist) 
thinking. The axiom is that only material substances (and their physical and chemical relationships) 
are the building blocks of nature. Science, therefore, only searches for material, physical hypothe-
ses and explanations. If something new arises in the development of an organism (form in time or 
space, qualia, consciousness, intuitions, etc.), it then consequently must also be the result of matter. 
This also accounts for all patterns (e.g. biological self-organization levels in organisms, and pat-
tern recognition in consciousness) that organize lower-level ‘material’ (e.g. proteins or processes 
in organisms, or words, perceptions or thoughts in consciousness). These organizing patterns even 
possess non-materialistic qualities such as qualia or dynamic structures in space, time and function 
on several levels of organisms (e.g. the organized movements of biological processes in time).  
Looking at both the described ontological unanswered questions and the current reductionist 
reasoning, it is time for a renewed scientific interest in additional explanations positing non-physi-
cal properties for the ‘substance’ and content of self-organizing patterns or structures in organisms 
and in consciousness. Science has revealed that, on the one hand, during most of human history, 
until far into the 19th century, non-reductionist explanations positing non-physical properties were 
a part of scientific reasoning. Secondly, science has taught people that new theories arise when 
the old ones appear to be unable to describe and explain all the facts. The several holistic but 
physicalist theories (e.g. epigenetics and emergence), which have been developed by scientists to 
explain the described ontology-related ‘problems,’ are not yet sufficient to describe and explain all 
the facts.
Therefore scientists, instead of labeling these approaches as unscientific or pseudoscientific 
[48], should keep an open attitude towards explanations positing alternative ontologies, such as the 
non-atomistic/holistic explanations used in anthroposophic medicine.
11.5  Synthesis
 The latest paradigm in medicine is the evidence-based medicine approach, which has 
brought a huge change to medicine since it was conceptualized in the early nineties. Since then, a 
huge amount of money and effort has been invested in providing evidence of the quality, safety, ef-
ficacy, effectiveness and cost-effectiveness of, for example, diagnostic procedures and treatments. 
The goal is to change medicine from expertise-based to evidence-based in order to provide optimal 
care for the individual patient.
However, after a while new paradigms grow old(er) and the shortcomings and unfulfilled ex-
pectations and unsolved problems become clearer. That is the time for new paradigms to arise, 
which provide new ways of thinking and new ways of solving problems in addition to the old 
paradigms. For example, the genome project brought a huge amount of information, but did not 
answer all questions on the direct influence of exposure to the environment, e.g. resulting in in-
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dividually different disease susceptibilities. As a reaction, scientific attention was directed more 
towards epigenetics. The same type of paradigmatic shift can be seen in the shift from molecular 
biology to systems biology.    
 Health promotion is also a relatively new paradigm that fits in with these other paradigmatic 
changes. As with all paradigm shifts, new paradigms have to demonstrate that they are able to solve 
the ‘left overs’, the problems that could not be solved by the older approaches, while at the same 
time remaining consistent with the already established evidence. New ways of considering and 
solving healthcare problems with ‘health promotion glasses’ will take some time until they have 
become sufficiently evidence-based, are proven to be important, have become more familiar, and 
are integrated into healthcare with the fighting disease approach in order to achieve the best of both 
worlds. This thesis contributes to this development.
11.6  Future perspectives
 Three major perspectives can be described based on the results of this thesis: implementa-
tion of new research lines, the further development of professional preventive and curative health 
promotion as a contribution to the further innovation of medicine and healthcare, and the invest-
ment in CAM/IM/AM research.
11.6.1 Implementation of new research lines
 Based on the results of this thesis, new research lines can be defined and implemented:
1. Development and validation of health promotion strategies:
a. Further development and validation of the health concept and its working mechanisms. 
b. Designing of preventive and curative health promotion strategies based on the valida-
ted health concept.
c. Testing of safety, efficacy, effectiveness and cost-effectiveness of preventive and cura-
tive health promotion strategies for specific indications.
d. Integration of fighting disease and health promotion strategies for specific indications.
2. Development and validation of pattern analysis methodologies:
a. Development and testing of statistical methods to explore, model and test patterns such 
as patterns of immunological elements representing higher organization and epigene-
tic levels.
b. The further development, validation and application of trained judgment and the quali-
tative Goethean phenomenological method as methods to acquire scientific objective 
knowledge on higher organization levels in science and clinical practice.
3. Development and testing of the contribution of CAM treatment for specific indications to 
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the innovation of system biology-orientated medicine. 
a. Development and testing of multi-therapy and multi-target treatments.
b. Diagnostic and therapeutic individualization using pattern recognition methodologies.
4. Optimizing and validation of Citrus/Cydonia comp. treatment of seasonal allergic rhinitis:
a. Testing of the different workings mechanisms of Citrus and Cydonia in vivo.
b. Optimizing, if necessary, the integration of the different working mechanisms of Citrus 
and Cydonia in one product in vivo.
c. Designing and execution of pragmatic and explanatory trials. 
d. Studying the extracellular matrix and the effects of the specific subcutaneous route of 
administration in this extracellular matrix compared to other routes of administration.
11.6.2 Further development of professional preventive and curative health 
promotion as a contribution to the further innovation of medicine and 
healthcare
 Based on the results of this thesis, new development programs can be defined and imple-
mented:
1. Programmatic development of qualitative effective CAM and IM products and the evi-
dence of safety, efficacy, effectiveness and cost-effectiveness, following the line of deve-
lopment from practice-based evidence to evidence-based practice.
2. Programmatic development of specific healthcare ‘products’ for specific diseases, integra-
ting the best of both worlds of conventional medicine and CAM into IM ‘products’.
3. Programmatic development of specific integrative products for specific diseases, integra-
ting the best of both worlds of the fighting disease and the health promotion approach.
4. Continuous professional support of the development of patient competence to its full po-
tential in all aspects of healthcare.
11.6.3 Investment in integrative medicine research
 Based on the results of this thesis and the strategic plans of, for example, the NCCAM [49] 
in the United States and ZonMW [50] in the Netherlands, the following investments in CAM and 
IM research are suggested: 
1. Advance research on CAM mind and body interventions, practices, and disciplines.
2. Advance research on CAM natural products.
3. Advance research on monitoring and balancing the demands of patients on the one hand 
and CAM and IM healthcare products on the other hand.
4. Advance research on context factors, healing environments and placebo effects.
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5. Increase understanding of the “real-world” patterns and outcomes of CAM use and its 
integration into health care and health promotion.
6. Improve the capacity of the field to conduct rigorous research.
7. Improve and/or develop methodologies that are in line with ontological and epistemologi-
cal aspects of IM streams.
8. Invest in cooperation between conventional and IM researchers and healthcare professio-
nals.
9. Develop and disseminate objective, evidence-based information on CAM aims, patient 
experiences, interventions, safety, efficacy, effectiveness, and cost-effectiveness.
11.7  Final conclusions
 The aim of this thesis is to contribute to the further development of the professional cura-
tive health promotion approach and its integration with the fighting disease approach in medicine. 
The specific contributions of this thesis to this development are:
• The development of a more valid concept of health than the WHO concept of 1948, 
which can serve as a theoretical fundament for preventive and curative health promotion.
• The development of systems biology-orientated, pattern variable biomarkers for the mo-
nitoring of health changes.
• The testing of the anthroposophic medicine Citrus/Cydonia comp. in SAR treatment as 
an example of curative health promotion, demonstrating the safety, moderate efficacy, 
and specific immunological working mechanism of the medicine. 
• The testing of the efficacy, effectiveness and cost-effectiveness of CAM compared to 
conventional medicine, demonstrating that CAM could be effective and might have sig-
nificant cost-saving potential. 
• The scientific underpinning of the holistic health promotion approach based on the cur-
rent developments regarding the ontological, epistemological and methodological as-
pects of the holism-reductionism scientific framework.
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Abstract
 Background: Health economists have largely ignored complementary and alternative 
medicine (CAM) as an area of research, although both clinical experiences and several empirical 
studies suggest cost-effectiveness of CAM. 
 Objective: to explore the cost-effectiveness of CAM compared to conventional medicine. 
 Methods: A data set from a Dutch health insurer was used containing quarterly informa-
tion on healthcare costs (care by general practitioner (GP), hospital care, pharmaceutical care, and 
paramedic care), dates of birth and death, gender and 6-digit postcode of all approximately 150,000 
insurees, for the years 2006 - 2009. Data from 1913 conventional GPs were compared to data from 
79 GPs with additional CAM training in acupuncture (25), homeopathy (28) and anthroposophic 
medicine (26). 
 Results: Patients whose GP has additional CAM training have 0 to 30 percent lower heal-
thcare costs and mortality rates, depending on age groups and type of CAM. The lower costs result 
from fewer hospital stays and fewer prescription drugs.
 Discussion: Since the differences are obtained while controlling for confounders including 
neighborhood specific fixed effects at a highly detailed level, the lower costs and longer lives 
are unlikely to be related to differences in socio-economic status. Possible explanations include 
selection (e.g. people with a low taste for medical interventions might be more likely to choose 
CAM) and better practices (e.g. less overtreatment, more focus on preventive and curative health 
promotion) by GPs with knowledge of complementary medicine. More controlled studies (replica-
tion studies, research based on more comprehensive data, cost-effectiveness studies on CAM for 
specific diagnostic categories) are indicated.
 Keywords: healthcare costs, life expectancy, complementary medicine.
 JEL classification: I11, I12. 
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Introduction
 Complementary and alternative medicine (CAM) has been largely ignored by health eco-
nomists as an area of research. That fact is possibly related to the low esteem of CAM in the medi-
cal profession.
Defining CAM is difficult, because the field is very broad and constantly changing. According 
to the National Center for Complementary and Alternative Medicine (NCCAM) CAM is a group of 
diverse medical and health care systems, practices, and products that are not generally considered 
part of conventional medicine [1]. The Cochrane Collaboration definition of complementary me-
dicine is that it includes all such practices and ideas which are outside the domain of conventional 
medicine in several countries and defined by its users as preventing or treating illness, or promoting 
health and well being. These practices complement mainstream medicine by satisfying a demand 
not met by conventional practices and diversifying the conceptual framework of medicine [2]. 
Patients around the globe are increasingly embracing CAM as a contributor to health. A recent 
study by the US National Institute of Health shows that 4 out of 10 Americans used some form of 
CAM in 2007. Another study on Switzerland reported that almost 11% of the population had used 
one of five CAM streams (anthroposophic medicine, homeopathy, neural therapy, phytotherapy 
and Traditional Chinese Medicine) in 2002. The CAM doctors in that study treated patients that 
tended to be younger, female and better educated. These patients also tended to have a favorable 
attitude towards complementary medicine and to exhibit chronic and more severe forms of disease. 
The majority of alternative medicine users appear to have chosen CAM mainly because they wish 
to undergo a certain procedure; additional reasons include desire for more comprehensive treat-
ment, and expectation of fewer side-effects [3]. In a referendum in Switzerland in 2009, two thirds 
of the voters were in favor of a wider coverage of CAM by public health insurance. In January 
2011, based on the positive outcome of a national referendum, the Swiss authorities decided that 
five main streams of CAM (anthroposophic medicine, homeopathy, neural therapy, phytotherapy 
and Traditional Chinese Medicine) will be covered by the mandatory health insurance for a period 
of six years (2012-2017) [4]. 
In many cases, the effectiveness of CAM has not been proven in clinical trials [5]. However, 
lack of proof of effectiveness is obviously not the same as proof of ineffectiveness. Clearly, the 
status of a treatment can change from CAM into conventional medicine once scientific evidence 
on effectiveness becomes available. Two examples of CAM treatments that have become (more) 
accepted by conventional medicine are St. John´s wort and acupuncture for specific indications. St. 
John´s wort, for more than 90 years used in anthroposophic medicine, has become part of the con-
ventional guidelines for the treatment of depression, based on scientific evidence from randomized 
controlled trials [6]. Hopton and McPherson [7] conclude on the basis of a systematic review of 
pooled data from meta-analyses that acupuncture is more than a placebo for commonly occurring 
chronic pain conditions. In addition, in her thesis, van den Berg [8] recently demonstrated positive 
effects of acupuncture on obstetric health problems (breech presentation). Also Servan-Schreiber 
[9] presents a series of recent examples of the transition from CAM to conventional medicine in 
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depression treatment. Some of the methods described by Servan-Schreiber have been practiced for 
centuries, cannot be patented, and are available at low costs. These findings underscore the fact that 
methods that are considered CAM today could be effective and have a large cost-savings potential. 
Anthroposophic medicine, acupuncture and homeopathy are three main streams of CAM. One 
of the core features of CAM is its orientation on preventative and curative health promotion as an 
additional approach to a more conventional fighting disease approach. Anthroposophic medicine 
is an integrative diagnosis and therapy concept, developed from 1921 onwards and practiced today 
in over 60 countries. It combines mainstream scientific medicine with Rudolf Steiner’s anthropo-
sophy.  Anthroposophic medicine considers a human being as a whole entity - body, mind, soul 
and individuality. It aims to stimulate the self-healing forces of the body, restoring the balance of 
bodily functions and strengthening the immune system, rather than primarily relieve the symptoms 
of disease. Specific anthroposophic approaches include anthroposophic medicinal products, mas-
sage therapy, art and music therapy, and speech and movement therapies [10]. 
Homeopathy is a form of alternative medicine, first proposed by the German physician Samuel 
Hahnemann in 1796, that attempts to treat patients with heavily diluted substances. These subs-
tances which cause certain symptoms in healthy individuals are given as the treatment for patients 
exhibiting similar symptoms. The appropriate homeopathic medicinal product aims to stimulate 
the body’s inherent forces of self-recovery [11]. 
Acupuncture is one of the main forms of treatment in Traditional Chinese Medicine (TCM). 
It involves the use of sharp, thin needles that are inserted in the body at very specific points. This 
process is believed to adjust and alter the body’s energy flow into healthier patterns, and is used to 
treat a wide variety of illnesses and health conditions [12]. 
In their review, Herman et al. [13] report that some studies indicate that CAM therapies may be 
considered cost-effective compared to usual care for various conditions: acupuncture for migraine, 
manual therapy for neck pain, spa therapy for Parkinson’s, self-administered stress management 
for cancer patients undergoing chemotherapy, pre- and post-operative oral nutritional supplemen-
tation for lower gastrointestinal tract surgery, biofeedback for patients with ‘functional’ disorders 
(eg, irritable bowel syndrome), and guided imagery, relaxation therapy, and potassium rich diet for 
cardiac patients. A systematic review of randomized clinical trials on the use of so-called Natural 
Health Products shows evidence of cost effectiveness in relation to postoperative surgery but not 
with respect to the other conditions assessed [14].  Studer and Busato [15] demonstrated that ge-
neral practitioners who have completed certified additional training in CAM after obtaining their 
conventional medical degree (GP-CAMs) (n = 257) with general practitioners who have not (GPs 
) (n = 174) have equal costs per patient per year, but significantly lower costs per doctor (29%) per 
year, although GP-CAMs take more time per patient. A NCCAM study in 2007 demonstrated that 
CAM costs were 11.2% of total out-of-pocket expenditures on health care in the USA [16].
GP care varies between European countries in terms of structure, working methods, and res-
ponsibilities. In the Netherlands GPs are the central gatekeepers for reference to the rest of heal-
thcare, like specialists and paramedics. Dutch general practitioners generally receive a quarterly 
fixed fee per patient plus a fee-for-service per consultation and per drug prescription. There is 
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no difference between the financial incentives faced by GPs and GP-CAMs. In the Netherlands 
purchasing basic health insurance is mandatory for all citizens. In addition, citizens are free to 
purchase supplementary insurance.
Since there is a lack of cost-effectiveness data of CAM in The Netherlands, in this paper, we 
compare the performance of general practitioners who have completed certified additional training 
in CAM after obtaining their conventional medical degree (GP-CAMs) with general practitioners 
who have not (GPs). More specifically, we consider GP-CAMs with additional training in anthro-
posophic medicine, homeopathy, or acupuncture (about 1 percent of GPs for each of these CAM 
types). 
Methods
Model overview
 We analyze costs at the patient level using linear and loglinear regression analysis. While 
the linear specification is more common, the loglinear specification can be argued to be more ap-
propriate given that costs are nonnegative and cost distributions typically have long tails. Given the 
large average differences in health and health care needs across age groups, the cost analysis has 
been performed separately for the age groups 0-24, 25-49, 50-74, 75+. In all cost regressions, the 
explanatory variables are: gender, age (linear, within each age category), dummies for each quarter, 
dummies for anthroposophy, homeopathy, and acupuncture, and 6-digit postal code fixed effects
Effects on mortality rates are analyzed using a Logit model with fixed effects at the 4-digit 
insuree postcode level. Given the relatively low proportion of deaths (less than 3 percent of insu-
rees died during our sampling period) fixed effects at 6-digit insure level are infeasible. To check 
for robustness against functional form specification we also analyze mortality using fixed effects 
Linear Probability Models.    
Dataset on healthcare costs and demographics 
 A dataset from health insurer Azivo, active primarily in the city of Hague and its wider 
vicinity, was used for the analyses. Azivo is a former Ziekenfonds (sick fund) founded in 1895. 
It merged with health insurer Menzis in 2008, but keeps operating as “Azivo” in the the Hague 
region. Its share in the market for basic and supplementary health insurance in this region is about 
one quarter. 
The data set contains quarterly information on the healthcare costs of all Azivo insurees for 
the years 2006 up to 2009. In addition, it contains the date of birth of the insuree, date of death 
(if applicable), gender, and 6-digit postcode of the insuree’s residence. For each insuree-quarter 
combination, information on the costs of four different types of care are available: care by GP, 
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hospital care, pharmaceutical care, and paramedic care (like physical therapy). The data set does 
not contain information on the supplementary insurance status of insures; the cost information is 
the sum of expenses covered by both the basic and (if applicable) supplementary health insurance.
General practitioners 
 The data set also contains the names and addresses of the general practitioners who have 
patients who are insured by Azivo, which allows us to distinguish between conventional GPs and 
GP-CAMs. We defined a general practitioner as anthroposophic GP-CAM if his or her name ap-
pears in the list of general practitioners with additional training in anthroposophic medicine as 
provided by their professional association [17]. GP-CAMs with homeopathy [18] and GP-CAMs 
with acupuncture [19] are defined similarly.
Statistical analyses
 Significance of coefficients is tested using t-test, with clustering of standard errors at the 
level of the insuree. Calculations were performed using StataSE 10.0. 
Results
Patient demographics
 The dataset contained information on 151,952 insurees with a mean age of 38.4 (SD=22.6); 
53 percent is female. These patients live in 21902 different 6-digit postal codes.
General practitioners
 The dataset contained information from 1992 GPs: 1913 conventional GPs and 79 comple-
mentary GPs (GP-CAM) (anthroposophy: 26, homeopathy: 28, acupuncture: 25). The number of 
patients insured with Azivo is highly unevenly distributed across GPs. For example, 5 out the 26 
anthroposofic GPs in the data set account for more than 95 percent of the claims by patients with 
anthroposofic GP. This is because Azivo has a relatively large market share (about one quarter) in 
the The Hague region and a very low market share in most other regions. The average number of 
Azivo patients with these 5 anthroposofic GPs is about 570. The corresponding figures for the other 
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GP types are 850 (conventional), 150 (homeopathy) and 360 (acupuncture). The differences can 
be due to variations in the size of the total practice as well as in variations in Azivo’s market share 
across the four groups of patients. 
Healthcare costs
 The costs of patients with a GP-CAM are 7 percent lower compared to conventional GPs, 
which amounts to 140 Euros per patient annually. However, this difference in raw means of total 
costs is significant only for anthroposophic GP-CAMs. The lower total costs result from lower hos-
pital and pharmaceutical costs. Patients with a GP-CAM have slightly higher costs for paramedic 
care, but this difference is small. When the costs are compared by age group, in absolute terms, the 
differences are particularly large for patients aged 75 and above with an anthroposophic GP-CAM 
(more than 1000 Euros on an annual basis) (Table 2).
The analyses also demonstrate large demographic differences between patients with a conven-
tional GP versus patients with GP-CAMs (Table 1). GP-CAMs have a larger fraction of female 
patients than conventional GPs and fewer patients from disadvantaged neighborhoods. Clearly, 
the costs differences reported in tables 1 and 2 are partly due to differences in the demographic 
composition of the various groups of patients, and therefore difficult to interpret.
After controlling for these demographic differences by means of regression analyses we find 
that for patients in the age group 25 to 49 with a GP-CAM with acupuncture total costs are 66 
euro lower per quarter (Table 3, left panel). Secondly, for patients aged 75 and above with an an-
throposophic GP-CAM total costs are about 400 Euros lower per quarter. The magnitude of this 
difference is large, about one third lower. The separate regressions for the costs components show 
that these lower costs come from lower hospital and lower pharmaceutical costs. The results for 
the loglinear specification show a somewhat different pattern. Homeopathic GP-CAMs have about 
15 percent lower costs in all three age categories below age 75. The lower costs for patients aged 
25-49 who have a GP-CAM with acupuncture are found again for the loglinear specification.
It is important to note that 6-digit postal codes in the Netherlands are highly detailed, repre-
senting on 16 households on average. Within such a code households are highly homogeneous 
in terms of socio-economic status. Given that we have controlled for 6-digit postal codes in the 
regressions, the results are unlikely to be due to differences in socio-economic status.
Health status
 In the present data set the only information available on health outcomes is mortality in the 
years 2006 up to and including 2009. For the population of insurees in our data, the mortality rate 
was approximately 3 percent. After controlling for demographics (including age) and 4-digit postal 
codes, we find that patients with a GP-CAM have significantly lower mortality rates (Table 4). For 
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all three types of CAM the effect is significant for some specifications, but not for all specifications. 
The magnitude of the effect again varies between 0 and 30 percent. 
Discussion
 There are four types of explanations for the differences reported in the previous secti-
on. First, the differences could be due to selection on unobservables in patients’ GP choice. For 
example, patients who are healthier and more health-conscious, or patients with a strong prefe-
rence to minimize exposure to medical interventions might be more likely to choose a GP-CAM. In 
both cases costs will be lower due to lower demand for health care. A standard approach to control 
for selection on unobservables is to use instrumental variables. A potential instrumental variable 
(IV) in this case is the distance between a patient’s home and the various GPs. However, the dis-
tance measures would be perfectly correlated with the 6-digit postal code dummies. As a conse-
quence, this IV would only work if we would control for less detailed neighborhood information, 
like 4-digit postal codes. However, since socio-economic differences within a 4-digit postal code 
are typically large, this would not be a credible approach for identifying a causal effect of CAM on 
costs.
Second, the results could be due to undertreatment by GP-CAMs. In the present data set we 
were only able to analyze mortality and found that patients with a GP-CAM tend to have lower 
mortality rates. A number of studies have reported that patients seeking anthroposophic or homeo-
pathic care have longer lasting and more severe health problems than patients in conventional care. 
At the same time, these patients report fewer adverse side effects of treatments and higher patient 
satisfaction [e.g., 20, 21]. These findings combined with the results in this study provide some 
indication that undertreatment by GP-CAMs is unlikely. Firmer conclusions require more data on 
outcomes.    
Thirdly, the results could be due to better practices of CAM due to a stronger focus on preven-
tive and curative health promotion and less overtreatment. For example, a GP-CAM might try a 
low cost CAM treatment first. As mentioned, the primary professional orientation of CAM doctors 
is to strengthen the self-healing capacity of the body and the self-management of the patient. This 
approach is associated with prescribing fewer conventional pharmaceuticals, tests, and operations.
Fourthly, the lower costs could be related to the fact that patients interested in CAM might have 
higher out-of-pocket expenses since CAM is not included in the basic health insurance package. 
On the other hand, patients interested in CAM are more likely to buy supplementary insurance that 
covers CAM. This would imply that the marginal out-of-pocket expenses for these insurees are 
lower than for insurees with a conventional GP, leading to more consumption of healthcare (recall 
that the Azivo data contain costs covered by basic health insurance plus costs covered by optional 
supplementary health insurance). Yet, we find that the costs of patients with a GP-CAM are lower. 
Clarifying the role of out-of-pocket expenses is an empirical issue that requires additional data.   
Several studies that compare the health status of patients treated in CAM and in conventional 
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medicine in primary care settings find that patients treated in CAM practices suffer more often 
from severe and chronic illnesses (e.g., [20, 21]). This suggests that if we could control for severity 
and chronicity of illnesses (with additional data), the estimated cost differences might be larger.   
Another result of this study is that GP-CAMs have a larger fraction of female patients than 
conventional GPs and fewer patients from disadvantaged neighborhoods. Similar findings have 
been reported for the US [22] and for Switzerland [20].
The major limitations of this study concern the limited dataset. First of all the dataset is from 
only one insurer in one specific Dutch region and the data reflect the behavior of only a small 
number of GPs with additional training in CAM. This challenges the generalizability of the results. 
Secondly, the dataset does not cover all the information needed to perform an optimal comparison 
of cost-effectiveness. Missing information includes costs distinguished by basic and supplemen-
tary insurance, out-of-pocket expenses, morbidity, work absence, subjective health, and patient 
satisfaction.
Consequently, a large number of issues remain for future research. We mention three of them 
specifically. First, replication studies based on similar data sets are needed to confirm the present 
results. Secondly, further research is needed to determine to what extent selection on unobserva-
bles and causal effects explain the lower costs and lower mortality rates of patients with a GP-
CAM. Thirdly, more research is needed with regard to the cost-effectiveness of CAM for specific 
diagnostic categories.  
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Table 1. Descriptive statistics on patients with GPs and GP-CAMs
GP GP-CAMs
Costs of health care Conventional 
GP
GP-CAM  
anthroposophy
GP-CAM  
homeopathy
GP-CAM
acupuncture
Total 515a 479*** 485 480
GP 32 33*** 31*** 32
Hospital 266 236*** 251 235**
Pharmaceutical 209 197* 192 206
Paramedic 9 13*** 10** 8*
Incidence of costs of 
health care (0/1)
(per quarter)
GP 1 1 1 1
Hospital 0.29 0.28*** 0.26*** 0.30
Pharmaceutical 0.68 0.67*** 0.62*** 0.65***
Paramedic 0.04 0.06*** 0.04** 0.04**
Hosp., Pharma, and/
or Paramedic
0.72 0.71* 0.66*** 0.69***
Mortality 0.026 0.021 0.038** 0.025
Insuree characteristics
Female (fraction) 0.53 0.57*** 0.56*** 0.54***
Birth year (average) 1969 1970*** 1965*** 1966***
Disadvantaged neigh-
borhood (fraction)b
0.22 0.09*** 0.07*** 0.04***
Number of Azivo 
insurees
151,952 3271 1181 1470
Number of GPs 1913 26 28 25
a Costs of healthcare are in Euros per quarter; ***, **, * indicate a statistically significant difference with Conventi-
onal GP at the 1, 5, 10 percent level, respectively.
 b Based on a government list of most disadvantaged neighborhoods in the Netherlands (“Vogelaar-wijken”). These 
neighborhoods are uniquely identified by their 4-digit postal code.
226   Evidence-based curative health promotion
Table 2. Costs of health care; by type of GP and insuree age category
GPs GP-CAMs
Costs of health care
(euros per quarter)
Conventional 
GP
GP-CAM  
anthroposophy
GP-CAM  
homeopathy
GP-CAM  
acupuncture
Age 0-24
Total 215a 190 275 191
GP 26 26 24*** 25
Hospital 103 85* 153** 96
Pharmaceutical 77 69 88 62
Paramedic 8 11*** 10 8
Age 25-49
Total 372 418*** 286** 296***
GP 28 31*** 25*** 26***
Hospital 186 201 156 146**
Pharmaceutical 155 180*** 103*** 122**
Paramedic 4 7*** 3 1***
Age 50-74
Total 824 752** 614*** 687***
GP 37 39*** 35*** 35***
Hospital 432 382** 270*** 324***
Pharmaceutical 342 311** 294* 317
Paramedic 12 19*** 14* 11
Age 75+
Total 1337 1088** 1309 1139*
GP 57 57 59 56
Hospital 727 576** 820 595
Pharmaceutical 527 426** 403* 466
Paramedic 27 30 27 21
a Costs of healthcare are in Euros per quarter 
***, **, * indicate a statistically significant difference with Conventional GP at the 1, 5, 10 percent level, respectively.
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Table 3. Effects of complementary care on costs per insuree age category
Linear Loglinear
dummy
 for GP-
CAM  
anthro-
posophy
dummy 
for GP-
CAM 
homeo-
pathy
dummy 
for GP-
CAM 
acupunc-
ture
dummy for 
GP-CAM  
anthro-
posophy
dummy 
for GP-
CAM 
homeo-
pathy
dummy 
for GP 
-CAM 
acupunc-
ture
Age 0-24
Total 6a 100 -32 0.016 -0.138** -0.052
GP 1 -2* 1 0.015 -0.043* 0.019
Hospital 3 76 -5 0.064 -0.153* -0.034
Pharmaceutical 1 25 -27 -0.078* -0.250*** -0.108
Paramedic 2 0 -1 0.048 -0.006 -0.008
Age 25-49
Total 14 -50 -66* 0.022 -0.160** -0.106**
GP 2*** -3*** 0 0.030** -0.045** -0.004
Hospital 3 4 -47** 0.008 -0.161** -0.135**
Pharmaceutical 8 -51** -17 -0.035 -0.365*** -0.136*
Paramedic 1 -1 -2*** 0.032 -0.029 -0.060***
Age 50-74
Total 63 -48 -2 -0.030 -0.153** -0.084
GP 4*** 0 0 0.040* -0.001 0.017
Hospital  60 -121 -64 0.032 -0.145 -0.073
Pharmaceutical -7 69 61 -0.204*** -0.352*** -0.162
Paramedic 6* 4 1 0.080 0.016 -0.009
Age 75+
Total -405** 81 214 -0.130 0.077 0.184
GP -2 6 7 -0.030 0.058 0.111
Hospital -263** 52 87 -0.029 0.069 0.171
Pharmaceutical -125* 31 127 -0.169 0.048 0.196
Paramedic -15 -8 -7 -0.106 -0.085 0.034
a Costs of healthcare are in Euros per quarter. Each row is based on two regressions with either costs (left panel) 
or the natural logarithm of costs (right panel) as the dependent variable. Explanatory variables are: gender, age (linear, 
within each age category), dummies for each quarter, dummies for anthroposophy, homeopathy, and acupuncture; the 
table reports the coefficients on the latter dummies. All regressions control for 6-digit insuree postcode fixed effects; 
standard errors clustered at the insuree level. 
***, **, * indicate a statistically significant difference with Conventional GP at the 1, 5, 10 percent level, res-
pectively.
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Table 4. Effects of complementary care on mortality
dummy for  
GP-CAM  
anthroposophy
dummy for 
GP-CAM  
homeopathy
dummy for  
GP-CAM
acupuncture Combined
Logit with fixed effects 0.031 -0.198 -0.333* -0.128
LPM with fixed effects -0.005* -0.004 -0.009** -0.006***
Women
Logit with fixed effects 0.034 0.010 -0.203 -0.031
LPM with fixed effects -0.007* 0.004 -0.008 -0.005*
Men
Logit with fixed effects 0.020 -0.627* -0.493 -0.291*
LPM with fixed effects -0.003 -0.014 -0.013** -0.008**
Dependent variable: death in 2006, 2007, 2008, or 2009. 
The table is based on models with the following explanatory variables: gender, age, dummies for anthroposophy, 
homeopathy, and acupuncture (dummy for complementary in the last column); the table reports the coefficients on the 
latter dummies. 
LPM regression controls for 4-digit insuree postcode fixed effects.  
***, **, * indicate a statistical significance at the 1, 5, 10 percent level, respectively.  
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Summary
 The prognosis of higher life expectancies of both men and women in the Netherlands, often 
related to chronic diseases and high healthcare costs, the changed role of patients into competent 
patients, and the increasing interest of patients in complementary medicine worldwide provides the 
scientific rationale to put more emphasis in healthcare on developing valid, effective, cost-effective 
and safe strategies that support and enable patients to actively contribute to their own health and 
disease status in order to promote their health in a preventive and/ or curative manner.
Although much effort has been invested worldwide, a lot of scientific and practical work still 
has to be done to develop the health promotion approach into one that is evidenced-based and 
professional like the fighting disease approach. This thesis focuses on some of the conceptual, 
methodological and empirical issues of developing professional preventive and curative health 
promotion as a contribution to the further innovation of medicine and healthcare. 
Chapter 2 analyzed historic and current health concepts and developed and preliminarily vali-
dated the new concept of ‘health by self-regulation’ by means of analyzing its internal consistency, 
its accordance with other scientific concepts (e.g. the concepts of epigenetics, systems biology, 
and emergence) and its accordance with empirical facts. Finally, it demonstrated two examples of 
integration of the fighting disease and the health promotion approach and discussed the theoretical 
and practical implications of this new concept.
In Chapter 3, the fundamental scientific discussion of holism versus reductionism was summa-
rized. This chapter demonstrated that there are several arguments against the current reductionist 
point of view. This provides a scientific opening for a more holistic or systems biology-orientated 
concept of health and a more holistic or systems biology-orientated methodological approach.
Chapter 4 described a new system’s biology-orientated methodological approach in developing 
immunological biomarkers for monitoring treatment effect in seasonal allergic rhinitis (hay fever) 
research. Using permuted stepwise regression, pattern variables that reflect immune system func-
tioning on the systems level were computed and tested. Computation was based on a dataset (from 
a randomized controlled trial comparing two routes of administration) of allergen-specifically in-
duced expression levels of cytokines (IL-1β, IL-5, IL-10, IL-12, IL-13, IL-17, IFN-γ and TNF-α) 
and symptom severity scores from 22 seasonal allergic rhinitis (SAR) patients measured before 
and after six weeks of treatment with medicinal products containing Citrus and Cydonia. Further 
computation and biomarker validation with larger datasets, including data from healthy persons 
and SAR patients, is indicated.
In Chapter 5, the experiences of 39 Dutch general practitioners with anthroposophic SAR treat-
ment were examined. The results of this survey provide the first practice-based evidence of posi-
tive treatment results of Citrus/Cydonia comp. for SAR.
Chapter 6 examined, in two in vitro studies, the immunological pathways of the effects of 
Citrus/Cydonia comp. from a healthy and an allergic donor, respectively. Peripheral blood mono-
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nuclear cells (PBMCs) were isolated out of peripheral blood and analyzed in vitro after polyclonal 
stimulation of T-cells. The differentiation capacity and the influence regarding Th1 (IFN-γ) and 
Th2 (IL-5) cells were examined. Citrus/Cydonia comp. has a selective effect on the differentiation 
of Th-cells by producing relatively more IL-10 than IL-12. It also seems to have an effect on the 
induction of regulatory (IL-10 producing) T-cell subsets. It is in vitro capable of partly neutralizing 
the changes, characteristic to allergic rhinitis, regarding the maturation, differentiation, and activity 
of the immune system. Thus, it was concluded that Citrus/Cydonia comp. can potentially restore 
the disturbed immune state of rhinitis patients, which essentially could be sufficient to make al-
lergic symptoms disappear permanently.
Chapter 7 examined the effects of the combined product, Citrus e fructibus/Cydonia e fructibus 
(Citrus/Cydonia), and separate products of Citrus and Cydonia on the immuno-pathological path-
ways involved in seasonal allergic rhinitis (SAR). Peripheral blood mononuclear cells (PBMCs) 
from five healthy and five grass pollen-allergic donors were isolated and analyzed in vitro after 
polyclonal and allergen-specific stimulation of T-cells in the presence of the three extracts. The 
analyses demonstrated acceptable cell survival with no signs of toxicity. Citrus mainly had a selec-
tive effect on reducing allergen-specific chronic inflammatory (TNF-α) and Th2 (IL-5) pathway 
activity; whereas both Cydonia and Citrus/Cydonia mainly affected the induction of the allergen-
specific Th1 (IFN-γ) pathway. Citrus and Cydonia demonstrated differential working mechanisms 
in the treatment of SAR, and the combination product did not demonstrate larger effects than the 
separate preparations. Hence, it was concluded that further effectiveness and efficacy studies com-
paring the effects of the products on SAR in vivo are required.
Chapter 8 studied a small group of 13 patients with a mean history of hay fever with grass 
pollen allergy of 9 years’ duration, who in previous years used conventional hay fever medication 
because of the severity of their symptoms during the pollen season. Gencydo injections were ad-
ministered to 12 patients before the onset of and during the grass pollen season, and in one patient 
during the grass pollen season only. Nasal and non-nasal hay fever symptom severity, use of rescue 
medication (antihistamines or corticosteroids), and the subjective experiences of patients were 
used as outcome measures. It was concluded that there are clear indications that Gencydo treatment 
is effective in a large subgroup of the research population.
Chapter 9 compared the efficacy and safety of two routes of administration (subcutaneous 
injections (SI) versus nasal spray (NS)) in a national, randomized, comparative clinical trial with 
two parallel groups.  A total of 23 patients fulfilled the study requirements. After a one- or two-
week wash-out period, twenty-three patients were randomized to a six-week treatment period. The 
outcomes assessed were immunological and symptom severity changes and safety. Immunologic 
outcome assessments were blinded to group assignment. It was concluded that both routes of ad-
ministration are safe and demonstrate immunological and clinical effects, with larger inflammatory 
and innate immunological effects of the NS route and larger allergen-specific clinical effects in the 
SI group. 
Chapter 10 reported a study that was aiming to update the safety status of anthroposophic and 
homeopathic solutions for injection through a systematic evaluation of the reported adverse drug 
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reactions (ADRs). ADRs were extracted from the pharmacovigilance databases of eight German 
anthroposophic and homeopathic manufacturers covering the period of 2000-2009. These eight 
manufacturers represent, in total, more than 94 percent of the sales of anthroposophic and homeo-
pathic solutions for injection in Germany. Analyzed ADRs included reports in humans only, re-
ports from post-marketing surveillance, literature cases and clinical/safety trials, and spontaneous 
reports from healthcare professionals and patients. The results suggest an excellent safety profile 
of solutions for injection as therapeutically applied in anthroposophic medicine and homeopathy, 
where the overall incidence of ADRs are very rare.
Chapter 11 presented the major findings of this thesis, studying the concept of health, the meth-
odology to monitor (changes in) health states, the effects and safety of Citrus/Cydonia comp. on 
seasonal allergic rhinitis as an example of curative health promotion, and the cost-effectiveness of 
integrative medicine in the Netherlands. The theoretical and practical implications of the results of 
this thesis were discussed and reflected on the scientific fundament of anthroposophic medicine. 
Future perspectives were also described for the implementation of new research lines, the further 
development of professional preventive and curative health promotion as a contribution to the fur-
ther innovation of medicine and healthcare, and the investment in CAM/IM/AM research.
In the Appendix, a cost-effectiveness study is presented in which the possible contribution of 
integrative medicine to the reduction of healthcare costs was studied. This study compared the 
performance of general practitioners who have completed certified additional training in CAM 
after obtaining their conventional medical degree (GP-CAMs) with general practitioners who have 
not (GPs). Patients whose GP has completed additional CAM training have 0–30 percent lower 
healthcare costs and mortality rates, depending on age group and the type of CAM. The lower 
costs result from fewer hospital stays and fewer prescription drugs. Since the differences are ob-
tained while controlling for confounders, including neighborhood-specific fixed effects at a highly 
detailed level, the lower costs and longer lives are unlikely to be related to differences in socio-
economic status. Possible explanations include selection (e.g. people with low interest in medical 
interventions might be more likely to choose CAM) and better practices (e.g. less overtreatment, 
more focus on preventive and curative health promotion) by GPs with knowledge of complemen-
tary medicine. More controlled studies (replication studies, research based on more comprehensive 
data, cost-effectiveness studies on CAM for specific diagnostic categories) are required. These 
findings highlight the fact that the health-promoting methods that are considered CAM today could 
be effective and might have significant cost-saving potential.
With the example of Citrus/Cydonia comp. in SAR treatment, this thesis demonstrates the 
safety, moderate efficacy and specific immunological working mechanism of this medicine, un-
derscoring that CAM could be effective and might have a significant cost-saving potential, and 
collectively, the validity of the concept of preventive and curative health promotion. 
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Samenvatting
Door in de gezondheidszorg meer nadruk te gaan leggen op een gezondheidsbevorderende 
benadering (‘health promotion’) in aanvulling op een ziektebestrijdende benadering (‘fighting 
disease’) kan ingespeeld worden op een aantal belangrijke ontwikkelingen in de gezondheidszorg 
in Nederland van de laatste decennia: de prognose van een hogere levensverwachting voor zowel 
mannen als vrouwen in Nederland, de daaraan gerelateerde hogere prevalentie van chronische 
ziekten en hoge kosten van de gezondheidszorg, de veranderde rol van patiënten in competente 
patiënten, en de toenemende wereldwijde belangstelling van patiënten voor complementaire vor-
men van geneeskunde. Het is daarom van belang valide, (kosten)effectieve en veilige strategieën 
te ontwikkelen die het patiënten mogelijk maken om actief bij te dragen aan hun eigen gezondheid- 
en ziektetoestand. Daarmee bevorderen zij hun gezondheid op een preventieve en/of curatieve 
manier. De verwachting is dat dit naast gezondheidswinst tevens een bijdrage levert aan het in de 
hand houden van de kosten in de gezondheidszorg.
Hoewel er wereldwijd al veel geld en menskracht is geïnvesteerd, moet er nog veel weten-
schappelijk werk en werk in de zorgpraktijk verricht worden om de gezondheidsbevorderende 
aanpak te ontwikkelen tot één die even evidence-based en professioneel ontwikkeld is als de 
ziektebe strijdende aanpak. Dit proefschrift richt zich op een aantal conceptuele, methodologische 
en empirische aspecten van het verder ontwikkelen van professionele preventieve en curatieve 
gezondheidsbevordering als een bijdrage aan de verdere innovatie van de geneeskunde en de 
gezondheidszorg.
Hoofdstuk 2 analyseert de definitie van gezondheid van de World Health Organization (WHO) 
uit 1948 en huidige gezondheidsdefinities en reviseert en presenteert een nieuwe definitie: ‘ge-
zondheid door zelfregulatie’. Door de interne consistentie van de definitie te analyseren, en de 
overeenstemming met andere wetenschappelijke concepten (bijvoorbeeld de concepten van de 
epigenetica, de systeembiologie en de emergentie) en met empirische feiten vast te stellen, wordt 
de kwaliteit van de definitie onderzocht. Vervolgens worden aan twee voorbeelden (hooikoorts en 
chronische, psychologische traumatisering) de mogelijkheden van een integratieve behandeling 
met ziektebestrijdende en gezondheidbevorderende onderdelen gedemonstreerd. Ten slotte worden 
theoretische en praktische implicaties van deze nieuwe definitie beschreven.
In hoofdstuk 3 wordt de basale wetenschappelijke discussie over holisme versus reductionisme 
samengevat. Aannemelijk werd gemaakt dat er een aantal argumenten bestaat tegen het huidige, in 
de wetenschap gangbare, reductionistische standpunt. Deze argumenten bieden een wetenschap-
pelijke opening voor een meer holistisch, systeembiologisch georiënteerde definitie van gezond-
heid en een meer holistische, systeembiologie georiënteerde methodologische benadering in de 
geneeskunde.
Hoofdstuk 4 beschrijft een nieuwe, op de systeembiologie georiënteerde, methodologische 
benadering bij de ontwikkeling van immunologische biomarkers voor het monitoren van effecten 
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van de behandeling van seizoensgebonden allergische rhinitis (SAR) (hooikoorts). Met behulp van 
gepermuteerde stapsgewijze regressie (‘permuted stepwise regression’) werden patroonvariabelen 
ontwikkeld en getest die de activiteit van het immuunsysteem op systeemniveau monitoren. Bij de 
ontwikkeling van de patroonvariabelen is uitgegaan van een dataset uit een gerandomiseerde, ge-
controleerde studie waarin twee toedieningswijzen (neusspray en subcutane injecties) van Citrus/
Cydonia comp. werden vergeleken.  De SAR gerelateerde cytokineproductie scores (IL-1β, IL-5, 
IL-10, IL-12, IL-13, IL-17, IFN-γ en TNF-α) en de ernst van de symptoomscores van 22 SAR 
patiënten werden vóór en na zes weken behandeling vergeleken. Op basis van deze resultaten 
wordt geconcludeerd dat het geïndiceerd is om patroonvariabelen-biomarkers met behulp van gro-
tere datasets verder te ontwikkelen en te valideren, waarbij de gegevens van SAR patiënten tevens 
vergeleken moeten worden met de gegevens van gezonde personen.
Hoofdstuk 5 vat de ervaringen van 39 Nederlandse huisartsen samen die een antroposofische 
SAR-behandeling hebben voorgeschreven. De resultaten van dit onderzoek vormen de eerste prac-
tice-based evidence van de positieve resultaten van de behandeling Citrus/Cydonia comp. voor 
SAR.
In hoofdstuk 6 worden twee in-vitro onderzoeken beschreven waarbij de immunologische wer-
kingsmechanismen van de effecten van Citrus/Cydonia comp. op voor SAR relevante cytokinepro-
ductie scores in het bloed van een gezonde en een allergische donor zijn geanalyseerd. Mononucle-
aire cellen werden geïsoleerd uit perifeer bloed (PBMCs) en in-vitro geanalyseerd na polyklonale 
stimulatie van T-cellen. De veiligheid en de effecten op Th1 (IFN-γ) en Th2 (IL-5) cellen werden 
onderzocht. Citrus/Cydonia comp. heeft een selectief effect op de differentiatie van Th-cellen wat 
zichtbaar wordt in het produceren van relatief meer IL-10 dan IL-12. Het lijkt ook een effect te 
hebben op de inductie van regulatoire (IL-10 producerende) T-cel subsets. Het geneesmiddel is 
in-vitro in staat om gedeeltelijk de veranderingen, kenmerkend voor SAR, ten aanzien van rijping, 
differentiatie en activiteit van het immuunsysteem, te neutraliseren. De conclusie van het onder-
zoek is dat Citrus/Cydonia comp. mogelijk de verstoorde toestand van het immuunsysteem van 
SAR-patiënten zodanig kan herstellen, dat de allergische symptomen permanent verdwijnen.
In hoofdstuk 7 worden de effecten onderzocht van het gecombineerde product, Citrus e fructi-
bus/ Cydonia e fructibus (Citrus/Cydonia), en de aparte producten Citrus en Cydonia op de immu-
nologische ´pathways´ van SAR. Perifere bloed mononucleaire cellen (PBMCs) van vijf gezonde 
en vijf graspollen-allergische donoren werden geïsoleerd en in-vitro geanalyseerd, na toediening 
van de extracten van de drie producten en aansluitend polyklonale en allergeen-specifieke stimula-
tie van T-cellen. De analyses toonden acceptabele overlevingscijfers van de immuuncellen, zonder 
tekenen van toxiciteit. Citrus had vooral een selectief effect op het verminderen van de allergische 
chronische ontsteking (TNF-α) en de Th2 (IL-5) activiteit. Zowel Cydonia als Citrus/Cydonia 
hadden vooral invloed op de inductie van de Th1 (IFN-γ) ‘pathway’. Citrus en Cydonia blijken 
verschillende werkingsmechanismen bij de behandeling van SAR te hebben. Bij het combinatie-
product werden geen grotere effecten aangetoond dan bij de afzonderlijke preparaten. Geconclu-
deerd werd dat verder onderzoek naar effectiviteit en werkingsmechanismen van de afzonderlijke 
producten en het combinatieproduct bij SAR in vivo geïndiceerd is.
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In hoofdstuk 8 wordt een groep van 13 patiënten onderzocht met een gemiddelde voorgeschie-
denis van 9 jaar hooikoorts (graspollenallergie), die in voorgaande jaren tijdens het pollenseizoen 
conventionele hooikoortsmedicijnen gebruikten in verband met de ernst van hun symptomen. Gen-
cydo (Citrus/Cydonia comp.) injecties werden toegediend aan 12 patiënten vóór aanvang en tijdens 
het graspollenseizoen, en bij één patiënt tijdens het graspollenseizoen alleen. De ernst van de na-
sale en niet-nasale hooikoortssymptomen, het gebruik van ‘rescue’ medicatie (antihistaminica of 
corticosteroïden), en de subjectieve ervaringen van patiënten werden gebruikt als uitkomstmaten. 
Er werd geconcludeerd dat er duidelijke aanwijzingen zijn dat de Gencydo behandeling effectief is 
in een grote subgroep van de onderzoekspopulatie.
Hoofdstuk 9 beschrijft een onderzoek naar de werkzaamheid en veiligheid van twee toedie-
ningswijzen (subcutane injecties (SI) versus neusspray (NS)) van Citrus/Cydonia comp. in een 
nationale, gerandomiseerde, vergelijkende klinische trial met twee parallelle groepen. 23 patiënten 
voldeden aan de inclusie- en exclusiecriteria. Na een één- of tweeweekse washout periode waarin 
patiënten geen hooikoorts medicatie gebruikten, werden 23 patiënten gerandomiseerd naar een 
van de twee behandelgroepen voor een behandelperiode van zes weken. Effectmaten waren SAR-
gerelateerde immunologische veranderingen, ernst van de SAR-symptomen en veiligheid. De 
immunologische analyses werden geblindeerd voor de groepstoewijzing uitgevoerd. Geconclu-
deerd werd dat beide toedieningswijzen veilig zijn en immunologische en klinische effecten geven. 
Wel zijn er grotere inflammatoire - en ‘innate’ immunologische effecten bij de NS-groep en grotere 
allergeen-specifieke en klinische effecten in de SI-groep.
Hoofdstuk 10 beschrijft een onderzoek dat gericht was op het beoordelen van de veiligheid van 
antroposofische en homeopathische injectievloeistoffen door middel van een systematische evalu-
atie van de gemelde bijwerkingen (Adverse Drug Reactions, ADR’s). ADR´s werden geëxtraheerd 
uit de farmacovigilantie (geneesmiddelenbewaking) databases van acht Duitse antroposofische en 
homeopathische fabrikanten over de periode van 2000-2009. Deze acht fabrikanten vertegenwoor-
digen in totaal bijna 95% van de verkochte antroposofische en homeopathische injectievloeistof-
fen in Duitsland. De resultaten demonstreren een uitstekend veiligheidsprofiel van therapeutisch 
toegepaste injectievloeistoffen in de antroposofische geneeskunde en de homeopathie, waarbij de 
totale incidentie van bijwerkingen geclassificeerd kan worden als zeer zeldzaam.
Hoofdstuk 11 beschrijft de algemene discussie van dit proefschrift.  Allereerst werden samen-
vattend de belangrijkste resultaten van dit proefschrift gepresenteerd: een gereviseerde WHO 
definitie van gezondheid; een methodologie om veranderingen in gezondheidtoestand te kunnen 
monitoren met zogenaamde patroonvariabelen op systeemniveau; bewijzen van veiligheid en 
immunologische en klinische effectiviteit van Citrus/Cydonia comp. op seizoensgebonden aller-
gische rhinitis als een voorbeeld van curatieve gezondheidsbevordering; en een voorbeeld van 
kosten-effectiviteit van integratieve geneeskunde in Nederland. De theoretische en praktische 
implicaties van de resultaten van dit proefschrift werden besproken. Tevens werd, vanwege het 
feit dat Citrus/Cydonia comp. een antroposofisch geneesmiddel is, op het wetenschappelijke fun-
dament van de antroposofische geneeskunde gereflecteerd. De analyse van de methodologische 
en epistemologische verschuivingen in de gezondheidszorg van een veelal reductionistische naar 
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een meer holistische benadering laat zien, dat de antroposofische gezondheidszorg steeds meer 
in overeenstemming komt met de hedendaagse wetenschappelijke methodologieën en concepten. 
Tot slot zijn scenario’s beschreven voor de implementatie van nieuwe onderzoekslijnen, voor de 
verdere ontwikkeling van professionele preventieve en curatieve gezondheidsbevordering als een 
bijdrage aan de verdere innovatie van de geneeskunde en gezondheidszorg, en voor de investering 
in CAM/IM/AG (Complementary & Alternative Medicine, Integrative Medicine, Anthroposophic 
Medicine) onderzoek.
In de bijlage zijn de resultaten van een kosten-effectiviteitsonderzoek gepresenteerd waarin 
de mogelijke bijdrage van integratieve geneeskunde (Integrative Medicine) aan de kostenreductie 
van de gezondheidszorg werd onderzocht. In deze studie werden de praktijken vergeleken van 
huisartsen die, na het behalen van hun reguliere huisartsopleiding, een gecertificeerde aanvullende 
opleiding in CAM hadden afgerond, met die van huisartsen die geen aanvullende CAM-opleiding 
hadden gevolgd. Bij patiënten van wie de huisarts een extra CAM-opleiding heeft afgerond blijkt 
in de verschillende analyses van 0 tot 30 procent minder gezondheidszorgkosten gemaakt te wor-
den. Bovendien zijn de  sterftecijfers significant lager. De leeftijdsgroep en de aard van de CAM-
behandeling waren bepalende factoren voor de uiteindelijke kostenbesparing. De lagere kosten 
zijn het gevolg van minder verblijf in het ziekenhuis en minder voorgeschreven geneesmiddelen. 
Deze verschillen blijken zeer waarschijnlijk onafhankelijk te zijn van sociaal-economische om-
standigheden zoals opleiding en woonsituatie. Mogelijke verklaringen voor de lagere kosten en 
sterftecijfers zijn selectie (bijvoorbeeld mensen die zo min mogelijk medische interventies willen, 
kiezen wellicht eerder voor CAM) en kwalitatief beter werkende praktijken (bijvoorbeeld min-
der overbehandeling en/of meer aandacht voor preventieve en curatieve gezondheidsbevordering) 
door huisartsen met kennis van complementaire geneeskunde. Meer gecontroleerde studies (repli-
catie studies, onderzoek op basis van meer uitgebreide gegevens, kosten-effectiviteit studies naar 
CAM voor specifieke diagnostische categorieën) zijn geïndiceerd.
Met het voorbeeld van Citrus/Cydonia comp. voor de behandeling van hooikoorts laat dit 
proefschrift de veiligheid, effectiviteit en specifieke immunologische werkingsmechanismen van 
dit geneesmiddel zien. Aan het voorbeeld wordt tevens duidelijk dat CAM werkzaam kan zijn en 
dat het een belangrijk kostenbesparend potentieel heeft. Het proefschrift als geheel ondersteunt de 
geldigheid van het concept van preventieve en curatieve gezondheidbevordering. 
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Dankwoord
Het proefschrift is af! Tijd om vooruit te kijken naar de verdediging en de bezegeling ervan: 
een mooi feestje met familie, vrienden en collega’s. Tijd ook om terug te kijken hoe het allemaal 
gelopen is en wie ik wil bedanken.
Ik wil allereerst beginnen met het gezin waarin ik opgroeide. Mijn vader, moeder en later Gery 
die mij altijd vanzelfsprekend de ruimte gaven om mijn eigen weg te gaan, te zoeken en vinden wat 
ik zelf belangrijk vond, en die het mij mogelijk maakten en die mij stimuleerden om te studeren. 
Naast en met hen mijn broer, zusters, hun partners en kinderen die gezorgd hebben dat zorgen voor 
de ander maar ook gezellig met elkaar zijn en veel lol maken in onze familie een vanzelfsprekend-
heid was. Vanuit dit warme nest heb ik in goede en slechtere tijden kunnen scharrelen, opgroeien 
en ben ik geworden tot wie ik nu ben en voor de toekomst weet ik dat ik en mijn gezin altijd van 
hun hulp op aan kunnen, mocht dat ooit nodig zijn en zal ik met hen van het familieleven genieten. 
Dat is een geweldig gevoel!
Veel mensen zijn van invloed geweest op mijn wetenschappelijke carrière. Vanzelfsprekend 
kan ik niet iedereen noemen, maar twee moeten er gewoon genoemd worden. De eerste is Guus 
van der Bie, met wie ik sinds mijn 25ste al op allerlei manieren met vraagstukken en projecten 
over antroposofie, zorg en wetenschap bezig ben. Guus, ik bewonder jouw enorme kennis, jouw 
voortdurende bereidheid om mensen (waaronder ikzelf als ‘jonge hond’ 25 jaar geleden) te coa-
chen, je gedrevenheid en vasthoudendheid om te gaan voor de zaak en voor gemeenschapsvorming 
en natuurlijk ‘last but not least’ je humor. Veel dank voor jouw vriendschap en samenwerken. Ik 
hoop dat we dat nog een tijdje kunnen volhouden, pensionado! De tweede die ik wil noemen en 
bedanken is Marko van Gerven. Marko, jij hebt op velerlei momenten in mijn professionele leven 
vertrouwen in mij gehad, in mij geïnvesteerd, en vanuit de functies die je vervulde en vervult, 
meegeholpen om mijn en ook andermans onderzoek (financieel) mogelijk te maken. Zonder jou 
was mijn wetenschappelijke ontwikkeling en het schrijven van een proefschrift waarschijnlijk veel 
minder vanzelfsprekend geweest. Net als Guus, wil ik ook jou zeer bedanken voor de vriendschap 
en het samenwerken in verleden, heden en hopelijk de toekomst.
Tenslotte wil ik al mijn andere collega’s (Ton, Dre, Miek, Inge, Mats, Anja en Peter) met wie 
ik in dit proefschrift samen geschreven of gewerkt heb enorm bedanken. Zonder jullie was het 
zeker niet gelukt en ook veel minder goed geworden en zeker veel minder gezellig geweest. Gerda, 
enorm bedankt voor het prachtig vormgeven van het boekje. Het is je, zoals zo vaak, weer enorm 
goed gelukt om er iets heel moois van te maken. De Weleda en Wala wil ik zeer bedanken voor 
het toezenden van de foto’s van de citroen en kweepeer. Ook wil ik diverse fondsen noemen die 
op enigerlei wijze een financiële bijdrage geleverd hebben aan het kunnen realiseren van projecten 
of het proefschrift (de Iona Stichting, de Stichting Phoenix, en de Stichting Triodos Foundation).  
Dit proefschrift biedt tevens de gelegenheid om mijn begeleiders van een eerder promotietra-
ject dat ik niet afgerond heb, te bedanken. Prof. Dr. Onno van der Hart, Prof. Dr. Gerrit Glas, Dr. 
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Nel Draijer en Dr. Ellert Nijenhuis, zeer bedankt voor jullie begeleiding. Helaas is dat proefschrift 
niet gerealiseerd, maar hebben we wel nog gezamenlijk een belangrijk artikel kunnen schrijven en 
publiceren.
 Dan komen we aan de laatste mensen. Allereerst wil ik de leden van de promotiecommissie 
(Prof. dr. ir. P. Struik, Prof. dr. R. Gerth van Wijk, Prof. dr. J. van der Greef en Prof. Dr. P. Koore-
man) zeer bedanken voor hun aandacht voor en het beoordelen van mijn werk. In de tweede plaats 
wil ik Prof. dr. E.M. Kingma zeer bedanken voor haar begeleiding van het artikel over de definitie 
van gezondheid en het co-promotorschap. 
Elselijn, het werk zit er nog niet helemaal op, maar ik wil je nu alvast heel erg bedanken voor je 
grote en integere bereidheid om te luisteren naar en te proberen te begrijpen wat ik wilde schrijven. 
Ik wil je tevens bedanken voor jouw hulp om dit vervolgens in adequate filosofische termen vorm 
te geven, ook al neem je inhoudelijk op bepaalde punten een duidelijk ander standpunt in dan ik. 
Op dit moment zijn we een heel eind op weg met het artikel en ik heb er groot vertrouwen in dat 
we het binnen afzienbare tijd onder jouw deskundige begeleiding, na nog enkele goede discussies 
en schrijfrondes naar ieders tevredenheid en met een goede kwaliteit kunnen afronden en indienen. 
Ik heb, ook al was de periode niet heel lang, erg genoten van de samenwerking.
In de derde plaats wil ik Prof. dr. ir. H.F.J. Savelkoul zeer bedanken. Beste Huub, in de afgelo-
pen jaren hebben wij onze samenwerking geïntensiveerd en hebben we in verschillende projecten 
gepionierd in het onderzoeken van de immunologische werkingsmechanismen van Citrus, Cy-
donia en Citrus/Cydonia comp. bij hooikoorts. Ik ben altijd weer zeer onder de indruk van jouw 
ongelooflijke kennis van de immunologie en jouw enthousiasme. Ik heb vele van onze gesprekken 
verlaten met nieuwe inzichten en met het gevoel dat we hard en goed gewerkt hadden en goede 
en open gesprekken over bijvoorbeeld wetenschap in het algemeen, immunologie, en het holisme-
reductionisme gehad hadden. Naar mijn beleven hebben deze gesprekken en ontmoetingen ons 
beiden verrijkt. Huub, ik wil je zeer bedanken voor je open geest en houding om nieuwe dingen te 
onderzoeken en nieuwe wegen te bewandelen. Het verantwoordelijkheid nemen voor en begelei-
den van een proefschrift als dit is niet geheel vanzelfsprekend en ik ben je dan ook zeer erkentelijk 
en dankbaar dat je vol overtuiging ‘ja’ zei toen ik je vroeg om mijn promotor te willen zijn. Tot aan 
het eind heb je mij met kleinere en grote vragen bijgestaan, hebben we heel boeiende gesprekken 
gevoerd en heb ik mij door jou zeer ondersteund gevoeld in het realiseren van mijn intentie en de 
concretisering van dit proefschrift. Ik hoop dat we in de toekomst nog veel projecten samen zul-
len doen waarin we ‘the best of both worlds’ samenbrengen en daarmee een meerwaarde kunnen 
creëren. 
En natuurlijk kom ik afsluitend aan bij een van de belangrijkste dingen in mijn leven, mijn 
gezin: Wietske, Bram en Marlieke. Lieve Wietske, jouw vader was hoogleraar en waarschijnlijk 
even betrokken bij zijn onderwerp als ik bij het mijne. Je bent dus opgegroeid met het leven van 
een onderzoeker en hebt misschien wel mede daardoor mij uitgekozen om samen door het leven te 
gaan ☺. Desalniettemin is het wel een feit dat de opvoeding van onze kinderen en het alledaagse 
leven in ons gezin nogal eens op jouw schouders terecht is gekomen. Je weet dat dit een van de 
redenen is waarom ik veel van je houd en dat ik je daar zeer dankbaar voor ben. Lieve Bram en 
Thesis Erik W. Baars   239
Marlieke, voor jullie is dit de eerste keer dat je met een wetenschapper leeft, die daarbij ook nog 
eens jullie vader is. Ik besef mij heel goed dat ik nogal eens afwezig was en dat veel van mijn tijd 
besteed is aan het werk en speciaal de laatste tijd met het afmaken van het proefschrift. Dat werk 
is nu gedaan en ik ga er vanuit dat ik nog de rest van mijn leven heb om het weer een beetje in 
evenwicht te brengen. Ik hou heel veel van jullie en hoop dat jullie net als ik iets zullen vinden dat 
het waard is om een belangrijk deel van je leven aan te geven.
En tenslotte wil ik allen die hier niet met name zijn genoemd maar die op een of andere ma-
nier bij de totstandkoming van mijn proefschrift betrokken zijn daar heel hartelijk voor bedanken. 
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